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“ Creating bridges 
with society is an 
integral part of 
what we do and 
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FOREWORD
With 2018 already behind us, we take this opportunity to 
reflect on the many achievements that the CNIO and its people 
accomplished throughout the year. We have continued to 
consolidate our strategy, reinforcing those institutional core 
values on which our Centre of Excellence rests. One of our 
main accomplishments continues to be our scientific output, 
which continues to excel and places the CNIO firmly on the 
map as a flagship research centre in Europe. This year, 
according to the Nature Index considering our scientific 
contributions in the life sciences and healthcare field, we 
moved up the ladder to reach the top position among cancer-
focused institutions in Europe. In 2018, the CNIO authored 
a total of 217 papers, 44 of which were published in journals 
with impact factor between 10 and 15, and 23 publications in 
journals with impact factor greater than 15. This achievement 
unquestionably portrays our international competitiveness 
and our leadership in cancer research.
Numerous collaborations are taking place with scientists 
throughout the world and the goal of the Centre is to continue 
fostering CNIO’s participation in international consortia and 
forums so that we can actively engage in and promote the 
dissemination of research advances. In line with these efforts 
of international outreach, we continued to nurture our alliance 
in 2018 with the Weizmann Institute of Science ( WIS ) in 
collaboration with the Ramon Areces Foundation. As a result, 
the first call for collaborative projects for CNIO-WIS went 
out in 2018 ; this will materialise in outstanding projects that 
will cross the boundaries of land and science in 2019.
Our commitment to Spanish science and to bolstering the 
future of new generations of researchers in Spain perseveres ; 
in 2018, we showed our support and involvement in SOMMa, 
the Severo Ochoa and Maria de Maetzu Alliance born in 2017. 
The first 100xCiencia, organised in the context of the Alliance, 
took place at the CNIO and successfully brought together 
various stakeholders, including scientists, science reporters, 
politicians from all main political parties in Spain and members 
of the society, in order to put together existing opportunities 
Maria A. Blasco Director
FOREWORD
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and challenges with the aim to forge a bridge between science 
and society. In 2018, I have come forward to assume the Vice-
Presidency of SOMMa, and from that position I am eager to 
further contribute towards the goals of the Alliance from the 
CNIO.
Science evolves, and so do we as a Centre. In 2018, we have 
said goodbye to several esteemed members of the CNIO who 
have contributed to CNIO’s excellence during their time at 
our Institution. Thus, we pay tribute to our colleagues Manuel 
Morente, Erwin Wagner, Maria J. Barrero, and Daniel Lietha 
for their contributions and the years they dedicated to the 
CNIO : we wish them all the best for their future personal and 
professional endeavours. This year, we have also reinforced 
our basic research arm by merging the Cancer Cell Biology 
Programme with our Molecular Oncology Programme. The 
promotion of Nabil Djouder to senior group leader also adds 
to the renewed muscle of our basic research programme. 
Moreover, Óscar Fernández-Capetillo, one of our more 
seasoned investigators, has been appointed as new Director 
of the Programme to steer the wheel and keep heading towards 
excellence in research and innovation. In 2018, we had the 
honour to host Scott Lowe from the Memorial Sloan Kettering 
Cancer Center in NY, as visiting scientist. We also established 
an agreement with Raúl Rabadán, renowned expert in cancer 
systems biology and full professor at Columbia University, to 
strengthen our position in this field and keep abreast of new 
technologies and developments in cancer genomics. We expect 
to continue consolidating this relationship next year. 2018 
has been an important year to start the recruitment of 2 new 
senior groups and 2 new junior groups to expand the Molecular 
Oncology and Structural Biology Programmes that will join 
our Centre in 2019.
It is by supporting our excellent science, stemming from both 
our basic, translational and clinical programmes, that we can 
achieve remarkable numbers that stand testament to our 
innovation activities. This is another core value at the CNIO, 
as we believe in contributing to society and our industry 
ecosystem by turning new discoveries into tangible beneficial 
products in biomedicine. Our Experimental Therapeutics 
Programme continues to develop new drug candidates to close 
the valley of death in drug discovery, bringing CNIO discoveries 
closer to the patient. This year, we made substantial progress 
in the development of novel TRF1 inhibitors for treating brain 
tumours, a project that has been awarded a CaixaImpulse 
grant. Another example of our work in biomedical innovation 
is another project also supported by CaixaImpulse, which 
exemplifies how leveraging gene editing can become a novel 
approach for treating cancer. More technologies are growing 
and developing in our pipeline, which is open to collaborations 
with investigators both at CNIO and abroad. Our efforts in 
drug discovery always reach beyond our borders, and we 
continue to be part of the international initiative Milner 
Therapeutics Institute at Cambridge, with our active 
participation in 2018 in the second symposium organised by 
the alliance. We continuously measure our innovation impact 
as we actively strive to improve with every year. In 2018, we 
obtained more than 580,000 euros in royalties, a 5% increase 
compared with 2017 ; this return feeds back into our research 
organisation, providing us with motivation, incentive and 
important support to help achieve our institutional goals.
Our training programmes are the main vessel that feeds into 
our investigators and groups. Creating highly prepared 
generations of researchers is a priority for the CNIO and we 
strongly thank our sponsors as they contribute to support our 
collaborations with investigators abroad. During 2018, we 
continued to participate in the “ Science by Women ” 
programme to host African researchers and contribute to the 
progress of science abroad. Thanks to this programme, Hayet 
Rafa from the University of Science and Technology Houari 
Boumediene in Algiers, will join the CNIO’s Melanoma Group 
for a 6-month stay as visiting scientist.
Society has become an integral part of our strategy and we 
are strengthening our initiatives to create the appropriate 
channels for dissemination and communication with citizens, 
including youngsters who could evolve into the next generation 
of scientists. In 2018, our media coverage increased by 46% 
over the previous year, featuring stories that have a strong 
impact worldwide. But we also want to create science and 
research awareness among our citizens through actions such 
as our event on the “ Present and Future of Cancer Research ”, 
co-organised with the Atresmedia media group and Fundación 
AXA, that was held at the Cibeles Palace with the support of 
the City of Madrid. We invited the Nobel Laureate Elizabeth 
Blackburn to be part of a discussion panel to spread the message 
that research is one of the pillars on which the fight against 
cancer rests. A special mention is reserved for our platform 
for scientific education and STEM support, CNIO & The City, 
which has again proven to be a success among participants as 
well as volunteers. In 2018, the project was again awarded by 
the FECYT, consolidating this initiative at the CNIO and in 
the educational community. In 2018, we aimed to reach out 
beyond the Region of Madrid ; a commitment that will continue 
in future editions of the project.
Our efforts to reinforce our initiatives to engage with society 
have translated into a new “ Office of Institutional Image and 
Outreach ”; this office is leading several projects that aim to 
open up new avenues to gain society’s trust and attention as 
well as emphasise the value of science. The very first step was 
the launch of our new website, a portal between the scientific 
community and society with the goal of opening up the CNIO 
and its discoveries to the world as well as making more CNIO 
Friends to support our goal to stop cancer. In fact, in 2018 our 
CNIO Arte project, which explored the common territories 
between scientific research and artistic creation, was exhibited 
in February and brought together the Spanish molecular 
biologist Margarita Salas and the artist Eva Lootz. This is an 
unparalleled project that we shared with the world via different 
forums, including ARCO. The funds obtained from the works 
of art totalled 100,000 euros, which contributes directly to 
our CNIO Friends philanthropic initiative. CNIO Friends has 
provided the funds and means to launch one pre-doctoral 
researcher contract and six CNIO Friends Postdoctoral 
Contracts, one of them supported by Juegaterapia Foundation 
to develop a project in brain tumours in children. The growing 
amount of donations, totalling over 370,000 euros, surpassed 
our record since the launch of the initiative in 2014. We 
enthusiastically thank all of our friends for their support and 
commitment to cancer research.
Finally, as an integral part of our alignment with the values 
of Responsible Research & Innovation, the CNIO demonstrates 
its full-blown commitment to gender equality. The work of 
the CNIO Women and Science ( WISE ) Office is instrumental 
to undertake the different initiatives that support women in 
science and to coordinate efforts with other departments and 
societal groups involved in closing the gender divide. 
During 2018, we had the pleasure of listening to many 
exceptional women in different fields who shared with us their 
experiences and wisdom. We are indebted to all of them for 
their support to women and our cause.
Continuing with our mission to stop cancer will always require 
a robust team effort — a team of scientists, administrative 
support personnel and societal partners — who all help to 
establish a solid foundation to further build upon.
Visual artist Eva Lootz in our CNIO Arte 
2018 exhibition.






in understanding how 
cancer originates, 
develops and 
progresses into a 
metastatic disease.”
The scientists at CNIO have one more year made many important 
contributions that keep us at the forefront of biomedical research. 
We have discovered barriers that limit brain metastasis, which 
could potentially be exploited to limit this phenomenon. We 
have also identified a novel connection between cancer and 
differentiation, opening up new avenues for the treatment 
of pancreatic cancer. We have identified genes that can drive 
carcinogenesis or suppress it depending on the context, and 
have revealed how some cancer drivers might be involved in the 
development of melanoma. We have identified new biomarkers 
of prognosis for breast cancer, and confirmed the relevance of 
DNA repair deficiencies in prostate cancer. We have created new 
tools to model cancer in cells or animals, and obtained important 
insights as to how our genome is spatially organised. We now 
also know that a gene therapy based on telomerase expression 
does not promote tumorigenesis, an important safety check 
on the development of this technology for the treatment of 
age-associated pathologies. While necessarily incomplete, this 
snapshot provides a quick panoramic view that illustrates the 
top-quality science that is constantly being produced by our 
scientists. This success is the combined outcome of the hard work 
carried out by all our research groups, with the instrumental help 
of the Biotechnology Units and all the personnel that supports 
our daily activities. My sincere thanks to all of you.
SPANISH NATIONAL CANCER RESEARCH CENTRE, CNIO 15ANNUAL REPORT 2018
TRANSLATIONAL RESEARCH






Hereditary Endocrine Cancer Group
Núria Malats 
Genetic and Molecular Epidemiology Group
Miguel Urioste 
Familial Cancer Clinical Unit
Sandra Rodríguez-Perales 




CLINICAL RESEARCH PROGRAMME Miguel Quintela-Fandino Acting Programme Director
Miguel Quintela-Fandino 
Breast Cancer Junior Clinical Research Unit
David Olmos 
Prostate Cancer Junior Clinical Research Unit
Luis J. Lombardía 
Molecular Diagnostics Unit
Joaquín Martínez-López 
H12O-CNIO Haematological Malignancies 
Clinical Research Unit
Luis Paz-Ares 
H12O-CNIO Lung Cancer Clinical Research 
Unit
BIOBANK Manuel M. Morente ( until July ) Director
Miguel Quintela-Fandino ( since August ) Acting Programme Director
INNOVATION
CAROLINA POLA DIRECTOR OF INNOVATION




Transgenic Mice Core Unit
Giovanna Roncador 
Monoclonal Antibodies Core Unit
Francisca Mulero 
Molecular Imaging Core Unit
Lola Martínez 
Flow Cytometry Core Unit
Diego Megías 
















CNIO-Lilly Cell Signalling Therapies Section












Maria A. Blasco, Oscar Fernández-Capetillo Acting Programme Directors
Maria A. Blasco 











María S. Soengas 
Melanoma Group
Héctor Peinado 
Microenvironment and Metastasis Junior 
Group
Manuel Valiente 
Brain Metastasis Junior Group
Alejo Efeyan 
Metabolism and Cell Signalling Junior Group
CANCER CELL BIOLOGY 
PROGRAMME
Erwin F. Wagner Programme Director
Erwin F. Wagner 
Genes, Development and Disease Group
Francisco X. Real 
Epithelial Carcinogenesis Group
Nabil Djouder 
Growth Factors, Nutrients and Cancer Group
Massimo Squatrito 






Macromolecular Complexes in DNA Damage 
Response Group
Daniel Lietha ( until September ) 
Cell Signalling and Adhesion Junior Group
Ivan Plaza-Menacho 
Kinases, Protein Phosphorylation and Cancer 
Junior Group
Rafael Fernández Leiro 
Genome Integrity and Structural Biology 
Junior Group
Ramón Campos-Olivas 







Crystallography and Protein Engineering Unit
Martin Krallinger 
Biological Text Mining Unit
SPANISH NATIONAL CANCER RESEARCH CENTRE, CNIO 17ANNUAL REPORT 2018 16
Basic Research Molecular Oncology Programme 18Telomeres and Telomerase Group 20Experimental Oncology Group 24Cell Division and Cancer Group 28
Genomic Instability Group 32
Chromosome Dynamics Group 36
DNA Replication Group 40
Melanoma Group 44
Microenvironment & Metastasis Junior Group 48
Brain Metastasis Junior Group 50
Metabolism and Cell Signalling Junior Group 52
Cancer Cell Biology Programme 54
Genes, Development and Disease Group 56
Epithelial Carcinogenesis Group 60
Growth Factors, Nutrients and Cancer Group 64
Seve Ballesteros Foundation-CNIO Brain Tumour Junior Group 68
Structural Biology Programme 70
Macromolecular Complexes in DNA Damage Response Group 72
Cell Signalling and Adhesion Junior Group 76
Kinases, Protein Phosphorylation and Cancer Junior Group 78
Genome Integrity and Structural Biology Junior Group 80
Spectroscopy and Nuclear Magnetic Resonance Unit 82
Bioinformatics Unit 84
Electron Microscopy Unit 86
Crystallography and Protein Engineering Unit 88
Biological Text Mining Unit 90
SPANISH NATIONAL CANCER RESEARCH CENTRE, CNIO 19ANNUAL REPORT 2018 18
Basic ReseaRch MoleculaR oncology PRogRaMMe
MOLECULAR ONCOLOGY 
PROGRAMME
The Molecular Oncology Programme ( MOP ) is the largest 
research programme at the CNIO, hosting 9 Senior and 4 
Junior Groups. Scientists at the MOP focus on trying to obtain 
a mechanistic understanding of how cells in our body work, 
as well as to identify the molecular alterations at the cellular 
level that drive carcinogenesis. To do so, MOP research groups 
use a wide range of technologies including molecular and 
cellular biology, mouse models, and genetic and chemical 
screens. The Programme encompasses expertise related to 
some of the most active areas of research in molecular oncology, 
including DNA and chromosome stability ( Maria A. Blasco, 
Óscar Fernández-Capetillo, and Ana Losada ), oncogenes and 
cell cycle kinases ( Mariano Barbacid ), DNA replication ( Juan 
Méndez ), mitosis ( Marcos Malumbres ), melanoma ( María 
S. Soengas ), metabolism and cell signalling ( Alejo Efeyan ), 
and metastasis ( Manuel Valiente and Héctor Peinado ). In 
addition, starting in 2019, the MOP will also host the Groups 
of Epithelial Carcinogenesis ( Francisco X. Real ), Growth 
Factors, Nutrients and Cancer ( Nabil Djouder ) and Brain 
Tumours ( Massimo Squatrito ), which will broaden our areas 
of interest and significantly strengthen the Programme.
In terms of scientific publications, this year once again, the 
Molecular Oncology Programme has continued its positioning 
on the frontline of oncology research. The top-level quality of 
the research conducted by each of these Groups is exemplified 
through 9 papers published in Nature journals ( Nature 
Medicine, Nature Reviews Cancer, Nature Cell Biology, Nature 
Communications, Nature Structural and Molecular Biology ), 4 
papers in Cell Journals ( Cancer Cell, Cancer Discovery ) and 1 
paper in a Science Journal ( Science Translational Medicine ); 
this in addition to the excellent contributions in Circulation 
Research, Current Opinion in Cell Biology, Journal of Clinical 
Investigation, Journal of Experimental Medicine and Nucleic 
Acids Research.
Besides from publications, scientists at the MOP have 
continued to be leaders in their respective areas of research 
and have made important contributions in several areas such 
as generating patents, organising conferences or bridging the 
gap with the clinical world.
Maria A. Blasco, Director 
Óscar Fernández-Capetillo, Vice Director
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We study the mechanisms by which tumour cells are immortal 
and normal cells are mortal. Immortality is one of the 
most universal characteristics of cancer cells. The enzyme 
telomerase is present in more than 95% of all types of human 
cancers and is absent in normal cells in the body. Telomeres are 
nucleoprotein complexes located at the ends of chromosomes 
and are essential for chromosome protection and genomic 
stability. Progressive shortening of telomeres associated with 
organism ageing leads to ageing. When telomeres are altered, 
adult stem cells have a maimed regenerative capacity.
Our research focuses on :
 ɗ Generating mouse models to validate telomeres and 
telomerase as therapeutic targets for cancer and age-
related diseases.
 ɗ The interplay between telomeres and DNA repair pathways.
 ɗ The role and regulation of non-coding telomeric RNAs 
or TERRA.
 ɗ Testing telomerase gene therapy in ‘ telomere syndromes ’ 
and age-related diseases.
 ɗ The role of telomerase and telomeres in adult stem cell 
biology and in nuclear reprogramming of differentiated 
cells to iPS cells.
“ We have demonstrated that 
telomerase activation in mouse 
models of pulmonary fibrosis can 







Isabel López de Silanes, Rosa M. 
Marión, Paula Martínez, Marinela 
Méndez ( until April )
Post-Doctoral Fellows
Giuseppe Bosso ( since June ), Sergio 
Piñeiro ( since June ), Sarita Saraswati 
( since October ), Kurt Whittemore
Graduate Students
Leire Bejarano, Iole Ferrara, José 
Carlos González ( since November ), 
Jessica Louzame ( since September ), 
Juan José Montero, Miguel Ángel 
Muñoz, Raúl Sánchez
Technicians
Aksinya Derevyanko ( since February ), 
Rosa M. Serrano
Visiting Students
Pawel Kordowitzki ( May-September ) 
( Polish Academy of Sciences ), 
Jessica Louzame ( until August ) ( Univ. 
of Amsterdam, The Netherlands ), 
Lydia T. Poluha ( until August ) ( Univ. 
of Salford, UK ), Tommaso Vicanolo 
( since October ) ( Sapienza Univ. of 
Rome, Italy )
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essential for telomere length maintenance and protection. 
Using 20q-TERRA knockout cells we have now addressed the 
direct role of TERRAs in telomeric heterochromatin formation. 
We discovered that TERRAs interact with components of the 
polycomb complex ( PCR2 ), an important epigenetic regulator 
of gene expression, thus facilitating the assembly of telomeric 
heterochromatin. We analysed telomere heterochromatin 
marks in cells deficient for 20q-TERRA and observed that 
their telomeres had decreased heterochromatic marks ; we 
discovered that they had lost a histone mark not previously 
recognised at telomeres ( H3K27 trimethylation ) that is 
catalysed by PCR2, a master regulator of gene silencing, which 
we found locates to the telomere in a TERRA-dependent 
fashion. Establishment of trimethylation marks in other 
histones ( H3K9 and H4K20 ) and HP1 binding at telomeres 
required PRC2-dependent H3K27me3 at telomeres. Our 
findings demonstrated an important role for TERRAs in 
telomeric heterochromatin assembly ( FIGURE 2 ). s
ReseaRch highlighTs
Telomerase gene therapy to cure pulmonary fibrosis 
in mice
Pulmonary fibrosis is a fatal lung disease that currently lacks 
effective treatment and is characterised by fibrotic foci and 
inflammatory infiltrates. Short telomeres can impair tissue 
regeneration and are found both in hereditary and sporadic 
cases. We have shown the therapeutic effects of AAV9-
telomerase gene therapy in a mouse model of pulmonary 
fibrosis from a combination of bleomycin-induced lung damage 
short telomeres. AAV9 targets preferentially regenerative 
alveolar type II cells ( ATII ). Treated mice show improved 
lung function and lower inflammation and fibrosis at 1-3 
weeks after treatment, and improvement or disappearance 
of the fibrosis at 8 weeks post treatment. Treatment results 
in longer telomeres and increased proliferation of ATII cells, 
as well as lower DNA damage, apoptosis, and senescence. We 
have provided a proof-of-principle that telomerase activation 
may represent an effective treatment for pulmonary fibrosis 
provoked by or associated to short telomeres.
Telomerase gene therapy does not increase risk 
of cancer in cancer-prone models
Short and dysfunctional telomeres result in various age-related 
conditions, including a group of diseases collectively known as 
“ telomere syndromes ” that are provoked by extremely short 
telomeres arising from germline mutations in telomere genes. 
This opens the possibility of using telomerase activation as 
a potential therapeutic strategy to rescue short telomeres, 
maintaining tissue homeostasis and ameliorating these 
diseases. In 2012, we designed a highly innovative strategy : 
a gene therapy that reactivates the telomerase gene using 
adeno-associated viruses ( AAV9 ). We have since shown 
its therapeutic efficacy in mouse models of cardiac infarct, 
aplasic anaemia, and pulmonary fibrosis. Although we did 
not observe, in any of the former models, an increased cancer 
incidence as a consequence of telomerase overexpression in 
any of those models, the potential medical use of telomerase 
still clashes with fears surrounding a possible increased cancer 
risk. We now tested the safety of AVV9-telomerase gene 
therapy in the context of a cancer-prone mouse model owing 
to expression of oncogenic K-ras. We found that telomerase 
overexpression resulted in longer telomeres in the targeted 
tissue ( lungs ; FIGURE 1 ) but does not accelerate carcinoma 
onset or progression. Telomerase activation by using AAV9-
mediated telomerase gene therapy has no detectable cancer-
prone effects in the context of oncogene-induced mouse 
tumours.
TERRAs are important epigenetic regulators
TERRAs are long non-coding RNAs that protect the telomeres. 
Our Group had already identified chromosome 20q as one of 
the main origins of human TERRAs and demonstrated that, 
by generating the first 20q-TERRA knockout models, they are 
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Figure 1 Representative 
images of lungs treated 
with gene therapy vectors 
( GTV ). Nuclei are in blue, 
alveolar type II cells in 
green and telomeres in 
red. Lung cells treated with 
telomerase present the 
most intense telomeres, 
indicating that they are 
the longest of all three 
scenarios.
Figure 2 TERRAs regulate the 
status of telomeric chromatin. 
After binding to the PRC2 
complex TERRAs bring PRC2 
to the telomere. Binding of PRC2 
makes possible the deposition 
of heterochromatin marks. These 
events cannot take place when 
TERRAs are absent. 
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KRAS oncogenes have been identified in at least one fifth of all 
human cancers. In spite of recent successes with checkpoint 
inhibitors, most KRAS mutant tumours, including lung 
adenocarcinomas, are still treated with cytotoxic compounds 
approved over 2 decades ago. Moreover, attempts to block 
KRAS oncogenic activity with selective inhibitors of the MEK 
kinase, a downstream effector, have turned out to be major 
failures. Two MEK inhibitors, Trametinib and Selumetinib, 
have failed to show significant anti-tumour activity in large 
phase III clinical trials due to unacceptable toxicities. In our 
laboratory, we have continued our quest to validate therapeutic 
targets using a new generation of genetically engineered mouse 
tumour models that allow us to evaluate their anti-tumour 
properties as well as their potential toxic effects in tumour-
bearing mice. These studies have allowed the identification 
of c-RAF as a target capable of inducing significant tumour 
regressions in advanced KRAS/TRP53 mutant lung tumours 
without inducing major toxicities. These observations suggest 
that forthcoming c-RAF inhibitors may provide significant 
therapeutic benefits in the clinic.
“ Systemic ablation of c-RAF 
induces regression of a significant 
percentage of advanced K-Ras/
Trp53 mutant lung adenocarcinomas 
by a mechanism independent of 
MAPK signalling that results in the 
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progression. It is generally accepted that cancer-associated 
fibroblasts ( CAFs ) stimulate tumour progression and might 
be implicated in drug resistance and immunosuppression. Yet, 
recent studies have shown that physical or genetic elimination 
of the stroma leads to more aggressive tumour development. 
In an attempt to clarify the role of the desmoplastic stroma in 
PDAC development and progression, we decided to reprogram 
the CAFs that make up the stromal tissue by identifying, and 
subsequently targeting, genes responsible for their pro-
tumorigenic properties. First, we compared the transcriptional 
profile of PDGFRα+ CAFs isolated from genetically engineered 
mouse PDAC tumours with that of normal pancreatic fibroblasts 
( NPFs ) in order to identify genes potentially implicated in their 
pro-tumorigenic properties. We have observed that the most 
differentially expressed gene, Saa3, a member of the acute-phase 
Serum Amyloid A ( SAA ) apolipoprotein family, is a key mediator 
of the pro-tumorigenic activity of PDGFRα+ CAFs. Whereas 
Saa3 competent CAFs stimulate the growth of PDAC tumour 
cells in an orthotropic model, Saa3 null CAFs inhibit tumour 
growth. Saa3 also plays a role in the cross-talk between CAFs and 
tumour cells ( FIGURE 2 ). Ablation of Saa3 in pancreatic tumour 
cells makes them insensitive to the inhibitory effect of Saa3 null 
CAFs. As a consequence, germline ablation of Saa3 does not 
prevent PDAC tumour development in mice ( FIGURE 2 ). The 
pro-tumorigenic activity of Saa3 in CAFs is mediated by Mpp6, 
a member of the palmitoylated membrane protein subfamily 
of the peripheral membrane-associated guanylate kinases. 
Finally, we interrogated whether these observations could be 
translated to a human scenario. Indeed, SAA1, the orthologue 
of murine Saa3, is overexpressed in human CAFs. Moreover, 
high levels of SAA1 in the stromal component correlate with 
worse survival. These findings support the concept that selective 
inhibition of SAA1 in CAFs may provide potential therapeutic 
benefit to PDAC patients. s
ReseaRch highlighTs
Regression of advanced K-Ras/Trp53 mutant lung 
adenocarcinomas upon systemic ablation of c-RAF 
expression
Almost a quarter of all solid tumours harbour K-RAS oncogenes. 
Yet, more than 30 years after their identification in human 
cancer, there are no selective therapies to treat these tumours. 
Inhibitors of K-RAS oncogenes activated by G12C mutations, a 
mutation frequently identified in lung adenocarcinomas, have 
already entered clinical trials. Yet, direct targeting of other 
mutations has proven to be challenging. Genetic interrogation 
of the MAPK pathway revealed that systemic ablation of Mek or 
Erk kinases in adult mice prevent tumour development but are 
unacceptably toxic. This year, we demonstrated that ablation 
of c-Raf expression in advanced mouse lung tumours driven by 
K-RasG 12V/Trp53 mutations led to significant tumour regression 
with no detectable appearance of resistance mechanisms 
( FIGURE 1 ). Tumour regression results from massive apoptosis. 
Importantly, systemic abrogation of c-Raf expression does not 
inhibit canonical MAPK signalling, hence, resulting in limited 
toxicities. These observations suggest that therapeutic strategies 
aimed at inhibiting c-RAF kinase activity may not be suitable 
since they may only block MAP Kinase activation. Indeed, three 
independent c-RAF kinase inhibitors have shown to be rather 
toxic even at non-therapeutic doses. Therefore, we need to 
explore other therapeutic strategies. Drugs capable of degrading 
the c-RAF protein could be most effective in the clinic. Yet, 
drugs that promote protein degradation are still at very early 
stages of development. Inhibition of c-RAF by small interfering 
RNA is another possible approach, but still faces significant 
technical challenges. Finally, selective targeting c-RAF effectors 
regulated through non-kinase mechanisms such as ROKalpha, 
ASK1 and MST2 will also be challenging since they will require 
to be activated. As Frank MacCormick put it in a Preview that 
accompanied our Cancer Cell paper ( San Clemente et al., 2018 ) 
“ In the effort to harness c-Raf biology to target KRAS mutant 
cancers, the goal posts seemed to have moved again ”. In any 
case, our results should provide the experimental bases to design 
novel c-RAF based therapeutics to treat K-RAS mutant cancers.
SAA3 is a key mediator of the pro-tumorigenic 
properties of cancer associated fibroblasts in pancreatic 
ductal adenocarcinomas
Pancreatic ductal adenocarcinoma ( PDAC ) is one of the most 
malignant human tumours for which there are no efficacious 
therapeutic strategies. This tumour type is characterised by 
an abundant desmoplastic stroma that promotes tumour 
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Figure 1 Systemic ablation of 
c-RAF expression results in equal or 
better levels of tumour regression 
while inducing acceptable toxicities. 
In contrast, inhibition of the MAP 
Kinase pathway induces tumour 
regression but with unacceptable 
toxicities both in mice ( Blasco et 
al., Cancer Cell 2011 ) and in patients 
( Trametinib and Selumetinib failed 
clinical trials ).
Figure 2 Crosstalk between pancreatic 
tumour cells and CAFs in the presence 
and absence of Saa3. Diagram depicting 
the in vivo orthotopic tumour assays in 
immunodeficient mice carried out to 
determine the pro-tumorigenic properties 
of Saa3 competent ( WT ) ( red ) and 
Saa3 null ( KO ) ( light blue ) CAFs on 
pancreatic tumour cells isolated from Saa3 
competent ( WT ) ( yellow ) and Saa3 null 
( KO ) ( green ) tumours.
 ∞ Manuel Sanclemente: Award for PhD- 
Authored Publications, CNIO Lab Day.
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The Cell Division and Cancer Group is interested in deciphering 
the mechanisms by which cell division and cell proliferation 
are regulated in mammalian cells. During the last years, 
we have used different mouse models to understand the 
relevance of cell cycle regulators, including cell cycle kinases 
and phosphatases, as well as proteins involved in ubiquitin-
dependent degradation, in the control of cell division and 
tissue physiology. Our interests are : i ) to understand the basic 
control mechanisms that regulate the cell division cycle ; ii ) to 
characterise the physiological and therapeutic consequences 
of cell cycle deregulation ; iii ) understanding self-renewal and 
pluripotency in stem cell biology and tumour development ; 
and iv ) to find and validate new targets for cancer therapy. 
As a final goal, we aim to generate information that may be 
useful to improve therapeutic strategies against cancer cell 
proliferation.
“ During 2018, we investigated 
the relevance of PLK1 and MASTL 
as oncogenes and as therapeutic 
targets in breast cancer, as well as 
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either using RNA interference or CRISPR-Cas systems, resulted 
in defective proliferation of a subset of breast cancer cells, both 
in vitro and in vivo, suggesting the therapeutic potential of 
inhibiting this kinase in breast cancer ( a collaboration with 
the Oncology R&D group at Pfizer ; Álvarez-Fernández et al., 
Cell Death Differ 2018 ).
Before the function of MASTL in mitosis was proposed, 
the corresponding human gene was found mutated in 
patients with thrombocytopenia. To understand the 
effects of this mutation we recently generated a knockin 
mouse model carrying that mutation ( Mastl E166D in the 
mouse ). Mastl E166D mice developed thrombocytopenia 
but, unexpectedly, this defect was not due to abnormal 
cell cycle in megakaryocytes but to defective activation of 
mutant platelets. In the presence of this mutation, PP2A is 
constitutively inhibited resulting in hyperphosphorylation 
of proteins involved in actin cytoskeleton signalling during 
platelet activation. Mastl E166D mutant platelets were 
prematurely activated and displayed defective morphology 
and function, as well as decreased survival, thus contributing 
to thrombocytopenia ( Hurtado et al., J Clin Invest, in press ). 
These data uncovered a new function of MASTL in the 
actin cytoskeleton in postmitotic cells, entailing important 
implications in human disease.
Plk1 : oncogene or tumour suppressor
Among the multiple kinases involved in cell cycle progression, 
PLK1 is considered an attractive cancer target and a few small-
molecule inhibitors are currently under evaluation in clinical 
trials. However, our knowledge about the relevance of this 
protein in adult mammalian tissues is still limited. In 2017, 
we described a critical role for the mouse Plk1 in controlling 
the contraction of smooth muscle cells and blood pressure ( de 
Cárcer et al., Nat Med 2017 ), suggesting possible toxic effects 
linked to the inhibiting of this kinase that need to be controlled 
in patients. More recently, we evaluated to what extent the 
expression levels of Plk1 contribute to tumour development 
in mouse models. Although Plk1 is frequently considered as 
an oncogene, we observed that Plk1 overexpression prevented 
proper cell proliferation by generating genomic aberrations 
in polyploid and aneuploid cells ( FIGURE 2 ). Overexpression 
of Plk1 impaired breast cancer development induced by Kras 
or HER2 oncogenes, thereby suggesting a tumour suppressor 
function for this protein in these models ( a collaboration with 
R. Sotillo, German Cancer Research Center ; de Cárcer et al., 
Nat Commun 2018 ). Specifically, in human breast cancer, PLK1 
overexpression correlated with better prognosis. Although 
these data do not argue against the use of PLK1 inhibitors 
in the clinic, they add new levels of knowledge that will be 
critical when optimising the use of mitotic inhibitors in cancer 
therapy. s
ReseaRch highlighTs
The Mastl-PP2A axis in the cell cycle and cancer
Cell cycle progression is typically triggered by phosphorylation 
of a large number of proteins involved in different cellular 
pathways. Several families of protein kinases involved in 
cell cycle progression, such as Cyclin-dependent kinases 
( CDKs ) or Polo-like kinases ( PLK ), have been thoroughly 
studied over the last few decades. However, the identity and 
relevance of phosphatases is less well-established. Recently, 
the cell cycle kinase Mastl ( also known as Greatwall ) emerged 
as a key player in cell cycle control by inhibiting the PP2A 
phosphatase during mitosis. Mastl phosphorylates 2 small 
proteins, endosulfine ( ENSA ) and ARPP19, which in their 
phosphorylated form bind and inhibit PP2A-B55 complexes, 
thus contributing to the phosphorylation of mitotic phospho-
proteins ( FIGURE 1 ).
However, its physiological relevance in normal tissue 
homeostasis or disease is less known. After an initial screening 
in several tumour types, we found that MASTL was upregulated 
in a significant fraction of breast tumours and correlated with 
poor prognosis in breast cancer patients ( a collaboration with 
M.A. Quintela, CNIO ; and C. Caldas, Cancer Research UK ). 
Importantly, genetic downregulation or ablation of MASTL, 
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Figure 1 A dual role for the MASTL-
PP2A/B55 pathway in cell cycle 
progression and actin cytoskeleton 
dynamics. During the cell cycle, 
MASTL inhibits PP2A/B55 to 
prevent dephosphorylation of mitotic 
phosphoresidues. In postmitotic cells 
such as platelets, the same pathway is 
involved in the control of cytoskeleton 
dynamics by modulating phospho-
residues in the signalling pathways 
that control the reorganisation of the 
actin cytoskeleton.
Figure 2 A central role for Plk1 in 
controlling genomic stability. Plk1 
controls several processes during 
the cell cycle, including centrosome 
maturation, spindle dynamics and the 
formation of the cytokinesis furrow. 
In normal conditions these functions 
support cell proliferation and tumour 
growth, and inhibiting Plk1 may 
prevent tumour cell proliferation. 
However, when Plk1 is overexpressed, 
tumour cells are genomically unstable 
resulting in defective growth of breast 
cancers.
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The Genomic Instability Group centres its research on 
understanding how cells respond to DNA damage, in particular 
to a specific type of harm known as replication stress ( RS ). 
Oncogene-induced RS has been confirmed as the main source 
of genomic rearrangements in cancer cells. In mammals, RS 
triggers a cellular response initiated by ATR and CHK1 kinases, 
known as the Replicative Stress Response ( RSR ). Throughout 
the years, our laboratory has developed a wide battery of 
cellular and animal tools for the study of the RSR. Among them, 
we have mice with enhanced or limited function of ATR and 
CHK1 kinases, cell lines in which the RSR can be activated at 
will and chemical inhibitors of ATR. Our studies have enhanced 
our understanding of the impact of RS on cancer and ageing, 
and have provided novel drugs with antitumoural potential that 
exploit the presence of RS in cancer cells. Overall, our goal is 
to understand the molecular mechanisms governing genome 
protection and repair – particularly during replication – and 
to exploit this knowledge as a way to fight against cancer.
“ In 2018 we have, among other 
achievements, extended our line 
of research on the mechanisms of 
resistance to cancer therapies and 
revealed a novel mechanism by 
which cells couple DNA replication 
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ReseaRch highlighTs
Coupling DNA replication termination 
to mitotic entry
The cell cycle consists of a sequence of ordered events 
leading to the duplication of DNA and ultimately cell 
division. According to this model, once DNA replication 
is finished, there is a G2 transition phase that precedes 
mitosis. However, how and when mitosis is triggered is not 
yet fully understood. In fact, it has been long speculated that 
some yet-to-be-discovered checkpoint prevents mitotic 
entry until DNA replication is completed. We previously 
described that inhibition of the USP7 deubiquitinase leads to 
the ubiquitination of replisome components and replication 
termination. We have now seen that DNA replication triggered 
by USP7 inhibitors occurs concomitant to a generalised 
activation of the mitotic kinase CDK1 throughout the entire 
cell cycle, which impairs chromosome segregation and is 
toxic for mammalian cells. Accordingly, the toxicity of USP7 
inhibitors is alleviated by CDK1 inhibition. Besides from its 
interest in clarifying how USP7 inhibitors kill cells, this work 
provides direct evidence for the existence of a ubiquitin-based 
signalling code that couples DNA replication termination 
to mitotic entry.
Rescuing RAS deficiency in mammalian cells
Previous work in our laboratory revealed the mechanisms 
of resistance to genotoxic anticancer agents such as ATR 
inhibitors. We have now looked into potential mechanisms 
of resistance to targeted therapies. In the context of targeted 
therapies, RAS is assumed to be the ‘ Holy Grail ’. More than 30% 
of all human cancers are driven by mutations in the RAS family 
of genes and, if not RAS, another member of the pathway is 
frequently altered. Since RAS inhibitors have been technically 
very difficult to develop, most drugs that have reached the clinic 
actually target some other components of the signalling route 
such as EGRF, RAF or MEK. However, all of these targeted 
therapies invariably confront the emergence of resistance. To 
which extent resistance would also occur to RAS inhibitors 
remains unknown. In this regard, we have recently identified 
a mutation – the loss of the ETS-domain factor ERF – that 
enables the growth and differentiation of mouse embryonic 
stem cells ( mESC ) lacking all RAS genes ( H-, N- and K-Ras ). 
Strikingly, ERF deficiency supports the generation of RAS-less 
teratomas, this being the first example of a tumour that can 
develop in the absence of RAS proteins. We believe this work 
indicates that, even if potent and selective inhibitors of RAS 
are finally developed, they might likely confront resistance 
through mutations of other genes such as ERF. We are currently 
investigating the role of ERF and other ETS-domain factors 
in the context of resistance to targeted therapies in cancer. s
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Figure 1 USP7 coordinates DNA 
replication with mitotic entry. ( A ) 
Immunofluorescence of PCNA 
( green ) and POLD1 ( red ) illustrating 
the effects of USP7 inhibition ( USP7i ) 
in replisome disassembly in MEF. DNA 
was stained with DAPI ( blue ). ( B ) 
Flow cytometry measuring CDK 
activity ( MPM-2 ) and DNA content 
( PI ) in cells exposed to USP7i, 
illustrating the generalised activation 
of CDK activity throughout the cell 
cycle in response to the inhibitor.
Figure 2 ERF deficiency is 
synthetically viable with the absence 
of RAS signalling. ( A ) Representative 
image of teratomas that are observed 
after injecting nude mice with mESC 
of the indicated genotypes ( RAS-less 
= deficient in H-, N- and K-Ras ). ( B ) 
Cell-Titer Glo assay in leukaemia-
derived KBM7 cells, illustrating the 
increased resistance of ERF-deficient 
cells to MEK inhibition.
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Our research focuses on a protein complex named cohesin 
that embraces DNA to mediate sister chromatid cohesion, a 
process essential for chromosome segregation and faithful 
DNA repair by homologous recombination. Cohesin also 
plays a major role in the spatial organisation of the genome by 
promoting long-range DNA looping, which in turn contributes 
to transcriptional regulation. Mutations in cohesin have been 
found in several tumour types, most prominently in bladder 
cancer, Ewing sarcoma and acute myeloid leukaemia. Germ 
line mutations in cohesin and its regulatory factors are also 
at the origin of human developmental syndromes collectively 
known as cohesinopathies.
Our goal is to understand how cohesin works, how it is 
regulated and how its dysfunction contributes to cancer and 
other human diseases. In particular, we are intrigued by the 
existence of different versions of the cohesin complex. We use 
human cells and mouse models carrying knock out alleles of 
genes encoding variant cohesin subunits to investigate their 
functional specificity.
“ We are dissecting the functional 
specificity of cohesin variant 
subunits to better understand 
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Cohesin consists of four core subunits, SMC1, SMC3, RAD21 
and SA. There are two versions of the SA subunit in vertebrate 
somatic cells, SA1 and SA2. Loss of function mutations in the 
STAG2 gene encoding SA2 have been identified in bladder 
cancer, Ewing sarcoma and myeloid malignancies, among 
others. In cells lacking cohesin-SA2, cohesin-SA1 performs 
the essential functions of cohesin related to cohesion. We 
suspect, however, that cohesin-SA1 cannot accomplish other 
functions of cohesin-SA2 related with chromatin organisation 
and gene regulation. Importantly, lack of cohesin-SA2 may 
also generate vulnerabilities that could be exploited in cancer 
therapy. We aim to identify the specific functions of the 
two variant complexes in chromatin architecture and gene 
regulation.
Dissecting the role of cohesin-SA1 and cohesin-SA2 
in human cells
We analysed the genome-wide distribution of the two variant 
cohesin complexes in several human cell lines and applied 
functional genomics to assess their enrichment in different 
regulatory elements as well as their co-localisation with other 
factors involved in genome organisation such as CTCF. We 
then addressed how this distribution changes when one or the 
other variant is missing and the subsequent alterations in the 
transcriptome and in chromatin organisation, analysed by Hi-C 
in collaboration with M. A. Marti-Renom ( CNAG-CRG ). Our 
results show that the two complexes fulfil different functions 
( FIGURE 1 ). Cohesin-SA1 is important for the organisation 
of the topological domains or TADs, which make up the global 
structure of the genome, and works always alongside the 
CTCF protein. In contrast, cohesin-SA2 is more versatile and 
is capable of interacting with diverse transcription factors to 
form local chromatin loops that bring together enhancers and 
promoters. Cohesin-SA2 is also more dynamic in its chromatin 
association, and a larger fraction of cohesin-releasing factor 
Wapl is found associated with SA2 than with SA1.
In the absence of cohesin-SA1, cohesin-SA2 can still cooperate 
with CTCF to demarcate contact domains although border 
strength is decreased. In the absence of SA2, however, cohesin-
SA1 cannot occupy the non-CTCF sites present at many 
enhancers. As a result, short-range, intra-domain contacts 
disappear while new, aberrant contacts are formed between 
neighbouring domains. These changes have more noticeable 
consequences for gene expression. Moreover, cohesin-SA2 is 
enriched at superenhancers, regulatory elements that control 
cell identity. Thus, the absence of this cohesin variant in 
tumour cells most likely alters their identity and/or affects 
cell differentiation.
Dissecting the role of cohesin-SA1 and cohesin-SA2 
in mice
We have generated a conditional Stag2 knockout allele in 
collaboration with Francisco X. Real ( CNIO ). Embryos 
lacking cohesin-SA2 die by mid-gestation and we are currently 
addressing the cause of this lethality. We are also using 
mouse embryo fibroblasts ( MEFs ) to further understand the 
specific contribution of cohesin-SA2 to cohesion and genome 
organisation. We observed loosened centromere cohesion and 
slower proliferation in the Stag2 deficient MEFs, consistent 
with reports in other cell lines ( FIGURE 2 ). However, the 
defects are milder than expected and are unlikely to be the 
sole cause of the embryonic lethality. Complementary to 
previous observations in Stag1 deficient MEFs, in which the 
distribution of cohesin changed to include new non-CTCF 
positions, the number of cohesin binding sites detected in 
Stag2 deficient MEFs is restricted to those overlapping with 
CTCF. This result is in line with the idea that cohesin-SA1 
cannot replace cohesin-SA2 at many non-CTCF sites, as 
described in human cells. Experiments aimed to identify the 
molecular determinants of the distinct behaviour of the two 
cohesin variants are underway. s
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Figure 2 Metaphase spreads of 
mouse embryo fibroblasts with 
( WT ) or without ( KO ) cohesin-
SA2 reveal loosened centromere 
cohesion in the latter. The “ tight ” and 
“ loose ” configuration of the sister 
centromeres in terms of cohesion is 
shown in the magnified chromosome 
at the bottom right.
Figure 1 Graphical summary of the 
distinct features of cohesin variant 
distribution and function in genome 
organisation in two cell types. TAD, 
topological associating domain 
encompassing several genes and 
demarcated by CTCF bound sites.
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Recent epidemiology studies indicate that up to two thirds 
of the mutations found in tumours are the consequence of 
inaccurate DNA replication ; the rest are inherited or caused by 
environmental factors. We study the process of DNA replication 
and its regulatory pathways, with a particular interest in the 
phenomenon of replicative stress ( RS ) caused by the temporal 
stalling or inhibition of the protein machinery responsible for 
DNA synthesis. In 2018, we focused on the following areas : 
( 1 ) the activation of ‘ dormant ’ replication origins in response 
to RS ; ( 2 ) the molecular connection between the speed of 
replication forks and the frequency of origin activation, the 
two main parameters affected by RS ; and ( 3 ) the function of 
PrimPol primase in ‘ replicative tolerance ’, i.e. the duplication 
of chemically damaged DNA molecules in order to facilitate 
their subsequent repair. We have also applied single-molecule 
methods to analyse the impact of RS in several biological 
processes.
“ We have developed a method to 
determine the primary cause of 
replicative stress as a necessary 
step towards the design of methods 
to restrict it in primary cells and/or 
enhance it in tumour cells.”
DNA REPLICATION GROUP Juan MéndezGroup Leader Staff ScientistsSusana Llanos, Sara Rodríguez Graduate StudentsElena Blanco, Daniel González, 
Patricia Ubieto
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Differential activation of replication origins upon 
replicative stress
Ten years ago, our laboratory reported that stalled replication 
forks induce the activation of extra origins as a backup 
mechanism to complete DNA replication. The genomic 
characteristics of these ‘ dormant ’ origins and their mode 
of activation remained largely unknown. We have now 
identified, in collaboration with Dr M. Gómez ( Centro de 
Biología Molecular “ Severo Ochoa ”, CSIC-UAM, Madrid ) 
and Dr V. Pancaldi ( formerly at CNIO ; currently at the 
Cancer Research Centre of Toulouse, CRCT ), the genomic 
positions and efficiency of activation of thousands of replication 
origins in mouse embryonic stem cells, in normal growth 
conditions or under stress to trigger extra origin activation. 
This comparative analysis has revealed that the vast majority of 
‘ stress-responsive ’ origins are active in a fraction of the control 
cell population, but their efficiency is significantly increased 
when stalled forks accumulate. The efficiency of activation of 
each individual origin correlates with its physical proximity to 
active or bivalent promoters, CpG islands, and the presence of 
‘ open chromatin ’ epigenetic marks. The integration of linear 
origin maps into 3D chromatin interaction networks reveals 
a hierarchical arrangement in which local clusters of origins 
are brought together by long-range chromatin interactions.
Cause and effect in replicative stress phenotypes
Replicative stress ( RS ) phenotypes are normally identified 
by specific nuclear patterns of markers γH2AX and RPA, 
but their detailed characterisation requires single-molecule 
analyses of fork speed and frequency of origin activation using 
DNA fibres. The interpretation of these assays is complicated 
because primary alterations in fork speed trigger the secondary 
activation of extra origins, and conversely, primary changes 
in the number of active origins also affect fork speed. We have 
designed interventions in which primary effects of RS on fork 
speed can be distinguished from primary effects on origin firing, 
and have applied them to our current research on PrimPol 
protein ( FIGURE ). Identifying the primary cause of RS may 
inform us about new methods to enhance it in cancer cells, 
increasing their susceptibility to chemotherapeutic agents 
that target DNA repair.
Primpol protein and its potential applications in cancer 
therapy
Besides Polα/primase, PrimPol is the only other primase in 
mammalian cells and it facilitates replication through damaged 
DNA templates. In 2018, we used Crispr/Cas9 technology to 
eliminate PrimPol expression in cancer cells, making them 
hypersensitive to DNA crosslinking agents. These results 
open the possibility of inhibiting PrimPol as a coadjuvant in 
chemotherapy. In collaboration with Dr L. Blanco ( Centro de 
Biología Molecular “ Severo Ochoa ”, CSIC-UAM, Madrid ), 
we have characterised a variant of PrimPol in which amino 
acid Tyr100 is changed to His, a mutation identified in certain 
types of lung cancer. Tyr100 mediates the enzyme selection 
of dNTPs over rNTPs, and Y100H is unusually proficient 
at using the latter, which may provide a cellular advantage 
during oncogenic transformation when the dNTP/rNTPs 
balance is disrupted.
Single-molecule analysis of DNA replication : shedding 
light on relevant biological processes
RS potentially impinges on all biological processes that involve 
cell proliferation. Over the past year, we participated in two 
collaborative projects to analyse RS in specific contexts. First, 
a study led by Dr I. Moreno de Alborán ( Centro Nacional 
de Biotecnología, CSIC-UAM, Madrid ), has uncovered the 
replicative defects linked to the loss of transcription factors 
c-Myc and Max during the differentiation of B lymphocytes. 
The second study, in collaboration with Dr G. Stoecklin 
( Heidelberg University ) and Dr O. Fernández-Capetillo 
( CNIO ), has led to the functional characterisation of TIAR, 
an RNA-binding protein that controls mitotic entry and is 
required for genomic stability. s
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Figure New methods to determine 
the primary cause of replicative stress. 
( A ) Test based on a CDC7 kinase 
inhibitor ( CDC7i ) to separate cause 
and effect when fork speed is reduced 
and origin density is increased. A 
complementary test can be applied 
in the opposite situation ( fork rate 
increased, origin density reduced ; 
not shown ). ( B ) CDC7i test applied 
to U2OS cells undergoing RS after 
PrimPol downregulation. In this case, 
RS is due to a primary defect in fork 
speed. Representative images of DNA 
fibres used to measure fork speed and 
origin usage are shown. Bar, 10 µm. 
Adapted from Rodríguez-Acebes et 
al. ( 2018 ).
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Melanomas are a prime example of how basic and translational 
research has been translated into improved prognosis for 
affected patients. Nevertheless, clinical responses are still 
incomplete. The long-term goals of our Group are to identify 
new progression biomarkers and therapeutic agents. Focusing 
on stress response programmes involving apoptosis, autophagy 
and endosome mobilisation, we have discovered lineage-
specific oncogenes that define the melanoma ‘ fingerprint ’. 
Transcriptomic and proteomic analyses of the melanoma 
secretome have enabled us to define how tumour cells 
remodel the ( lymph )angiogenic vasculature and avoid 
immune recognition. Moreover, we have generated a unique 
set of animal models for non-invasive imaging of melanoma 
progression in vivo. These systems have led to the validation 
of nanoparticle-based treatments that are currently being 
tested in clinical trials. Our ultimate objective is to improve the 
management of patients with otherwise refractory metastatic 
melanomas.
“ Combining a series of –omic 
studies with in vivo imaging in 
mouse models, we have identified a 
melanoma-associated signature of 
prometastatic genes that make this 
tumour uniquely aggressive.”
MELANOMA GROUP María S. SoengasGroup Leader Staff ScientistDavid Olmeda
Post-Doctoral Fellows
Paula Penacchi, Susana Frago
Graduate Students
Xavier Catena, Daniela Cerezo, Marta 
Contreras, Raúl Martínez, Cristina 
Tejedo
Technicians
Tonantzin Calvo, Estela Cañón ( TS )*
*Titulado Superior ( Advanced Degree )
Visiting Student
Davide Liccardo ( Universitá Degli 
Studi Della Campania Luigi Vanvitelli, 
Italy )
Clinical Collaborators
José L Rodríguez-Peralto ( Pathology, 
Hospital 12 de Octubre, Madrid ), 
Pablo Ortiz-Romero ( Dermatology, 
Hospital 12 de Octubre, Madrid )
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in Cancer Cell ( Cancer Cell, 2019 ), and were spotlighted on 
the cover of the journal.
‘ MetAlert ’ mice for the visualisation of premetastatic 
niches in melanoma and as a platform for gene discovery 
and target validation
We have also made great progress in regards to one of the most 
pressing needs in the melanoma field, namely, the mechanisms 
that enable melanoma cells to disseminate already from lesions 
of barely 1 mm in depth. Last year, we reported a series of 
mouse models of melanoma that have the unique feature 
of revealing how these cells act ‘ a distance ’ from very early 
stages of tumour development, activating the lymphatic 
vasculature and preparing metastatic niches before their 
colonisation ( Olmeda et al., Nature 2017 ). These ‘ MetAlert ’ 
animals, together with histological validation in patient 
biopsies, revealed the growth factor MIDKINE as a new driver 
of lymphangiogenesis and melanoma metastasis. We have now 
exploited the MetAlert mice for pharmacological analyses of 
anticancer agents. These studies revealed the dsRNA-based 
mimic BO-112 as potent blockers of neolymphangiogenesis 
and melanoma metastasis ( Olmeda et al. in preparation ). 
BO-112, a derivative of the polyplex BO-110 generated at the 
CNIO, is now being tested in Phase I clinical trials. s
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CNIO Melanoma Group : objectives and model systems
Melanomas are aggressive solid tumours and provide a prime 
example of how integrated basic and clinical research has 
significantly improved patient prognosis. Nevertheless, 
despite great successes achieved with targeted and immune-
based therapies, sustained clinical responses are still limited. 
Moreover, the field lacks molecular markers of diagnosis, and 
the knowledge on how melanomas progress and metastasise 
is largely incomplete. In addition, one of the main hurdles to 
advance in this disease is the lack of animal models to monitor 
melanoma initiation and progression in vivo. To this end, our 
Group focuses on 3 main objectives ( FIGURE 1 ):
 ɗ Aim 1. Oncogenic pathways selectively deregulated in 
melanoma that may represent new diagnostic indicators.
 ɗ Aim 2. Risk factors and prognostic markers.
 ɗ Aim  3. Animal models that allow for non-invasive 
monitoring of pre-metastatic niches.
Lineage-specific oncogenic dependencies in melanoma
One of the long-term objectives of the Melanoma Group 
is to discover new melanoma drivers. We have previously 
identified a cluster of endolysosomal-associated genes that 
distinguish melanoma from over 35 additional malignancies 
( Alonso-Curbelo et al., Cancer Cell 2014 ). Further analyses of 
lysosomal-dependent pathways also revealed unique features 
of autophagy genes ( ATG5 ) in melanoma ( García-Fernández 
et al., Autophagy 2016 ). Other melanoma-enriched regulatory 
mechanisms were identified by focusing on RNA binding 
proteins ( RBPs ). We selected RBPs because they are largely 
unexplored in melanoma. Performing a series of genome wide 
studies, we found novel roles of the RBPs CPEB4 and CUGBP1 
in the modulation of mRNA stability, with targets involving 
master specifiers of the melanocyte lineage ( Perez-Guijarro 
et al., Nat Commun 2016 ; Cifdaloz et al., Nat Commun 2017 ).
Most recently, we identified additional RBPs in a screen 
for modulators of melanoma progression. Specifically, we 
discovered a selected set of RBPs as unexpected binding 
partners of p62/SQSTM1, a factor we had selected for analysis 
based on previous reports in the literature linking this 
protein to autophagy. However, proteomic, transcriptomic 
and interactomic analyses showed that p62 was largely 
dispensable for autolysosome maturation in melanoma 
cells, again differentiating this disease from other tumour 
types. Instead, we found that p62 acts via a subset of RBPs, 
exemplified by CUGBP1, as a global coordinator of mRNA 
half-life of a spectrum of pro-metastatic factors. These 
include FERMT2 and other transcripts with no previous 
links to melanoma ( FIGURE 2 ). The relevance of these data 
is emphasised by follow-up analyses of patient prognosis 
revealing p62 and FERMT2 as adverse determinants of 
disease-free survival. These studies were recently published 
Figure 1 Main objectives of the CNIO 
Melanoma Group aimed to identify new 
progression biomarkers and validate 
more efficient anticancer agents. 
Indicated are main experimental 
systems and representative publications.
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Figure 2 New functions for pro-
metastatic drivers in melanoma. 
Schematic representation of a set 
of pro-tumourigenic factors with no 
previous links to melanoma identified 
by addressing the expression and 
functional requirement of p62/SQSTM1 
in this disease. Different from roles of 
p62 in autophagy described in a broad 
spectrum of types, this protein was 
found in melanoma to bind a selected 
set of RNA binding proteins ( RBPs ), 
here exemplified by CUGBP1. -Omic 
studies in cell lines combined with 
histopathological studies in genetically 
modified mouse models ( GEMM ) and 
histopathological validation in clinical 
biopsies identified the scaffolding factor 
FERMT2 as a downstream target of 
the p62-CUGBP1 axis. Both, p62 and 
FERTM2 were found overexpressed in 
advanced melanomas, representing new 
indicators of poor prognosis.
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Novel factors involved in melanoma progression, 
the future of liquid biopsies
In this project, we study the function of tumour-secreted 
exosomes in the establishment of pre-metastatic niches within 
the lymph node ( FIGURE ). We are analysing the role of the 
matrix-anchored proteins and neurotrophin receptors in 
lymph node metastasis and melanoma progression. We are 
also using novel biofluids ( e.g. lymph node exudative seroma 
obtained post-lymphadenectomy ) as a source of biomarkers, 
analysing protein cargo and BRAF mutations. Our laboratory 
is also interested in the study of microenvironmental factors 
influencing melanoma progression such as obesity.
Obesity modulates breast cancer behaviour
Obesity has drastically increased to become one of the most 
serious health problems worldwide and is now recognised 
as a risk factor for breast cancer incidence, progression, and 
prognosis. In this project, we aim to understand cellular and 
molecular mechanisms that underlie inflammation, obesity, 
and breast cancer metastasis. Furthermore, we are analysing 
the interaction of cancer cells with immune cells and platelets 
in metastasis and evasion of immune supervision. Our goal is to 
understand how obesity modulates breast metastatic behaviour 
defining novel factors involved and to define new therapies.
Defining novel targets in rare diseases
Malignant peripheral nerve sheath tumours ( MPNSTs ) are 
highly aggressive and metastatic sarcomas with poor prognosis 
that are commonly related to neurofibromatosis type 1 ( NF1 ) 
disease. In this project, we aim to find new biomarkers and 
novel therapeutic targets to prevent MPNST progression. The 
data obtained from a multidrug screening on MPNSTs cell 
lines and the mass spectrometry analysis of their exosomes 
identified several proteins as top candidates. Thus, we are 
currently testing the combination of MEK inhibitors, which 
are already used in the clinic, with novel drugs targeting these 
two proteins in order to define a new therapeutic window for 
MPNSTs. s
oVeRVieW
Cancer treatment is no longer only focused on tumour cell 
analysis. The Microenvironment and Metastasis Group studies the 
communication between tumour and stromal cells along tumour 
progression. Cancer treatment requires the analysis of the tumour 
microenvironment to define specific therapies targeting both the 
tumour and surrounding cells. Data support that combination of 
therapies against the tumour and its microenvironment are the 
future of cancer treatment. In our laboratory, we have focused on 
understanding the message of a novel ‘ language ’ between tumour 
cells and the environment ; these are small extracellular vesicles 
called exosomes. Our data support that tumour-secreted exosomes 
contain specific signatures of molecules ( e.g. proteins, DNA ). 
Exosomes secreted from the tumour can reach metastatic organs 
and prepare pre-metastatic niche formation, aiding metastatic 
homing and further metastatic progression.
“ Tumour-secreted exosomes are 
“ the forefront edge ” of tumour 
metastasis, they reach local 
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Nat Cell Biol 20, 332-343.
 ∞ Casanova-Acebes M et al. (incl. García -Silva 
S, Peinado H) ( 2018 ). Neutrophils instruct 
homeostatic and pathological states in 
naive tissues. J Exp Med 215, 2778-2795.
 ∞ Nogués L, Benito-Martin A, Hergueta-Re-
dondo M, Peinado H ( 2018 ). The influence 
of tumour-derived extracellular vesicles 
on local and distal metastatic dissemina-
tion. Mol Aspects Med 60, 15-26.
 ∞ Colletti M et al. (incl. Peinado H). Ex-
pression profiles of exosomal miRNAs 
isolated from plasma of patients with 
desmoplastic small round cell tumor. 
Epigenomics. PMID : 30569756.
 ∞ Di Paolo et al. (incl. Peinado H) ( 2018 ). 
Evaluation of Endoglin ( CD105 ) expres-
sion in pediatric rhabdomyosarcoma. 
BMC Cancer 18, 31.
 ∞ García-Rodríguez A et al. (incl. Peinado H) 
( 2018 ). Human prostasomes from normo-
zoospermic and non-normozoospermic 
men show a differential protein expression 
pattern. Andrology 6, 585-596.
 ∞ Robado de Lope L, Alcíbar OL, Amor 
López A, Hergueta-Redondo M, Peina-
do H. ( 2018 ). Tumour-adipose tissue 
crosstalk : fuelling tumour metastasis 
by extracellular vesicles. Philos Trans R 
Soc Lond B Biol Sci 373, pii : 20160485.
 ∞ PATENT
 ∞ García Silva S, Peinado H ( 2018 ). Im-
proved detection of BRAF V600 in 
post-operative Melanoma patient for 
prediction of residual disease and re-
lapse. US62664446.
Figure Analysis of the distribution 
of tumour-derived exosomes from 
B16-F10 melanoma cells ( red ) in GFP-
PROX mice ( lymphatic endothelial 
cells in green ), demonstrating 
that tumour-derived exosomes 
use the lymphatic vasculature to 
be transported from the injection 
site to lymph nodes. Image from 
collaborators Raghu Kataru and 
Babak Mehrara at the Memorial Sloan 
Kettering Cancer Centre.
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We pioneered the first report proving the importance of glial 
heterogeneity associated with metastatic brain tumours. 
As previously shown in other diseases affecting the brain, 
understanding the contribution of specific glial subpopulations 
could provide novel therapeutic targets.
The use of genetic and pharmacological approaches has 
enabled us to discover the critical role of this disease-specific 
subpopulation of reactive astrocytes in brain metastasis, 
which is characterised by activation of the STAT3 pathway. 
Its presence, induced by metastatic cells, involves the 
establishment of an immunosuppressive local environment 
that favours tumour growth.
In collaboration with four different national and international 
clinical institutions we have proved the importance of this 
finding in patients with brain metastasis. Treatment of stage 
IV lung adenocarcinoma patients with the STAT3 inhibitor 
silibinin reduced brain metastasis in 75% of them, which led to 
an increased survival. This finding involves a proof-of-concept 
regarding the possibility of developing effective therapies 
against metastasis by targeting the microenvironment. s
oVeRVieW
Brain metastasis is the most common neurological complication 
of cancer. When metastatic cells reach the brain, prognosis 
is poor given that local therapies ( i.e. surgery and radiation ) 
have limited benefits for patients and the disease inevitably 
progresses. The rise in the number of patients with brain 
metastasis is partially due to the increasing number of systemic 
therapies that work extra-cranially but are unable to provide 
the same therapeutic benefit in the brain. Consequently, cancer 
cells present at this secondary site have additional time to evolve 
and to grow into clinically detectable lesions. In the laboratory, 
we study why and how cells from different cancer types ( breast 
cancer, lung cancer and melanoma ) are able to access the brain, 
survive and colonise this vital organ. We dissect the biology of 
these processes in vivo using experimental models in order to 
challenge the current status of this unmet clinical need.
“ We have treated brain metastasis 
by targeting the microenvironment. 
We have used a novel therapy both 
in mice and in patients that reduces 
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astrocytes required for brain metastasis. 
Nat Med 24, 1024-1035. (*) Correspond-
ing author.
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 · Trends Mol Med. DOI : 10.1016/j.
molmed.2018.07.002.
 · Nat Rev Cancer. DOI : 10.1038/s41568-
018-0042-3.
 · Nat Rev Neurol. DOI : 10.1038/s41582-
018-0037-4.
 · Nat Medicine. https://www.nature.com/
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Agrawal S, Hu J, Griscom B, Rosenblum 
M, Boire A, Brogi E, Giancotti FG, Schach-
ner M, Malladi S, Massagué J ( 2018 ). Per-
icyte-like spreading by disseminated 
cancer cells activates YAP and MRTF for 
metastatic colonization. Nat Cell Biol 20, 
966-978. (*) Shared authorship.
See also :
 · Nat Cell Biol. DOI : 10.1038/s41556-
018-0162-8.
 ∞ Mustafa DAM, Pedrosa RMSM, Smid M, 
van der Weiden M, de Weerd V, Nigg AL, 
Berrevoets C, Zeneyedpour L, Priego N, 
Valiente M, Luider TM, Debets R, Martens 
JWM, Foekens JA, Sieuwerts AM, Kros 
JM ( 2018 ). T lymphocytes facilitate brain 
metastasis of breast cancer by inducing 
Guanylate-Binding Protein 1 expression. 
Acta Neuropathol 135, 581-599.
 ∞ Verdura S et al. (incl. Valiente M) ( 2018 ). 
Silibinin is a direct inhibitor of STAT3. 
Food Chem Toxicol 116 ( Pt B ), 161-172.
 ∞ Valiente M * et al. ( 2018 ). The evolving 
landscape of brain metastasis. Trends 
Cancer 4, 176-196. (*) Co-correspond-
ing author.
See also :
 · Review of the year by Trends in Cancer : 
http ://crosstalk.cell.com/blog/best-
reviews-we-published-in-2018-part-1.
 ∞ Preusser M et al. (incl. Valiente M) ( 2018 ). 
Recent advances in the biology and treat-
ment of brain metastases of non-small 
cell lung cancer : summary of a multidis-
ciplinary roundtable discussion. ESMO 
Open 3, e000262.
 ∞ AWARDS AND RECOGNITION
 ∞ Research Award, Royal Academy of 
Science, University of Zaragoza. Spain.
 ∞ Clinic and Laboratory Integration Pro-
gram ( CLIP ) Award, Cancer Research 
Institute, USA.
 ∞ Elected Member of the Scientific Com-
mittee of the European Association of 
Neuro Oncology.
 ∞ Keynote speaker at the Annual Congress 
of the European Society of Veterinary 
Oncology.
 ∞ Laura-Álvaro Espinosa was recipient of a 
MINECO-Severo Ochoa PhD Fellowship.
 ∞ Neibla Priego received the CNIO Award 
for Excellence in Research by Postdoc-
toral/Staff Investigators, CNIO Lab Day.
 ∞ Lucía Zhu received the ‘ Best Poster ’ 
Award at the CNIO Lab Day.
 ∞ STAT3 labels a subpopulation of reactive 
astrocytes required for brain metastasis, 
by Priego et al., was selected as paper 
of the month by the Spanish Society 
for Biochemistry and Molecular Biology.
Figure A subpopulation of reactive 
astrocytes ( GFAP ), characterised 
by activated STAT3 ( pSTAT3 ), 
is present in experimental brain 
metastasis models (  a,b ) and 
human samples ( e,f ). Targeting this 
glial subpopulation in mice ( c ) and 
humans ( g ) impaired the viability 
of intracranial metastasis. pSTAT3 
reactive astrocytes are required to 
maintain a pro-metastatic niche ( d ).
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Nutrient signalling in B cell lymphoma
One of the most rapid proliferation bursts in mammalian 
cells is that of B lymphocytes upon encountering certain 
pathogens or antigens. This proliferation suddenly multiplies 
the energetic and metabolic demands of the activated B cell 
and, accordingly, precise nutrient sensing and signalling are 
key to successfully accomplish the energetically onerous 
rounds of growth and division. Recently, components of the 
Rag GTPase pathway, a key nutrient signalling pathway that 
enables the anabolic capacity of the cell for rapid proliferation, 
were found mutated in follicular lymphoma ( FL ), an incurable 
B lymphocyte tumour. By means of novel strains of mice that 
express mutant variants of the RagC GTPase, we found that 
subtle increases in nutrient signalling unleash activation 
and proliferation of B cells, suppress cell death and drive the 
development of FL ( FIGURE ). These results pave our way 
towards a novel therapeutic strategy against B cell lymphoma, 
aimed at targeting its corrupted nutrient signalling. In addition, 
and surprisingly, this mild increase in the signalling of nutrient 
abundance in B lymphocytes also drives an autoimmune 
disease.
Chronic signalling of elevated nutrients and premature 
ageing
The study of genetically engineered mice expressing a mildly 
activating form of RagC revealed that, in the absence of 
lymphoma, these mice suffer from symptoms and pathologies 
consistent with premature ageing, including a shortened 
lifespan ( FIGURE ). While caloric restriction ( CR ) and other 
fasting-like regimes are well-known to delay ageing, as is also 
the case with the pharmacological inhibition of mTOR with 
rapamycin in mammalian model organisms, this is the first 
time that a moderate increase in nutrient signalling in mice 
shows compromised longevity. We are currently investigating 
the cellular and molecular alterations responsible for this 
shortening of the life span. s
oVeRVieW
In the Metabolism and Cell Signalling Lab we study the 
interplay of nutrients, metabolism and cancer. Every cell in 
the organism integrates signals emanating from the abundance 
of intracellular nutrients and from the nutritional state of 
the organism as a whole. Integration of cellular and systemic 
nutrient abundance cues is key for adequate cellular and 
organismal functions, and importantly, the components of 
these signalling cascades are generally corrupted in disease 
states, such as cancer. Together with genetic mutations, 
environmental perturbations (such as those occurring in 
obesity) corrupt the cellular signalling cascades that control the 
responses to nutrients and hormones. In the lab, we combine 
mouse genetics and cell biological tools to gain insight into the 
genetic and environmental corruptions of nutrient signalling 
cascades, aiming to conceive therapeutic interventions in the 
context of cancer, obesity and the process of ageing.
“ Mouse models with a very 
mild genetic activation of 
nutrient signalling foster cancer, 
autoimmunity, and ageing; this has 
profound implications when thinking 
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Figure (  A, B & C ) Readouts of 
enhanced B lymphocyte activation 
in RagC mutant mice. ( D & E ) Bred 
to the VavP-BCL2 strain ( prone to 
lymphoma and autoimmunity ), RagC 
mutant mice exhibit accelerated 
lymphomagenesis and autoimmune 
disease. ( F ) Lifespan consistent with 
accelerated ageing of RagC mutant 
mice.




ERWIN F. WAGNER Programme Director
The overall strategic goals of the Cancer Cell Biology 
Programme are to achieve a better understanding of the events 
leading to cancer development, progression and metastasis, 
and to discover molecular mechanisms that could provide 
a basis for novel therapies. The 4 Groups investigate how 
tumours grow as ‘ external organs ’ in close interaction with 
tumour - associated cells. The spectrum of investigations 
ranges from epithelial cancers such as liver, pancreas, skin 
and intestine, to bone and brain tumours. The research covers 
aspects of tumour cell biology, ranging from tumour stem cells, 
tumour cell interactions with host cells/environment such as 
tumour-associated macrophages and fibroblasts, to the role of 
inflammation, metabolism and metastasis. Powerful state-of-
the-art mouse genetic models, human cellular systems, high-
throughput genomic/proteomic and biochemical tools, as well 
as patient-derived materials, are employed. These aspects are 
successfully covered by the complementary research areas 
of 3 Senior and 1 Junior Groups.
The Senior Group, led by Francisco X. Real, studies epithelial 
tumours focusing mainly on pancreatic and bladder cancer. 
The Group employs an integrative approach to understand 
the molecular patho-physiology of these tumours and 
applies this knowledge in the clinical setting. Real’s Group, 
with contributions from the Wagner lab, made an important 
discovery demonstrating an inflammatory transcriptional 
switch in pancreatic cancers involving the nuclear receptor 
NR5A2 and Jun/AP. Nabil Djouder’s Group aims to dissect the 
contribution of various environmental stressors, including 
the nutrient and growth factor signalling pathways, to cancer 
development and associated diseases, in particular related to 
the gastro-intestinal tract. Massimo Squatrito’s Group, which 
is partly supported by the Seve Ballesteros Foundation, studies 
how brain tumours, mainly glioblastomas, develop and how 
they respond to therapy. Finally, my own Group focuses on 
understanding the role of the transcription factor complex 
AP-1 ( Fos/Jun ) in physiological and pathological processes, 
with a strong focus on aspects of inflammation and cancer in 
liver, lung, skin and bone. We also investigate the role of AP-1 
in inflammatory skin diseases, such as psoriasis, and aim to 
molecularly define the causes leading to lung fibrosis. We have 
continued to study how the whole organism responds to a 
locally growing tumour in the context of a complex immune-
metabolic impairment in cancer-associated-cachexia.
“ Our main goal is to keep 
CNIO globally competitive 
and to ensure that CNIO 
remains an international 
institution. Members of 13 
different nationalities 
from 4 continents are 
represented in our 
Programme with the goal 
to perform top-level cancer 
cell biology as well as to 
train students and postdocs 
to become the next-
generation of promising 
scientists.”
canceR cell Biology PRogRaMMe
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Our studies aim to analyse gene function in healthy and 
pathological conditions, e.g. in tumour development, using 
the mouse as a model organism, but also employing patient-
derived samples. Specifically, the functions of the AP-1 ( Fos/
Jun ) transcription factor complex regulating cell proliferation, 
differentiation and oncogenesis, as well as the cross-talk 
between organs, are being investigated. The goal is to define 
molecular pathways leading to disease/cancer development 
and to identify novel therapeutic targets ( FIGURE ). We focus 
on :
 ɗ Elucidating a causal link between inflammation, cancer 
and AP-1 ( Fos/Jun ) expression, using cell type-specific, 
switchable genetically engineered mouse models ( GEMMs ).
 ɗ Developing and characterising new GEMMs for cancer 
and human diseases, such as bone loss, arthritis, fibrosis 
and psoriasis, and applying these to preclinical studies.
 ɗ Using multiple approaches to compare mouse models of 
disease to human disease and to identify therapeutically 
relevant targets.
 “ Our goal was for the CNIO 
to remain an international and 
competitive institution. At present, 
3 out of 4 Group Leaders in our 
department are foreigners, one 
of whom is partly funded by the 
Seve Ballesteros Foundation. 
Thirteen different nationalities 
from 4 continents are testimony 
to an international science culture, 
all focussing on unravelling 
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Cancer-associated cachexia ( CAC )
CAC is a complex wasting syndrome characterised by loss of 
muscle and fat along with ‘ browning ’, a switch from white to 
brown fat, as previously described. Our aim is to understand 
the systemic events taking place in CAC and to identify novel 
biomarkers and therapeutic targets. Systemic inflammation is 
a consistent event in CAC with innate immune cells, such as 
neutrophils, as a major cell type. Interestingly, Lipocalin-2, an 
adipokine important in innate immunity is highly upregulated 
in CAC and may be a potential new biomarker. We found that 
CAC is not prevented in a neutropenic situation suggesting that 
neutrophils may not be the key factor. Ongoing studies show 
that the Renin-Angiotensin-Aldosterone System ( RAAS ) is 
dysregulated in CAC in humans and mice, potentially leading 
to cardiac dysfunction. We are now dissecting, in mice and 
in human CAC samples, the involvement of the central and 
peripheral nervous system, the RAAS as well as the tissue-
specific role of Ucp-1 ( in collaboration with R. Señarís, Spain, 
M. Petruzzelli, UK, H. Watzke, M. Poglitsch, P. Benedikt and 
R. Zechner, Austria ).
Fra-2 in lung fibrosis and cancer
Lung fibrotic diseases and non-small cell lung cancer 
( NSCLC ) lack effective treatments and lead to high mortality. 
Using GEMMs we found that Fra-2, an AP-1 transcription 
factor, contributes to both diseases. Fra-2 expression is 
increased in lung fibrosis patient samples and correlates 
with poor survival in human NSCLC. In lung fibrosis, Fra-2 
is associated with macrophage-specific expression of Type VI 
collagen in a type2 immune response and mediates disease 
progression, while in NSCLC, Fra-2 promotes growth in 
K-Ras-mutated tumours. We aim to find new therapeutic 
targets and potential disease biomarkers downstream of 
AP-1. The lung fibrosis studies are conducted in collaboration 
with Acceleron Pharma ( USA ), and the cancer studies with 
Mariano Barbacid’s and Luis Paz-Ares ’ Groups at CNIO and 
Silvestre Vicent in Pamplona.
Skin inflammation, cancer and human disease
Characterisation of the systemic inflammatory disease 
in epidermal-deficient JunB GEMMs indicated a skin 
inflammation to bone cross-talk by Il-17A-mediated 
inhibition of Wnt signalling in osteoblasts. These mice also 
suffer from dysbiosis and chronic S. aureus colonisation, 
which is exacerbated in the absence of adaptive immunity. 
We have also generated several GEMMs to define the role of 
the antimicrobial proteins ( AMPs ), such as S100A8/A9 and 
Lipocalin-2, in inflammatory skin diseases with a focus on 
the systemic effects beyond the skin.
Using lineage tracing in the psoriasis-like mouse model, 
we found that mutant epidermal stem cells ( ESCs ) initiate 
epidermal hyperplasia and skin inflammation by priming 
neighbouring non-mutant epidermal cells to acquire a 
psoriasis-like phenotype. Mechanistically, TSLP neutralisation 
reduces non-mutant keratinocytes proliferation and VEGFα 
expression, an important pro-inflammatory mediator in 
psoriasis. These findings unravel specific roles of epidermal 
populations in psoriasis-like disease and provide novel 
mechanistic insights into epidermal cell interactions under 
inflammatory conditions.
It has been suggested that psoriatic patients have decreased 
skin cancer risk. Using our psoriasis-like mouse model and 
the well-established DMBA/TPA chemical carcinogenesis 
protocol, we observed that psoriasis-like mice with severe 
phenotype have a significant decrease in DMBA/TPA-
induced skin papillomas compared to controls. Detailed 
characterisation suggests that in the context of chronic skin 
inflammation, elevated expression of senescence markers 
may modulate papilloma formation. s
ReseaRch highlighTs
We have developed a powerful technology for switchable, 
reversible and tissue-specific ectopic gene expression of 
specific AP-1 monomers/dimers in the liver, lung, skin and 
bone. We use mouse and human tissue samples for large-scale 
studies, such as deep sequencing ( RNA-Seq, ChIP-Seq ) and 
mass spectrometry analyses. We evaluate possible biomarkers 
and therapeutic approaches in small-scale preclinical studies 
based on these screens.
Bone development, osteosarcomas and arthritis
We are studying the function of AP-1 proteins in bone 
development and disease using loss-( LOF ) and gain-of-
function mouse models. In mice, transgenic c-Fos expression 
leads to osteosarcomas ( OSs ). Using an inducible bone-specific 
Wntless LOF GEMM, we found that loss of Wnt signalling 
delays Fos-induced OS development. Our data also demonstrate 
that increased Wnt7b and Wnt9a and non-canonical Wnt 
signalling are causally involved in OS.
Rheumatoid, Psoriatic and Osteoarthritis ( OA ) are destructive 
joint pathologies linked to chronic inflammation. Using cell 
type-specific and inducible AP-1 LOF mouse models, combined 
with experimental arthritis models, we found that c-Fos is a 
key regulator of surgery- and age-induced OA.
Using mice with inducible epidermal deletion of JunB and 
cJun ( DKO *) that develop skin inflammation and a psoriatic-
arthritis-like ( PsA ) disease, we aim to elucidate potential 
therapeutic targets to alleviate skin and joint inflammation. 
We previously identified the S100A8/A9 complex as highly 
elevated in our GEMM as well as in human psoriatic skin 
samples. We have now generated new DKO *-GEMM with 
epidermal and global deletion of S100A9 to determine the 
specific role of keratinocyte-derived and neutrophil-derived 
S100A9 in skin or joint inflammation.
Liver disease—metabolism, fibrosis, inflammation 
and cancer
AP-1 proteins are important modulators of hepatic lipid 
metabolism as specific AP-1 dimers can either activate or 
repress PPARγ transcription. Therefore, fatty liver disease 
and obesity most likely depend on AP-1 dimer composition. 
In addition, ectopic expression of specific Fos or Fra-2, but 
not Fra-1-containing AP-1 dimers in hepatocytes, leads to 
liver dysplasia, inflammation, fibrosis and tumours with 
HCC signatures. Mechanistically, molecular analyses 
point to the involvement of pathways connected to human 
hepatocellular carcinoma ( HCC ), such as the Wnt/ß-catenin 
and Myc pathways and/or to altered cholesterol and bile acids 
metabolism. A robust connection between c-Fos expression and 
the activity of the LXR/RXR pathway, an important regulator 
of cholesterol homeostasis, was unravelled and most likely 
contributes to the oncogenic function of c-Fos in hepatocytes. 
We are currently testing whether any of the pathways we 
discovered can be exploited therapeutically to treat liver 
cancer in preclinical models.
 ∞ PUBLICATIONS
 ∞ Cobo I, Martinelli P, Flández M, Bakiri L, 
Zhang M, Carrillo-de-Santa-Pau E, Jia 
J, Sánchez-Arévalo Lobo VJ, Megías 
D, Felipe I, Del Pozo N, Millán I, Thom-
mesen L, Bruland T, Olson SH, Smith J, 
Schoonjans K, Bamlet WR, Petersen 
GM, Malats N, Amundadottir LT, Wag-
ner EF, Real FX ( 2018 ). Transcriptional 
regulation by NR5A2 links differentia-
tion and inflammation in the pancreas. 
Nature 554, 533-537.
 ∞ Linder M, Glitzner E, Srivatsa S, Bakiri L, 
Matsuoka K, Shahrouzi P, Dumanic M, 
Novoszel P, Mohr T, Langer O, Wanek T, 
Mitterhauser M, Wagner EF and Sibilia 
M ( 2018 ). EGFR is required for FOS-de-
pendent bone tumor development via 
RSK2/CREB signalling. EMBO Mol Med 10, 
pii : e9408.
 ∞ Galluzzi L et al. ( incl. Wagner EF ) ( 2018 ). 
Molecular mechanisms of cell death : 
recommendations of the Nomenclature 
Committee on Cell Death 2018. Cell Death 
Differ 25, 486-541.
 ∞ Linder M, Hecking M, Glitzner E, Zwerina 
K, Holcmann M, Bakiri L, Ruocco MG, 
Tuckermann J, Schett G, Wagner EF, 
Sibilia M ( 2018 ). EGFR controls bone 
development by negatively regulating 
mTOR-signaling during osteoblast differ-
entiation. Cell Death Differ 25, 1094-1106.
 ∞ Luo Y, Grötsch B, Hannemann N, Jimen-
ez M, Ipseiz N, Uluckan O, Lin N, Schett 
G, Wagner EF, Bozec A ( 2018 ). Fra-2 
expression in osteoblasts regulates 
systemic inflammation and lung injury 
through osteopontin. Mol Cell Biol 38, 
pii : e00022-18.
 ∞ Riedel M, Berthelsen MF, Bakiri L, Wagner 
EF, Thomsen MK ( 2018 ). Virus delivery 
of CRISPR guides to the murine prostate 
for gene alteration. J Vis Exp 134, e57525.
Figure Tet-switchable AP-1 transgenic 
mice were generated for ectopic 
expression of specific AP-1 monomers/
dimers in skin, bone, liver and lung, which 
are complemented by loss-of-function 
mouse models. Proteomics, expression 
profiling, RNA-sequencing and ChIP-
sequencing are employed to compare 
mouse models to human disease and to 
identify novel targets. Furthermore, we 
are investigating the systemic response 
of the mouse organism to a growing 
tumour in cancer cachexia. Preclinical 
studies are performed using different 
genetically engineered mouse models 
( GEMMs ) with compounds that target 
the identified molecules to determine 
the potential of translating our findings 
for the treatment of human disease.
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We focus on the molecular pathophysiology of pancreatic ductal 
adenocarcinoma ( PDAC ) and urothelial carcinoma ( UC ), with 
a disease-oriented approach. We use patient samples, cultured 
cells, and genetically modified mice, giving a similar weight 
to the 3 model systems. Observations made at either of these 
levels are then extended through additional work. To translate 
the findings, we bring this knowledge to a ‘ population ’ level 
leveraging on information and samples from large patient 
cohorts.
In PDAC, a main hypothesis is that cell differentiation is a potent 
tumour suppressor mechanism acting early in carcinogenesis. 
We use the excellent genetic mouse models available because 
these processes cannot be readily studied in humans. In mice, 
PDAC can originate in pancreatic progenitors and in adult 
acinar and ductal cells. Understanding the contribution of 
early molecular events is crucial to design better strategies 
for early tumour detection and prevention in subjects at risk.
In UC, we focus on identifying new genes, using them for 
improved tumour taxonomy, characterising the mechanisms 
of action, and applying this knowledge for improved prediction 
of outcome and therapy.
“ We have shown that, in the 
pancreas, the control of cell 
differentiation and the suppression 
of inflammation depend on similar 
transcriptional regulators indicating 
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Our studies with patient samples have provided novel markers 
predictive of response to cisplatin-based chemotherapy and 
are guiding the design of novel clinical trials with targeted 
therapies and immune checkpoint inhibitors in collaboration 
with N. Malats, A. Font, D. Castellano, and an extended group 
of Spanish uro-oncologists. s
ReseaRch highlighTs
Pancreas cancer molecular pathophysiology
The genetic/genomic changes associated with PDAC have 
been extensively described over the last few years by the 
genome consortia, but the contribution of precursor lesions 
and the molecular changes that precede tumour development 
are less well established. Our lab has pioneered the notion 
that incomplete acinar cell differentiation is associated with 
a scenario of pre-inflammation or inflammation and with 
predisposition to PDAC development using mutant KRas-
driven genetic mouse models. These studies provide the basis 
for the pharmacological – or genetic - manipulation of acinar 
differentiation as a tumour preventative strategy.
NR5A2 is an orphan nuclear receptor for which putative 
endogenous ligands as well as pharmacological agonists 
have recently been identified. In mice, Nr5a2 germline 
heterozygosity is associated with a pre-inflammatory 
state that sensitises the mice to the oncogenic effects of 
mutant KRas. Deletion of one Nr5a2 allele is sufficient to 
cause a striking genomic redistribution of the protein in 
cooperation with AP-1 components. To further explore how 
this occurs, we have analysed the NR5A2 interactome using 
immunoprecipitation and mass-spectrometry. We find that 
reduction of NR5A2 protein levels by 50% ( either genetically or 
during pancreatitis ) is also associated with profound effects on 
the interactome, highlighting the relevance of subtle changes 
in protein dosage in cells ; one of the proteins identified is the 
ubiquitous transcription factor NFIC ( FIGURE 1A,B ). At the 
transcriptomic level, Nfic-/- pancreata display a mild defect in 
acinar cell maturation as well as a significant down-regulation 
of the protein synthesis machinery. NFIC is a novel regulator 
of acinar differentiation playing an important role in the 
endoplasmic reticulum stress response. Similar to knockouts of 
other genes coding for proteins involved in acinar homeostasis, 
constitutive Nfic-null mice developed significantly more 
PanINs in a mutant KRAS context. The function of NFIC in 
acinar cells appears to be highly conserved between mice and 
humans ( FIGURE 1C ).
Urothelial carcinoma ( UC ) genetics, biology, and clinical 
translation
We are interested in refining our understanding of new genes 
involved in UC, using organoids to unravel their function, and 
to apply this knowledge in the clinical setting.
Through exome sequencing we identified mutations in STAG2, 
coding for a cohesin subunit, and in RBM10, coding for a 
splicing regulator, as new UC genes that are more broadly 
involved in human cancer. We have generated conditional 
mouse models for these two genes and are exploring their 
role in development and urothelial biology as well as their 
cooperation with other bladder cancer genes.
RBM10 somatic mutations occur in several epithelial tumour 
types, including UC. Germline RBM10 mutations are associated 
with TARP syndrome. Our preliminary studies indicate that 
Rbm10-null mice recapitulate facets of this developmental 
condition. We have generated Rbm10-null normal urothelial 
organoids and are characterising their biological features. In 
addition, we collaborate with J. Paramio ( CIEMAT, Madrid ) 
to identify how tumour cells bypass growth requirements in 
organoid cultures. Also, through single-cell RNA-Seq, we are 
identifying urothelial cell populations that could shed light 
on the cell of origin of UC.
In collaboration with J. Valcárcel ( CRG, Barcelona ), we are 
analysing the mechanisms through which RBM10 contributes 
to UC development using a combination of cellular, molecular 
and bioinformatics approaches. In addition, we are assessing 
whether RBM10-mutant tumours display specific therapeutic 
vulnerabilities using a variety of experimental strategies.
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Figure 1 The NR5A2 interactome 
is dynamic and reveals novel players 
involved in acinar homeostasis. 
( A ) NR5A2 interactors identified 
by immunoprecipitation with 
anti-NR5A2 antibodies and mass 
spectrometry using pancreatic 
tissue from wild type mice in basal 
conditions ( Nr5a2+/+ 0h ), or 1 h 
after administration of one dose 
of caerulein ( Nr5a2+/+ 1h ), and from 
Nr5a2 heterozygous mice in basal 
conditions ( Nr5a2+/- 0h ). ( B ) NFIC is 
a novel NR5A2 interactor identified 
in all three analysed settings. ( C ) 
Genesets including differentially 
expressed genes ( DEG ) in the 
pancreas of young Nfic-/- vs. wild 
type mice : down-regulated genes 
are expressed at significantly 
lower levels in normal pancreas 
from subjects with low levels of 
NFIC ( comparison of lower vs top 
decile of NFIC mRNA expression ) 
( in collaboration with F. García and 
J. Muñoz, CNIO Proteomics Unit ).
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Our laboratory devotes effort to understand the molecular 
mechanisms linking environmental stresses to disease 
pathogenesis. Research in the last decade has focused mainly 
on understanding the functions and roles of newly discovered 
mutated genes in the development of cancer and associated 
disorders. However, the exposure to environmental factors, 
through the regulation and expression of virulent eukaryotic 
proteins, has often been an ignored permanent challenge for 
an organism.
Based on the integration of experimental mouse models, 
combined with the use of state-of-the art technologies and 
human data, we aim to provide a comprehensive study 
for a rational approach towards the development of novel 
mechanism-based therapies to prevent and treat diseases.
 “ We aim to understand mechanisms 
of disease by generating new 
mouse models that recapitulate 
pathological features of human 
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Poor diets ( under-nutrition, micronutrient deficiencies, 
over-nutrition, high-fat and low-fibre diets, etc.), alcohol 
consumption, ionising radiation, bacteria and virus infections, 
etc., are risk and pathogenic factors for disease development. 
How these environmental factors can alter the host’s eukaryotic 
epithelial cells to cause various pathologies, potentially 
progressing to cancer, remains largely unknown. Finding new 
genes affected by environmental stressors, and understanding 
their functions and role in disease development, may pave 
the way for future therapies. In our lab, we therefore focus on 
the identification and understanding of mechanisms of likely 
causal links between environmental stresses and pathologies 
in order to develop new preventive and therapeutic options.
Unconventional prefoldin RPB5 interactor ( URI )
The responses of eukaryotic cells to a variety of environmental 
stresses involve changes in the expression profile of 
molecular chaperones. These chaperones are essential to 
engage protective mechanisms to ensure cellular and protein 
homeostasis caused by injurious environmental stimuli. In 
our lab, we focus on studying the roles and functions of the 
unconventional prefoldin RPB5 interactor ( URI ), a member of 
the prefoldin chaperone family, whose expression is modulated 
by various pathogenic environmental factors. Principally, 
lessons from genetically engineered URI gain- and loss-of-
function mouse models taught us that high URI expression 
may lead to uncontrolled protein substrate regulation, and 
decreased URI may induce over-functioning of protein clients 
− both conditions may lead to various pathologies.
Microspherule protein 1 ( MCRS1 )
We also recently discovered MCRS1 ( Microspherule protein 1 ) 
with scaffolding activities regulating mTORC1 activity in 
response to amino acids.
Mechanisms of gastrointestinal tract disease
Our interest is therefore driven by the discovery of URI and 
MCRS1 proteins, both regulated by environmental stressors, 
which may compromise their functions and activate pleiotropic 
circuits supporting non-oncogene addiction functions and 
dependence, provoking severe outcomes. Using URI and 
MCRS1 mouse models generated in our lab, combined with 
cutting-edge technologies, we are studying mechanisms of 
disease predominantly associated to the gastrointestinal tract, 
often related to pathogenic environmental factors ( ionising 
radiation, bacteria, viruses and poor diet ), with the objective 
of developing new strategies for treatment. Our research is 
mainly focussed on the study of intestinal, gastric, pancreatic 
and liver disorders ( FIGURE ).
In this regard, we made the following discoveries :
 ɗ Inflammatory cues up-regulate hepatic URI, which inhibits 
de novo NAD+ synthesis causing DNA damage and thereby 
initiating hepatocellular carcinoma ( HCC ). Replenishing 
the pools of NAD+ by using nicotinamide riboside prevents 
HCC. Our data suggest that metabolic alterations initiate 
tumorigenesis prior to genomic instability.
 ɗ Nutrient overload increases hepatic URI, which results in 
NAD+ deficit-induced DNA damage that activates metabolic 
inflammation-associated IL-17A to cause non-alcoholic 
steatohepatitis ( NASH ) and HCC. Boosting NAD+ by using 
nicotinamide riboside or blocking IL-17A axis prevents 
NASH and HCC.
 ɗ Hepatocellular carcinoma originates from transformed 
hepatocytes, whereas hepatic progenitor cells give rise 
to benign lesions including regenerative nodules and 
adenomas.
 ɗ Cells exposed to prolonged inadequate glucose 
concentrations elicit first a protective and adaptive response 
to optimise glucose utilisation and suppress death, in order 
to give to the cells an opportunity to recover from metabolic 
stress. OGT regulation by URI is a sophisticated mechanism 
conferring c-MYC-dependent survival functions in response 
to glucose fluctuations.
 ɗ MCRS1 has oncogenic and tumour suppressive activities 
by regulating mTORC1. Inhibition of mTORC1 via MCRS1 
deletion in the intestine protects from APC loss-dependent 
tumorigenesis, whereas it promotes colitis-induced 
colorectal cancer ( CRC ). Our work reveals mTORC1 
oncogenic and tumour-suppressive roles in intestinal 
epithelium and avenues to optimised and personalised 
therapeutic regimens for CRC.
We intend to make significant progress over the next few 
years in order to elucidate mechanisms of disease associated 
to the digestive system. This will be made possible thanks to 
the specific environment at the CNIO providing state-of-the-
art facilities and access to key technological platforms with 
advanced technologies, as well as the availability of various 
genetically engineered mouse models generated in our lab, 
patient-derived xenograft models, organoids, cell biological 
and biochemical techniques, and the large number of omics 
and human data. s
Figure Representation of our 
research directive. Our lab is mainly 
interested in understanding how 
pathogenic environmental factors 
lead to disease associated to the 
gastrointestinal tract. Molecular 
chaperones are essential to engage 
protective mechanisms to ensure 
cellular and protein homeostasis 
caused by injurious environmental 
stimuli. Environmental stress 
modulates thus URI and MCRS1 
expressions to maintain cellular 
homeostasis or cause disease 
development.
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Novel therapeutic approaches for therapy-resistant 
malignant brain tumours
The standard therapies for GBM patients, IR and Temozolomide 
( TMZ ), generate double-strand DNA breaks ( DSBs ), which are 
the most deleterious form of DNA damage. The DSBs are then 
responsible for the initiation of the DNA Damage Response 
( DDR ) and consequently the activation of DNA repair pathways 
and cell-cycle checkpoints. We have previously presented 
evidence that alterations in key DNA repair and checkpoint 
proteins can modulate the GBM treatment response.
The DDR signalling is a very intricate pathway and many of its 
elements can be altered in a given tumour patient, offering both 
challenges and opportunities from a treatment perspective. 
Loss of components of a specific DNA repair pathway might 
be balanced by the increased activity of other components or 
pathways. Upregulated DNA repair pathways could lead to 
resistance to radiotherapy and DNA-damaging chemotherapy, 
therefore inhibitors of these pathways could potentially 
increase the sensitivity of the cells to these therapies. By 
contrast, pathways that are lost represent weaknesses in 
the DNA repair ability of the tumour cell and they could be 
exploited by choosing a suitable chemotherapy to induce 
unrepairable ( more toxic ) DNA damage. It is estimated that 
the efficacy of radiotherapy and chemotherapy would be 
improved if tumour cells could be rendered more sensitive 
without altering the sensitivity of normal tissues.
Through different functional genetic studies, we have 
observed that defects in components of the Mismatch 
Repair ( MMR ) system are significantly associated with 
resistance to TMZ. Moreover, we have discovered that 
chromosomal rearrangements of the O-6-methylguanine-
DNA methyltransferase ( MGMT ) lead to overexpression 
of MGMT and contribute to TMZ resistance, both in high-
grade and low-grade gliomas. Most importantly, we have 
identified another alkylating agent that is able to overcome 
these resistance mechanisms and that has a synergistic effect 
when used in combination with TMZ ( FIGURE ). s
oVeRVieW
Glioblastoma ( GBM ) is the most common and lethal 
primary central nervous system tumour in adults. Despite 
the recent advances in treatment modalities, GBM patients 
generally respond poorly to all therapeutic approaches and 
prognosis remains dismal. Radiation and chemo-resistance 
are characteristic of various cancer types, however it is not 
clear if this therapy resistance is a consequence of tumour 
progression or if it is intrinsically associated with the genetic 
events that lead to tumour formation in the first place. Gaining 
insights into the pathways that determine this poor treatment 
response will be instrumental for the development of new 
therapeutic modalities.
In our laboratory, we use a variety of approaches − both genetic 
and small molecule drug screenings − coupled with in vivo 
GBM mouse models in order to identify genes involved in 
therapy resistance of gliomas. We reason that these studies 
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“ The current most effective 
treatment for GBM patients is a 
combination of radiotherapy and 
alkylating agents. Increasing the 
sensitivity of the tumour cells to 
these therapies will possibly extend 
the survival of the patients.”
Figure Overcoming TMZ resistance. 
( A ) Silencing of MMR component 
( MSH2 and MSH6 ) leads to resistance 
to TMZ ( left ) but not to the novel 
alkylating drug ( right ). ( B-C ) TMZ 
and Drug-X have synergistic effects 
both in vitro ( B ) and on brain-tumour 
slices cultured ex-vivo ( C ).
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STRUCTURAL BIOLOGY  
PROGRAMME
ÓSCAR LLORCA Programme Director
Programme’s research areas and strategic goals
The aim of the Structural Biology Programme ( SBP ) is to 
provide mechanistic understanding at the molecular level of 
how proteins and macromolecular complexes related to cancer 
function. The ultimate goal is to use the new mechanistic 
insights, and the solved structures, to help guide the search 
for new compounds and molecules that could interfere with 
the function of these complexes. Our current research focuses 
on the study of protein kinases and the DNA damage response. 
SBP undertakes this thanks to the multiple technologies 
available via CNIO’s Units and Research Groups and through 
the constant lookout for synergies with other CNIO groups. 
This year a focus was placed on setting up cryo-electron 
microscopy ( cryo-EM ) methods at SBP, a revolutionary 
technology to observe individual macromolecules at high 
resolution that is reshaping biological research.
Summary of milestones & major achievements 
during 2018
It has been approximately a year now that 3 new Groups started 
at SBP ; many positive changes have taken place since then. 
Looking back, we can be proud of our many achievements 
in 2018. The Groups and Units at SBP have made a collective 
effort to promote collaborations between them, as well as 
with other groups at the CNIO. The new Groups have set up 
their labs and new equipment has been acquired. In many 
cases these resources have been shared between groups, 
thereby fostering a spirit of scientific interactions, as well as 
rationalising the use of our resources.
We have made every effort to make our new Programme 
known around the world. Several top researches in the field 
of Structural Biology came to the CNIO as speakers, including 
John L. Rubinstein ( University of Toronto, Canada ), and Kiyoshi 
Nagai ( LMB-MRC, Cambridge, UK ), among others. In addition, 
we actively advertised the Programme abroad ; we visited the 
LMB-MRC ( Cambridge, UK ), the Institute of Cancer Research 
( ICR, London, UK ) and the Max Planck Institute of Biochemistry 
( Munich, Germany ). We are also organising a CNIO Frontiers 
Meeting to be held in the spring of 2019 for which we will be 
bringing in some of the most renowned experts in Structural 
Biology of the DNA damage response.
On June 25th, SBP was granted a competitive project to access 
the Electron Bio-Imaging Centre ( eBIC ) at the Diamond Light 
Source ( UK ). Our project, titled “ Stop cancer - structural studies 
of macromolecular complexes involved in cancer by cryo-EM ”, 
will allow access to this top cryo-EM facility. The Electron 
Microscopy Unit forms part of this project ; the intention is to 
allow the access to eBIC for CNIO groups that are outside the 
SBP through a collaboration with the Electron Microscopy Unit.
As part of our achievements, the 2 new Junior Groups were 
awarded ‘ Ramon y Cajal ’ research contracts and also both 
obtained grants from the Spanish Government, an excellent 
boost to start off their independent research. In 2018, SBP 
published the first atomic structure obtained using cryo-
electron microscopy methods. In addition, Daniel Lietha 
published new insights into the mechanisms involved in the 
activation of Focal Adhesion Kinase.
Finally, I would like to acknowledge the work of Daniel Lietha, 
Junior Group Leader at SBP. Over the last few years, Daniel 
has significantly contributed to the structural and mechanistic 
understanding of Focal Adhesion Kinase, and other signalling 
pathways important for proliferation, adhesion and cancer 
survival. Daniel has also invested considerable effort to look for 
new ligands to inhibit Focal Adhesion Kinase using structural 
approaches. On top of all this, Daniel has been an exceptional 
colleague, always available to help everyone. Daniel Lietha is now 
moving to CSIC as a ‘ distinguished researcher ’ and we all wish him 
and his team the best in this new phase of their scientific career.
In summary, during 2018, SBP has set up the infrastructure, the 
collaborations and the working environment that we will need in 
the coming years to push our research, improve our connectivity 
with CNIO, and to contribute to provide a mechanistic and 
structural understanding of processes relevant in cancer.
“ SBP endeavours to define 
structures of macromolecules 
relevant in cancer in order 
to provide mechanistic 
understanding, which is a first 
step towards new therapies. 
In 2018, SBP determined its 
first cryo-EM structures.”
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Activation and assembly of many protein complexes implicated 
in cancer, such as kinases and polymerases, require the 
assistance of HSP90, a molecular chaperone. Thus, HSP90 
inhibitors are being evaluated as anticancer agents.
HSP90 is needed for the activation and stability of the PI3-
kinase-like kinases ( PIKKs ), including mTOR, ATM and 
ATR that regulate the DNA damage response and cell growth. 
Surprisingly, these kinases require the action of HSP90 but 
working in concert with the R2TP/Prefoldin-like ( R2TP/
PFDL ) complex. R2TP/PFDL is the most complex HSP90 
co-chaperone yet described. R2TP/PFDL contains multiple 
subunits and growing evidence links this complex to cancer.
Yet, how all these processes work is largely unknown. We are 
using cryo-electron microscopy ( cryo-EM ) to fully understand 
the molecular mechanisms of R2TP/PFDL and to bring us 
a step closer to designing strategies to interfere with PIKK 
assembly and activation.
“ How kinase complexes implicated 
in cancer are assembled by HSP90 
and R2TP is unclear. The structure 
of R2TP brings us a step closer to 
mechanistic understanding and the 
design of anticancer strategies.”
MACROMOLECULAR 










Adrián Del Rincón ( since March ), 
Carlos Fernández
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Cryo-EM and structure of macromolecular complexes in 
cancer
A defining feature of our Group is our interest in understanding 
the structural and molecular mechanisms of macromolecular 
complexes involved in the DNA damage response. For this, 
we use mostly biochemical and molecular biology tools in 
combination with cryo-electron microscopy ( cryo-EM ). 
Cryo-EM is used to visualise large macromolecular complexes, 
to observe their flexibility and motions, and to build atomic 
models. Cryo-EM is especially helpful for complex and flexible 
assemblies, which are typically difficult to crystallise. The 
structural and functional information provides mechanistic 
details to help understand the DNA damage response, and it 
is an input for the design of new strategies to interfere with 
these processes.
The Group is currently working on several complexes 
implicated in the response to DNA damage, but this 
year our main area of focus was the characterisation and 
understanding of how HSP90 and the R2TP co-chaperone 
function to assemble large macromolecular complexes of 
relevance in cancer.
How cells build protein interactions in protein kinase 
complexes
Assembly, activation and cellular stability of a growing list 
of macromolecular complexes, many of which are relevant 
in cancer, require the assistance of molecular chaperones. 
Among these, the kinases of the PI3-kinase-like family ( PIKKs ) 
function as part of large multi-subunit complexes that require 
HSP90 for assembly.
The PIKK family comprises proteins such as ATM, ATR 
and DNA-PKcs, implicated in DNA repair and DNA damage 
signalling, and mTOR, which controls cell growth. These 
kinases interact with other proteins in order to function 
properly and be active, as in the mTOR complex 1 ( mTORC1 ) 
or ATR-ATRIP. Building these protein interactions needs 
the concerted action of the HSP90 chaperone and the R2TP/
Prefoldin-like ( R2TP/PFDL ) co-chaperone. Interestingly, 
cells control the level of activation for some of these kinases, 
such as mTOR, by regulating the building of their functionally 
active complexes. How all this happens, the molecules involved, 
the mechanistic details and the implications in cancer remain 
poorly understood.
Our current aim is to improve our molecular understanding 
of the structural basis of R2TP-mediated protein complex 
assembly. In 2018, we reported the 3D structure of the human 
R2TP complex at a resolution of 3.6Å as part of a collaborative 
effort between our group and the group of Laurence H. Pearl 
at the Genome Damage and Stability Centre in the University 
of Sussex ( UK ).
Cryo-EM reveals that a C-terminal domain in RPAP3 ( RNA 
Polymerase Associated Protein 3 ), one of the components 
of the human R2TP complex, binds to one hexameric ring of 
the RUVBL1 and RUVBL2 ATPases. This interaction provides 
a tight anchor that frees the N-terminal regions of RPAP3 
involved in HSP90 binding. Cryo-EM images of R2TP show 
that HSP90 binding regions are extremely flexible, moving 
around the core provided by the RUVBL1-RUVBL2 hexameric 
ring. We propose that such flexible attachment is essential for 
placing HSP90 in the proximity of the clients, while providing 
sufficient conformational freedom to interact with a diversity 
of clients.
Together, our findings provide the first structural view of 
human R2TP, an essential complex for the HSP90-mediated 
assembly of mTORC1, ATR-ATRIP and other complexes of 
the PIKK family. Our structures also highlight important 
differences between the human complex and the much simpler 
homologs found in yeast. We have discovered an intricate 
architecture of the human R2TP complex, providing a flexible 
tether for HSP90, needed to cope with the assembly of multiple 
and diverse macromolecular complexes. A structural view 
of how HSP90 and its co-chaperone assists the assembly of 
proteins involved in cancer will bring us a step closer to the 
potential design of new anticancer strategies. s
 ∞ PUBLICATIONS
 ∞ Martino F, Pal M, Muñoz-Hernández H, 
Rodríguez CF, Núñez-Ramírez R, Gil-Car-
ton D, Degliesposti G, Skehel JM, Roe 
SM, Prodromou C, Pearl LH, Llorca O 
( 2018 ). RPAP3 provides a flexible scaf-
fold for coupling HSP90 to the human 
R2TP co-chaperone complex. Nat Com-
mun 9, 1501.
 ∞ de Jorge EG, Yebenes H, Serna M, Torta-
jada A, Llorca O, de Córdoba SR ( 2018 ). 
How novel structures inform understand-
ing of complement function. Semin Im-
munopathol. 40, 3-14.
Book Chapter
 ∞ Muñoz-Hernández H, Pal M, Rodríguez 
CF, Prodromou C, Pearl LH, Llorca O 
( 2018 ). Advances on the structure of 
the R2TP/Prefoldin-like complex. Adv 
Exp Med Biol 1106, 73-83.
Figure 1 Selected views of the 
human R2TP complex as observed 
by cryo-EM. ( a ) Several domains can 
be localised, and the flexibility of the 
HSP90-binding regions in RPAP3 is 
detected.
Figure 2 Cryo-EM map of the 
RUVBL1-RUVBL2 hexamer ( blue 
colour ) bound to the C-terminal 
domain of RPAP3 ( yellow colour ), 
as seen from the top ( a ) and side ( b ). 
( c ) Detail of the ADP binding site. 
The quality of the cryo-EM density, 
represented in mesh, is sufficient 
to detect the ADP and side chains 
of residues in the binding site for 
nucleotides.
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Focal Adhesion Kinase ( FAK ) is a key regulator of adhesion 
signals and localises into a signalling layer on the plasma 
membrane in focal adhesion complexes. We previously 
discovered that FAK interacts with PIP2 lipids in focal adhesions 
and this triggers its activation by inducing FAK oligomerisation, 
conformational changes that facilitate its autophosphorylation, 
Src recruitment and FAK phosphorylation by Src. Currently, we 
are studying the atomic architecture of FAK oligomers bound to 
PIP2 membranes by electron microscopy ( EM ). We have obtained 
a 5.9 Å map, which reveals the mode of oligomerisation and large 
membrane induced rearrangements of FAK’s regulatory FERM 
and kinase domains ( FIGURE ). The observed conformation 
suggests that FAK adopts a ‘ preactivated ’ primed state when 
bound to the membrane. We are further investigating how force, 
induced at focal adhesion sites by actomyosin contraction, 
can induce changes to these structures to fully activate focal 
adhesion signalling. We utilise these mechanistic insights to 
discover highly specific allosteric FAK inhibitors. We employ a 
fragment based approach to identify allosteric ligands and then 
use structure based drug design to develop these fragments into 
inhibitory lead compounds.
SHIP phosphatases remove the 5-phosphate from PIP3 and 
thereby, like PTEN, negatively regulate PIP3 levels in the plasma 
membrane. Despite their importance, little is known about 
mechanisms of SHIP regulation. We previously solved a crystal 
structure containing the catalytic and C2 domains of SHIP2, 
which, together with extensive biochemistry and cell biology 
experiments, showed how the C2 domain induces catalytic 
activation of SHIP2. Currently, we are studying the role of the PH 
domain flanking the catalytic domain. We find that the domain 
binds the PIP3 substrate and PIP2 product, and that this binding 
allosterically further activates SHIP. Together, this shows how 
the C2 and PH domains concertedly act to recruit SHIP to PIP3 
rich membranes in order to adopt a highly active state. s
oVeRVieW
Our Group studies regulatory mechanisms of key signalling 
switches controlling growth and adhesion signals, 
which regulate important cellular processes such as cell 
proliferation, migration and survival. We use structural 
techniques, such as X-ray crystallography and electron 
microscopy, in combination with biochemical and functional 
studies to understand these mechanisms at atomic detail 
and to rationalise how oncogenic events result in their 
deregulation. The structural understanding allows us to 
design potential anti-cancer therapeutics that interfere with 
oncogenic deregulation.
We focus on growth and adhesion signalling systems that 
interact and are regulated by specific lipids in the plasma 
membrane. Specifically, we pursue 2 main questions :
 ɗ How are adhesion signals in focal adhesion complexes 
triggered by membrane interactions ?
 ɗ How are the levels of specific lipids regulated by the SHIP 
lipid phosphatase to control growth signals ?
CELL SIGNALLING AND 
ADHESION JUNIOR GROUP
Daniel Lietha ( until September )
Junior Group Leader
Post-Doctoral Fellows
Iván Acebrón, Johanne Le Coq
Graduate Student
Marta Acebrón ( until January )
Technician
Pilar Redondo
“ Using structure-based design, we 
generated the first irreversible and 
sub-nanomolar inhibitor targeting 
adhesion signals that trigger cancer 
invasion.”
 ∞ PUBLICATIONS
 ∞ Toledo RA, Garralda E, Mitsi M, Pons T, 
Monsech J, Vega E, Otero Á, Albarran 
MI, Baños N, Durán Y, Bonilla V, Sarno 
F, Camacho-Artacho M, Sanchez-Perez 
T, Perea S, Álvarez R, De Martino A, 
Lietha D, Blanco-Aparicio C, Cubillo A, 
Domínguez O, Martínez-Torrecuadrada 
JL, Hidalgo M ( 2018 ). Exome sequencing 
of plasma DNA portrays the mutation 
landscape of colorectal cancer and dis-
covers mutated VEGFR2 receptors as 
modulators of antiangiogenic therapies. 
Clin Cancer Res 24, 3550-3559.
 ∞ Bauer MS, Baumann F, Daday C, Redondo 
P, Durner E, Jobst MA, Milles LF, Mer-
cadante F, Pippig DA, Gaub HE, Gräter 
F, Lietha D. Structural and mechanistic 
insights into mechanoactivation of Focal 
Adhesion Kinase. Proc Natl Acad Sci USA, 
doi :10.1073/pnas.1820567116.
 ∞ Yen-Pon E, Li B, Acebrón-Garcia-de-Eu-
late M, Tomkiewicz-Raulet C, Dawson J, 
Lietha D, Frame MC, Coumoul X, Garbay 
C, Etheve-Quelquejeu M, Chen H ( 2018 ). 
Structure-based design, synthesis, and 
characterization of the first irreversible 
inhibitor of Focal Adhesion Kinase. ACS 
Chem Biol 13, 2067-2073.
Figure ( a ) FAK 2D crystals ( with 
Fourier transforms ) formed on PIP2 
membranes imaged by negative 
stain ( upper ) or cryo-EM ( lower ). 
( b ) EM maps at 5.9 Å fitted with FAK 
domains. Each colour represents one 
FAK molecule containing a FERM and 
kinase domain. ( c ) EM structure of 
oligomeric FAK on a lipid membrane.
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During 2018, we have set up the different experimental systems 
and techniques needed for the adequate functioning of the lab 
and have established 3 main research lines :
 ɗ Structural and molecular determinants of RET catalytic 
activity and signalling, both in cis by intrinsic elements and 
in trans by effector kinases and adaptor proteins.
 ɗ Structure-function studies of RET oncogenic variants, i.e. 
point mutations targeting the kinase domain and oncogenic 
fusions generated by DNA-rearrangements.
 ɗ Structure-based drug-discovery of ( allosteric ) RET 
inhibitors.
Furthermore, upon invitation by the journal Endocrine-Related 
Cancer, we contributed to a special issue to commemorate 
the 25th anniversary of the discovery of the RET proto-
oncogene as the cause of Multiple Endocrine Neoplasia type 2 
( see publication list ). s
oVeRVieW
Rational and precise targeting of oncogene driven signalling 
is a crucial and yet outstanding challenge in cancer research 
today. Understanding the structural and molecular bases of 
oncogene activation and signalling is key for the design and 
development of better therapeutics. Our research focuses 
on the structural and molecular understanding of protein 
kinase function : how protein kinases are activated and 
regulated by post-translational modifications and allosteric 
inputs, and how they assemble into macromolecular protein 
complexes to transmit signals inside the cell. We put a special 
emphasis on how these mechanisms are corrupted in cancer 
and disease due to oncogenic mutations and other oncogenic 
insults. Crucially, such atomic and molecular information 
can be translated into the design and development of more 
potent and specific protein kinase inhibitors, eventually 










Nicolás Cuesta ( since July )
Visiting Graduate Student
Alba Morán ( until June, Universidad 
Autónoma )
Visiting Master Student
Moustafa Ahmed Shehata ( since 
July, Cairo University )
 ∞ PUBLICATIONS
 ∞ Plaza-Menacho I ( 2018 ). Structure and 
function of RET in multiple endocrine 
neoplasia type 2. Endocr Relat Cancer 25, 
T79-T90.
 ∞ Redaelli S, Plaza-Menacho I, Mologni L 
( 2018 ). Novel targeted therapeutics for 
MEN2. Endocr Relat Cancer 2, T53-T68.
Figure Structural identification of a 
RET αC hydrophobic PIF-like allosteric 
pocket based on the superimposition 
of the RET ( PDB code 5FM3 ) and 
PKACA ( 1ATP ) crystal structures, and 
the resemblance of the c-terminal FxxF 
hydrophobic motifs of RET ( FTRF ) and 
PKACA ( FTRF ).
“ Understanding protein kinase 
function and inhibition for better 
cancer therapeutics.”
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Mismatch repair
DNA mismatch repair ( MMR ) is critical for genome stability. 
The DNA mismatch repair machinery loads onto newly 
synthesised DNA and searches for mismatches. The recognition 
of an error in DNA by the MutS protein leads to an ATP-
dependent conformational change that transfers MutS into 
a sliding clamp state. Only this MutS state can activate the 
MutL ATPase that in turn promotes the cleavage of the DNA 
for repair. These protein complexes are incredibly dynamic and 
flexible, and many steps of the cycle have remained elusive to 
structural analysis. Using cryo-EM, we have captured multiple 
functional steps and we have studied the conformational 
changes that these proteins undergo in order to recognise 
the mismatch and license downstream events that lead to 
repair. These studies are carried out in collaboration with 
Titia Sixma ( Netherlands Cancer Institute ) and Meindert 
Lamers ( Leiden University ).
DNA replication & repair - focus on mitochondria
Eukaryotic cells have two genomes : nuclear and mitochondrial. 
However, how the integrity of the mitochondrial genome is 
maintained through the equilibrium between DNA replication, 
repair and degradation, and organelle dynamics, remains 
unclear. We are interested in understanding these pathways 
because of their implications for ageing and disease, and in 
particular, their relation to cancer.
Cryo-electron microscopy ( cryo-EM )
Combined with many other approaches already established at 
the CNIO, we use cryo-EM to study diverse macromolecular 
complexes involved in cancer. Significant recent technological 
developments in microscopes, detectors and image processing 
tools have significantly improved the resolution of the 
technique, enabling the structural analysis of many elusive 
macromolecules to an unprecedented level of detail. Last 
year, we worked together with the Óscar Llorca Group and 
the EM Unit to bring the cryo-EM facility at the CNIO to 
a state-of-the-art level. Moreover, we have been awarded 
access to high-end microscopes at the Biological Electron 
Bio-Imaging Centre ( eBIC ) in Oxford ( UK ). We can now 
efficiently prepare samples and solve their structures, using 
the in-house facilities, to a high level of detail. s
oVeRVieW
Safeguarding the genetic information is essential to all forms 
of life. Two key cellular processes keep it free from errors : 
DNA replication and repair. Importantly, when these do not 
work correctly, genetic information may be damaged or lost, 
ultimately leading to disease. Deregulation and malfunction 
of the protein machinery that safeguards our genome are a 
hallmark of cancer, but it remains unclear how this happens 
at the molecular level. The devil is in the detail, and we aim to 
understand to the highest level of detail what and when things 
can go wrong with these molecular machines, so we can act 
on it to correct it and prevent it from happening.
These macromolecules are like real life machines, with 
intricate mechanisms that enable them to perform their 
activities. To understand how they work, we use cryo-electron 
microscopy and biochemistry in an integrative approach. 
Beyond fundamental research, this structural information 
provides the necessary detail for drug development.






Samuel Míguez ( since April )
Technicians
Ana González ( since July ), Araceli 
Grande ( TS )*
*Titulado Superior ( Advanced Degree )
 ∞ AWARDS AND RECOGNITION
 ∞ Awarded with a Ramón y Cajal Fellowship, 
Spanish Ministry of Science, Innovation 
and Universities.
“ The high-end cryo-electron 
microscopy setup at the CNIO allows 
us to look at every detail of the 
cell’s protein machinery, so that we 
can understand how it works and 
intervene.”
F i g u r e   H i g h - r e s o l u t i o n 
reconstruction of a protein structure 
from the lab to 2.1Å resolution ( to be 
published ). ( A ) Shows the overall 
atomic density of the protein, and 
( B ) shows close-ups of density and 
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Our Core Unit incorporates a broad range of instrumentation 
for the biophysical characterisation of biomolecules and their 
interactions, including spectrophotometers, a fluorimeter, 
isothermal titration and differential scanning calorimeters, 
a circular dichrograph, dynamic and multi-angle static light 
scattering devices, and a surface plasmon resonance ( SPR ) 
instrument. Research groups mostly from, but not limited 
to, the Structural Biology Programme extensively used these 
technologies throughout 2018. For example, in collaboration 
with the Experimental Therapeutics -ETP- Programme, we 
conducted quantitative binding measurements using NMR 
( see FIGURE ) to establish that a cell-active small molecule 
compound interacts weakly with telomeric double stranded 
DNA. Thus, telomeric DNA binding appears not to be a 
significant mode of action of the compound to explain its 
cellular activity.
The Unit hosts a 700 MHz NMR spectrometer that is well 
equipped with probes, and a sample changer for running up 
to 120 samples automatically. This provides the required 
throughput for the screening of small molecule protein 
binders ( together with the CNIO’s Structural Biology and ETP 
Programmes ), as well as for metabonomics measurements that, 
this year, were performed in collaboration with the CNIO-Lilly 
Cell Signalling Therapies Section ( from the ETP ), the Cell 
Division and Cancer Group (-CDC- Group, from the Molecular 
Oncology Programme ), as well as the Growth Factors, Nutrients 
and Cancer and the Epithelial Carcinogenesis Groups ( from 
the Cancer Cell Biology Programme ). For example, in 
collaboration with the CDC Group, we conducted cell media 
and intracellular metabolite measurements to characterise the 
metabolic changes associated to the silencing of the Mastl gene. 
Collectively, with these and other groups, we implemented 
sample preparation protocols and developed spectroscopic 
and analytical tools to characterise the metabolites present 
in different biological samples. s
oVeRVieW
The Unit unifies the technical and scientific management of 
Nuclear Magnetic Resonance ( NMR ) Spectroscopy and other 
molecular biophysics instrumentation available through the 
Structural Biology Programme. It provides CNIO researchers 
with equipment and technical support for a variety of techniques 
used in biophysical studies of molecules involved in cancer. This 
includes the application of NMR to the in vitro characterisation 
of the structure and dynamics of biomolecules ( proteins in 
particular ) and their interactions with other biopolymers, 
as well as with small molecules that could represent initial 
hits in the drug discovery process or research compounds for 
biophysical and functional studies. Furthermore, we use NMR 
to characterise the metabolic profiles of biofluids, cell growth 
media and cell and tissue extracts from both animal models of 
cancer and human samples.
“ In 2018, we identified and 
quantified interactions of small 
molecule compounds with tumour-
relevant proteins and DNA, thereby 
contributing to the discovery of 
possible macromolecular inhibitors, 
as well as to the understanding 
of the molecular bases of the cell 




Clara M. Santiveri ( TS )*
*Titulado Superior ( Advanced Degree )
Figure NMR study of the interaction 
of a small molecule compound 
with a DNA duplex containing 7 
telomeric repeats. ( A ) Superposition 
of the aromatic region of the  1H 
NMR spectrum of the compound 
( 100 µM ) recorded after addition 
of increasing amounts of dsDNA 
( from bottom to top : 0-8.9 µM ). The 
tilted arrows mark signals changing 
position upon dsDNA addition, 
identifying the chemical moieties 
directly involved in dsDNA binding. 
In contrast, the 3 signals from the 
phenyl ring of the compound only 
experience broadening as a result of 
complex formation, but not change of 
position, as the phenyl moiety does 
not directly contact the dsDNA. ( B ) 
Linear variations in the chemical shift 
( spectral positions ) of three signals as 
a function of added dsDNA indicate 
weak binding ( KD >> 10 µM ).
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In 2018, the CNIO Bioinformatics Unit published 16 peer-reviewed 
articles ( see full list on our web site https ://bioinformatics.cnio.
es/) as a result of our ongoing research projects and scientific 
collaborations with CNIO Research Groups and other national 
and international research institutions.
During this year, we developed several bioinformatics tools for 
in silico prescription of anticancer drugs : PanDrugs ( https ://
www.pandrugs.org/) in collaboration with SING group 
( Universidad de Vigo ), and VulcanSpot ( http ://vulcanspot.
org/) for detecting and targeting cancer genetic dependencies. 
All our tools are freely available and have been applied in 
different genomic studies from our numerous scientific 
collaborations such as : transcriptomics analysis using our 
tool nextpresso ( Djurec M et al., 2018 ) or in collaboration 
with M. Robledo’s Group from the Human Cancer Genetics 
Programme to study pheochromocytoma and paraganglioma 
( PPGLs ) tumours. In addition, the Bioinformatics Unit has 
published an update of the APPRIS database ( http ://appris.
bioinfo.cnio.es/). The principal and alternative isoforms 
annotated in the APPRIS database are being used to refine 
and extend the Ensembl/GENCODE human reference set. 
APPRIS annotations have now also been expanded to cover 
both the human and mouse proteomes in UniProtKB as well 
as the clinically relevant RefSeq human and mouse gene sets.
The Bioinformatics Unit, as a new node of INB/ELIXIR-ES 
( https ://inb-elixir.es/), aims to provide the tools, infrastructure 
and expertise for the systematic analysis and interpretation 
of cancer genomes. Importantly, the Bioinformatics Unit is 
extensively involved in teaching activities − with an important 
focus on the translational bioinformatics area − to train 
bioinformatics users and developers. We co-organise the Master en 
Bioinformática Aplicada a Medicina Personalizada y Salud ( ISCIII-
ENS ) as well as advanced Bioinformatics courses for sequencing 
analysis ( visit our web page for a full list of activities ). s
oVeRVieW
Bioinformatics is a key discipline for furthering our 
understanding of the cancer genome and for the future of 
cancer therapeutics. Bioinformatics-based approaches have 
the ability to transform the huge amount of biological data into 
comprehensive models that provide an in-depth understanding 
of cancer disease and the complex relationships among 
genotype and phenotype that are needed to identify cancer 
driver molecular alterations and new therapeutic targets.
The CNIO Bioinformatics Unit ( BU ) has several goals : i ) to 
develop new computational methodologies and bioinformatics 
tools to enable the integration of biological and clinical data ; 
ii ) to achieve genome analysis in cancer patients ’ data in order 
to identify new biomarkers and mechanisms of drug response ; 
iii ) to provide bioinformatics support with data analysis and 
interpretation using computational and statistical methods ; 
and iv ) to maintain the CNIO’s scientific computing facilities 
and provide training in bioinformatics tools and methods.
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 ∞ SELECTED PUBLICATIONS *
 ∞ Zagorac I et al. (incl. Al-Shahrour F ... Quinte-
la-Fandino M) ( 2018 ). In vivo phosphopro-
teomics reveals kinase activity profiles that 
predict treatment outcome in triple-neg-
ative breast cancer. Nat Commun 9, 3501.
 ∞ Rodriguez JM, Rodriguez-Rivas J, Di Do-
menico T, Vázquez J, Valencia A, Tress 
ML ( 2018 ). APPRIS 2017 : principal iso-
forms for multiple gene sets. Nucleic 
Acids Res 46, D213-D217.
 ∞ Abascal F, Juan D, Jungreis I, Martinez L, 
Rigau M, Rodriguez JM, Vazquez J, Tress 
ML ( 2018 ). Loose ends : almost one in five 
human genes still have unresolved coding 
status. Nucleic Acids Res 46, 7070-7084.
 ∞ Djurec M, Graña O, Lee A, Troulé K, Espinet 
E, Cabras L, Navas C, Blasco MT, Martín-
Díaz L, Burdiel M, Li J, Liu Z, Vallespinós 
M, Sanchez-Bueno F, Sprick MR, Trumpp 
A, Sainz B Jr., Al-Shahrour F, Rabadan R, 
Guerra C, Barbacid M ( 2018 ). Saa3 is a key 
mediator of the protumorigenic proper-
ties of cancer-associated fibroblasts in 
pancreatic tumors. Proc Natl Acad Sci U 
S A 115, E1147-E1156.
 ∞ Piñeiro-Yáñez E, Reboiro-Jato M, Gómez-
López G, Perales-Patón J, Troulé K, 
Rodríguez JM, Tejero H, Shimamura T, 
López-Casas PP, Carretero J, Valencia 
A, Hidalgo M, Glez-Peña D, Al-Shahrour 
F ( 2018 ). PanDrugs : a novel method to 
prioritize anticancer drug treatments 
according to individual genomic data. 
Genome Med 10, 41.
 ∞ Paumard-Hernández B et al. (incl. Al-Shah-
rour F ... Benítez J) ( 2018 ). Whole exome 
sequencing identifies PLEC, EXO5 and 
DNAH7 as novel susceptibility genes in tes-
ticular cancer. Int J Cancer 143, 1954-1962.
 ∞ López-Nieva P et al. ( 2018 ). RNA-Seq 
reveals the existence of a CDKN1C-
E2F1-TP53 axis that is altered in human 
T-cell lymphoblastic lymphomas. BMC 
Cancer 18, 430.
* please see BU’s web site for a list of all 
publications.
“ VulcanSpot is a novel 
computational method used to 
prioritise drugs that can target 
cancer-specific gene dependencies, 
unlocking therapeutic options 
beyond known actionable driver 
genes.”
Figure VulcanSpot workflow : 
1 ) identification of genome-wide 
vulnerable Gene Dependencies 
( GD ) integrating functional genomics 
datasets ; 2 ) to propose drugs to 
target GDs following a dual strategy ; 
and 3 ) therapeutic prioritisation as a 
final output targeting GDs detected 
in the user’s gene list.
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ReseaRch highlighTs
Over the last decade, cryo-EM has emerged as a key technique 
for studying how biomolecules function and interact. Our 120-
kV Spirit G12 EM, equipped with the TVIPS CMOS detector, 
has cryo-capabilities that enable sample screening and low 
resolution analysis of standard biological specimens. For 
high resolution cryo-EM data collection, CNIO’s Structural 
Biology Programme has been granted access to high-end 
cryo-EM microscopes at the Electron Bio-Imaging Centre 
( eBIC ) ( Oxford, UK ) through peer-reviewed Block Allocation 
Group ( BAG ) access.
Throughout 2018, the Unit has performed EM experiments with 
all the research groups from the Structural Biology Programme, 
as well as with several groups from other CNIO Programmes 
and outside our Centre. For example, in collaboration with 
CNIO’s Microenvironment and Metastasis Group, we have 
contributed to the characterisation of circulating extracellular 
vesicles from the lymph and plasma of melanoma patients. 
Our data supported their analysis of lymph-circulating 
extracellular vesicles for the detection of residual disease and 
its reappearance in melanoma. The most frequent mutation 
in amyotrophic lateral sclerosis and frontotemporal dementia 
patients involves mutation of the C9ORF72 gene, resulting, to 
a certain extent, in the expression of toxic di peptide arginine 
repeats ( PR ). We have evaluated, by electron microscopy, in 
collaboration with the CNIO Genomic Instability Group, that 
the presence of ( PR )20 did not affect the in vitro assembly of 
purified 40S and 60S subunits into 80S particles in the absence 
of mRNA. Moreover, in collaboration with Dr Iván Ventoso 
− from the Centro de Biología Molecular ‘ Severo Ochoa ’ ( CSIC-
UAM ) and the Departamento de Biología Molecular of the 
Universidad Autónoma de Madrid ( UAM ) − we used electron 
microscopy to localise gold-labelled eukaryotic initiation 
factor-4A ( eIF4A ) in the ribosomal translation initiation 
complex 48S. Our results have contributed towards the 
proposal of a topological model of the scanning ribosomal 43S 
pre-initiation complex. s
oVeRVieW
The Electron Microscopy ( EM ) Unit is a central core facility as 
well as a research laboratory. It is available to CNIO researchers 
and the wider research community, providing investigators 
with instruments and support for Transmission Electron 
Microscopy analysis. The Unit offers negative staining and 
cryo-EM specimen preparation techniques for proteins, 
protein complexes and vesicles. We also give training to regular 
users on the use of our equipment and provide further guidance 
regarding specimen preparation.
“ Over the past year, the Electron 
Microscopy Unit has endeavoured to 
adapt its facility to better meet the 
needs of the new members of our 
Programme, particularly in relation 
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 ∞ PUBLICATIONS
 ∞ Toribio R, Díaz-López I, Boskovic J, 
Ventoso I.( 2018 ).Translation initiation 
of alphavirus mRNA reveals new insights 
into the topology of the 48S initiation 
complex. Nucleic Acids Res 46, 4176-4187.
 ∞ Lafarga V, Sirozh O, Diaz-Lopez I, Hisaoka 
M, Zarzuela E, Boskovic J, Jovanovic B, 
Fernandez-Leiro R, Munoz J, Stoecklin G, 
Ventoso I, Fernandez-Capetillo O ( 2018 ). 
DNA and RNA binding mediate the tox-
icity of arginine-rich peptides encoded 
by C9ORF72 GGGGCC repeats. BioRxiv, 
doi : https ://doi.org/10.1101/441808.
Figure ( A ) Representative electron 
micrograph of negative stained 
exosomes derived from the lymph 
of a melanoma subject, after density 
gradient centrifugation. Scale bar, 
500 nm. ( B ) Analysis of exosome 
structure and size after density 
gradient.
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ReseaRch highlighTs
The Unit works closely with the Experimental Therapeutics 
Programme on several projects that have since led to the 
production of recombinant proteins ( full-length human MASTL, 
full-length mouse TRF1 and human TRF1 dimerization domain ) 
for biochemical experiments. We also focus on structural 
characterisation by X-ray crystallography in support of drug 
discovery projects, as in the case of the kinase HASPIN − 
crystallised in the presence of compounds developed at the 
Medicinal Chemistry Section ( FIGURE ) − and other projects 
like MASTL, DDR1 and the dimerization domain of TRF1 
( FIGURE ), the latter in strict collaboration with the Telomeres 
and Telomerase Group. We have continued our work on the 
production of proteins for the generation of antibodies by 
the Monoclonal Antibody Unit ( Biotechnology Programme ), 
including several cancer-involved proteins such as IL11R, TET2, 
NGFR, ECT2, CDK16, Pot1A, MIDKINE, GPSM3, Ly9, CD85A, 
and HASPIN, among others. The Unit is also engaged in numerous 
internal collaborations with other CNIO Research Groups and 
Units ; noteworthy are the following : Telomeres and Telomerase, 
Experimental Oncology, Genomic Instability, Cell Division 
and Cancer, Molecular Imaging Unit, Microenvironment and 
Metastasis, Gastrointestinal Cancer Clinical Research Unit, 
Melanoma, Epithelial Carcinogenesis, Familial Cancer Unit, 
H12O-CNIO Lung Cancer Clinical Research Unit, and the 
H12O-CNIO Haematological Malignancies Clinical Research 
Unit. Additionally, our Unit has ongoing collaborations with 
external groups such as the Environmental Biology Department 
( CIB-CSIC ), the Pharmacology and Therapeutics Department 
( Roswell Park Cancer Institute, USA ), the Protein Tools Unit 
( CNB-CSIC ), the Biomedical Application of Radioisotopes Unit 
( CIEMAT ), the Department of Molecular Engineering ( Aarhus 
University, Denmark ) and the IVI Foundation.
Throughout 2018, the Unit also sustained its own scientific 
projects. We continued working on targeting the function 
of the Mdm2-MdmX E3 complex activity, in collaboration 
with the Department of Pharmacology and Therapeutics at 
Roswell Park Cancer Institute. Also, we have solved, by SAXS, 
the structure in-solution of two mAbs that correspond to the 
first generation 4-1BB agonistic IgG 1D8, and which are specific 
tumour-targeted trimerbodies ( FIGURE ). Our collaborators, 
at the Department of Molecular Engineering ( Denmark ), have 
shown their high tumour inhibition potency in vivo. Finally, 
the Unit is taking part in a project, in collaboration with the 
Biomedical Application of Radioisotopes Unit at CIEMAT and 
the CNIO’s Molecular Imaging Unit, to develop new antibody-
based positron emission tomography ( immunoPET ) imaging 
tools for tumour visualisation. s
oVeRVieW
The Crystallography and Protein Engineering Unit 
( XTPEUnit ) is a central core facility as well as a research 
laboratory whose main goal is to supply the requests of 
the research groups within the CNIO, as well as external 
groups, by providing on-demand services at different levels. 
The Unit covers all the services that range from the coding 
sequence cloning to the resolution of the 3D structure, whilst 
always focusing on helping the research groups in reaching a 
broader characterisation of their proteins of interest. These 
services span the production of proteins for different types 
of biochemical/biophysical assays, monoclonal antibody 
production, and macromolecular structural determination 
at low resolution by small-angle X-ray scattering ( SAXS ) 
or at high resolution by X-ray crystallography. The latter 
includes protein co-crystallisation − a method that we routinely 
combine with the quantification of the protein thermal stability 
( thermofluor assay ) − in the presence of inhibitors during the 
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 ∞ PUBLICATIONS
 ∞ Compte M et al. (incl. Muñoz I, Martín-
ez-Torrecuadrada J ) ( 2018 ). A tu-
mor-targeted trimeric 4-1BB-agonistic 
antibody induces potent anti-tumor 
immunity without systemic toxicity. Nat 
Commun 9, 4809.
 ∞ Mortuza GB et al. (incl. Muñoz I) ( 2018 ). 
Molecular basis of Tousled-Like Kinase 2 
activation. Nat Commun 9, 2535.
 ∞ Toledo RA et al. (incl. Otero A, Martínez-
Torre cuadrada J) ( 2018 ). Exome se-
quencing of plasma DNA portrays the 
mutation landscape of colorectal cancer 
and discovers mutated VEGFR2 recep-
tors as modulators of anti-angiogenic 
therapies. Clin Cancer Res 24, 3550-3559.
 ∞ Morcillo MÁ et al. (incl. Martínez-Torre-
cuadrada J) ( 2018 ). MT1-MMP as a PET 
imaging biomarker for pancreas cancer 
management. Contrast Media Mol Imag-
ing 2018, 8382148.
 ∞ AWARDS AND RECOGNITION
 ∞ Member of the Board of Directors, Asoci-
ación de Usuarios de Sincrotrón de España.
“ We aim to show how protein 
information at atomic resolution 
is crucial for understanding the 
processes occurring in the biology 
of cancer.”
Figure ( a ) Protein crystals of TRF1 
dimerization domain. (  b ) X-ray 
structure of HASPIN in complex with 
the drug ETP-885. ( c,d ) SAXS study 
of two trimerbodies developed for 
cancer therapy. Fit of the ab initio 
SAXS structures ( envelopes in grey ) 
and the corresponding generated 
trimerbodies models ( chains in blue, 
magenta and cyan ).
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The Biological Text Mining Unit has provided consultancy, 
guidance and technical support for clinical text mining use 
cases posed by several healthcare institutions ( Hospital Virgen 
del Rocio, Hospital XII de Octubre, Hospital Son Espases, 
Hospital Clinic ), national and regional health-related agencies 
( Spanish Medical Agency, Instituto Aragonés de Ciencias de la 
Salud, Servicio Andaluz de Salud, Fundació TIC Salut Social ), 
and natural language as well as medical informatics academic 
research groups. The Unit has contributed to benchmarking 
efforts of clinical text mining systems by organising shared 
tasks in the context of community challenges organised by the 
Sociedad Española para el Procesamiento del Lenguaje Natural 
( SEPLN-IberEval ) and releasing high quality evaluation 
datasets. The Unit has published a collection of clinical 
NLP resources, all freely available at : https ://zenodo.org/
communities/medicalnlp and https ://github.com/PlanTL. 
In addition to annotation guidelines and Gold Standard 
corpora for developing and evaluating the quality of systems 
for automatically detecting biomedical and clinical concepts, 
the Unit has implemented software tools for automatic medical 
term recognition and normalisation ( CUTEXT ), an electronic 
health record sectionizer, a medical sentence boundary 
recognition system, a medical text tokenizer, lemmatizer 
and PoS-tagger. Moreover, we have also contributed to the 
first Protected Health Information ( PHI ) masker for the 
Spanish language, a system for medical negation detection, 
clinical temporal expression detection based on HeidelTime, 
a medical machine translation system and word embeddings. 
These key constituents are being integrated into the clinical 
NLP pipeline developed by the Unit. s
oVeRVieW
Biomedical cancer research is a particularly data-heavy 
discipline, where key information sources are not only limited 
to genomic information or raw experimental data. Especially 
unstructured data, such as the scientific literature, clinical texts, 
medicinal chemistry patents or patient generated content, 
constitute a valuable resource for a range of scenarios like drug 
discovery, interpretation of large scale experimental results, 
drug repurposing or evidence based medicine. Medical big data 
approaches are only able to efficiently exploit running texts 
through the use of natural language processing ( NLP ) techniques 
relying on deep learning and artificial intelligence strategies. 
Our Unit is financed through the Plan for the Advancement of 
Language Technologies ; the aim is to generate resources that 
can improve the exploitation of biomedical data by means of 
implementing and evaluating the underlying quality of systems 
for automatic recognition of medical concepts, generation 
of specialised neural machine translation models for the 
medical domain and the implementation of a medical language 
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“ Language technologies, together 
with artificial intelligence, 
are driving the technological 
transformation of biomedical 
and clinical data into actionable 
information at all levels of cancer 
research.”
Figure Clinical NLP framework for processing electronic health records in Spanish and Catalan.
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Human CanCer GenetiCs ProGramme |  TranslaTional research
HUMAN CANCER 
GENETICS PROGRAMME
JAVIER BENÍTEZ Programme Director
The Human Cancer Genetics Programme ( HCGP ) is a 
translational research programme working on areas related to 
genetics, genomics, pharmacogenetics, molecular cytogenetics 
and the environmental bases of human cancer. The HCGP 
works in close collaboration with the clinical community.
Currently, the HCGP is composed of three Research Groups and 
three Units. The Human Genetics Group, led by Javier Benítez, 
focuses on contributing to the understanding of the genetic 
bases of some hereditary tumours. Mercedes Robledo leads 
the Hereditary Endocrine Cancer Group that aims to identify 
new major susceptibility genes related to hereditary endocrine 
tumours as well as to define markers associated with differences 
in anticancer drug response and toxicity. Both Groups are also 
involved in the search for low susceptibility alleles that explain 
sporadic cancers. The Genetic and Molecular Epidemiology 
Group, led by Núria Malats, works not only from a genetic but 
also from a non-genetic point of view. She analyses exogenous 
factors that contribute to explain, together with genetic factors 
( low susceptibility alleles ), the susceptibility to pancreatic and 
bladder cancer. The Genotyping Unit, headed by Anna González-
Neira, supports our three research groups from a technical point 
of view, and provides support to other CNIO groups as well as 
to external users. They also work in pharmacogenetics within 
the framework of their own line of research. The Molecular 
Cytogenetics and Genome Editing Unit, headed by Sandra 
Rodríguez-Perales, contributes to this provision of support with 
classical and molecular cytogenetics techniques and with new 
genome editing technologies. In addition, her research is focused 
on the design of human stem cell models carrying cytogenetic 
alterations. Finally, the Familial Cancer Unit coordinates the 
clinical part of the Programme through the CNIO Familial Cancer 
Consultancy, which is located at the Hospital de Fuenlabrada. 
Miguel Urioste is responsible for these activities and leads a 
research line focused on hereditary colorectal cancer.
The Programme collaborates closely with the clinical 
community, not only to foster cooperation in genetic 
diagnosis but also to promote training and education. This 
year the Familial Cancer Consultancy attended around 550 
consultancies, performed 1,417 genetic diagnoses and carried 
out 1,290 cytogenetic studies. In addition, the Programme’s 
Groups have hosted 6 resident physicians from different 
Spanish hospitals who rotated in the Groups and Units 
for 3-month periods. We also offer professionals from different 
national and international research centres the opportunity 
to join us, either as visitors or for training visits consisting of 
short-term stays of 1-3 months ( a total of 6 international and 10 
national visitors were hosted in 2018 ). In terms of education, 1 
foreign and 10 national Master’s students and 9 national PhD 
students have worked on their research projects, 1 of whom 
has already successfully defended their thesis.
Finally, one of the main objectives of the Programme is to 
establish research collaborations with national and international 
groups ; this is well demonstrated by our publication record as 
well as the key roles held by several of the Programme’s members 
in consortia and international projects. Currently, we collaborate 
with 14 international Consortia that are representative of 
the main types of tumours that we focus on. In addition, we 
participate in 2 international  projects from Europe.
Summary of milestones and major achievements during 2018 :
 ɗ Mercedes Robledo : the identification of DLST as a new 
peochromocytoma and/or Paraganglioma ( PPGL ) 
susceptibility gene.
 ɗ Anna González-Neira : the identification of pharmacogenetic 
variants predicting response to neoadjuvant single-agent 
doxorubicin or docetaxel.
 ɗ Núria Malats : interaction of FHC and smoking increases 
pancreatic cancer risk.
 ɗ Javier Benítez : the identification of three susceptibility 
genes PLEC, EXO5 and DNAH7 as novel susceptibility 
genes in testicular cancer.
 ɗ Sandra Rodríguez-Perales : gene editing cancer therapy 
project, selected by CaixaImpulse Programme in the 2018 
edition.
 ɗ Mercedes Robledo : became member of the ENS@T Steering 
Committee ( European Network for the Study of Adrenal 
Tumours ).
 ɗ  Javier Benítez’s Group : was accepted in the international 
Consortium of Testicular Cancer.
“ We use different omics 
and epidemiologic studies 
to achieve our goals; this is 
combined with functional 
studies that validate 
our results. Finally, we 
translate our conclusions 
into clinical practice.”
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oVerVieW
We have continued to decipher the genetic bases of hereditary 
and sporadic breast cancer. In addition, we participated in a 
project that combines the genotype and the phenotype in order 
to stratify and select women at high risk of developing breast 
cancer. Other families with rare tumours are also the object of 
our studies, for example, testicular cancer whose genetic bases 
are unknown. More recently, we started working on a study to 
elucidate the common genetic origin of different autoimmune-
originated pathologies : gastric neuroendocrine tumours or 
chronic atrophic gastritis plus different immune diseases in 
other tissues, such as thyroiditis, diabetes or arthritis. We have 
identified several genes thereby opening up new avenues for 
new treatments. Finally, we have progressed in understanding 
the role of glycosylase genes as modifiers of hereditary breast 
cancer and their role along the cell cycle.
“ We have discovered 3 new 
genes that confer susceptibility to 
testicular cancer and a moderate 
breast cancer susceptibility 
gene. A whole pathway with 
several genes associated to 
gastric neuroendocrine tumours 
or chronic atrophic gastritis plus 
several immune diseases, has been 
identified.”
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risk modifier in BRCA2 mutation carriers ( Baquero et al., 
submitted ). We found that an SNP rs34259 is associated with 
significant UNG down-regulation and a better performance 
of the enzyme, measured by a lower accumulation of uracil at 
the telomeres in BRCA2 mutation carriers. Our findings could 
help to explain the association of this variant with a lower 
cancer risk in BRCA2 mutation carriers. In addition, we want 
to study the role of this and 2 other glycosylases previously 
studied, OGG1 and NEIL2, across the cell cycle.
Familial cancer exome project
In 2015, we identified a gene responsible for families with 
cardiac tumours ( POT1 ) ( Calvete et al., 2015 ). Recently, we 
described its relation not only to cardiac tumours but also 
to other different types of tumours ( Calvete et al., 2016 ). We 
investigated why the malfunction of this gene involves not 
only abnormal telomere length but is also able to generate 
different tumours in different tissues in a similar way as P53. 
We analysed the somatic changes in several cardiac tumours 
with and without POT mutations and have concluded that the 
inhibition of POT1 gene function, and the damage-response 
malfunction, would activate ATR-dependent DNA damage 
signalling, which increases cell cycle arrest in asymptomatic 
tissues and might interfere the apoptosis mechanism ; this 
would permit the further acquisition of somatic mutations 
in the VEGF/angiogenesis pathway ( POT1 deregulation ) 
and other angiosarcomas ( mutations in damage-signalling ), 
which drives tumour formation. The same observation was 
made in sporadic cardiac lesions ( Calvete et al., submitted ).
In 2015, we published the identification of the ATP4A gene 
as being responsible for families with gastric neuroendocrine 
tumours ( Calvete et al., 2015 ). In 2017, we extended this 
study to a new family that presented the same lesion along 
with hypothyroidism and arthritis. The family presented 2 
mutations in ATP4A and PTHR1 in a digenic model ( Calvete 
et al., 2017 ). We further explored the apparent relation of 
gastric autoimmune disease ( gastric neuroendocrine tumour 
or chronic atrophic gastritis ) plus a second immune disease ; we 
found several mutations in new genes involved in homeostasis 
function ( solute carriers ) altering ATP4A function. We have 
designed a panel of 15 genes from this pathway and we are 
currently performing a screening in a large number of patients 
carrying these combinations. Several gastroenterologists, 
pathologists and endocrinologists are collaborating in this 
project.
During the past few years, we have been collecting families with 
testicular cancer and also sporadic tumours. We conducted 
a first study in 17 families with over 71 members and by 
whole exome sequencing we identified several candidate 
genes ; 3 of them ( PLEC, EXO5 and DNAH7 ) were validated 
in a large case-control association study ( Paumard et al., 
2018 ). We then continued the study with more cases and 
separated 2 main histologic groups, seminomas and non-
seminomas. We differentiated several altered pathways and 
the spermatogenesis pathway was significantly altered. We 
studied this pathway in depth and discovered a biomarker 
that differentiated familial, bilateral and sporadic cases, as 
well as seminomas from non-seminomas. s
research hiGhliGhTs
Deciphering the role of rare variants in breast cancer
The European project BRIDGES, in which we participate, 
has 3 main phases. The first one was the study of 36 candidate 
genes in 60,000 breast cancer cases and controls in order 
to determine their role as possible moderate susceptibility 
genes. This part of the work has been completed and we have 
confirmed 20% of them. The second phase will involve the 
whole sequencing of these 60,000 cases, trying to discover 
new susceptibility genes. The work will start towards the 
end of year or the beginning of next year ; our group will be 
responsible for coordinating this Work Package.
Breast cancer susceptibility genes
In a whole-exome sequencing study of 4 BRCAX families 
we identified a mutation in the moderate susceptibility 
gene ATM as being responsible for the disease in one of the 
families ( Tavera-Tapia et al., 2017 ). In a second family, we 
found a deleterious mutation in an excellent candidate gene 
RECQL5 that belongs to a family of DNA helicases that have 
a role in the Homologous Recombination ( HR ) DNA repair 
pathway. Using a combination of targeted next-generation 
sequencing and genetic and functional assays, we identified 7 
deleterious or likely deleterious mutations in the gene in a 
series of 700 BRCAX cases and only 1 deleterious mutation 
in 700 controls, suggesting that the gene could actually explain 
a small percentage of the BRCAX families ( Tavera-Tapia et 
al., submitted ).
SNPs and the BER pathway
We investigated the molecular basis underlying the effect 
of an SNP in the DNA glycosylase UNG as an ovarian cancer 
Figure Tumorigenic mechanisms for cardiac 
angiosarcomas ( CAS ). ( A ) Mutations found in POT1 and 
other genes involved in the damage response signalling 
( ATR/ATM and TP53 ), correlate with the constitutional 
deregulation of the cell cycle, which triggers senescence 
and tissue stress due to the depletion of the progenitor cells. 
( B ) Malfunction of the tissue stress would arise a bypass 
in the apoptotic regulation. ( C ) Apoptosis bypass would 
fuel the acquisition of multiple somatic events. ( D ) In all 
the studied CAS ( familial − carrying POT1 mutation − and 
sporadic CAS ), somatic activating mutations were found in 
the angiogenesis pathway, which drives tumour formation.
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Our Group is mainly interested in identifying genetic risk 
factors involved in endocrine tumour susceptibility. Through 
a comprehensive analysis of tumour genomic features we 
have been able to propose diagnostic and prognostic markers, 
to identify altered pathways that could be therapeutically 
targeted, and to identify new major susceptibility genes.
We are also interested in defining markers associated with 
differences in anticancer drug response and toxicity. We 
are applying targeted and whole-exome next-generation 
sequencing to a large series of clinically well-characterised 
patients. The aim is to identify new therapeutic approaches 
to personalise cancer treatment. These efforts will collectively 
improve the diagnosis, prognosis and treatment of patients.
“ We identified a new susceptibility 
gene for paraganglioma, discovered 
predictive markers of mTORi 
response, and uncovered the Hsa-
miR-139-5p/HNRNPF axis as a 
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Significantly, mRNA abundance of HNRNPF, an alternative 
splicing factor mainly involved in cryptic exon inclusion/
exclusion, showed an anti-correlation with hsa-miR-139-5p 
expression in human tumours. Analysis of alternative splicing 
from RNA sequencing data revealed 174 events differentially 
regulated upon HNRNPF repression in genes and signalling 
cascades critical for thyroid cancer ( FIGURE ). These results 
point at hsa-miR139-5p/HNRNPF/gene-transcripts balance as 
a novel regulatory axis associated with tumour virulence and 
modulation of major thyroid cancer signalling pathways. s
research hiGhliGhTs
Recurrent germline DLST mutations in patients with 
multiple pheochromocytomas and paragangliomas 
( PPGLs ). Taking as a starting point the involvement of the 
TCA cycle in PPGL development, we aimed to identify novel 
disease-related genes involved in this key metabolic pathway 
that could explain additional patients lacking mutations in 
known susceptibility genes. To this end, targeted sequencing 
of thirty-seven TCA cycle-related genes was applied to DNA 
from 104 PPGL patients with no mutations in the major 
known predisposing genes. In order to decipher the role of 
the identified variants, omic-based analyses, TCA-related 
metabolite determination and  13C5 -glutamate labelling assays 
were performed. We identified DLST germline variants in ~7% 
of patients. A recurrent mutation, p.Gly374Glu, found in 43% 
of patients, triggered accumulation of 2-hydroxyglutarate, both 
in tumours and in a heterologous cell-based assay designed 
to functionally evaluate DLST variants. p.Gly374Glu-DLST-
mutated tumours exhibited loss of heterozygosity as well as 
consistent methylation and expression profiles. We also found 
positive DLST immunostaining not only in DLST-mutated 
tumours, but also in other tumours in which the TCA cycle 
was disrupted. In summary, this study reveals DLST as a new 
PPGL susceptibility gene and further strengthens the relevance 
of the TCA cycle in PPGL development.
Mutations leading to extraordinary responses to mTOR 
inhibitors. The inhibitors of the mammalian target of 
rapamycin ( mTOR ) are key drugs for the treatment of several 
tumours. However, we lack markers able to identify patients 
with enhanced treatment sensitivity. To discover molecular 
determinants of drug response and to contribute to the 
definition of predictive biomarkers, we recruited renal cancer 
patients with extraordinary responses to these drugs and 
performed a comprehensive genomic, immunochemical and 
functional characterisation of the tumours. In two young adults 
with metastatic cancer, a renal epithelioid angiomyolipoma 
( EAML ) and a chromophobe renal cell carcinoma, that upon 
rapalog treatment had a complete response at metastatic 
sites and durable responses, we could identify TSC2 somatic 
mutations as causative of the extraordinary responses. 
These findings support a high efficacy of mTOR inhibitors in 
malignant EAML and in a subset of patients with chromophobe 
renal cancer, and propose sequencing of mTOR pathway genes 
to guide therapy with these drugs.
Deep sequencing of small RNAs reveals a prognosis marker 
functionally associated with alternative splicing modulation 
in thyroid cancer. It is urgent to identify biomarkers and 
functional networks associated with aggressive thyroid cancer 
in order to anticipate disease progression and facilitate patient-
personalised management. The miRnome sequencing of 
thyroid tumour series enriched for advanced disease patients 
uncovered miRnome profiles correlated with tumour-specific 
histopathological and molecular features, such as stromal-
cell infiltration and tumour-driver mutation. Differential 
analysis considering disease prognosis revealed a consistent 
hsa-miR139-5p down-expression in primary carcinomas 
from patients with recurrent/metastatic disease. Exogenous 
expression of hsa-miR-139-5p significantly reduced migration 
and proliferation abilities of anaplastic thyroid cancer 
cells. Proteomics analysis pointed to RICTOR, SMAD2/3 
and HNRNPF as hsa-miR-139-5p putative targets in vitro. 
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Figure Hsa-miR-139-5p/HNRNPF axis modulates gene-
transcripts balance. ( A ) Alternative splicing analysis 
experiment. DeSeq2 differential expression analysis showed 
a reduction of HNRNPF mRNA abundance ( Log2 FC=-1.058 ) 
upon hsa-miR139-5p expression induction. rMATS method 
identified differences in alternative splicing. ( B ) Events with a 
significant different inclusion level ( FDR<0.05 ) upon hsa-miR-
139-5p/HNRNPF axis regulation. Analysis considers junction 
and target exon counts from RNA sequencing data. SE : Skipped 
exon, MXE : Mutually exclusive, A5SS : Alternative 5 ’ splice site, 
A3SS : Alternative 3 ’ splice site ; RI : Retained intron.
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The scope of the research carried out by our Group ranges from 
the identification of aetiological agents and mechanisms, to the 
translation of the findings into the clinical and Public Health 
domains, focusing on bladder, pancreatic, and breast cancers.
We employ a wide variety of biomarkers to better characterise 
exposures, genetic susceptibility patterns, and cancer 
outcomes. Omics data provide a unique opportunity in this 
regard and the Group explores its integration in epidemiologic 
studies.
The strategic goals of the Group are to :
 ɗ Identify non-genetic and genetic factors, as well as their 
interactions, associated with cancer development and 
progression and with its molecular/omics subphenotypes.
 ɗ Develop and apply statistical/informatics tools to model 
the risk, prediction, and clinical course of patients with 
cancer by integrating epidemiologic with omics information.
 ɗ Assess clinical and public health strategies for cancer 
control using current genomic tests and data.
“ The integration of omics and 
non-omics data in the same risk 
models poses several challenges and 
demands of appropriate analytical 
strategies. We are contributing to 
this field towards a personalised 
prevention of cancer.”
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the challenges in OnO data integration and presented, 
discussed, and proposed integrative analytical strategies 
towards its integration.
Translational activities
The Group actively provides support in several clinical trials 
on immunotherapy and vitamin D in bladder cancer at the 
methodological level. We continue to sustain the Spanish 
Familial PC Registry ( PanGen-FAM ) and the establishment 
of the European Registry of PC ( PancreOS ). We lead the 
Research Work Stream of the Pancreatic Cancer Europe ( EPC ) 
multistakeholder platform, with who we hosted a session on PC 
Liquid Biopsy during the 2018 ESMO GI Meeting. To increase 
awareness of PC among health policy makers and discuss the 
urgent need to invest in PC research, we participated and 
co-organised sessions with MEPs at the European Parliament 
and with delegates at the Annual Meeting of the European 
Alliance of Personalized Medicine. s
research hiGhliGhTs
Research findings
In 2018, the Group mainly focussed its research on pancreatic 
cancer while building resources for bladder cancer research. 
For pancreatic cancer ( PC ), we continued exploiting the data 
generated by the PanGenEU Study to further characterise 
pancreatic cancer risk. Two main articles exemplify our 
contributions to this domain. First, by applying complementary 
analytical approaches we reported that, regardless of non-
genetic risk factors, the risk of PC was 2.5 higher among family 
members with more than 2 relatives affected with PC, with 
this risk being stronger in current smokers ( FIGURE 1 ). 
Furthermore, we confirmed that PC was diagnosed at younger 
ages among those subjects with a family history of PC who 
smoked than in non-smokers. In the second article, we reported 
on the underlying genetic basis behind PC and its associated 
multimorbidities network through a computational approach 
using the DisGeNET. This strategy allowed us to identify several 
autoimmune diseases linked to PC and the shared altered genes 
( FIGURE 2 ). These associations were subsequently confirmed 
at the individual level in the PanGenEU study population 
of 1,705 PC cases and 1,084 controls that resulted in a reduced 
risk of PC in subjects having >2 autoimmune diseases. These 
findings again pointed to the role of the immunological status 
in PC carcinogenesis. We also continued to participate in 
international large-scale investigations to further characterise 
the genetic susceptibility and somatic alteration landscape 
of PC. For bladder cancer ( BC ), the Group reported on the 
inverse association between asthma and BC using the Spanish 
Bladder Cancer/EPICURO Study resources. This reduced risk 
of BC was especially observed among aggressive tumours. 
The Group also participated in the discovery and validation 
of both urine and tumour prognostic marker combination in 
large European studies of non-muscle invasive BC. We also 
performed a review of the genetic susceptibility to BC risk and 
progression based on GWAS hits. Most of the variants were 
common and conferred small risk and, therefore, they were 
not clinically actionable at the individual level.
Methodological contributions
The Group made contributions to both integrative analytic 
approaches considering omics and non-omics ( OnO ) data as 
well as in the nutrition epidemiological filed. Regarding the 
latter, we compared the antioxidant profiles of 21 a priori-
defined Mediterranean diet indexes and reported that the level 
of dietary antioxidant intake captured through the different 
indexes differed due to the variation in their construction. As 
of the data integrative efforts, we observed that only a small 
number of published studies performed a ‘ real ’ integration of 
OnO data, primarily to predict cancer outcomes. We identified 
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Figure 1 Odd ratios for the joint 
effect of family history of cancer 
( FHC ) / Family history of pancreatic 
cancer ( FHPC ) and smoking on 
pancreatic cancer risk. PanGenEU 
case-control study.
Figure 2 Pancreatic cancer gene-
based comorbidity network. ( A ) Gene 
network of 27 medical conditions. 
Edge width represents the strength 
( Jaccard index, JI ) for each disease 
pair. Node size represents the number 
of genes obtained through DisGeNET 
for each medical condition. (  B ) 
Venn diagram showing the number 
of shared genes among pancreatic 
cancer and 4 autoimmune diseases. 
Squares show the genes shared 
between pancreatic cancer and 
autoimmune conditions.
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The clinical and diagnostic activities carried out by the FCCU 
through the consultancy in the Medical Oncology Department 
of Fuenlabrada’s University Hospital, have contributed to the 
selection of patients who are good candidates for targeted 
therapies. In order to extend the study, we apply a multigene 
panel test to an increasingly larger number of pathologies. 
Ovarian cancer ( OC ) for instance, is a genetically heterogeneous 
malignancy that is po tentially driven by multiple aberrant 
molecular pathways. Germline BRCA1/2 mutations account 
for 65–85% of all hereditary OC, while mutations in Lynch genes 
( DNA mismatch repair genes ) are responsible for 10–15% of 
these hereditary OC. Germline mutations drive the therapeutic 
strategy : OC associated to BRCA1/2 mutations have a 
demonstrated sensitivity to PARP inhibitors, while immune 
checkpoint inhibitors are indicated for metastatic solid tumours 
associated with DNA mismatch repair deficiency.
Our clinical and diagnostic activities this year can be 
summarised as follows : 550 patients visited our consultancy 
at HUF ( 8.69% increase over 2017 ); and 508 genetic diagnostic 
studies were performed in the FCCU laboratory ( 18.69% 
increase ). Among these studies, we identified 25 tumours 
with MSI, all of them potential candidates to be treated with 
monoclonal antibodies that target PD-1.
Our research in colorectal cancer ( CRC ) focuses on early-
onset forms and multiple primary tumours. We recently 
reported the largest series of Synchronous Colorectal 
Cancers ( SCRC ), in which clonality was analysed by Single-
Nucleotide Polymorphism array, and the subsequent statistical 
application ; we were the first to correlate it with clinical 
phenotypes. Thirty-six per cent of our SCRC fulfilled clonality 
features. The existence of clonality within SCRC has important 
consequences throughout therapeutic management. The 
stratification in different categories may also serve as a starting 
point to more selectively analyse the molecular basis of SCRC 
and its relationship with environmental factors.
The FCCU also focuses its research efforts on less frequent 
cancer predisposition syndromes. One of these is the PTEN 
hamartoma tumour syndrome ( PHTS ), in which several 
aspects such as the high clinical heterogeneity usually result in 
a late diagnosis. We have studied this pathology at the clinical 
and molecular level in the largest series of Spanish patients 
with PHTS ( 145 probands ). Overall, our findings are consistent 
with the syndrome descriptions in other populations, with a few 
exceptions such as a higher proportion of carriers of mutations 
in PTEN exon 1. We have also discussed the usefulness of the 
different diagnostic criteria proposed to date for this disease 
and have suggested recommendations based on our results. We 
are currently focusing on the search for phenotype modifiers, 
as in the case of the KLLN gene, as well as for other genetic 
factors that may explain the disease in PTEN wild type patients. 
For this last purpose, we are using a gene panel to look for 
mutations on the main pathway antagonised by PTEN − the 
PI3K/AKT/mTOR pathway − and are analysing whole exome 
sequencing data from selected cases. Our study continues to 
contribute to a better definition of PHTS and to help accelerate 
the diagnosis of the patients.
Addressing the functional consequence of germline missense 
variants involved in cancer genes is very important when 
prophylactic surgical removal of organs is the only therapeutic 
option to prevent the development of an aggressive cancer. In 
this context, we found 3 unrelated families with hereditary 
diffuse gastric cancer carrying the same germline missense 
variant in the CDH1 gene : c.1679C>G. Through genetic and 
in vitro studies, we explored the effect of this variant and 
finally demonstrated its deleterious effect, suggesting that 
gastrectomy should be considered in patients harbouring 
this variant. s
oVerVieW
Lynch syndrome is a very complex entity associated with high 
risks for a wide variety of malignancies, including colorectal, 
endometrial, ovarian, gastric, urinary tract, pancreatic, biliary, 
small intestinal, prostatic, and brain cancers. Until now, the 
malignancies developed in people with Lynch syndrome were 
treated exactly in the same way as their sporadic counterparts. 
However, recent therapeutic advances in the immunologic 
effects of microsatellite instability ( MSI ), the hallmark 
of Lynch syndrome associated tumours, have resulted in 
important changes in the treatment of these patients.
MSI, by definition, is characterised by the somatic 
accumulation of mutations, which subsequently produce 
potentially antigenic frameshift neopeptides that account 
for the infiltrating lymphocyte reaction classically observed 
in Lynch-associated tumours. The recent emergence of 
immune checkpoint inhibitors that work on the patients’ 
own immune system has led to the use of this underlying 
biological characteristic to advance in the treatment of Lynch 
syndrome-associated tumours.
The Familial Cancer Clinical Unit ( FCCU ) is not only 
committed to screening blood samples with the aim of 
identifying germline mutations, but also to analysing tumour 
samples to determine their microsatellite status. Both findings 
play a critical role in the understanding of the molecular 
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Modelling cancer using CRISPR/Cas9 genome editing 
technology
Efficient methodologies for recreating cancer-associated 
chromosome aberrations and gene mutations are in high 
demand as tools for investigating how such events initiate 
cancer. We have recently demonstrated the feasibility of 
utilising gRNA/Cas9 ribonucleoprotein ( RNP ) complexes 
to model cancers driven by fusion genes generated by 
chromosomal rearrangements. We have optimised new 
strategies to enhance the efficiency of the CRISPR-mediated 
translocation induction in human stem cells, including 
mesenchymal and induced pluripotent stem cells. We found 
that the generation of targeted translocation is significantly 
increased by using a combination of ribonucleoprotein 
complexes ( Cas9 protein+sgRNA ) and ssODNs. The CRISPR-
Cas9-mediated generation of targeted translocations in human 
stem cells opens up new avenues to model cancer.
Technological and translational activities
We provide state-of-the-art Molecular Cytogenetic and Genome 
Editing services. The Unit supplies research groups with various 
techniques that may provide more sensitive and accurate tools to 
analyse cancer cells, such as chromosome stability studies based 
on a combined array CGH-FISH approach, or the use of CRISPR 
libraries to perform high-throughput functional analysis. For gene 
editing experiments, we have set up a specific PCR-based FISH 
analysis to detect genome integration sites of small constructs 
including LV particles. As the field of cancer cytogenomics moves 
forward with the identification and cataloguing of recurrent 
chromosomal aberrations and gene mutations in a variety of 
human cancers, our CRISPR-based cellular platforms offer a rapid, 
precise and affordable opportunity to functionally interrogate 
the cancer genome. In 2018, we carried out over 1,500 assays for 
experimental and clinically-oriented projects. s
oVerVieW
Recurrent chromosomal rearrangements are very common 
and well-known hallmarks of cancer. One of their main 
consequences is the creation of new chimeric genes as a 
result of the fusion of the coding sequences of 2 different 
genes. The research activity of the Molecular Cytogenetics and 
Genome Editing Unit ( MC&GEU ) is focused on increasing the 
knowledge about the genetics of tumours and the discovery of 
new therapeutic targets. With the combined used of CRISPR 
genome editing and cytogenetic technologies, we are creating 
human in vitro models that recapitulate chromosomal, genetic 
and epigenetic cancer alterations. The goal of the Unit is to 
provide the CNIO and external researchers with the latest 
technologies used in the fields of molecular cytogenetics and 
genome editing. The Unit is constantly implementing and 
developing new technologies in the gene editing field. We 
also participate in collaborative projects with clinical and 
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“ We have applied genome 
engineering approaches for 
cancer modelling, reproducing 
chromosome rearrangements 
and gene alterations. We provide 
access to the latest Cytogenetic 
and CRISPR technologies.”
Figure Overview of efficient 
approaches for recreating cancer-
associated chromosome translocations. 
Usage of RNP and ssODN efficiently 
recreates human chromosomal 
translocations.
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Pharmacogenetic variants and response to neoadjuvant single-
agent doxorubicin or docetaxel : a study in locally advanced breast 
cancer patients participating in the NCT00123929 phase 2 
randomised trial. Docetaxel and anthracycline are widely used 
in the treatment of breast cancer despite the benefit being limited 
to a small proportion of patients, and preoperative biomarkers 
predictive of clinical outcome remain lacking. We carried out a 
pharmacogenetic study in 181 patients with locally advanced breast 
cancer who were previously enrolled in a phase 2 randomised 
clinical trial ( NCT00123929 ), in which patients were randomly 
assigned to receive doxorubicin ( anthracycline ) or docetaxel 
( taxane ) in neoadjuvance. We assessed whether genetic variants 
in 15 key transport or metabolism genes relevant to doxorubicin 
and docetaxel drugs could play a role as predictive biomarkers. We 
identified a genetic variant, located in the promoter of ABCC2, as 
having the strongest association with tumour response observed 
in patients treated with doxorubicin ( P=0.009 ). We also identified 
a significant association for an intronic variant, located in CYP1B1, 
associated with docetaxel tumour response ( P=2.15x10-4 ). Our 
integrated pathway-based approach allows revealing promising 
genetic biomarkers for treatment outcome in breast cancer 
patients ( Ruiz-Pinto S et al., 2018 ).
Genome-wide association study (GWAS) identifies three new loci 
associated with Ewing sarcoma susceptibility. Ewing sarcoma 
( EWS ) is a paediatric cancer characterised by the EWSR1-
FLI1 fusion. Our previous GWAS identified susceptibility loci 
at 1p36.22, 10q21 and 15q15. We performed a GWAS of 733 EWS 
cases and 1346 unaffected individuals of European ancestry. 
Our study replicates previously reported susceptibility loci 
at 1p36.22, 10q21.3 and 15q15.1, and identifies new loci at 6p25.1, 
20p11.22 and 20p11.23. In the analyses of the new loci, there 
is evidence of informative eQTLs with nearby biologically 
plausible candidate genes that could be likely target genes 
for future functional investigations. It is remarkable that 6 
independent susceptibility regions with relatively large effect 
sizes ( estimated OR > 1.7 ) have been discovered in a sample 
of 733 EWS cases. In conclusion, our study provides support for 
a strong inherited genetic component to EWS risk and suggests 
that interactions between germline variation and somatically 
acquired EWSR1-FLI1 translocations are important etiologic 
contributors to EWS risk ( Machiela MJ et al., 2018 ).
New loci associated with risk to develop tobacco-induced lung 
cancer : genome-wide association study in heavy smokers. We 
genotyped 2.37 million SNPs across the genome in heavy smokers 
that either developed NSCLC at an early age ( extreme cases ), or 
did not present NSCLC at an advanced age ( extreme controls ), 
selected from a discovery set ( n = 3631 ). We validated significant 
SNPs in 133 additional subjects with extreme phenotypes 
selected from databases including >39,000 individuals. Two 
SNPs were validated : rs12660420 ( p combined = 5.66 × 10-5 ; 
OR combined = 2.80 ), mapping to a noncoding transcript exon 
of PDE10A ; and rs6835978 ( p combined = 1.02 × 10-4 ; OR 
combined = 2.57 ), an intronic variant in ATP10D. We assessed 
the relevance of both proteins in early-stage NSCLC. PDE10A 
and ATP10D mRNA expressions correlated with survival in 821 
stage I-II NSCLC patients ( p = 0.01 and p < 0.0001 ). PDE10A 
protein expression correlated with survival in 149 patients with 
stage I-II NSCLC ( p = 0.002 ). In conclusion, we validated 2 novel 
variants associated with risk of developing tobacco-induced 
NSCLC in heavy smokers ( Fusco JP et al., 2018 ). s
oVerVieW
The most abundant types of genetic variation are single 
nucleotide variants ( SNVs ) and copy number variants ( CNVs ). 
Association studies involving the large-scale analysis of 
both SNVs and CNVs in thousands of patients can help to 
identify genes underlying complex diseases such as cancer 
and drug responses. In this Unit we implement different high-
throughput and cost-effective methods to measure from one 
to millions of SNVs and CNVs. In addition, epigenetic studies 
using whole-genome methylation arrays are performed in this 
Unit. Complementarily, research focused on the identification 
of predictive biomarkers for precision medicine is also 
undertaken.
“ Matching cancer patients with 
treatments that are likely to be 
more effective and cause fewer side 
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The Clinical Research Programme ( CRP ) has two main aims : 
1 ) to translate preclinical research into novel clinical care 
standards ; and 2 ) to address novel clinical oncology challenges 
with preclinical research. The specific areas of work include : 
1 ) development of novel agents ; 2 ) study of mechanisms of 
action of novel compounds and tackling drug resistance ; 
and 3 ), moving forward in the field of biomarkers, functional 
taxonomy and precision medicine.
Currently, the CRP is composed of four Clinical Research 
Units and one supporting Unit. The Breast Cancer Clinical 
Research Unit has successfully completed the first kinase-
based taxonomy of triple-negative breast cancer. The 
Prostate Cancer Clinical Research Unit, under David Olmos’ 
supervision, has completed its prospective observational 
PROCURE study involving >1000 patients, whereby different 
predictive associations are being explored ; two major 
manuscripts regarding the role of germline and somatic 
variants in response to antiandrogens or conventional 
chemotherapy have already been published thanks to this 
effort. The Lung Cancer Clinical Research Unit, led by Luis 
Paz Ares, has significantly contributed to the discovery of 
biomarkers that will impact the selection tools for targeted 
therapies in advanced lung cancer. They have also led several 
practice-changing international clinical trials. Finally, the 
Haematological Malignancies Clinical Research Unit, headed 
by Joaquín Martínez-López, has developed novel tools for the 
diagnosis and surveillance of the clinical course of different 
haematological malignancies. Regarding drug development 
and novel treatment approaches, an exciting novel line of 
research based on the ex vivo expansion of natural killer cells 
is currently ongoing. Finally, the Molecular Diagnostics Unit, 
led by Luis Lombardía, has continued to provide support to 
hospitals in the diagnosis of haematological malignancies.
Several contracts with ‘ Big Pharma ’ were signed during 2018 
in order to progress in the development of cancer 
immunotherapies ( Lung Cancer Unit ). The Prostate Cancer 
Unit was awarded with a Department of Defense Grant in 2018. 
These achievements highlight the relevance of the translational 
research activities conducted by the CRP during 2018 ; we hope 
to further enhance these activities through future alliances 
with tertiary hospitals and medical societies over the next 
few years.
“ The Clinical Research 
Programme aims to improve 
cancer care by developing 
novel agents and 
personalising therapeutic 
approaches on the basis of 
biomarkers.”
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BREAST CANCER JUNIOR 
CLINICAL RESEARCH UNIT
research hiGhliGhTs
This year, we completed the first phosphoproteomic taxonomy 
of triple-negative breast cancer ( TNBC ), the most deadly 
subtype of this disease. Next-generation sequencing studies 
have failed in the task of finding simple biomarkers for complex 
phenotypic traits, such as response or resistance to therapeutic 
agents or disease course outside the context of penetrant 
oncogenic-addiction drivers. Rather, the TNBC phenotype 
traits are the result of multiple contributing low-penetrance 
mutations. We have found that different clusters of mutations 
collapse into discrete patterns of activation of the proteome in 
the form of protein phosphorylation, and that such patterns are 
driven by a small number of hyperactive/hypoactive kinases. 
Specifically, we found 6 kinases that, when all of them are 
“ switched off ”, patients are long-term disease-free after >10 
years. However, when 1 or more of those kinases are “ on ”, 
the risk of relapse increases 10-fold. More importantly, all 6 
kinases are actionable and we have found profound synergy 
in all 2-by-2 combinations in preclinical models.
On the clinical side of our activities, during 2018, we completed 2 
clinical trials that were launched based on our research. 
Specifically, one of the trials explored the reversal of immune-
tolerance induced by chronic hypoxia observed after prolonged 
exposure to antiangiogenics. A second trial explored the reversal 
of the metabolic switch of tumours experiencing vascular 
normalisation in response to antiangiogenics. Both trials 
implement targeted agents ( a PD-L1 inhibitor or a mitochondrial 
inhibitor, respectively ) directed against the 2 main regulatory 
nodes in each of the 2 major patterns of angiogenesis inhibitor 
escape identified during the period 2015-2017. s
oVerVieW
The Breast Cancer Clinical Research Unit ( BCCRU ) focuses on 
the translational interface of therapeutic development. Breast 
cancer is a heterogeneous disease, and thus, there are large 
inter-patient variations in terms of disease course, prognosis, 
relapse and resistance to conventional or targeted therapeutics. 
Our activities are directed towards personalised treatment, and 
range from preclinical models to the sponsoring of multicentric 
clinical trials. Specifically, our research areas are :
 ɗ Discovery of new targets for breast cancer prevention.
 ɗ Breast cancer functional taxonomy : by using a systems 
biology approach, we are clustering the disease into subtypes 
defined by biologic features that constitute therapeutic 
targets.
 ɗ Study of the mechanisms of resistance against targeted 
therapies.
Miguel Quintela-Fandino
Junior Clinical Research Unit Head
Staff Scientists
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Figure ( A ) Phosphorylation profiles 
of whole tumours from TNBC with 
and without relapse were obtained 
by mass spectrometry. ( B ) Kinases 
with increased function accounting 
for such profiles were solved through 
an in-house algorithm (“ Kinase-set 
enrichment analysis ” or KSEAS ”). ( C ) 
This information was then translated to 
immunohistochemistry ; the left sample 
shows a patient with hyperactivated 
ERK, compared to a hypoactive one. 
( D ) Combined treatment with agents 
targeting the 2 top-hits ( CDK4/6 plus 
ERK inhibitors ) in TNBC xenografts 
achieved a synergistic effect.
 ∞ PUBLICATIONS
 ∞ Zagorac I, Fernandez-Gaitero S, Penning 
R, Post H, Bueno MJ, Mouron S, Manso L, 
Morente MM, Alonso S, Serrra V, Muñoz J, 
Gomez-Lopez G, Lopez-Acosta JF, Jimen-
ez-Renard V, Gris-Oliver A, Al-Shahrour F, 
Piñeiro-Yañez E, Montoya Suarez JL, Apala 
JV, Moreno-Torres A, Colomer R, Dopazo 
A, Heck AJR, Altelaar M, Quintela-Fandino 
M ( 2018 ). In vivo phosphoproteomics 
reveals kinase activity profiles that pre-
dict treatment outcome in triple-negative 
breast cancer. Nat Commun 9, 3501-15.
 ∞ Alvarez-Fernandez M, Sanz-Flores M, 
Sanz-Castillo B, Salazar-Roa M, Partida 
D, Zapatero-Solana E, Ali HR, Manchado E, 
Lowe S, VanArsdale T, Shields D, Caldas C, 
Quintela-Fandino M, Malumbres M ( 2018 ). 
Therapeutic relevance of the PP2A-B55 
inhibitory kinase MASTL/Greatwall in 
breast cancer. Cell Death Differ 25, 828-40.
“ In 2018, the BCCRU completed 
the first study elaborating a kinase-
based taxonomy of triple-negative 
breast cancer. This will enable 
therapeutic and biomarker-based 
precision-medicine initiatives.”
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PROREPAIR-B study. The primary analyses of the 
PROREPAIR-B study will be published early in 2019 in the 
Journal of Clinical Oncology. The highlights of this study 
can be briefly summarised as follows : up to 16% of mCRPC 
may carry germline pathogenic mutations in DDR genes ; a 
BRCA2 germline mutation has twice the risk of progressing 
to castration-resistant disease and of death from prostate 
cancer. We have just started analysing the prevalence of 
somatic aberrations in DDR genes in this study as part of 
a DoD IMPACT award. In addition, we are completing the 
genomic and transcriptomic characterisation of a large 
collection of BRCA2 mutated prostate cancers in order to 
identify secondary events that may contribute to the poor 
prognosis of the affected men.
AR gain and mCRPC treatment selection. As part of an 
ongoing international collaboration with Dr Attard’s lab ( UCL, 
London ) and Dr di Giorgi’s team ( IRCSS, Meldola ), we have 
determined that mCRPC, having a normal number of copies 
of the androgen receptor ( AR ) gene in ctDNA, have a lower 
risk of disease progression and a higher life expectancy when 
they are treated with abiraterone/enzalutamide, with a 50% 
improvement compared to docetaxel. On the other hand, the 
patients with more copies of the AR gene respond slightly 
better to docetaxel.
SWITCH phase II study. This study, recently published in 
the British Journal of Cancer, demonstrated that the simple 
change of the supporting steroid, switched from prednisone 
to dexamethasone, while maintaining abiraterone, helps to 
re-induce the response to abiraterone in about 4 out of every 10 
patients progressing by PSA criteria. This response does not 
occur in patients with AR gain detected in plasma ctDNA, 
while patients with AR normal status benefit the most. s
oVerVieW
Prostate cancer remains a major health burden as over a million 
men around the world are annually diagnosed with prostate 
cancer. Up to 30% of them may develop metastatic prostate cancer, 
which is the advanced form of this disease, once it has spread 
outside the prostate and is no longer curable. This metastatic 
stage causes about 6,000 deaths every year in Spain alone, whilst 
in the US over 30,000 men succumb to the disease every year. In 
recent years, different subtypes of prostate cancer have been 
identified based on different genomic profiles. We believe 
that a better understanding of cancer biology, as well as an 
improved human prostate cancer taxonomy linked to clinical 
outcomes, could lead to improved patient outcomes through 
the application of tailored treatment strategies as opposed 
to the current one-fits-all approach. As an example of one 
of these clusters, 20-25% of all metastatic prostate cancers 
have aberrations in DNA repair genes ; about half of these 
aberrations may correspond to inherited mutations.
research hiGhliGhTs
During  2018, our Group made significant progress in 
many projects. We finalised the primary analyses of our 
PROREPAIR-B study and have also completed recruitment 
in 3 additional studies from our PROCURE platform of 
prospective biomarker studies : PROSTAC, PROSABI & 
PRORADIUM. Over 1,000 men with metastatic castration-
resistant prostate cancer ( mCRPC ) have been enrolled in 
these studies to this day. Our clinical CNIO-IBIMA unit has 
been consolidated as 1 of the top prostate cancer clinical 
trials units in Europe, playing a leading role in several early 
and pivotal clinical trials. We have also reported our first 
investigator-initiated phase II study. At the preclinical level, 
we have made some advances in the characterisation of the 
biological role in prostate cancer of different DDR defects, 
including Atm loss. We have also made progress in developing 
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 ∞ PUBLICATIONS
 ∞ Smith MR et al. ( 2018 ). Apalutamide 
treatment and metastasis-free survival 
in prostate ancer. New Engl J Med 378, 
1408-1418.
 ∞ Lawrence MG et al. ( incl. Lopez-Campos F, 
Castro E ) ( 2018 ). Patient-derived models 
of abiraterone and enzalutamide resist-
ant prostate cancer reveal sensitivity to 
ribosome-directed therapy. Eur Urol 74, 
562-572.
 ∞ Lorente D, Olmos D et al. ( 2018 ). Circulat-
ing tumour cell increase as a biomarker 
of disease progression in metastatic cas-
tration-resistant prostate cancer patients 
with low baseline CTC counts. Ann On-
col 29, 1554-1560.
 ∞ Mikropoulos C et al. ( incl. Castro E ) ( 2018 ). 
Prostate-specific antigen velocity in a 
prospective prostate cancer screening 
study of men with genetic predisposition. 
Br J Cancer 118, 266-276.
 ∞ Romero-Laorden N et al. (incl. Castro E, 
Olmos D) ( 2018 ). Phase II pilot study of 
the prednisone to dexamethasone switch 
in metastatic castration-resistant prostate 
cancer ( mCRPC ) patients with limited pro-
gression on abiraterone plus prednisone 
( SWITCH study ). Br J Cancer 119, 1052-1059.
 ∞ Cassinello J et al. (incl. Olmos D) ( 2018 ). 
SEOM clinical guidelines for the treatment 
of metastatic prostate cancer ( 2017 ). Clin 
Transl Oncol 20, 57-68.
 ∞ AWARDS AND RECOGNITION
 ∞ Member of the Board of Directors, Eu-
ropean Organization for Research and 
Treatment of Cancer ( EORTC ).
 ∞ Impact Award ( Partnering PI ). US Depart-
ment of Defense, Congressionally Directed 
Medical Research Programs.
 ∞ Faculty Board Member, EORTC-EC-
CO-AACR-ESMO Methods in Clinical 
Cancer Research Workshop, Zeist, The 
Netherlands.
 ∞ Elena Castro: Faculty Board Member, 
ESMO Preceptorships in Prostate Cancer.
 ∞ Rebeca Lozano was awarded the ‘ Mer-
it Award ’, American Society of Clinical 
Oncology GU Cancers Symposium, San 
Francisco ; ‘ Best Com munication ’ Award, 
2018 SEOM annual Meeting ; and the Rio 
Hortega Fellowship 2018, Instituto de 
Salud Carlos III, Spain.
Figure PROREPAIR-B study. 
Distribution of the pathogenic 
mutations in DDR genes identified in 
the study ( top ). Kaplan-Meier curves 
for cause-specific survival from 
diagnosis of mCRPC : BRCA2 mutant 
vs noncarriers ( bottom ).
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core uniT hiGhliGhTs
During 2018, we have added and/or expanded 3 diagnostics 
tests.
First of all, the detection of the fusion gene BCL1-IgH 
by PCR was added to our list of services. Although the 
genetic translocation t( 11 ;14 )( q13 ; q32 ) is present in other 
lymphoproliferative diseases, it occurs mainly in mantle cell 
lymphomas ( 50-70%), which are more aggressive and have, 
in general, a worse prognosis than other low-grade B-cell 
lymphomas. This assay will be used not only to diagnose 
patients with a suspected mantle cell lymphoma, but also to 
monitor and evaluate recurrences of the disease.
We have also complemented the MYD88 gene testing of 
patients with Lymphoplasmacytic Lymphoma/Waldenström’s 
Macroglobulinemia ( LPL/WM ), by implementing a test that 
enables the detection, by Sanger sequencing, of nonsense 
and frameshift mutations in the CXCR4 gene. The protein 
coded by this gene activates the AKT1/MAPK pathways in 
B-lineage cells and facilitates cell migration. Mutations in 
CXCRA, commonly found in association with MYD88 L265P 
mutation, are associated with primary resistance and initial 
lack of response to BTK, PI3K, and mTOR inhibitors. Thus, 
this assay will be used to aid in the prognosis and therapeutic 
management of LPL/WM patients ( FIGURE ).
Additionally, we directed our efforts towards improving the 
clinical utility of molecular testing based on the BRAF gene. 
In this regard, to complement the detection of the recurrent 
V600 mutation of BRAF in melanoma patients, we extended the 
analysis by bi-directional sequencing of exon 11 to enable the 
management of patients with lung cancer. Mutations in exon 11 
are regularly found in lung tumours that are wild type for EGFR, 
KRAS, ALK, and other driver alterations. Moreover, these 
patients, with decreased sensitivity to gefitinib, responded 
to dasatinib with no additional treatment for several years.
Finally, during 2018, in the framework of our training policy, we 
hosted one medical resident and 2 undergraduate students. s
oVerVieW
The main objectives of the Molecular Diagnostics Unit ( MDU ) 
are directed towards offering quality molecular tests for 
patients with cancer in order to support the current clinical 
services and diagnostic laboratories in hospitals of the Spanish 
National Health System ( NHS ). In this regard, the Unit 
provides a wide range of highly sensitive molecular assays to 
determine changes in the sequence or expression levels of key 
genes involved in cancer, and to enable the detection of Minimal 
Residual Disease in patients showing clinical remission as well 
as to follow-up on their response to therapy. Likewise, MDU 
is also devoted to implementing recent up-to-date cancer 
diagnostics solutions, not only to support the NHS but also 
to assist the Clinical Research Units and Research Groups at 
the CNIO. In addition, MDU collaborates with international 
and national groups dedicated to standardising and improving 
molecular diagnostics tests in cancer, and participates in 
teaching as well as in educational programmes for clinical 







 ∞ AWARDS AND RECOGNITION
 ∞ Member of the Committee for Ethical 
Research ( CEI ; Comité de Ética de la In-
vestigación ), Instituto de Salud Carlos III, 
Madrid, Spain.
“ In this new era of precision 
medicine in cancer, Molecular 
Diagnostics is playing a fundamental 
role as demonstrated by the 
increasing variety of assays 
requested by haemato-oncologists 
throughout 2018.”
Figure Molecular testing of MYD88 
and CXCR4 genes in plasmacytoid 
lymphocytes allows for different 
prognostic and/or therapeutic options 
for patients with Waldenström’s 
Macroglobulinemia. ( Wt : Wild Type ; 
L265P : Leucine to Proline substitution 
at position 265 ; Ct-Mut : C-terminus 
nonsense/frameshift mutations ).
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oVerVieW
The Haematological Malignancies Laboratory focuses on 
investigating novel drivers, biomarkers, diagnostic tools 
and therapeutic targets and approaches in haematological 
neoplasms such as myeloma and acute myeloid leukaemia.
Five main lines define our research project :
 ɗ Generation of mouse models focused on the molecule 
hnRNP K, a novel driver of lymphoma and leukaemia.
 ɗ Development of novel diagnostic and follow-up tools, 
such as minimal residual disease analysis in acute myeloid 
leukaemia ( AML ).
 ɗ Screening of novel drivers, biomarkers and therapeutic 
targets by next-generation-sequencing ( NGS, e.g. exome 
sequencing of amyloidosis ).
 ɗ Innovation of immunotherapy approaches. Generation of 
NK CARs and in vitro/in vivo validation.
 ɗ Novel therapeutic approaches. Screening of novel 
compounds ( e.g. hnRNP K inhibitors ) and pre-clinical 
trials of new drugs or drug combinations.
“ We have developed a strategy 
to identify undetectable levels of 
minimal residual disease using an 
NGS method, thereby improving 
the capacity to predict AML 
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the tyrosine kinase inhibitor midostaurin, inhibiting different 
FLT3 downstream pathways.
Our data provide preclinical evidence that combining a tyrosine 
kinase inhibitor, such as midostaurin, with a MEK inhibitor, such 
as trametinib, is a rational and efficacious treatment regimen for 
a wide range of acute myeloid leukaemias ( work under review 
in the Journal of Experimental & Clinical Cancer Research ).
DNA methylation mutations predict azacitidine 
response in myelodysplastic syndromes
Alterations in DNA methylation are involved in the 
pathogenesis of myelodysplastic syndromes ( MDS ), however, 
whether they can also influence their response to azacitidine/
decitabine treatment has not been clearly elucidated.
We analysed frequently mutated regions in 34 genes that are 
likely candidates to be involved in the pathogenesis of MDS. We 
have found that the profile of several gene mutations identified 
at diagnosis may represent a useful predictive biomarker of 
the response to azacitidine therapy. Meta-analysis identified 
the TET2 gene as the strongest biomarker of treatment 
success. Additionally, the presence of mutations in the DNA 
methylation pathway and the number of driver mutations are 
predictors of response to hypomethylating agents in patients 
with MDS ( work published in Oncotarget ). s
research hiGhliGhTs
Minimal residual disease monitoring in acute myeloid 
leukaemia
Assessment of minimal residual disease ( MRD ) is critical for 
monitoring patients in morphological remission as well as to 
inform decisions about further therapy.
We designed and validated a high-throughput sequencing 
method for MRD assessment of cell clonotypes with 4 typical 
AML. Our analysis showed better sensitivities ( 10- 4 for SNVs 
and 10- 5 for InDels ) than current methods or other novel 
techniques such as dPCR : the sensitivity of dPCR for InDels 
was similar to that reported in a previously published study 
( 10- 2 ). It should be noted that the prediction of survival and 
progression of AML using MRD-NGS was improved over the 
other methodologies employed.
In conclusion, we have optimised a new targeted sequencing 
method with high sensitivity for MRD evaluation and 
applicability for a high percentage of AML patients, thereby 
improving the capacity to predict AML outcome over MFC 
or qPCR in our cohort ( work published in Haematologica ).
Novel therapeutic combination for primary myelofibrosis
Ruxolitinib is the frontline non-palliative treatment for 
myelofibrosis ; however, a significant number of patients 
lose or present suboptimal response, are resistant, or have 
unacceptable toxicity. We found that the combination of 
ruxolitinib and nilotinib had a synergistic effect against 
myelofibrosis. Moreover, the addition of prednisone to the 
ruxolitinib/nilotinib combination improved the synergistic 
effect in all myelofibrosis samples studied.
We provide evidence that the ruxolitinib/nilotinib/prednisone 
combination is a potential therapy for myelofibrosis, 
possibly through the anti-fibrotic effect of nilotinib, the 
immunomodulatory effects of ruxolitinib and prednisone, and 
the anti-proliferative effect of ruxolitinib. This combination 
will be further investigated in a phase Ib/II clinical trial 
in myelofibrosis ( work accepted with major changes for 
publication in Haematologica ).
Novel therapeutic combination for acute myeloid 
leukaemia
Different tyrosine kinase inhibitors have been used in FLT3 
targeting, but their effects are limited by drug resistance. 
In order to rationally combine them with other agents, we 
explored the alternative pathways activated during the 
development of resistance.
Differentially phosphorylated proteins and resistance 
mechanisms after tyrosine kinase inhibitor resistance were 
identified. Efficacy and safety of rational combinational 
therapies were assayed in vitro, ex vivo and in vivo.
The results suggested activation of the MEK pathway, therefore, 
we characterised the effect of the MEK inhibitor trametinib 
in vitro and ex vivo. Trametinib exerted strong synergy with 
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 ∞ AWARDS AND RECOGNITION
Joaquín Martínez-López: 
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Salud ( DTS ) 2018 Healthcare Technology 
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 ∞ Proyectos de Investigación en Salud ( PI ) 
2018 Health Research Project.
Figure NSG method for MRD 
detection. ( A ) Workflow of NGS-MRD 
method. ( B ) InDels calibration curve 
of MRD in serial dilutions. Top, 10-fold 
dilution curve for the assessment of 
sensitivity of sequencing in InDels. 
( C ) SNV calibration curve of MRD in 
serial dilutions. Top, 10-fold dilution 
curve for the assessment of sensitivity 
of sequencing in SNV. ( D ) Prognosis 
analysis of OS in AML patients stratified 
according to MRD levels by Kaplan-
Meier conventional methods. (  E ) 
Prognosis analysis of DFS in AML 
patients stratified according to MRD 
levels by conventional methods. Kaplan-
Meier plots.
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CLINICAL RESEARCH UNIT
oVerVieW
Lung cancer continues to be the most frequent cause of cancer-
related deaths worldwide. Our Unit focuses on the study of 
lung cancer, from fundamental research proposals to other 
more clinically oriented ones that are closer to solving the 
problems of lung cancer patients. The two main research 
areas of our Unit involve : the identification of new molecular 
biomarkers that can be used in the clinic for diagnostic, 
prognostic and predictive purposes ; and the development of 
novel treatment strategies that include targeted therapies 
and immunotherapeutics. For example, we have contributed 
to elucidating the molecular determinants of EGFR or FGFR 
oncogenicity and have discovered biomarkers that may guide 
the efficacy of inhibitors of those receptors in lung cancer. 
On the other hand, we have developed a patient-derived 
xenograft ( PDX ) platform of non-small-cell lung cancers to 
test new therapeutic strategies. Finally, our Unit has extensive 
experience in taking new drugs to the clinic ( phase I trials ), 
as well as in conducting practice-changing phase II/III trials 
in the fields of precision oncology and immuno-oncology.
“ Our Unit has significantly 
contributed to the development 
of novel biomarkers that have 
impacted the currently availble 
selection of targeted therapies 
( e.g. EGFR mutation in the clinic ) 
and novel inmunotherapeutics ( e.g. 
tumour mutational burden ). We 
have led randomised clinical trials 
with novel agents ( e.g. erlotinib, 
afatinib, Nivolumab, M7824 ) as 
well as combinations of checkpoint 
inhibitors ( e.g. Ipilimumab plus 
Nivolumab, chemotherapy plus 
Pembrolizumab, Durvalumab 
following chemoradiation ) in lung 
cancer that have impacted clinical 
practice worldwide.”
Luis G. Paz-Ares
Clinical Research Unit Head
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research hiGhliGhTs
Biomarker discovery and implementation
The Group has deciphered the biological role of FGFR1 and 
FGFR4 in non-small cell lung cancer ( NSCLC ) and has developed 
new biomarkers with a predictive role for anti-FGFR therapy in 
NSCLC. Currently, we are validating the results on a series of 
well characterised PDX models, generating a diagnostic kit and 
carrying out the technical validation of the biomarker, as well 
as planning a phase II trial proposal with an FGFR inhibitor in 
NSCLC patients with high expression of the novel biomarker.
The Group has also validated an NGS-based algorithm for the 
determination of genomic aberrations ( in tumour tissue but 
also in cfDNA ) that may guide treatment for clinical practice. 
More recently, we have led the first clinical validation of tumour 
mutational burden as a predictive biomarker for checkpoint 
inhibitors in lung cancer, and particularly, for Ipilimumab 
plus Nivolumab.
Early clinical trials
Our Group has significantly expanded its activities regarding 
the testing of new molecules and combinations in solid tumours, 
particularly in the field of immune-based approaches ; in 2018, 
we participated in more than 35 projects in this research area. 
Recently, our Group provided feasibility and encouraging initial 
data on the anti-tumour activity of M7824, a bifunctional 
fusion protein targeting PD-L1 and TGF-beta in pretreated 
NSCLC ( response rate in PD-L1 expressing tumours in more 
than 50% of the cells : 71%). Encouraging tumour-agnostic data 
of Entrectinib in tumours driven by activated NTRK fusion 
proteins were presented at the ESMO 2018 Congress ( response 
rate 57.4%; median progression-free survival of 11.4 moths ).
Changing standard-of-care treatments in clinical practice
The Lung Cancer Clinical Research Unit has led phase III trials 
whose results have significantly impacted the clinical practice 
in the context of stage IV lung cancer with combinations 
of chemotherapy plus Pembrolizumab or Ipilimumab plus 
Nivolumab ( Hellmann MD et al., NEJM 2018 ; Paz-Ares 
L et al., NEJM 2018 ). In addition, the Group has actively 
contributed to the results of a Phase III trial showing a 
significant improvement in survival for stage III NSCLC 
patients treated with the anti PD-L1 agent Durvalumab 
following chemoradiation ( Antonia S et al., NEJM 2018 ). s
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Figure 1 Results of the KeyNote 407 
randomised clinical trial, showing 
an improvement in overall survival 
(  OS  )  of chemotherapy plus 
Pembrolizumab, as compared to 
chemotherapy alone ( HR 0.64 ; 
p<0.001 ) in stage IV Non-Small-Cell 
Lung Cancer ( NSCLC ) patients.
F i g u r e  2   R e s u l t s  o f  t h e 
Checkmate 227 randomised clinical 
trial, showing the superiority in 
progression-free survival ( PFS ) 
for the Ipilimumab plus Nivolumab 
combination, as compared to 
platinum chemotherapy ( HR 0.58 ; 
p<0.001 ) in stage IV NSCLC with high 
mutational burden (>10 mutations 
per MB ).





In 2018, the CNIO Biobank ceded tissue samples from 675 cases 
thereby supporting 7 research projects. The accumulated impact 
of this year’s activity resulted in 6 ( Q1 ) publications acknowledging 
CNIO’s Biobank contributions. The mean impact factor ( IF ) of 
the 6 published articles in 2018 ( Nat Commun, EMBO Mol Med, 
Cell Metab, Int J Cancer, Proc Natl Acad Sci USA and Oncotarget ), 
for which our Unit provided support, was 10.409.
Other activities
 ɗ Sample processing of 107 frozen samples to generate slices 
for extraction and staining.
 ɗ Management of project-driven and diagnostic collections :
 · The Familial Cancer Unit collection : we collaborated 
with the Familial Cancer Unit in the acquisition of 66 
new tissue cases, the histopathological diagnostic revision 
of 30 cases, and the histopathological evaluation of 80 
cases in a research context.
 · Management of 659 human samples for 3 different 
collections.
 · Histopathology evaluation of 294 cases in collaboration 
with the Human Cancer Genetics and Clinical Research 
Programmes.
 ɗ Virtual catalogue including 269 images ; 139 of them 
are histological H&E stainings. Work on expanding this 
catalogue to include whole section paraffin-embedded 
samples is ongoing.
 ɗ CNIO projects were supported for ethical evaluation by 
the Instituto de Salud Carlos III ( ISCIII ) Research Ethics 
Committee.
The CNIO Biobank coordinates the extended Spanish 
Biobank Platform Project funded by the ISCIII. CNIO’s 
Biobank managed 20 projects and 37 requests from basic 
and clinical researchers, as well as from the industry. It also 
implemented mobility grants for biobank personnel ( 10 pers.) 
and organised 5 specialised Scientific Meetings plus the Spanish 
Biobank Congress in Oviedo.
The CNIO Biobank participates in 3 multicentre research 
projects :
 ɗ Optimark project ( PI16/00946 ) ( led by the CNIO Biobank ): 
focused on the identification of quality markers for tissue 
samples sensitive to pre-analytical variables.
 ɗ Exospore project : aimed at defining the optimal procedures 
for collecting human samples for micro-vesicle studies.
 ɗ Histological images banking : a repository for digital images.
Teaching activities
During 2018, we actively participated in 3 school visits and 
hosted the stays of several internship students : 2 FCT students 
( Laboratory Training Programme for Technicians ), 4 high 
school students ( CNIO & The City Outreach Programme ), 2 
students from the “ 4ºESO+Empresa ” Programme ( Comunidad de 
Madrid ), and 1 Erasmus predoctoral student ( Erasmus Internship 
Programme ). The CNIO Biobank also co-organises a Master’s 
degree in Biobanking at the Universidad Católica de Valencia. s
oVerVieW
The CNIO Biobank − authorised by the Health Authorities of 
the Comunidad Autónoma de Madrid ( CAM ) and registered in 
the National Registry of Biobanks with reference B.000848 − is 
a ‘ biobank for biomedical research purposes ’, as defined by 
the Spanish Law 14/2007 and the Royal Decree RD 1716/2011. 
It is therefore defined as a public, non-profit organisation 
that hosts several collections of human biological samples 
for biomedical research, specifically in cancer and related 
diseases. The main objective of the CNIO Biobank is to facilitate 
access to human samples for researchers, ensuring that both 
the acquisition and use of human samples complies with all 
the legal and ethical principles that protect donors ’ rights.
In addition to this biobanking activity, a number of services 
have been implemented, both for sample processing and for 
supporting different aspects of the management of human 
samples for biomedical research, in order to facilitate the use 
of human samples for CNIO researchers. Additionally, the 
CNIO Biobank participates in Biospecimen Science research 
projects.
Therefore, the CNIO Biobank is a cross-service platform for 
CNIO researchers, as well as the general scientific community, 
and is geared towards the promotion of biomedical research 
in cancer and related diseases.
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Acting Director
Manuel M. Morente ( until July )
Director
Technicians
Nuria Ajenjo ( TS )*, Inmaculada 
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Figure Virtual catalogue of human samples.
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into society as new 
medicines and 
technologies is a 
goal that we nurture 
with an overarching 
strategy and team 
effort.”
Identifying how to leverage our innovation capacities and 
providing the means and framework to make it happen is the 
objective of the Direction of Innovation. To turn a scientific 
discovery into a product requires the identification of those 
specific scientific results that have the potential to change 
how a disease, such as cancer, is diagnosed, treated or managed.
The excellent science that emanates from the research carried 
out by CNIO’s investigators is the ideal ground for innovation 
to thrive. As such, the CNIO has taken part in the Milner 
Therapeutics Institute since its inception as an affiliate 
academic institution. In this role, the Centre has had the 
opportunity to interact with numerous industry partners 
during the first symposium held in Cambridge in October 2018. 
This year, the reach out activities of the Direction of Innovation, 
in close collaboration with the Office of Technology Transfer 
and Valorisation, also included the marketing of our 
technologies and capabilities in bio-business meetings, such 
as BioSpain that was held in Seville, Spain, as well as in other 
forums. Such efforts have resulted, among others, in meetings 
with four important venture capitals looking for new 
opportunities in the biomedical field, and a myriad of 
interactions with other industry partners, including their 
open innovation and academic scouting departments.
Our academic drug discovery programme continues to 
contribute to closing the valley of death and to developing a 
pipeline that feeds from the invaluable discoveries made by 
CNIO investigators as novel targets and innovative phenotypic 
screenings. This year, we have made great strides to increase 
the openness of the programme in order to become the drug 
discovery unit of reference for other centres of excellence in 
Spain, which currently lack our drug discovery capabilities.
In 2018, CaixaImpulse awarded two innovation projects led 
by CNIO researchers : an innovative project to further advance 
one of our lead drug discovery programmes, led by Maria 
Blasco ; and another innovative advanced therapeutic approach, 
headed by Sandra Rodríguez-Perales. Moreover, collaborations 
with industry, along with the licensing activities of our 
antibodies and sales, underscore co-development opportunities 
and also represent about 15% of the total income of the CNIO. 
In 2018, up to 7 discoveries and technologies were identified 
and protected to be further developed into novel technologies, 
and conversations continue with a recently created start-up, 
Senolytic Therapeutics, in order to identify synergies for 
advancing their products. We expect 2019 to be a year in which 
we will continue to reap an increasing amount of benefits 
from our efforts.
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InnovatIon BIotechnology Programme
The main mission of the Biotechnology Programme is to 
provide expert technical support and advice to CNIO Research 
Groups in a number of disciplines and technologies widely used 
in biomedical research, as well as to implement and develop 
state-of-the-art biotechnological tools and reagents for cancer 
research. The Programme is currently composed of nine Core 
Units covering major areas in Biotechnology, namely Genomics, 
Proteomics, Monoclonal Antibodies, Histopathology, Flow 
Cytometry, Confocal Microscopy, Molecular Imaging and 
Transgenic Mice, as well as an Animal Facility. Although 
the Core Units are mainly focused on meeting the internal 
demand and collaborating with the CNIO Research Groups, 
they also provide support and collaborate with groups from 
other public institutions as well as with private companies.
Faithful to its mission, a number of different technological 
innovations have been explored or implemented by the Core 
Units during 2018, often in collaboration with CNIO Groups. 
Among the new technologies introduced at the CNIO this year, 
it is particularly worth mentioning the acquisition of a 10X 
Chromium System for cell encapsulation, mainly dedicated 
to single cell RNAseq. This platform, which has been installed 
at the Genomics Unit, will allow to implement at the CNIO 
the technology of single cell gene expression analysis, as 
well as other applications involving deep sequencing, highly 
demanded by the CNIO Groups.
In 2018, the Programme and its Core Units were very active 
in networking activities. Thus, the Programme Director was 
elected President of the Spanish Society of Biotechnology 
( SEBiot ), which represents the community of researchers 
working in any of the multiple aspects of biotechnology in 
Spain. Also, in addition to participating in the activities of 
the Core Technologies for Life Sciences ( CTLS ), including 
the presence of two of our members in the Executive Board 
of this association, the Unit Heads were very active in 
participating in other networks and scientific societies from 
their corresponding fields. As an example, the Proteomics 
Unit participates in EPIC-XS − a coordinated project that 
was granted funding in 2018 from the H2020 programme − 
together with some of the most prominent European Groups 
and Core Facilities in the field of proteomics.
Also, as an indication of our high commitment with 
training, education and outreach, the Programme has been 
deeply involved in the organisation of courses, workshops, 
student visits, and specialised meetings. We collaborated 
with the ‘ CNIO & the City ’ project, organised by the CNIO 
Communication Department with funding from the FECYT 
( Fundación Española para la Ciencia y la Tecnología ). The 
EuroMabNet network, chaired by the Head of the Monoclonal 
Antibodies Unit, held two workshops on the validation of 
antibodies, and specific training courses were put in place 
by the Flow Cytometry and the Confocal Microscopy Units. 
Moreover, several members of our staff have participated in 
an increasing number of Masters and other training activities 
at the CNIO and elsewhere.
As usual, the Core Units were active in attracting funding 
from external sources through activities related to innovation, 
including several contracts and agreements with private 
companies and public institutions based on the technologies 
mastered by several of our Core Units. Also, the royalties derived 
from the sales of the antibodies produced by the Monoclonal 
Antibodies Unit continue representing a significant funding 
source for the CNIO, with an increase of 6% compared to 
the previous year ; in addition, several new agreements have 
been signed with different companies to sell and distribute 
those antibodies.
Last but not least, 2018 has again been a very productive year 
scientifically for the Programme. The contribution of the Units 
to the overall scientific performance of the CNIO is reflected 
in 25 publications co-authored by members of the Units, many 
of them published in top journals.
BIOTECHNOLOGY 
PROGRAMME
FERNANDO PELÁEZ Programme Director
“ In order to undertake 
biomedical research of 
excellence, it is absolutely 
essential to have access to 
cutting-edge technologies 
and the necessary expertise 
to put those technologies to 
the best service of research 
projects.”
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GENOMICS CORE UNIT
reSearch hIghlIghtS
The Genomics Unit contributes to the advancement of research 
projects carried out by multiple CNIO Research Groups. It 
provides services that survey different levels of complexity. A 
wide genomic level is addressed mainly by deep-sequencing 
( NGS ) techniques and their applications. NGS permits a 
variety of different explorations, such as whole genome or 
whole exome tumour sequencing, transcriptome analyses 
− long non-coding RNA included − or location of interacting 
protein factors or RNA binding sites on chromatin. This year, 
the demand for NGS services has been stable and the number 
of samples processed has been similar to that of 2017. At a 
more focused single locus level, other services, such as the 
traditional DNA capillary sequencing service, are also provided ; 
this service is used to find and confirm mutations in candidate 
genes, or in the verification of cloned genes or inserts. The Unit 
also provides a transgenic mouse genotyping service, based 
on allele-specific quantitative PCR for a quick and efficient 
turnaround time. The genotyping service has a catalogue of 
about 120 genetic modifications and 2018 has seen a steady 
increase in demand over that of former years.
Some of our activities have contributed to two research reports 
being published in 2018, with the authorship of some of the 
members of the Unit. When searching for the genetic causes of 
resistance to antiangiogenic therapies in a metastatic colorectal 
cancer patient, a collaborator’s project sought to recapitulate 
the tumour exome from circulating tumour DNA ( ctDNA ). 
An L840F somatic mutation in the KDR/VEGFR2 gene was 
found as the cause of the resistance. This tumour mutation 
blocks the angiogenic inhibitors ’ binding to VEGFR2. This 
study demonstrates new opportunities for analyses on ctDNA 
in order to explain therapy resistance mechanisms and to 
detect prognostic biomarkers ( Toledo RA et al.).
RAS proteins are mostly known as oncogenic factors, but they 
also play a key role in pluripotency. The second report shows 
how embryonic stem cells devoid of RAS genes are unable 
to abandon pluripotency ( Mayor-Ruiz C et al.), a feature 
that depends on the phosphorylation state and subsequent 
activation of inhibiting transcription factor ERF. Relative to 
cancer, this work further suggests the possibility that selective 
RAS inhibitors, which could eventually be used in therapy, 
would promote the emergence of resistance mechanisms 
through the inactivation of mediators such as ERF. s
overvIeW
The Genomics Unit provides on-demand scientific services 
to the CNIO research community. Cutting-edge technologies 
have the capacity to interrogate whole genomes in a single 
assay, such as next-generation sequencing ( NGS ). These 
methodologies reveal the genetic diversity of cancer and 
contribute to dissect its molecular processes. Structural 
features, such as mutation landscapes, DNA-binding of protein 
factors, variations in chromatin structure, as well as functional 
activation states reflected on changes of transcriptomic profiles 
( mRNA, miRNA ), are being elucidated with these technologies 
in order to uncover basic mechanisms, therapeutic targets and 
prognostic biomarkers. We offer a broad range of applications, 
including powerful solutions such as exome mutational 
landscapes, protein location analysis by ChIP-seq analysis 
and transcriptome profiles by RNA-seq technologies, besides 
from the more traditional microarray platform − suitable for 
whole genome gene expression, array comparative genomic 
hybridisation ( aCGH ) − and capillary DNA sequencing. Among 
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“ The genetic and genomic services 
provided by the Genomics Unit 
to assist CNIO’s scientists all 
help to contribute towards the 
understanding of the molecular 
processes of cancer at different 
levels of biological complexity.”
Figure The enrichment of ERF 
chromosomal location in Rasless 
OHT-treated mESCs, at or nearby 
enhancers, suggests a role for 
ERF in the global rewiring of the 
transcriptional gene expression 
programme associated with 
pluripotency ( Mayor-Ruiz et al., 
Genes Dev, 2018 ). Figure prepared 
with ngs.plot ( Shen et al., BMC 
Genomics, 2014).
 ∞ PUBLICATIONS
 ∞ Toledo RA, Garralda E, Mitsi M, Pons T, 
Monsech J, Vega E, Otero Á, Albarran 
MI, Baños N, Durán Y, Bonilla V, Sarno F, 
Camacho-Artacho M, Sanchez-Perez T, 
Perea S, Álvarez R, De Martino A, Lietha D, 
Blanco-Aparicio C, Cubillo A, Domínguez 
O, Martínez-Torrecuadrada JL, Hidalgo 
M ( 2018 ). Exome sequencing of plasma 
DNA portrays the mutation landscape 
of colorectal cancer and discovers mu-
tated VEGFR2 receptors as modulators 
of antiangiogenic therapies. Clin Cancer 
Res 24, 3550-3559.
 ∞ Mayor-Ruiz C, Olbrich T, Drosten M, 
Lecona E, Vega-Sendino M, Ortega S, 
Dominguez O, Barbacid M, Ruiz S, Fer-
nandez-Capetillo O ( 2018 ). ERF deletion 
rescues RAS deficiency in mouse embry-
onic stem cells. Genes Dev 32, 568-576.
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The laboratory mouse is the most widely used experimental 
model for genetic studies and preclinical drug development 
in cancer. The Transgenic Mice Unit is dedicated to the 
genetic edition of the mouse germ line and to the generation 
of genetically modified mouse strains. Hundreds of these 
strains have been created at our Unit. In many cases, they 
contain modifications that reproduce the genetic alterations 
found in human cancer and are introduced in the mouse to 
generate preclinical models of the disease, thereby contributing 
to the development of more efficient targeted therapies. 
Genetically modified mice are also created for testing in vivo, 
in a physiological context, hypothesis related to the molecular 
mechanisms that convert a normal cell to a malignant cell or 
that contribute to tumour expansion and invasion of distant 
organs, ultimately causing death. Cancer is an extremely 
complex disease that cannot be sufficiently well studied in 
vitro in a tissue culture plate. The generation of genetically 
modified mice is one of the basic pillars that sustain cancer 
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“ CRISPR/Cas based genome editing 
technology has improved the 
generation of genetically edited 
mice, thereby promoting research 
progress and accelerating drug 
discovery in many fields including 
cancer.”
reSearch hIghlIghtS
CRISPR/Cas based tools have revolutionised the way we 
approach genetic studies. The Unit has incorporated CRISPR/
Cas gene editing tools for mouse germ line precise modification, 
replacing, in many cases, gene targeting in embryonic stem 
cells ( ES cells ) for the generation of knockout and knockin 
mice with high efficiency. CRISPR reagents are introduced 
directly into mouse zygotes by pronuclear injection or 
electroporation, avoiding difficult and time-consuming ES 
cell culture and manipulation. Knockout allele generation by 
CRISPR is often around 80% to 90% efficient and bi-allelic 
knockout animals are frequently obtained. Point mutations 
or small tag insertions are also easily created by CRISPR-
induced homologous recombination directly in zygotes, 
using single stranded oligodeoxynucleotides as donor DNA 
for repair. We have also developed strategies to increase 
the efficiency of CRISPR-mediated large ( more than 2 Kb ) 
knockin integrations using, in this case, circular plasmids as 
donor DNA. A high proportion of the pups born after zygote 
CRISPR microinjection carry targeted knockin inserts. Zygote 
electroporation is a good alternative to microinjection for gene 
knockout generation. Moreover, zygotes obtained by in vitro 
fertilisation can be edited the same day in a fast and efficient 
way through CRISPR electroporation.
The CRISPR gene editing system may also be used in forward 
genetics for genome wide screenings of new genes relevant in 
different aspects of cancer. In the Unit, we have established haploid 
ES cell lines from genetically modified mice generated at the CNIO, 
by induction of parthenogenetic division of unfertilised mouse 
eggs. Haploid ES cells are especially useful for the identification 
of recessive mutations in genome-wide screenings. We have set 
up several screenings based on genetic rescue of lethal mutations 
using lentiviral libraries of gRNAs in combination with the Cas9 
endonuclease. We are also using activating CRISPR libraries based 
on the expression of the dead Cas9-VP64 fusion and modified 
gRNAs that bind transcription activators, targeted to the promoter 
regions of coding genes and microRNAs. This approach is being 
used in a genome-wide search for genes and pathways that activate 
expression of fluorescent reporters knocked-in in cancer related 
genes ( FIGURE ). s
Figure Example of a genome-wide 
screening for genes and pathways 
that induce expression of a gene of 
interest ( GOI ) using transcriptional 
activating CRISPR/Cas gRNA libraries 
and embryonic stem cells containing a 
knockin GFP reporter in the GOI. Flow 
cytometry analysis and confocal images 
confirm increased expression of GFP 
upon infection with the CRISPR library.
 ∞ PUBLICATIONS
 ∞ Villahoz S et al. (incl. Ortega S) ( 2018 ). 
Conditional deletion of Rcan1 predispos-
es to hypertension-mediated intramural 
hematoma and subsequent aneurysm 
and aortic rupture. Nat Commun 9, 4795.
 ∞ Mayor-Ruiz C, Olbrich T, Drosten M, 
Lecona E, Vega-Sendino M, Ortega S, 
Dominguez O, Barbacid M, Ruiz S, Fer-
nandez-Capetillo O ( 2018 ). ERF deletion 
rescues RAS deficiency in mouse embry-
onic stem cells. Genes Dev 32, 568-576.
 ∞ Lynch CJ, Bernad R, Calvo I, Nóbrega-Pereira 
S, Ruiz S, Ibarz N, Martinez-Val A, Graña-Cas-
tro O, Gómez-López G, Andrés-León E, 
Espinosa-Angarica, V, del Sol A, Ortega S, 
Fernandez-Capetillo O, Rojo E, Muñoz J, 
Serrano M ( 2018 ). The RNA Polymerase II 
factor RPAP1 is critical for mediator-driven 
transcription and cell identity. Cell Rep 22, 
396-410.
 ∞ Vilas JM et al. (incl. Ortega S) ( 2018 ). Adult 
Sox2+ stem cell exhaustion in mice results 
in cellular senescence and premature ag-
ing. Aging Cell 17, e12834.
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During the last 18 years, the Monoclonal Antibodies Unit has 
generated a large number of mAbs, against more than 140 
different antigens, mostly targeting molecules for which mAbs 
are not commercially available. Many of those mAbs have 
been licensed to external companies, generating royalties 
that represent an important source of revenue for the CNIO.
Each year, we prepare and update a detailed CNIO mAbs 
catalogue, which contains the datasheets of more than 90 
thoroughly validated high-quality mAbs ( accessible at http ://
www.cnio.es/ing/servicios/anticuerpos/default.aspx ).
Research activities
In collaboration with Prof. Pablo Engel from the University 
of Barcelona, we have produced and characterised a new 
monoclonal antibody against the protein T-lymphocyte surface 
antigen Ly-9. Ly9, also known as CD229 or SLAMF3, is one of 
the 9 members of the immunoglobulin superfamily ( SLAM ). 
It is expressed in T and B-lymphocytes and plays an important 
role in lymphocyte activation and cytotoxicity.
We have investigated the expression of the Ly9 protein 
in normal and neoplastic lymphoid tissue using a novel 
rat monoclonal antibody ( PIZCU426A ) against the Ly9 
intracellular domain ; this novel mAb recognises its target in 
paraffin-embedded tissue sections. A large series of normal 
tissues and B and T-cell lymphomas have been studied using 
whole sections and tissue microarrays.
In human reactive tissues, we found that Ly9 is restricted to 
lymphoid tissue, specifically to mature B and T cells. Ly9 was 
strongly expressed in all cases of myelomas, marginal zone 
and MALT lymphomas. This new monoclonal antibody may 
help pathologists in the identification of neoplastic B and T 
cells in routinely processed tissue samples, and may be used 
to achieve a better understanding of the pathogenic role of 
Ly9 in inflammatory and malignant diseases.
EuroMAbNet, a European consortium of experts in 
monoclonal antibody technology
In  2008, in collaboration with Oxford University, we 
founded EuroMAbNet ( www.euromabnet.com ), a non-profit 
organisation that currently spans 11 European countries. 
Members include internationally distinguished academic 
laboratories that generate and validate monoclonal antibodies. 
EuroMAbNet is strongly committed to improving the education 
and training of junior scientists in the field of antibody 
validation. This aim is materialised through the organisation 
of annual Antibody Validation Workshops in different venues 
across Europe.
The final goal of EuroMAbNet is to strengthen European 
leadership in mAb technology, improve education in the field 
on an international level, and actively engage with industrial 
partners to ensure the optimum benefits from using mAb 
technology to improve human health. s
overvIeW
The application of hybridoma technology for the production 
of monoclonal antibodies ( mAbs ) represents one of the most 
relevant methodological advances in biomedicine of the 
past decades. The availability of monoclonal antibodies has 
significantly improved our knowledge about the processes 
involved in tumour generation and development, opening up 
a vast array of new possibilities for basic and applied research.
The Monoclonal Antibodies Unit provides CNIO Research 
Groups with an ‘ à la carte ’ generation of mAbs. We are highly 
specialised in the production of mouse and rat monoclonal 
antibodies. The Unit also offers mAb characterisation and 
validation, medium-scale mAb production, as well as a service 
of Mycoplasma testing for the cell culture facility.
“ The Monoclonal Antibodies Unit 
is highly specialised in mAbs 
production and characterisation, 
providing CNIO researchers with 
reliable and well-validated reagents 
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Figure The confocal image shows the colocalisation of Ly9 ( green ) and 
Clathrin ( red ) proteins in the myeloma cell line U266.
 ∞ PUBLICATIONS
 ∞ Carreras J, Yukie Kikuti Y, Miyaoka M, 
Hiraiwa S, Tomita S, Ikoma H, Kondo Y, 
Shiraiwa S, Ando K, Sato S, Suzuki Y, Mi-
ura I, Roncador G, Nakamura N ( 2018 ). 
Genomic profile and pathologic features 
of diffuse large B-cell lymphoma subtype 
of methotrexate-associated lymphopro-
liferative disorder in rheumatoid arthritis 
patients. Am J Surg Pathol 42,936-950.
 ∞ Manso R ,  Gonzá lez-R incón  J , 
Rodríguez-Justo M, Roncador G, Gómez S, 
Sánchez-Beato M, Piris MA, Rodríguez-Pi-
nilla SM ( 2018 ). Overlap at the molecular 
and immunohistochemical levels between 
angioimmunoblastic T-cell lymphoma 
and a subgroup of peripheral T-cell lym-
phomas without specific morphological 
features. Oncotarget 9, 16124-16133.
 ∞ Vojkovics D, Kellermayer Z, Kajtár B, 
Roncador G, Vincze Á, Balogh P( 2018 ). 
Nkx2-3-A slippery slope from devel-
opment through inflammation toward 
hematopoietic malignancies. Biomark 
Insights 13, 1177271918757480.
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reSearch hIghlIghtS
The Molecular Imaging Unit provides CNIO researchers with 
state-of-the-art molecular imaging equipment and human 
resources in order to guarantee the highest quality studies, 
to develop and update protocols and imaging techniques 
that serve to optimise visualisation of tumours in both the 
preclinical and clinical fields, and also to assess and advise 
researchers on the best-suited imaging modality for their 
research projects ( FIGURE ).
We continue to test and incorporate new applications to the 
ImmunoPET strategy in the context of a new collaborative project 
with CIEMAT group, granted by the BBVA Foundation, in which 
we will develop a nanobody produced by camelids that is labelled 
with  68Ga. By adopting this novel approach, we expect that the 
antibody, due to its small size, will be able to better cross the 
blood-brain barrier and detect brain metastases. The ImmunoPET 
technique combines the high specificity and selectivity of the 
antibodies with the high sensitivity and quantitative capabilities of 
PET. This combination makes this technique suitable to conduct 
an in vivo non-invasive, quantifiable, 3D immunochemistry for 
the diagnosis and monitoring of tumours.
This year, the Molecular Imaging Unit participated in a Network 
Programme for Developing Imaging Probes funded by the 
Comunidad de Madrid ( RENIM-CM ). This programme is mostly 
focused on the use of nanoparticles to perform optical imaging 
and multimodality ( optical-MRI or PET-MRI ) for the detection 
of primary tumours and distant metastasis. The results of this 
research will directly benefit the CNIO scientists who will be 
able to use and test these new imaging probes. s
overvIeW
Molecular Imaging can be defined as the ability to visualise, 
characterise and quantitatively measure biological and cellular 
processes and functions in vivo. One of the main advantages of 
in vivo molecular imaging is that it enables characterisation of 
the pathology of tissue diseases without the need of invasive 
biopsies or surgical procedures ; with this information at 
hand, a more individualised treatment-planning approach 
can be applied. Molecular imaging encompasses a range of 
imaging techniques that rely on the utilisation of probes 
exogenously added to target and detect specific cellular or 
molecular processes in a living organism.
“ Molecular imaging provides the 
ability to make visible what would 
otherwise be invisible, uncovering 
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 ∞ Muñoz-Espín D, Rovira M, Galiana I, Gimén-
ez C, Lozano-Torres B, Paez-Ribes M, Llanos 
S, Chaib S, Muñoz-Martín M, Ucero AC, 
Garaulet G, Mulero F, Dann SG, VanArsdale 
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Martínez-Máñez R, Serrano M ( 2018 ). A 
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senescent cells. EMBO Mol Med 10, e9355.
 ∞ Gambera S, Abarrategi A, Rodríguez-Milla 
MA, Mulero F, Menéndez ST, Rodriguez R, 
Navarro S, García-Castro J. Role of activa-
tor protein-1 complex on the phenotype 
of human osteosarcomas generated from 
mesenchymal stem cells ( 2018 ). Stem 
Cells 36, 1487-1500.
 ∞ Cussó L, Musteanu M, Mulero F, Barbacid 
M, Desco M ( 2018 ). Effects of a ketogenic 
diet on [  18F ]FDG-PET imaging in a mouse 
model of lung cancer. Mol Imaging Biol. 
PMID : 29968182.
 ∞ Morcillo MÁ, García de Lucas Á, Oteo M, 
Romero E, Magro N, Ibáñez M, Martínez 
A, Garaulet G, Arroyo AG, López-Casas 
PP, Hidalgo M, Mulero F *, Martínez-Tor-
recuadrada J * ( 2018 ). MT1-MMP as a PET 
imaging biomarker for pancreas cancer 
management. Contrast Media Mol Imag-
ing 2018, 8382148. eCollection 2018. * 
Corresponding authors.
 ∞ AWARDS AND RECOGNITION
 ∞ Academic Editor, PLoS ONE Journal.
Figure CT images of the 
evolution of lung fibrosis 
before and after treatment. 
Healthy lung tissue is shown 
in red ; fibrotic lung lesions 
are shown in grey. Note the 
practically complete recovery 
of the lung after treatment 
with the new drug delivery 
system based on Galactose 
encapsulated nanoparticles. 
One of these images was 
featured on the cover of the 
September issue of EMBO 
Molecular Medicine.
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We provide state-of-the-art equipment and software packages 
in flow cytometry and collaborate with CNIO investigators 
in the setting up and optimisation of the flow cytometry 
techniques of their interest. Some of the applications developed 
and validated at our Unit are :
 ɗ Cell proliferation studies ( CFSE, Cell Trace Violet, BrdU 
or EdU, DNA content, etc.).
 ɗ Apoptosis studies ( Annexin V, Mitochondrial Membrane 
Potencial, Caspase 3, etc.).
 ɗ Multicolour Immunophenotyping panels ( B and T cell 
development, Tregs, Inflammation, etc.).
 ɗ Functional Assays ( side population detection, Ca 2+ flux, 
intracellular pH, etc.).
 ɗ Cytometric Bead Arrays to measure several cytokines from 
cell extracts and plasma.
 ɗ Platelet studies.
 ɗ Extracellular vesicle detection ( microvesicles and 
exosomes ).
 ɗ Single cell sorting for OMICs analysis.
We have further optimised our multicolour flow cytometry 
panels for the characterisation of the immune response in 
various samples, such as haematopoietic tissues, pancreas, 
skin, liver, lung, brain, as well as different tumour types. Single 
cell deposition into 96 or 384 PCR plates to perform single 
OMICs techniques is now part of our routine portfolio. We are 
performing 4-way sorting based on DNA content on live stained 
samples, and are moving forward to separate even further to 
isolate 6 different fractions of DNA content. Additionally, we 
are also pushing the power of our analytical tools by moving 
towards high dimensional analysis, performing ‘ unsupervised ’ 
clustering analysis on our multiparametric panel assays. s
overvIeW
Flow Cytometry is an indispensable tool in the oncology field. 
It enables multiparametric analysis for the identification, 
quantification and isolation of defined subpopulations of cells, 
based on the levels of expression of fluorescent markers and 
their relation to each other.
Our aim is to provide CNIO Groups with technical and 
scientific advice regarding the use of cytometric technologies, 
collaborating with them in the design, acquisition, data analysis 
and interpretation.
We count with 4 analysers and 3 high-speed cell sorters with 
different configurations of lasers and detectors, to cater for all 
our users' needs. We also have an automated magnetic bead 
separation system ( AutoMACS ) and 2 automated cell counters. 
Analysers are user operated upon appropriate training and 
cell sorters are operated by the Unit staff. Our sorters can 
separate up to 4- or 6- defined populations simultaneously 
as well as perform single cell cloning. We can accept human 
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“ The development and optimisation 
of immunophenotyping panels 
by flow cytometry has been a key 
contributing factor, among others, 
to help us better understand the role 
of the immune system in the context 
of brain metastasis.”  ∞ PUBLICATIONS
 ∞ Priego N, Zhu L, Monteiro C, Mulders M, Wa-
silewski D, Bindeman W, Doglio L, Martínez 
L, Martínez-Saez E, Ramón Y Cajal S, Megías 
D, Hernández-Encinas E, Blanco-Aparicio 
C, Martínez L, Zarzuela E, Muñoz J, Fuste-
ro-Torre C, Piñeiro-Yáñez E, Hernández-Laín 
A, Bertero L, Poli V, Sanchez-Martinez M, 
Menendez JA, Soffietti R, Bosch-Barrera J, 
Valiente M ( 2018 ). STAT3 labels a subpop-
ulation of reactive astrocytes required for 
brain metastasis. Nat Med 24, 1024-1035.
 ∞ Hurtado B, Trakala M, Ximénez-Embún 
P, El-Bakkali A, Partida D, Sanz-Castil-
lo B, Álvarez-Fernández M, Maroto M, 
Sánchez-Martínez R, Martínez L, Muñoz J, 
García de Frutos P, Malumbres M ( 2018 ). 
Thrombocytopenia-associated mutations 
in Ser/Thr kinase MASTL deregulate actin 
cytoskeleton dynamics in platelets. J Clin 
Invest 128, 5351-5367.
 ∞ Costa-Machado LF, Martín-Hernández R, 
Sanchez-Luengo MÁ, Hess K, Vales-Vil-
lamarin C, Barradas M, Lynch C, de la Nava 
D, Diaz-Ruiz A, de Cabo R, Cañamero M, 
Martinez L, Sanchez-Carbayo M, Herranz D, 
Serrano M, Fernandez-Marcos PJ. ( 2018 ). 
Sirt1 protects from K-Ras-driven lung car-
cinogenesis. EMBO Rep 19, e43879.
 ∞ Pérez-Olivares M, Trento A, Rodri-
guez-Acebes S, González-Acosta D, 
Fernández-Antorán D, Román-García 
S, Martínez D, López-Briones T, Torroja 
C, Carrasco YR, Méndez J, Moreno de 
Alborán I ( 2018 ). Functional interplay 
between c-Myc and Max in B lymphocyte 
differentiation. EMBO Rep 19, e45770.
 ∞ AWARDS AND RECOGNITION
 ∞ Executive Council Member, European Core 
Technologies for Life Science Association 
( CTLS ).
Figure Multiparametric panels 
for cancer immunomonitoring 
are commonly used in research 
worldwide. As the number of markers 
increase, so does the complexity of 
the analysis. Current options are 
conventional dot plots analysis to 
look at the different subsets ( A ) or 
the use of mathematical algorithms to 
look at the relation of all the markers 
at once ( B ).
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The Confocal Microscopy Unit is equipped with : 3 laser 
scanning confocal systems ( Leica SP5 ) that incorporate UV 
and multiphoton excitation, as well as a white light laser and 
Hybrid Detection ; and 2 wide field systems ( a Deltavision 4D 
deconvolution station and a Leica DMRI6000 system, equipped 
with microinjection and microfluidics control ). All the 
microscopes are automated and equipped with incubators 
for live cell imaging.
In addition, the Unit has implemented the use of high 
throughput technologies applied to confocal microscopy 
using 2 different systems :
 ɗ An Opera ( Perkin Elmer ) High Content Screening ( HCS ) 
system, which allows running HCS experiments on fixed and 
live cells in multiwell plates, and enables the monitoring 
of cell dynamics ( translocation, cell division, etc.) through 
the use of fluorescence.
 ɗ A Matrix Screening Application integrated into the SP5 
confocal systems, enabling high throughput feeding of 
the instrument, not only in multiwell plates but also in 
tissue sections.
These advances enable us to increase the level of information 
obtained from a sample as well as carry out the automated 
screening of cell behaviour under different treatments.
The Confocal Microscopy Unit continues to dedicate significant 
efforts towards the development and implantation of High 
Content Screening technology at the CNIO. In 2018, we 
successfully organised the ‘HCS week ’, which included the 
HCS South European meeting, generating a great discussion 
forum on the latest trends in the field. Additionally, during 
the same week, we launched the first edition of CNIO’s HCS 
School with the aim of teaching future experts in HCS the 
latest applications and informatics tools.
The Unit is promoting and helping with novel sample 
preparation protocol development, bringing knowledge in 
tissue clearing as well as in expansion microscopy. Moreover, 
Microfluidics, used for live cell assays in perfusion chambers, 
has also experienced a great increase in performance and 
demand. Intra-vital microscopy experiments are available at 
the Unit and we are now running several projects for studies 
of metastasis, skin alterations and the immune system 
response. s
overvIeW
Optical microscopy has traditionally been an indispensable 
tool in cell biology studies. In fact, one of the main challenges in 
oncology research is the study of specific markers, expression 
patterns or individual cells in the tumour environment.
The Confocal Microscopy Unit provides the CNIO Research 
Groups with all the standard methodologies as well as the 
latest advances in microscopy, offering access to state-of-
the-art equipment and software packages related to confocal 
microscopy, including technical and scientific advice and support 
to the CNIO scientists. The Unit is also actively involved in 
developing, testing and implementing new microscopy 
technologies, tools and imaging applications that could be of 
interest to the Research Groups at the CNIO. Training activities 
are also an essential component of our mission.
“ The Confocal Microscopy 
Unit is fully committed to 
disseminating advanced microscopy 
methodologies that are useful for 
cancer research and society at large ; 
we have organised courses, talks 
and visits, always with the aim of 
increasing our understanding of cell 
biology and the disorders of cells 
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 ∞ PUBLICATIONS
 ∞ Cobo I, Martinelli P, Flández M, Bakiri L, 
Zhang M, Carrillo-de-Santa-Pau E, Jia J, 
Sánchez-Arévalo Lobo VJ, Megías D, Felipe 
I, Del Pozo N, Millán I, Thommesen L, Bru-
land T, Olson SH, Smith J, Schoonjans K, 
Bamlet WR, Petersen GM, Malats N, Amun-
dadottir LT, Wagner EF, Real FX ( 2018 ). 
Transcriptional regulation by NR5A2 links 
differentiation and inflammation in the 
pancreas. Nature 554, 533-537.
 ∞ Priego N, Zhu L, Monteiro C, Mulders M, 
Wasilewski D, Bindeman W, Doglio L, 
Martínez L, Martínez-Saez E, Cajal SRY, 
Megías D, Hernández-Encinas E, Blan-
co-Aparicio C, Martínez L, Zarzuela E, 
Muñoz J, Fustero-Torre C, Piñeiro-Yáñez 
E, Hernández-Laín A, Bertero L, Poli V, 
Sanchez-Martinez M, Menendez JA, Soffi-
etti R, Bosch-Barrera J, Valiente M ( 2018 ). 
STAT3 labels a subpopulation of reactive 
astrocytes required for brain metastasis. 
Nat Med 24, 1024-1035.
 ∞ Karras P, Riveiro-Falkenbach E, Cañón E, 
Tejedo C, Calvo TG, Martínez-Herranz R, 
Alonso-Curbelo D, Cifdaloz M, Perez-Gui-
jarro E, Gómez-López G, Ximenez-Embun 
P, Muñoz J, Megias D, Olmeda D, Moscat J, 
Ortiz-Romero PL, Rodríguez-Peralto JL, 
Soengas MS. p62/SQSTM1 fuels melanoma 
progression by opposing mRNA decay of 
a selective set of pro-metastatic factors. 
Cancer Cell. PMID : 30581152.
 ∞ Montero JJ, López-Silanes I, Megías D, 
F Fraga M, Castells-García Á, Blasco MA 
( 2018 ). TERRA recruitment of polycomb 
to telomeres is essential for histone try-
methylation marks at telomeric hetero-




of thousands of 
fluorescent images 
acquired at the 
Unit.
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Throughout 2018, the Proteomics Unit has acquired 2 novel 
Liquid Chromatography-Tandem Mass Spectrometry ( LC-MS/
MS ) platforms. The Q Exactive Plus and the Q Exactive HF-X, the 
latter of which is the fastest instrument on the market, are now 
part of the equipment available for research projects in our Unit. 
Both mass spectrometers are coupled to nanoHPLC systems with 
plug-and-play nESI interfaces. The application of this technology 
in the CNIO will have a major impact on the characterisation 
of complex proteomes as well as on the analysis of small 
protein amounts ( e.g. FACS sorted cells, post-translational 
modifications…). In addition, the high resolution of the Orbitrap 
detector enables the analysis of TMT11-plex, increasing the range 
of possibilities during the experimental design with the inclusion 
of biological replicates and/or different conditions. Furthermore, 
if coupled to modified pre-fractionation strategies based on basic 
pH reverse phase HPLC, full proteome coverage can be achieved 
across 11 samples ( FIGURE ). The Unit has also continued to 
work in close collaboration with CNIO Research Groups in 
several projects. To highlight some of them, together with the 
Brain Metastasis Group, we analysed the secreted factors of 
a subpopulation of pSTAT positive astrocytes that mediate 
brain metastasis. In collaboration with the Cell Division and 
Cancer Group, we performed a time course phosphoproteome 
analysis of activating platelets and have identified important 
defects in the phosphorylation of actin cytoskeleton proteins 
in a model of thrombocytopenia, which is caused by mutations 
in MASTL, a cell cycle kinase. Also, in a multi-omic project led 
by the Melanoma Group, we performed a proteomic analysis 
to define the interactors of sequestosome, aka p62, which have 
revealed unexpected roles for this protein in extending the 
mRNA half-life of several pro-metastatic factors. s
overvIeW
Proteins are the molecular effectors of cells and catalyse almost 
all biological processes. The levels of protein abundance, 
together with their modification states and interactions, adapt 
dynamically to external or internal ( genetic ) stimuli and thus 
define the cell’s functional state and determine its phenotype. 
Mass spectrometry-based proteomics is the most powerful tool 
to study the proteome, providing fundamental basic biology 
information. In addition, recent improvements in sensitivity 
and throughput now enable the analysis of larger cohorts of 
samples including biopsies, thereby making proteomics a part 
of the clinical research toolbox. All these efforts are providing 
new insights into the molecular mechanisms underlying cancer 
development as well as the identification of novel biomarkers.
“ The new generation of mass 
spectrometers enables the 
analysis of complex samples to 
unprecedented depth levels, thereby 
becoming a real alternative to 
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 ∞ PUBLICATIONS
 ∞ Priego N, Zhu L, Monteiro C, Mulders M, Wa-
silewski D, Bindeman W, Doglio L, Martínez 
L, Martínez-Saez E, Ramón Y Cajal S, Megías 
D, Hernández-Encinas E, Blanco-Aparicio 
C, Martínez L, Zarzuela E, Muñoz J, Fuste-
ro-Torre C, Piñeiro-Yáñez E, Hernández-Laín 
A, Bertero L, Poli V, Sanchez-Martinez M, 
Menendez JA, Soffietti R, Bosch-Barrera J, 
Valiente M. STAT3 labels a subpopulation 
of reactive astrocytes required for brain 
metastasis. Nat Med 24, 1024-1035.
 ∞ Hurtado B, Trakala M, Ximénez-Embún 
P, El Bakkali A, Partida D, Sanz-Castil-
lo B, Álvarez-Fernández M, Maroto M, 
Sánchez-Martínez R, Martínez L, Muñoz J, 
García de Frutos P, Malumbres M ( 2018 ). 
Thrombocytopenia-associated mutations 
in Ser/Thr kinase MASTL deregulate actin 
cytoskeleton dynamics in platelets. J Clin 
Invest 128, 5351-5367.
 ∞ Zagorac I, Fernandez-Gaitero S, Penning 
R, Post H, Bueno MJ, Mouron S, Manso L, 
Morente MM, Alonso S, Serra V, Muñoz J, 
Gómez-López G, Lopez-Acosta JF, Jimen-
ez-Renard V, Gris-Oliver A, Al-Shahrour F, 
Piñeiro-Yañez E, Montoya-Suarez JL, Apala 
JV, Moreno-Torres A, Colomer R, Dopazo 
A, Heck AJR, Altelaar M, Quintela-Fandino 
M. In vivo phosphoproteomics reveals 
kinase activity profiles that predict treat-
ment outcome in triple-negative breast 
cancer. Nat Commun 9, 3501.
 ∞ Lynch CJ, Bernad R, Calvo I, Nóbre-
ga-Pereira S, Ruiz S, Ibarz N, Martin-
ez-Val A, Graña-Castro O, Gómez-López 
G, Andrés-León E, Espinosa Angarica V, 
Del Sol A, Ortega S, Fernandez-Capetillo 
O, Rojo E, Munoz J, Serrano M. The RNA 
Polymerase II Factor RPAP1 is critical for 
mediator-driven transcription and cell 
identity. Cell Rep 22, 396-410.
 ∞ Segura V, Valero ML, Cantero L, Muñoz J, 
Zarzuela E, García F, Aloria K, Beaskoetx-
ea J, Arizmendi JM, Navajas R, Parad-
ela A, Díez P, Dégano RM, Fuentes M, 
Orfao A, Montero AG, Garin-Muga A, 
Corrales FJ, Pino MMSD ( 2018 ). In-depth 
proteomic characterisation of classical 
and non-classical monocyte subsets. 
Proteomes 6, E8.
Figure Samples are digested and 
labelled with new isobaric tagging 
TMT 11-plex. The pull of peptides is 
then pre-fractionated by High pH 
and 35 non-concatenated fractions 
are analysed on a Q Exactive 
instrument at high resolution using 
short gradients. This enables the 
identification of nearly full proteome 
coverage.
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In line with the activity carried out during the last years, the 
Unit has maintained the portfolio of services demanded by 
its users in accordance with the needs of their projects. Thus, 
about 34,000 paraffin blocks of tissue samples were generated, 
and ca. 35,000 techniques performed, including histological 
and IHC techniques, in-situ chromogenic hybridisation, tissue 
microarrays, slide scanning, etc. Also, during this time we 
introduced new IHC markers useful for the study of tumour 
development, as well as new chromogenic substrates for the 
visualisation of those markers.
Our main key goals are to guarantee the standardisation and 
quality of the techniques offered by the Unit, and to focus 
on the implementation of innovative methodologies. The 
implementation of new equipment for the routine techniques 
has been key for the standardisation of the protocols. This 
has made it possible to introduce new approaches, such as 
multiplexed IHC staining, which enables the simultaneous 
visualisation of several markers ( up to 4 ) on the same tissue 
section. With this new methodology, combined with the 
slide scanner AxioScan and the ZEN image analysis software 
available at the Unit, it is now possible to study the distribution 
and expression levels of different proteins of interest in a 
single experiment in order to better understand complex 
pathological processes.
The high quality of the techniques run by the Unit continues 
being endorsed by External Quality Assessment Schemes. In 
this respect, it is worth mentioning that our haematoxylin-
eosin staining technique was commended in the framework of 
the evaluation, carried out by UK NEQAS, of our histochemical 
techniques. On the other hand, NordiQC has evaluated a subset 
of our IHC techniques under different modules, including 
general markers, breast cancer markers and PD-L1 ; these all 
obtained very high scores.
Training and outreach activities are also a critical component 
of the activity of the Unit. This includes our participation in 
modules of Formación Profesional for pathology technicians, 
mentoring of high school students in short-term stays at 
the Unit, guided visits to the laboratories for students and 
other audiences, as well as offering practice sessions on the 
different technologies mastered by the Unit in Masters and 
other courses, among other activities. s
overvIeW
Pathology is devoted to the study of the structural, biochemical 
and functional changes in cells, tissues and organs that underlie 
disease. By using molecular, immunological and morphological 
techniques, pathology aims to serve as the bridge between 
basic science and clinical medicine.
The Histopathology Unit offers assistance and expertise 
through a full range of services covering from paraffin 
embedding and tissue sections to histochemical stains, research 
and diagnostic immunohistochemistry ( IHC ) testing, antibody 
validation, and in situ hybridisation ( ISH ), as well as the 
construction of tissue microarrays. Furthermore, the Unit 
offers other value added services assisted by a team of highly 
specialised technicians, such as laser-capture microdissection ; 
slide digitalisation for bright-field, polarisation light and 
fluorescence ; image analysis ; and quantification. The Unit 
collaborates with researchers at any stage of their scientific 
career in the histological characterisation of phenotypically 
relevant animal models of disease, thus providing them with the 
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“ The implementation of multiplexed 
immunohistochemistry staining to 
enable the detection of several markers 
on the same tissue section is an 
example of the compromise of the 
Unit with innovation to facilitate the 
progress of research projects at CNIO.”
 ∞ PUBLICATIONS
 ∞ Compte M, Harwood SL, Muñoz IG, 
Navarro R, Zonca M, Perez-Chacon G, 
Erce-Llamazares A, Merino N, Tapia-Gal-
isteo A, Cuesta AM, Mikkelsen K, Caleiras 
E, Nuñez-Prado N, Aznar A, Lykkemark S, 
Martínez-Torrecuadrada J, Melero I, Blanco 
FJ, de la Serna JB, Zapata JM, Sanz, L Al-
varez-Vallina L ( 2018 ). A tumor-targeted 
trimeric 4-1BB-agonistic antibody induc-
es potent anti-tumor immunity without 
systemic toxicity. Nat Commun 9, 4809.
 ∞ de Cárcer G, Venkateswaran SV, Salgueiro 
L, El Bakkali A, Somogyi K, Rowald K, 
Montañés P, Sanclemente M, Escobar B, 
de Martino A, McGranahan N, Malum-
bres M, Sotillo R ( 2018 ). Plk1 overexpres-
sion induces chromosomal instability and 
suppresses tumor development. Nat Com-
mun 9, 3012.
 ∞ Toledo RA, Garralda E, Mitsi M, Pons T. 
Monsech J, Vega E, Otero A, Albarrán 
MI, Baños N, Duran Y, Bonilla V, Sarno F, 
Camacho Artacho M, Sánchez-Pérez T, 
Perea S, Alvarez R, De Martino Rodríguez 
A, Lietha D, Blanco-Aparicio C, Cubillo A, 
Domínguez O, Martínez-Torrecuadrada 
J, Hidalgo M ( 2018 ). Exome sequencing of 
plasma DNA portrays the mutation land-
scape of colorectal cancer and discovers 
mutated VEGFR2 receptors as modulators 
of anti-angiogenic therapies. Clin Cancer 
Res 24, 3550-3559.
 ∞ Mosteiro Ll, Pantoja C, de Martino A, Serra-
no M ( 2018 ). Senescence promotes in vivo 
reprogramming through p16INK4a and 
IL-6. Aging Cell 17, e12711.
 ∞ Vilas JM, Carneiro C, Da Silva-Álvarez S, 
Ferreirós A, González P, Gómez M, Or-
tega S, Serrano M, García-Caballero T, 
González-Barcia M, Vidal A, Collado M 
( 2018 ). Adult Sox2+ stem cell exhaustion 
in mice results in cellular senescence and 
premature aging. Aging Cell 17, e12834.
 ∞ Puñet-Ortiz J, Sáez Moya M, Cuenca M, 
Caleiras E, Lazaro A, Engel P ( 2018 ). Ly9 
( CD229 ) antibody targeting depletes mar-
ginal zone and germinal center B cells in 
lymphoid tissues and reduces salivary 
gland inflammation in a mouse model of 
Sjögren’s syndrome. Front Immunol 9, 2661.
Figure Co-expression of 
different proteins in the same 
tissue section can be assessed 
by means of multiplexed IHC 
staining under brightfield. ( A ) 
Triple multiplexed staining of 
Nestin ( brown ) + phospho-
STAT3 ( purple ) + p21 ( light 
blue ) on fibrosarcoma tissue. 
( B ) Dual staining of Ki-67 
( brown ) + c-MET ( red ) on 
melanoma tissue. ( C ) Dual 
staining of BCL-6 ( brown ) + 
PD-1 ( purple ) on lymphoid 
germinal centre tissue. ( D ) 
Visual isation of HMB45 
expression in melanoma tissue 
using a new chromogenic 
substrate from the Roche 
Discovery Teal HRP kit ( light 
blue ).
Histochemical techniques are often a quick 
way to analyse the properties of the tissues. 
Sirius red staining of fibrotic liver under 
brightfield ( E ) and polarised light ( F ) allows 
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The CNIO has a state-of-the-art Animal Facility, managed by 
Vivotecnia Management & Services. The Animal Facility’s primary 
responsibility is the supply, husbandry and quality control of 
laboratory animals used by the Research Programmes in their 
experimental protocols. The strict compliance to national, EU 
and international recommendations regarding the use and care 
of animals in research is of paramount importance to the CNIO.
The high standards achieved by the CNIO with regards 
to the use and care of animals for experimentation have 
been recognised by the Association for Assessment and 
Accreditation of Laboratory Animal Care International 
( AAALAC ), which granted us full accreditation in October 2016. 
AAALAC International is a private non-profit organisation 
that promotes the humane treatment of animals in science 
through voluntary accreditation and assessment programmes. 
Nearly 1,000 companies, universities, hospitals, government 
agencies and other research institutions in 44 countries have 
earned AAALAC accreditation, which is considered one of the 
top international recognitions in this field.
The CNIO Animal Facility was established to assist researchers 
in the development and analysis of in vivo models. We are 
currently collaborating with as many as 28 Research Groups, 
Sections and Units from different Research Programmes.
Our Animal Facility has the capacity to house 19,000 type IIL 
cages. Our mouse lines are maintained and bred in the Facility’s 
barrier area, which assures Specific Pathogen Free ( SPF ) 
health status through a comprehensive health surveillance 
programme. Microbiological and environmental parameters in 
the animal areas are constantly monitored. All mouse strains 
housed in the barrier are either generated within the barrier 
or introduced by rederivation. We also have an additional area 
with a capacity for 1,800 type II cages dedicated for the use of 
non-replicative strains of adenovirus, lentivirus and retrovirus, 
as well as for xenograft models. In this area, mice are housed 
in ventilated racks with integration of Individually Ventilated 
Caging ( IVC ) units in the building ventilation systems. Mice 
are always manipulated in Type II biosafety cabins.
Daily operations and husbandry procedures are highly automated 
in order to safe-guard our personnel from any associated risks ; 
robotic devices perform the potentially hazardous tasks such 
as the processing of dirty bedding, the washing/filling of cages 
and bottles, etc. These automated systems maximise the 
productivity and ensure the quality standards in our washing 
and sterilising areas. All records concerning breeding protocols 
and animal inventory are computerised and stored in a web-
based application accessible via the CNIO intranet.
The Animal Facility currently harbours more than 40,000 mice 
representing more than 3,000 genetically modified mouse 
lines, either as live animals or as cryopreserved embryos or 
sperm, carrying close to 400 gene targeted alleles and more 
than 200 transgenic integrations. The Facility also provides 
access to more than 50 tool strains, including constitutive 
and inducible Cre strains, Flp strains, reporter strains, Tet 
transactivator strains and others. The Animal Facility offers 
the possibility of running a broad number of experimental 
procedures in the premises, including the use of gamma 
irradiation, UV light and volatile carcinogenic agents, as well as 
surgical procedures, some behavioural studies, a non-invasive 
blood pressure system, and a lab animal monitoring system 
( Oxylet ) that enables measuring a number of physiological 
parameters for metabolic profiling and phenotyping of mouse 
models. Additionally, the monitoring of the mouse models 
through non-invasive imaging technologies is provided by 
the Molecular Imaging Core Unit, which has integrated all 
its image acquisition instruments within the Animal Facility. 
Likewise, the work of the Transgenic Mice Unit is performed 
in a laboratory inside the SPF barrier. Finally, the necropsy 
laboratory is equipped with instruments for the haematological 
and biochemical analysis of blood and urine, which complement 
the pathology and clinical diagnostics.
In addition to mice, the Animal Facility hosts over 100 
specimens of the Xenopus laevis frog that are used to obtain 
eggs for chromosome dynamics studies. Also, in 2018, as 
new tools in cancer research, we introduced a colony of rats 
for 2 specific projects : a project involving the generation of 
monoclonal antibodies directed against mouse antigens, and an 
ETP project aimed at testing new compounds against cancer.
All the work carried out by the Animal Facility complies with 
both national and EU legislation –Spanish Royal Decree 
RD53/2013 and EU Directive 2010/63/UE– for the protection of 
animals used for research experimentation and other scientific 
purposes. Experimental procedures and projects are reviewed 
and evaluated by the Research Ethics and Animal Welfare 
Committee of the Instituto de Salud Carlos III, as well as by 
the Institutional Animal Care and Use Committee ( IACUC ). 
The Orden ECC/566/2015 stipulates that all animal procedures 
are to be carried out by qualified people in the possession of 
the corresponding accreditation as issued by the competent 
authority. The Animal Facility offers CNIO’s new staff a short 
course focused on the training of personnel performing work 
with laboratory animals ; this is complementary to the online 
courses that are a requisite to gain access to the facility.
In accordance with our commitment of maintaining the 
highest possible standards in relation to animal research 
issues, the CNIO has joined the Agreement on Openness on 
Animal Research, promoted by the Federation of Scientific 
Societies in Spain ( COSCE ) in collaboration with the European 
Animal Research Association ( EARA ), which was launched 
on September 2016. An institutional statement on the use of 
research animals can be consulted on the CNIO website. s
ANIMAL FACILITY Isabel BlancoCore Unit Head ManagementVivotecnia Management & Services
“ The Animal Facility provides 
CNIO researchers with all the 
support required to work with 
mouse models, which are critical 
to understand the processes 
involved in tumour generation 
and development, as well as for 
the validation of new targets and 
therapeutic approaches.”
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EXPERIMENTAL THERAPEUTICS 
PROGRAMME
JOAQUÍN PASTOR Programme Director
The Experimental Therapeutics Programme ( ETP ) serves 
as a bridge between basic research results in cancer biology 
( i.e. novel therapeutic targets and hypothesis ) and the 
development of potential antitumour drugs. This is achieved 
by the application of early drug discovery phases to obtain 
advanced compounds with proven in vivo Proof of Concept 
( PoC ) results. ETP assists target validation activities by 
providing high quality chemical probes and participates in 
the identification of novel targets using its expertise in target 
deconvolution.
CDK8 inhibitors. As previously reported, we selected our 
first leads, ETP-27 and ETP-93, as dual CDK8/Haspin 
inhibitors, which have yielded positive results in PoC studies 
after oral ( PO ) administration. Now, we have added ETP-
18, a highly selective orally bioavailable CDK8 inhibitor, to 
our set of advanced leads. ETP-18 has demonstrated good 
biomarker modulation ( pSTAT1 ) after PO administration in 
pharmacokinetics and pharmacodynamics ( PK/PD ) studies 
in MOLM13 xenografts. Currently, we are performing in vivo 
efficacy experiments to complete our PoC studies. Importantly, 
we have started toxicity studies of our advanced leads in rats 
to establish their therapeutic index. The results of these 
experiments will determine the destiny of these series of 
CDK8 inhibitors regarding their further development.
Haspin and Mastl Inhibitors ( in collaboration with Marcos 
Malumbres’ laboratory ). We have generated 2 distinct chemical 
series of highly potent Haspin inhibitors, which have proven to 
be very specific after profiling against more than 450 kinases. 
These molecules have been profiled against a diverse panel of 40 
cell lines. Haspin inhibitors showed limited antiproliferative 
potential as single agents. Now, we are evaluating their effect 
in combination with clinical antitumour agents ; the results of 
this study will help to define the therapeutic scope for these 
inhibitors. During 2018, we completed the Structure-Activity-
Relationships ( SAR ) of 2 families of potent Mastl inhibitors ; 
this information has helped to deploy a hit generation campaign 
to increase the chemical diversity of our Mastl inhibitors. The 
generation of diverse Mastl inhibitors will increase our chances 
to identify the most interesting series in terms of potency, cell 
activity and above all off-target selectivity for pharmacological 
target validation studies. Interestingly, we have identified the 
solvent accessible areas in our initial Mastl inhibitors ; this 
information has been used in the design of Mastl-Protacs to 
target the degradation of this kinase.
TRF1 ( in collaboration with Maria Blasco’s laboratory ). TRF1 
modulators as potential cancer therapeutics. As reported earlier, 
we discovered a series of TRF1 inhibitors ( ETP-946 series 2 ) 
with unknown molecular mechanism of action. Therefore, 
several target deconvolution strategies were put in place to 
identify its target. During 2018, we focused our efforts on 
the preparation of reversible and irreversible affinity probes 
with proven TRF1 inhibition capacity. As an example, ETP-
093, an irreversible probe, has been used in a first pull-down 
experiment rendering several nuclear proteins as potential 
target candidates. We are doing replicates of this study in order 
to have a final selection of candidates for further validation. 
Furthermore, we have progressed in the SAR generation 
of series 2 by the synthesis of numerous analogues. These 
compounds have been included in a recently filed patent 
application. We have gathered information about the drug-
likeness of this series and we are now targeting its optimisation 
as well as the reinforcement of its intellectual property ( IP ). 
These activities are part of an awarded CaixaImpulse project 
( M. Blasco’s lab ) in which ETP participates. Importantly, we 
have contributed to the discovery of novel cellular pathways 
able to modulate TRF1 binding to telomeres. As reported earlier, 
ETP has helped to establish the connection of the PI3K/
AKT axis and TRF1. During 2018, we identified other cell 
signalling pathways involved in TRF1 regulation ( currently 
under detailed investigation at M. Blasco’s lab ) by the screening 
of our ETP-antitumour library.
Finally, we have also helped other CNIO groups to carry out 
screening campaigns, both targeted and phenotypic, and have 
supported the follow up of the identified hits in several projects.“ Interrogate biology with 
chemistry and you will get 
responses that can trigger 
unimaginable research and 
discoveries.”
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The Medicinal Chemistry Section is part of the interdisciplinary 
Experimental Therapeutics Programme that is dedicated 
to early Drug Discovery in the oncology field. Our aim is to 
discover new anticancer agents based on the hypotheses and 
targets generated by CNIO’s Basic Research Groups ; this is 
done in close collaboration with these Groups. Medicinal 
Chemistry activities start with the identification of hits through 
High Throughput Screening ( HTS ) campaigns from targeted or 
phenotypic assay or hits generated in our Section by applying 
Rational Drug Design Strategies ; these are then optimised to 
obtain novel lead compounds with in vivo activity in different 
animal models. For hits obtained from phenotypic screenings, 
we help to decipher the mechanism of action responsible for 
the observed phenotype, synthesising affinity probes that 
will be used for cellular localisation ( imaging techniques ) 
and extracting the target/s ( pull down experiments ). We are 
also developing PROTACs ( proteolysis targeting chimeras ) 
as promoters of cell protein degradation to establish their 
applicability across diverse drug discovery projects.
“ We have successfully designed 
and synthesised an irreversible 
affinity chemical probe of ETP-
946 that is to be used for imaging 
and pull-down/proteomics analysis 
experiments ; the aim is to decipher 
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Cyclin-dependent protein kinase 8 inhibitors ( CDK8i ) 
project
ETP-93, with demonstrated proof of concept studies ( PoC ) in 
mouse models, and ETP-18 were identified as potent, selective 
and orally bioavailable CDK8 inhibitors. We are involved 
in the multigram scale up of these compounds in order to 
perform toxicity studies in rats, as well as to determine if the 
compounds/inhibition of the target is safe enough to progress 
them to the next phases of drug development. With these 
results in hand, we will be able to initiate the transfer of our 
results to companies interested in developing our compounds 
into drugs. Additionally, we will also perform PoC studies 
( efficacy and biomarker modulation ) with ETP-18.
Microtubule-associated serine/threonine protein 
kinase-like ( MASTL ) inhibitors
In collaboration with the CNIO Cell Division and Cancer 
Group, we continue with the exploration around the chemical 
series identified to obtain potent and selective compounds. 
Strategies to generate MASTL-PROTACs are also contemplated 
in order to generate degrader compounds of the protein ; the 
first PROTACs have been synthesised with moderate MASTL 
activity ( FIGURE ). We are initiating a hit generation phase 
to obtain novel Mastl inhibitor hits.
HASPIN inhibitors
Highly selective hits identified from 2 previously generated 
chemical series were scaled up to be characterised in vivo in 
order to determine their pharmacokinetics in mice as well as to 
be used in the biological characterisation to study the relevance 
of HASPIN in cancer, including their effect in antiproliferative 
experiments as single agents and in combination with other 
antitumour agents. We continue with the chemical exploration 
around the hits to conclude the SAR activities and to define 
the scope of their kinase activity.
Telomeric repeat binding factor 1 ( TRF1 ) inhibitors
This project is undertaken in collaboration with the CNIO 
Telomeres and Telomerase Group ( TTG ). ETP-946 was 
identified as a TRF1 modulator under screening assay 
conditions, and we are currently working on deciphering its 
mechanism of action. One of the approaches that we have 
taken is to use affinity chemical probes. We generated SAR 
information from the chemical exploration in the hit-to-lead 
phase ( approximately 150 compounds were synthesised ), 
and with this information we identified those parts of the 
hit molecule at which to install linkers and synthesise 
probes. During this year, we accomplished synthesis of 
an irreversible affinity chemical probe ( ETP-093 ), which 
contains photoreactive and reporter groups, made as small 
as possible to minimise the interference upon binding to 
the target proteins. The aliphatic diazirine photoreactive 
group of ETP-093 enables, after incubation with cells, short 
irradiation to generate the highly reactive carbene species 
that will react with the binding protein/s. The terminal alkyne 
reporter of ETP-093 was then used for subsequent target 
identification by conjugation to suitable reporters ( biotin-N3 ) 
using biorthogonal click chemistry conditions, which enable 
pull-down experiments. So far, we have performed the first 
pull down experiment and the proteomic analysis, which will 
be further repeated 3 more times for a robust interpretation of 
the results. Pull down experiments with the reversible affinity 
probe ETP-455 were generated. This chemical probe lacks the 
photoreactive group, so its binding with affinity protein/s is not 
covalent and we may lose some relevant information during the 
washing steps phase. Nevertheless, once we have finalised all 
the experiments, we will compare results between reversible/
irreversible affinity chemical probes. We have filed a patent 
application to cover the chemical series of ETP-946. This 
project was recently awarded a grant from the CaixaImpulse 
programme and we are currently working on the optimisation 
of the drug-like properties of ETP-946 together with the 
generation of novel chemical space for patent reinforcement.
Collaborations with other CNIO groups
We continue our collaborations with other researchers from the 
Centre, for instance, with Alejo Efeyan ( Metabolism and Cell 
Signalling Group ) performing stability, reactivity studies of the 
hits and synthesis of tools to help decipher their mechanism of 
action ; and with Paco Real ( Epithelial Carcinogenesis Group ) 
for the synthesis of reference compounds. s
Figure ( A ) Graphical representation 
of the mechanism of action of PROTACs 
and associated main features ( adapted 
from CM Crews, Curr Opin Chem 
Biol 2017, 39, 46-53 ). ( B ) Fragments 
required/used for synthesis of PROTACs.
 ∞ PATENT
 ∞ Pastor JA, Blasco MA, Martinez S, Blan-
co-Aparicio C, García AB, Gómez-Casero 
E, Bejarano, L, Méndez-Pertuz M, Martín-
ez P, García-Beccaria M ( 2018 ). Novel 
TRF1 modulators and analogues thereof. 
EP18382659.3. 
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The early Drug Discovery ( eDD ) process encompasses 
screening campaigns for hit identification, hit generation and 
hit lo lead and lead optimisation phases, in order to end up with 
a lead compound able to demonstrate in vivo proof-of-concept. 
ADME − an acronym for absorption, distribution, metabolism 
and excretion − describes the disposition of a pharmaceutical 
compound within an organism. ADME properties influence 
the drug levels and the kinetics of drug exposure to the tissues, 
and hence influence the performance and pharmacological 
activity of the compound as a drug. It is fundamental to assess 
the parameters for ADME properties early on during the 
discovery stage, since they provide critical information that 
can help to better interpret the screening results and to design 
new molecules. Drug-like properties should be optimised 
in parallel to pharmacological activity against the target. 
For that reason, we perform ADME characterisation of the 
compounds during the initial steps of eDD projects and we 
carry out PK, PK/PD and distribution studies to validate the 
drug properties of our advanced molecules.
“ The screening of the ETP-
antitumour library in the phenotypic 
TRF1 assay has enabled us to 
identify new signalling pathways 
modulating TRF1 levels that will 
contribute to a better understanding 
of TRF1 biology.”
BIOLOGY SECTION Carmen BlancoSection Head Post-Doctoral FellowElena Hernández TechniciansM. Isabel Albarrán ( TS ) *, Antonio 
Cebriá ( TS ) *, Jennifer García, 
Elena Gómez-Casero ( TS ) *,
Javier Klett ( TS )*, M. Carmen 
Rodríguez de Miguel ( TS ) *
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During 2018, our Section was involved in several projects :
Cyclin-dependent kinase 8 ( CDK8 )
We started proof-of-concept studies in mouse models with 
ETP-18, a selective advanced orally bioavailable lead compound 
that demonstrated both plasma and tumour levels as well 
as biomarker modulation ( pSTAT1 ), in a dose dependent 
manner up to 8 h after oral administration in PK/PD studies 
in MOLM13 xenografts. Tolerance and efficacy studies will be 
performed. In parallel, after pharmacokinetics studies of 3 
more selective CDK8 inhibitors, we have identified ETP-24 
as a backup of ETP-18.
To determine if the inhibition of the target by our compounds 
is safe enough to progress them to the next phases of drug 
development, we are running toxicity studies in rats with the 
leads ETP-93 ( dual CDK8/HASPIN-i ) and ETP-18 ( selective 
CDK8-i ), in comparison with known inhibitors.
Microtubule-associated serine/threonine protein 
kinase-like ( MASTL ) and HASPIN
These projects are undertaken in collaboration with the CNIO 
Cell Division and Cancer Group. For MASTL, we tested 85 
new compounds in our biochemical assay with active human 
full length MASTL protein ; 11% of them were tested as part 
of the hit generation phase and we have also tested our ETP-
antitumour library to identify novel hits. One drug is under 
validation as a putative MASTL-inhibitor. For HASPIN, we 
tested in biochemical and cellular assays, 42 compounds to 
complete the SAR exploration of the chemical series. We have 
evaluated the antiproliferative activity of highly selective 
HASPIN-inhibitors ( S( 35 ) of 0.025 and 0.007 ) from 2 different 
chemical series in a panel of 40 cell lines covering the more 
relevant tumour types. Now, we are evaluating their effect 
in combination treatments. We have also characterised in 
ADME assays representative compounds for the 2 chemical 
series. We have performed a preliminary pharmacokinetic 
study with 1 selected compound with good ADME properties 
and we are running a distribution study to validate it as a good 
tool compound for in vivo proof-of-concept.
Telomeric repeat binding factor 1 ( TRF1 )
This project is carried out in collaboration with the CNIO 
Telomeres and Telomerase Group. A phenotypic assay to 
measure the association of TRF1 to telomeres has been used to 
test 30 compounds, which include ETP-946 analogues and its 
corresponding irreversible chemical probes. We have identified 
an active irreversible chemical probe, ETP-093, and we are 
running pull-down experiments with it. Several nuclear targets 
have been identified as potential targets and we want to validate 
them with 2 more pull-down experiments. In the meantime, 
we have used ETP-455, a reversible chemical probe, to perform 
pull-down experiments in triplicate. After comparison of the 3 
experiments, we have identified 2 putative targets that we are 
trying to validate by orthogonal assays. We will compare the 
pull-downs with both reversible and irreversible chemical 
probes in order to select the best candidates. On the other 
hand, we have performed distribution studies with ETP-946 
and have observed that the compound is distributed in tissues. 
Furthermore, by using a chemical biology approach, we have 
validated 3 more signalling pathways that were identified in the 
screening of the ETP-antitumour library that modulates TRF1 
levels at telomeres ; Maria Blasco’s laboratory is deciphering 
the molecular mechanism behind this. These results are part 
of a patent application PCT/EP2018/074832. Finally, we 
have started a virtual screening with the aim of identifying 
disruptors of TRF1 dimerization ( FIGURE ).
Collaborations with other CNIO Groups
ETP-Biology continued providing support to follow-up on the 
results obtained from the screenings performed by the Brain 
Metastasis Group and the Metabolism and Cell Signalling 
Group. Moreover, we have provided support by testing and 
analysing the ETP-antitumour library, either alone or in 
combination, in order to identify : i ) novel treatments of NSCLC 
mouse cell lines mutant in KRas with and without C-RAF 
and CDK4, in collaboration with the Experimental Oncology 
Group ; and ii ) novel modulators of Midkine expression, in 
collaboration with the Melanoma Group. s
 ∞ PUBLICATIONS
 ∞ Priego N, Zhu L, Monteiro C, Mulders M, 
Wasilewski D, Bindeman W, Doglio L, 
Martínez L, Martínez-Saez E, Ramón Y 
Cajal S, Megías D, Hernández-Encinas E, 
Blanco-Aparicio C, Martínez L, Zarzuela 
E, Muñoz J, Fustero-Torre C, Piñeiro-Yáñez 
E, Hernández-Laín A, Bertero L, Poli V, 
Sanchez-Martinez M, Menendez JA, Soffi-
etti R, Bosch-Barrera J, Valiente M ( 2018 ). 
STAT3 labels a subpopulation of reactive 
astrocytes required for brain metastasis. 
Nat Med 24, 1024-1035.
 ∞ Toledo RA, Garralda E, Mitsi M, Pons T, 
Monsech J, Vega E, Otero Á, Albarran 
MI, Baños N, Durán Y, Bonilla V, Sarno F, 
Camacho-Artacho M, Sanchez-Perez T, 
Perea S, Álvarez R, De Martino A, Lietha D, 
Blanco-Aparicio C, Cubillo A, Domínguez 
O, Martínez-Torrecuadrada JL, Hidalgo 
M ( 2018 ). Exome sequencing of plasma 
DNA portrays the mutation landscape 
of colorectal cancer and discovers mu-
tated VEGFR2 receptors as modulators 
of antiangiogenic therapies. Clin Cancer 
Res 24, 3550-3559.
 ∞ PATENTS
 ∞ Pastor JA, Blasco MA, Martinez S, Blan-
co-Aparicio C, García AB, Gómez-Casero 
E, Bejarano, L, Méndez-Pertuz M, Martín-
ez P, García-Beccaria M ( 2018 ). Novel 
TRF1 modulators and analogues thereof. 
EP18382659.3.
 ∞ Blasco MA, Pastor JA, Bejarano L, Mén-
dez-Pertuz M, Martínez P, Blanco-Apari-
cio C, Gómez-Casero E, García-Beccaria 
M ( 2018 ). Modulation of TRF1 for brain 
cancer treatment. EP18382658.5.
Figure Flow chart of 
a virtual screening to 
identify small molecules 
as disruptors of TRF1 
dimerization. We have 
confirmed the druggability of 
the dimerization of the TRF1 
interface and have prioritised 
the ZINC15 public database 
of commercial compounds. 
Thereafter, we ran Fast 
Structure-Based Virtual 
screening implemented in 
FLAP of 3000K molecules. 
The top  5000 structures 
were run in HT-Docking 
and 1000 compounds have 
been selected for Visual 
Inspection and estimation 
of Binding Energy. The final 
selected hits will be validated 
by wet assay.
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Cancer can be defined as the uncontrolled growth and 
division of cells, leading to tumour formation, invasion, and 
metastases. Unlike normal cells that require growth factor 
signals, tumour cells often have mutations that result in 
constitutively active (‘ always on ’) signalling pathways that 
drive aberrant cell growth and division. In order to fulfil the 
high nutrient demand required for their continuous growth, 
tumour cells have reprogrammed their basal metabolism from 
an oxidative to a more glycolytic/anabolic one, even in the 
presence of oxygen. Otto Warburg proposed in the early XX 
century that, ‘ this altered metabolic state was the underlying 
cause for cancer ’ ( Warburg 1956 ). The past decade has been a 
period of very active research in the area of tumour metabolic 
reprograming, and major molecular mechanisms involved 
in the process have been identified and characterised. It was 
found that both oncogenes ( Ras, Myc ) and tumour suppressor 
genes ( p53, RB, LKB1 ) impart an altered metabolic phenotype 
in cancer cells through the regulation of genes involved in 
central metabolic pathways such as glycolysis, fatty acid 
metabolism, oxidative phosphorylation, nucleotide synthesis 
and the one carbon pool ( reviewed by Gilmour & Velasco, 
2017 ). All these alterations have led tumours to rely heavily 
on specific metabolic pathways to obtain their energy, while 
using other pathways to grow in order to give tumour cells a 
growth advantage. This situation may leave tumour cells in a 
frail position under certain treatments or circumstances, while 
normal cells may be able to compensate, adapt and survive. Our 
laboratory is searching for this metabolic weakness in order 
to stop tumour growth.
Furthermore, the high requirements of nutrients and other 
soluble factors as well as the release of metabolites with 
immunosuppressive properties, together with the hypoxic 
conditions found in tumours, create a ‘ non-friendly ’ 
microenvironment for an anti-tumour immune surveillance, 
while facilitating the growth of other tumour-promoting 
cells such as stroma and myeloid cells ( FIGURE A, B ). Thus, 
the mechanistic understanding of cancer metabolism has 
led to renew interest in developing therapeutics that target 
key enzymes involved in this process. Checkpoint-blockade 
immunotherapy has been one of the most exciting advances 
made in cancer treatment in recent years. Metabolic interplay in 
the local microenvironment can mediate T cell differentiation 
and function. ‘ Checkpoint-blockade ’ antibodies can also 
influence cellular metabolism. Finally, recent clinical trials have 
shown that combination immunotherapy, based on immune 
checkpoints blockade and targeted and non-targeted therapies, 
provides even higher response rates than either approach 
alone. Several clinical trials are currently using this approach, 
however, not all patients respond to immunotherapy and it 
is, therefore, necessary to determine which patients would 
be good candidates for the treatment. It has been found that 
an inflammatory tumour microenvironment – ‘ hot ’ tumours 
− greatly increases patient survival. One of the objectives 
of our laboratory has been to identify, and characterise the 
expression of novel and known tumour markers that may 
enable a better patient stratification for future therapies. This 
approach has shown that, in addition to the levels of expression 
of an immunotherapy target, the type of cells that express the 
marker may also be a feature to consider. s
ScoPe oF the elI lIlly - cnIo PartnerShIP
Eli Lilly and CNIO are collaborating on the identification and 
validation of novel targets in cancer immunometabolism. 
Our Section is funded through a research contract with Eli 
Lilly and focuses on the identification of small molecular 
weight molecules that regulate the metabolism of malignant 
cells, with the objective of killing them either directly, acting 
synergistically with other anti-tumour agents, or activating 
the anti-tumour immune response. Exploring how to better 
target these mechanisms would lead to better and more efficient 
therapeutic options.
A combination of in vitro and in vivo approaches is being utilised 
to obtain a complete understanding of tumour metabolic 
reprogramming. For this purpose, we have developed a series 
of biochemical and cell-based assays exploiting advanced 
techniques such as extracellular flux analysis ( Seahorse 
technology ), NMR, metabolomics and immunophenotyping. 
Finally, each target goes through an in vivo validation process 
using xenografts, allografts and mouse models developed at 
the CNIO that includes the use of non-invasive in vivo imaging 
technologies, and the immunohistochemical characterisation 
of tumours for different metabolic, immune and tumour 
markers. The final step is the validation in human samples 
from healthy donors or patients using PBMCs or tumour 
tissue arrays.
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Figure Targeting cancer 
m e t a b o l i c  i m m u n e 
suppression. (  A ) Tumour 
cells produce a battery 
of immunosuppressive 
metabolites such as lactic 
acid, kynurenine or adenosine 
that result in an anergic 
T cell phenotype, while 
consuming key metabolites 
such as glucose or tryptophan 
necessary for a proper Teff 
( CD8+) activity. As a result, 
T cells are metabolically 
incapable of mounting an 
antitumour immune response. 
Metabo l i c  regu lat ion , 
together with immunotherapy 
and other classical therapies 
( radiation, chemotherapy ) of 
the tumour and/or the tumour 
microenvironment, would 
diminish the production 
of immune suppressive 
metabolites and increase the 
levels of metabolites such as 
glucose, or the tryptophan 
necessary for a proper anti-
tumour T cell response. ( B ) 
Extracellular flux analysis 
for the acidification rate 
(  g lycolyt ic  test   )  and 
O 2 consumpt ion  OCR 
( mitochondrial test ). Fully 
active effector T cells require 
an activated glycolytic and an 
oxidative metabolism in order 
to synthesize cytokines and 
other molecules necessary 
for their cytotoxic activity. 
I m m u n e  s u p p re s s i ve 
metabolites, like kynurenine, 
suppress the metabolic 
activity of effector T cells 
inhibiting their cytotoxic 
activity.
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Recent studies have shown that the alterations that take place 
in cancer cells not only occur at the DNA sequence but also 
at the level of the epigenome. Eukaryotic DNA is wrapped 
around histone proteins to constitute chromatin, which plays 
fundamental structural and regulatory roles. The epigenome 
consists of chemical changes in both DNA and histones that 
can be inherited through cell division and are controlled by 
the action of a large set of epigenetic regulators that possess 
enzymatic activity. Ultimately, DNA and histone modifications 
control the level of chromatin condensation, which in turn 
regulates the accessibility of transcription factors to the 
chromatin and, therefore, gene expression.
During the past few years several studies, including our 
own, have suggested that the deregulation of the chromatin-
modifying machineries can lead to aberrant gene expression 
causing cancer and other human diseases. The epigenome 
is regulated in a highly dynamic fashion by the coordinated 
action of regulators able to write, erase and read histone and 
DNA modifications. Thus, contrary to genetic mutations, 
epigenetic aberrations can be reversed through the targeting 
of the appropriate epigenetic regulators. Indeed, drugs 
targeting DNA methyltransferases and histone deacetylases 
have successfully demonstrated anticancer properties and 
are currently used in the clinic. Therefore, identifying the 
molecular function of critical epigenetic regulators and their 
complex relationship with the cancer epigenome ( FIGURE ), 
as well as the development of small molecular inhibitors of 
their activities holds great promise for the therapeutics of 
cancer. s
ScoPe oF the cnIo - elI lIlly PartnerShIP
Eli Lilly and CNIO were collaborating on the identification 
and validation of novel targets in cancer epigenetics. Our 
Section was funded through a research contract with Eli Lilly 
and focuses on the identification of small molecular weight 
molecules able to modulate the epigenome of malignant 
cells and ultimately block the growth and spread of tumours. 
Potential targets were validated in vitro and in vivo using 
animal models developed at the CNIO. Furthermore, we 
set up biochemical and cell-based assays with the aim of 
understanding the mechanism of action of such targets at 
the molecular level ( FIGURE ).
CNIO - LILLY 
EPIGENETICS SECTION
María José Barrero (until May)
Section Head
Staff Scientist
Sergio Ruíz (until March)
Technicians
Verónica García (until March) ( TS )*, 
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Figure In vivo and in vitro strategies for target validation.
 ∞ PUBLICATIONS
 ∞ Garcia-Carpizo v, Ruiz-Llorente S, Sarmen-
tero J, Graña-Castro O, Pisano DG, Barrero 
MJ (2018). CREBBP/EP300 bromodo-
mains are critical to sustain the GATA1/
MYC regulatory axis in proliferation. Epi-
genetics Chromatin 11, 30.
 ∞ Garcia-Carpizo v, Ruiz-Llorente S, Sar-
mentero J, Barrero MJ (2018). Therapeu-
tic potential of TAF1 bromodomains for 
cancer treatment. bioRxiv. doi: https://
doi.org/10.1101/394254.
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Discoveries made by CNIO scientists result in the development 
of useful novel biomedical solutions, including diagnostic and 
therapeutic applications, all for the benefit of cancer patients 
and the health system in general. The Technology Transfer 
and Valorisation Office ( TTVO ) plays an integral part of the 
conversion of discoveries into technologies that are ready to 
be taken up by companies and entrepreneurs.
The TTVO carries out the all-round management of all aspects 
needed to ensure the appropriate intellectual property 
protection and commercial viability of the research results 
generated by CNIO’s scientist. Additionally, the TTVO Office 
provides advice and guidance to CNIO scientists regarding 
the development of research projects that have the potential 
to create social and economic value and, thereby, also helps 
to valorise their research.
To this end, the TTVO Office proactively monitors the progress 
of scientific activity at the CNIO in order to identify projects 
with high transfer potential. In 2018, a total of 13 new ideas 
were incorporated to the Technology Transfer portfolio, of 
which 7 turned into patent applications. These cover a wide 
range of products, including novel TRF1 inhibitors and their 
use to treat brain tumours, oligonucleotides for the treatment 
of lung cancer and other proliferative diseases, combined 
therapies for the treatment of pancreatic tumours driven by 
Kras/Trp53 mutations, gene editing based therapies to treat 
tumours driven by genomic rearrangements, biomarkers for 
predicting resistance to immunotherapy, and biomarkers for 
the prediction of residual disease and relapse in melanoma.
Several new valorisation projects have been launched in 2018. 
To highlight some of them : a project, in collaboration with a 
national company, was developed for the screening of compounds 
of natural origin useful in ageing and cancer treatment ; a 
senescence project based on a CNIO patent aims at the 
characterisation of antagonists of a novel modulator of cellular 
senescence ; the FuGe project is directed towards the 
development of a cancer therapy based on CRISPR ; and a drug 
discovery project aims at the characterisation and development 
of TRF1 inhibitors as a means to modulate telomere activity. 
The latter 2 projects have been awarded a grant under the 
CaixaImpulse initiative and thereby benefit from funding and 
mentoring by experts of the national bio-ecosystem.
Additionally, the TTVO identifies appropriate commercial 
partners for a timely development of technologies, negotiates 
technology transfer agreements, and manages the relationship 
with licensees including the payment of royalty fees. In 2018, 
the TTVO managed 291 technology transfer records related 
to industrial and intellectual property generated by CNIO’s 
researchers ; 171 correspond to agreements ( MTAs, CDAs, 
Research Collaborations, licences, etc.). The majority of these 
agreements ( 65%) were established with international entities, 
which is an indicator of the internationalisation of the CNIO’s 
research activity. Through research collaborations with 
industry, up to 2.9M euros were secured for research activities. 
Moreover, 5% of the agreements are licences to commercial 
partners. Patents and unpatented research tools are licensed 
in order to increase their availability to the scientific 
community, as well as to create opportunities for our business 
partners and to provide a financial return on public investment. 
The net income derived from licences in 2018 increased 
to 582,500 euros. Altogether, the net royalty income obtained 
from the exploitation of industrial and intellectual property 
assets in the last 5 years has exceeded 17M. This income reverts 
back to CNIO research activities as well as to the inventors 
themselves. A total of 36 inventors have contributed towards 
and benefited from this achievement.
Fostering an innovation culture among our scientists is one 
of our priorities. With the support of the Fundación Banco 
Santander, we uphold our collaboration with the prestigious 
IE Business School, through which many of our investigators 
− 2 new ones in 2018 − have already obtained training in market-
oriented innovation strategies. Additionally, the TTVO 
organised events and seminars directed towards the promotion 
of the innovation culture among CNIO’s scientist.
All the above mentioned achievements stand testament to 
the excellence and hard work of the CNIO scientists and to 







Rocío Manzano ( until October ) ( TS )*
* Titulado Superior ( Advanced Degree )
“ Discoveries by CNIO 
scientists result in the 
development of useful 
biomedical solutions, 
including diagnostic and 
therapeutic applications, 
all for the benefit of cancer 
patients and the health 
system.”
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Cristina de Martos ( until July ) ( TS )*
Vanessa Pombo ( since September ) 
( TS )*
*Titulado Superior ( Advanced Degree )
The mission of CNIO’s Communications Department is to 
bring the Centre’s research activity closer to those who can 
benefit the most from it, namely patients and their families 
as well as society at large. In order to fulfil this objective, the 
Communications Department uses all the information 
channels available, both traditional and digital.
In 2018, our news items got extensive media coverage with 
over 3,400 press appearances, either online or in print ( 29 % 
more than in 2016, with heightened impact ), and 225 mentions 
on radio and television. Overall, media coverage increased 
by 46 % over the previous year. Throughout the year, the 
featured stories received nearly 71,733 hits (EurekAlert! news 
service ) from around the world.
In an increasingly competitive information environment, 
some of the scientific news items produced at CNIO made the 
headlines in the leading media outlets in Spain and other 
countries : BBC, Clarín and El Universal, among others. For 
instance, the findings on the lengthening of telomeres to cure 
lung fibrosis in mice made by Maria A. Blasco and published 
in January in eLife ; the protective effects of silibinin against 
brain metastases made by the team led by Manuel Valiente, 
published in Nature Medicine in June ; or the article published 
in August in Nature Communications on the discovery of a 
protein panel as an early indicator for the prognosis of the 
most aggressive type of breast cancer by the team led by Miguel 
Ángel Quintela.
In 2018, strategic work was undertaken in order to better 
publicise scientific events like the CNIO Distinguished 
Seminars, offering lectures by leading researchers from all 
over the world, or the CNIO−”la Caixa ” Foundation Frontiers 
Meetings, gathering the foremost experts on ground-
breaking topics in cancer research, such as immunotherapy 
or ageing. These events were covered by many different 
media channels, including general newspapers, radio stations 
and TV channels.
In an effort to reach out to the community, a new edition of 
the “ Present and Future of Cancer Research ” with the 
Atresmedia media group and Fundación AXA was organised. 
The event, held at the Cibeles Palace with the support of the 
City of Madrid, featured Nobel laureate Elizabeth Blackburn, 
Laura García Estévez ( MD Anderson Cancer Center ), María 
José Alonso Fernández ( University of Santiago de 
Compostela ), Luz Casal ( singer, musician, writer and cancer 
survivor ) and CNIO Director Maria A. Blasco. Hosted by 
Mamen Medizábal, from La Sexta TV, it once again spread 
the message that research is one of the pillars on which the 
fight against cancer rests.
Once again, the activities associated with the philanthropic 
initiative ‘ CNIO Friends ’ drew the attention of the media. 
Among them was CNIO Arte, a ground-breaking project in 
Spain carried out with the collaboration of Fundación Banco 
Santander, exploring the common ground of scientific research 
and artistic creation. This first edition called ‘Binomio, a 
Dialogue between Art and Science’, which brought together 
pioneering molecular biologist Margarita Salas and visual 
artist Eva Lootz, made quite an impact on the press and got 
coverage in El Pais Semanal, Mujer Hoy, and Atención Obras 
( La 2 ), among others.
Last but not least, the Communications Department kept 
working on strengthening ties with patients ’ associations, 
participating in events such as the 13th GEPAC Conference, 
which drew 2300 attendees and was organised by the Spanish 
Group of Cancer Patients ( GEPAC ), which comprises 87 
cancer patients ’ associations. Once again, CNIO researchers 
gathered over the weekend to publicise CNIO’s scientific 
activity – our teams ’ findings and their impact on the future 
of cancer prevention and treatment.
“ Spreading	knowledge	
to valorise	science.”
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B I O T E C N O L O G Í A
El programa de Biotecnología del 
Centro Nacional de Investigacio-
nes Oncológicas (CNIO) cumple 20 
años. Nació en torno a 1998 y fue 
uno de los primeros programas del 
CNIO, surgiendo cinco años an-
tes de que el centro se inaugura-
ra como tal, cuando diversos gru-
pos ya funcionaban pero sin com-
partir una misma ubicación fí-
sica.  
Fernando Peláez, director del 
programa, explica a DM que sur-
gió para aglutinar todas las plata-
formas tecnológicas de las que se 
vale el CNIO, un modelo diferen-
te -por entonces, hace 20 años- al 
que solía utilizarse en España. En 
la mayoría de centros (“era el mo-
delo típico del CSIC”) había un pe-
queño equipo de investigadores 
que, en cada unidad, daban ser-
vicio a sus grupos, en vez de te-
ner esta labor centralizada en un 
programa que nutriera a todo el 
centro.  
Peláez reconoce que, en el fondo, 
casi todo lo que se hace en el CNIO 
es biotecnología: “El programa po-
día haberse llamado de otra mane-
ra, porque en realidad lo que hace 
es reunir todas las core facilities, 
las plataformas tecnológicas, y dar 
servicio a los demás programas 
y unidades del centro”. En todo 
caso, el nombre no es del todo ba-
ladí: “Todas las plataformas se ba-
san en técnicas biotecnológicas, 
y dan pie a productos biotecno-
lógicos”. 
DAR SERVICIO E ¿INVESTIGAR? 
El programa de Biotecnología tie-
ne una organización diferente a los 
demás, que se centran en el desa-
rrollo de investigaciones propias. 
De hecho, las nueve unidades que 
componen el programa no tienen 
entre sus funciones la realización 
Plataformas tecnológicas,  
“uno de lo grandes alicientes” del CNIO 
MADRID JOSÉ A. PLAZA  
japlaza@unidadeditorial.es
Fernando Peláez, 
director del Programa de Biotecnología del 
CNIO, en su 
despacho.
de líneas propias de investigación, 
sino la mera cobertura de servicios 
tecnológicos para todo el CNIO.  
Las nueve unidades son: Proteó-
mica, Genómica, Microscopia Con-
focal, Imagen Molecular, Ratones 
Transgénicos, Anticuerpos Mo-
noclonales, Histopatología y Cito-
metría de Flujo. Peláez explica así el modelo de 
trabajo: “La misión fundamental 
es dar soporte a la investigación de 
otros, no desarrollar líneas pro-
pias. Si, además de la labor de ser-
vicio, las unidades quieren hacer 
investigación propia, pueden, pero 
como algo extra y sin que afecte 
a su labor principal”. 
BUSCANDO EL EQUILIBRIO 
No es sencillo mantener este equi-
librio entre dar servicio e investi-
gar. Peláez, que trabaja en el CNIO 
desde hace diez años, recuerda 
cómo ha ido evolucionando: “Al 
principio había mucha libertad en 
el programa para investigar, pero 
se valoró si existía cierto riesgo de 
que el modelo se desvirtuara si 
se prestaba mucha atención a la 
investigación propia en detrimen-
to de los servicios tecnológicos, así 
que se pusieron límites a la in-
vestigación propia. Para hacerla, 
había que seguir un protocolo es-
pecífico un poco restrictivo”. 
Tras este efecto rebote, el CNIO 
decidió “volver a abrir la mano, 
ya que la investigación propia per-
mite que entren fondos en el cen-
tro, al aplicar a más proyectos, y 
logramos trabajar sin riesgo de 
que se desvirtúe el sistema. Las 
unidades dedican más  tiempo a 
dar servicio y, cuando pueden, ha-
cen sus propias líneas de investi-
gación. No hay conflicto”. 
El Programa de Biotecnología 
da, principalmente, servicios in-
ternos pero también ofrece cober-
tura a otros centros de investiga-
ción y empresas: “Lo único que se 
pide es que las unidades del CNIO 
no se vean afectadas por los servi-
cios externos que se prestan”.  
Como uno de los programas 
fundacionales del CNIO, Biotecno-
logía se ha convertido en una de 
las señas de identidad del centro. 
Peláez define así su valor: “Es uno 
de los factores claves para atraer 
talento al CNIO: el profesional se 
beneficia de un gran programa 
de unidades de apoyo tecnológico. 
Es un gran aliciente para recalar 
en el CNIO”. 
¿QUÉ GENERA EL PROGRAMA?  
Los desarrollos tecnológicos del 
programa son variados: puestas a 
punto de técnicas ya existentes, 
como evoluciones en la micros-
copia de alto rendimiento; desa-
rrollo de nuevas líneas de transgé-
nicos en expresión génica; aplica-
ción de tecnología CRISPR para 
generación de modelos murinos; 
creación de anticuerpos monoclo-
nales; enfoques proteómicos para 
estudio de exosomas; abordajes de 
inmuno-PET para visualización 
tumoral... 
MÁS ‘ROYALTIES’  
Un caso destacado es la Unidad de 
Anticuerpos Monoclonales, una de 
las claves de generación de royal-
ties: “Es una de las mayores fuen-
tes de generación externa de fon-
dos con transferencia de tecno-
logía en el centro: unos 600.000 eu-
ros el último año”. De hecho, según señala la pá-
gina web del centro, el año pa-
sado las nueve unidades del pro-
grama de Biotecnología “tuvieron 
especial éxito en la atracción de 
fondos externos mediante activi-
dades innovadoras. Se formali-
zaron diversos contratos y acuer-
dos con empresas privadas e ins-
tituciones públicas”. En concre-
to, los royalties derivados de la 
venta de los anticuerpos monoclo-
nales “crecieron en torno a un 16 
por ciento con respecto al año an-
terior, alcanzando un nuevo máxi-
mo histórico”.
El Programa de Biotecnología, uno de los puntales del CNIO, cumple 20 años. Aglutina las plataformas tecnológicas que dan 
servicio a todo el centro y, además, hace investigación propia
“El programa fue uno de los fundacionales del CNIO y nació con un modelo diferente a los que primaban en la época, aglutinando todas las plataformas” 
La misión básica es dar soporte; si, además, las unidades quieren hacer investigación propia, pueden, si no afecta a su labor principal” 
Quien viene al CNIO se beneficia de un gran programa de unidades de apoyo tecnológico. Es un gran aliciente para recalar en el centro”
La Unidad de Anticuerpos Monoclonales es una de las principales fuentes de ‘royalties’; logró el año pasado unos 600.000 euros” 
D
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E N T R E V I S TA 
D O C U M E N TO S
Marisol Soengas“Las científi cas no somos unos bichos raros”
Es una de las investigadoras más prestigiosas del mundo 
en la lucha contra el melanoma, el cáncer de piel más común 
y también el más letal. Se formó junto a la histórica científi ca 
Margarita Salas y su ejemplo le sirvió para que siempre 
considerase natural que una mujer ocupara cargos de 
responsabilidad en la ciencia. Hoy ella dirige su propio equipo 
en el Centro Nacional de Investigaciones Oncológicas (CNIO).
por Patricia Fernández de Lis
fotografía de Sofía Moro
2170 DOC entrevista marisol soengas.indd   54
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nen restringida la contratación indefinida desde 2012, 
y eso ha llevado a muchos gestores a concatenar con-
tratos temporales como si fueran indefinidos. Y así, los 
tribunales han obligado a readmitir o a indemnizar a 
242 trabajadores de los organismos públicos de inves-
tigación entre 2013 y 2017.“Lo que ha ocurrido con la ciencia en España de-
muestra una falta de visión total. Los equipos se des-
montan, dejamos de hacer cosas que tienen valor, 
muchos investigadores se marchan y otros dejan de 
venir”, afirma Óscar Llorca, inves-tigador del Centro Nacional de In-vestigaciones Oncológicas (CNIO). 
“La burocracia nos asfixia”, incide 
Pilar Martín, del Centro Nacional 
de Investigaciones Cardiovascula-res (CNIC). “Si seguimos así, esto 
es irreversible, estamos perdiendo 
una generación de científicos”, aña-de Ángela Nieto. “No somos menos 
inteligentes que los alemanes y pro-bablemente estemos igual de bien 
formados, pero necesitamos más 
inversión e infraestructuras”, expli-ca Carlos Matute. “Si no tienes moti-
vación, no tienes ideas, y sin ideas no tienes ciencia”, 
resume Roderic Guigó, del Centro de Regulación Ge-
nómica (CRG).
Los investigadores españoles creen que también 
hay que redefinir la carrera científica para que resulte 
clara y atractiva para los jóvenes, renovar las plantillas, 
reducir la endogamia, comprar tecnología de frontera 
que nos permita hacer también ciencia de frontera, 
crear las condiciones para atraer el talento internacio-
nal, mejorar la transferencia de la investigación básica 
a la práctica clínica, la relación con 
las empresas y el mecenazgo, y que 
se tomen decisiones políticas cientí-ficamente informadas. Hasta hace unas semanas, estas 
reivindicaciones eran ignoradas. 
Ahora, por primera vez desde 2011, 
hay un ministerio dedicado a la cien-cia y la innovación, y un ministro, 
conocido por la sociedad y recono-cido por los investigadores, que pue-de revertir la situación. “¿Que qué le 
pido a Pedro Duque? Que escuche”, 
resume Félix de Moya. Y el ministro 
asegura que está escuchando.
“EN LA CIENCIA ESPAÑOLA HA HABIDO DEMASIADAS HEROICIDADES”, DICE EL 
ASTRONAUTA Y MINISTRO PEDRO DUQUE
2182 DOC reportaje cientificos.indd   44





D O C U M E N TO S
REPORTAJE
por Patricia Fernández de Lis
fotografía de Samuel Sánchez
2182 DOC reportaje cientificos.indd   34
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GONZALO LÓPEZ SÁNCHEZ MADRID 
Rafael Yuste (Madrid, 1963) es el direc-tor del Centro de Neurotecnología de la Universidad de Columbia (Nueva York). También es el principal impul-sor de BRAIN, una iniciativa estadou-nidense tan ambiciosa como el Proyec-to Genoma Humano y que el expresi-dente Barack Obama anunció en 2013. Su objetivo es desarrollar la tecnología 
que permitirá comprender cómo fun-ciona el cerebro en realidad. Hoy en día, todavía se desconoce cómo sus 90.000 millones de neuronas se comunican en-tre sí para originar pensamientos o por qué surgen muchas de sus enfermeda-des. La clave está, en opinión de Yuste, en estudiar cómo trabajan los circui-tos que forman y que actúan como au-ténticas unidades funcionales. Vino a Madrid invitado por el Centro Nacio-nal de Investigaciones Oncológicas (CNIO) y la Fundació Banc Sabadell. —En el cerebro existen billones de co-nexiones entre neuronas. ¿Se puede entender su funcionamiento?  —Eso es algo que se lleva intentando hacer desde hace un siglo y que aún no hemos conseguido. Parte del pro-
blema es que el enfoque tradicional ha consistido en tratar de entender estas marañas de células mirándolas una a una. Represento a un grupo de cientí-ficos que estamos desarrollando téc-nicas para aprender cómo las neuro-nas se disparan en grupo. Poder ver-los sería como mirar una selva desde arriba, distinguiendo el curso de ríos y montañas, en lugar de mirar la es-pesura desde dentro. —Pero el cerebro cambia a cada mo-mento, ¿no es así?  —Sí, queremos medir la actividad de las células en distintos lugares y en di-ferentes instantes. Es complejo, por-que  el cerebro cambia a cada instante, es líquido y fluye constantemente.  —¿Qué investigaciones están desa-rrollando en este momento?  —Intentamos descifrar sistemas más simples, la corteza visual de ratones y el sistema nervioso de hidras –unos cni-darios, como las medusas–, para com-prender los sistemas más complejos.  —Ahora se están dando los primeros pasos. ¿Presenciaremos una revolu-ción en este campo?   —Es difícil predecirlo porque la cien-cia depende mucho de la suerte. Pero es posible que estas nuevas neurotec-
nologías cambien completamente la neurociencia, la clínica asociada y la psiquiatría. También crearán una nue-va industria. 
—¿Qué tipo de enfermedades podrían curarse así? 
—No se sabe todavía, pero sospecho que muchas enfermedades dependen 
del mal funcionamiento de conjuntos de neuronas. Pero primero hay que po-ner los cimientos. Lo primero es tener las herramientas, lo segundo entender los sistemas, después se entenderán las patologías y, por último, se curarán. —¿Cuáles son los objetivos del proyec-to BRAIN?  
—Su principal misión es diseñar nue-vas herramientas para estudiar el ce-rebro. Hay tres retos fundamentales. El primero es poder registrar toda la ac-tividad de las neuronas. El segundo reto es poder modificar su actividad con es-pecificidad y éxito. El tercer reto es teó-rico y computacional. Imagínese la can-tidad de datos que va a generar el me-dir la actividad de todas las neuronas del cerebro en cada milisegundo. —¿Qué capacidad de computación ha-ría falta para estudiar un cerebro? —Es enorme, pero no es imposible. En Australia una red de telescopios tiene un ancho de banda capaz de manejar tantos datos como haría falta para re-gistrar la actividad de un millón de neu-ronas. Esto bastaría para controlar un hemisferio de la corteza cerebral de la musaraña etrusca, el mamífero más pe-queño, durante una hora. Actualmen-te, Google o Facebook manejan ya vo-lúmenes de datos mucho mayores. De hecho Google ya trabaja en reconstruir el conectoma, el conjunto de las cone-xiones entre neuronas, en animales simples. 
—¿Se podría volcar un cerebro en un ordenador? 
—Depende de cómo funcione el cere-bro. Si es como un ordenador, se podría subir a la red y relacionarlo con otros computadores. Pero si es un sistema orgánico, cuyo funcionamiento depen-de íntimamente del hardware, no se podrá replicar, salvo que lo hagas en otro cerebro.  
—¿Se podrá leer la mente? —Antes o después ocurrirá. Ya estamos empezando a dar pasos en esa direc-ción. Con técnicas todavía no muy po-tentes podemos escanear el cerebro y adivinar algunas de las cosas que un paciente está pensando.  —El siguiente paso sería manipular la mente... 
—Sí, y estas futuras técncias se podrían usar para el bien o el para mal. Esto crea problemas éticos muy profundos. Es-tamos empezando a desarrollar tecno-logías ques nos permiten alterar y vi-sualizar la esencia de nuestra mente. 
Por esto estoy intentando conjuntar, desde hace un año, a expertos en neu-rociencia y bioética para establecer cin-co nuevos derechos humanos: los neu-roderechos.  
—¿Es optimista ante el futuro?   —Sí. Estamos en los umbrales de un nuevo renacimiento en el que por fin vamos a entender cómo funciona nues-tro cerebro de forma objetiva. Vamos a comprender quiénes somos los hu-manos y por qué hacemos las cosas que hacemos, y eso llevará a muchos cam-bios sociales positivos. Si en el Renaci-miento hubo una explosión del huma-nismo cuando se comprendió cómo funcionaba el cuerpo, cuando se com-prenda el cerebro aparecerán nuevos humanismos. 
ISABEL PERMUY 
Rafael Yuste en un momento de la entrevista, celebrada en Madrid  
«Pronto podremos alterar y ver la esencia de nuestra mente» 
Rafael Yuste 
Neurocientífico e impulsor de BRAIN
Entrevista
Neuroderechos para evitar 
«superpersonas» 
Según Rafael Yuste, los avances en neurociencia permitirán acceder el cerebro y a la esencia de la mente. Por eso, ha impulsado el reconoci-miento de unos neurodere-chos centrados en el respeto a la privacidad mental, a la identidad personal y al libre albedrío. «Debemos proteger-los para evitar que con la tecnología pueda alterarlos o descifrarlos», apunta. Tam-bién resalta la importancia de que el acceso a la tecnología sea equitativo y que no esté restringido a unos pocos. Eso llevaría de una élite de personas aumentadas. 
√
Un nuevo Renacimiento   «Por fin vamos a comprender quiénes  somos los humanos, lo que llevará a muchos cambios sociales positivos»
abc.es/conocer
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En adultos y adolescentes entre 12 y 17
años, para el tratamiento habitual del AS
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cuando es adecuado el uso de una com
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Inmunoterapia y moléculas 
dirigidas: frente antirresistencias
Las asociaciones 
terapéuticas son la 
gran esperanza 
para detener las 
resistencias que se 
observan con las 
nuevos abordajes 
La eficacia innovadora de las nue-
vas terapias de precisión para las 
enfermedades tumorales no esca-
pa al fenómeno de las resistencias 
farmacológicas, lo que motiva que 
grandes grupos de investigación 
se centren en cómo limitar este fe-
nómeno. En inmunoterapia, por 
ejemplo, “el abordaje de las resis-
tencias se orienta hacia la iden-
tificación de subgrupos de pacien-
tes que pueden obtener el máximo 
beneficio. Los análisis genéticos 
ofrecen estratificaciones. El ma-
yor esfuerzo se está invirtiendo en 
lo que los oncólogos que tratan 
con inmunoterapia denominan tu-
mores hot y cool, y convertir los tu-
mores fríos o cool que no respon-
den en calientes o hot, dirigiendo 
células del sistema inmune para 
conseguir respuestas”, ha explica-
do a  DM Scott Lowe, investigador 
del Memorial Sloan Kettering Can-
cer Center, en Nueva York, Estados 
Unidos, centro pionero en ensayos 
sobre resistencias y del que James 
Allison, último premio Nobel de 
Medicina, ha sido un buen expo-
nente.  
DIANA EN SARCOMA SINOV
IAL  
Lowe, que ha participado en la 
presentación del Programa Inves-
tigadores Visitantes de la Funda-
ción Jesús Serra, gracias a la cual 
Scott ha realizado una estancia sa-
bática en el Centro Nacional de In-
vestigaciones Oncológicas (CNIO), 
en Madrid, insiste en que lo más 
importante es entender la interac-
ción entre célula tumoral e inmu-
ne porque “las resistencias surgen 
cuando los tumores encuentran 
vías para escapar al reconoci-
miento de las células inmunita-
rias”, pero no pasa de largo el he-
cho de que “una de las direcciones 
futuras, aunque ya hay ensayos 
clínicos, es combinar estrategias: 
inmunoterapia con moléculas di-
rigidas que actúan sobre una mu-
tación genética concreta, ya que se 
está observando que la terapia 
molecular puede potenciar el efec-
to de la inmunoterapia”.  
El pasado mes de marzo, Cancer 
Cell publicaba los resultados de un 
estudio en el que el equipo de 
Lowe identificaba una mutación 
que parecía estar involucrada en 
el desarrollo del sarcoma sinovial, 
un tumor que suele afectar a ni-
ños, adolescentes y jóvenes adul-
tos, y para el cual no se dispone de 
un tratamiento efectivo en estos 
momentos. La proteína KDM2b, y 
más concretamente la fusion abe-
rrante en la expresión y fusión de 
otros dos genes, el SS18 y SSX, es-
taría en el epicentro de este tipo de 
cáncer. El hallazgo ha abierto la 
entrada a nuevas terapias, como 
inhibidores peptídicos, entre 
otros, pero “la estrategia sigue 
siendo compleja e implica un de-
safío tecnológico”. Scott 
Lowe, del Memorial Sloan Kettering Can
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The topics that most attracted the attention of our followers 
on our social media accounts, besides from the scientific news 
generated by CNIO’s research groups and units, were the stories 
and interviews depicting the more human side of our research 
and of the people involved, such as Juegaterapia’s visit with the 
singer David Bisbal to support ‘ CNIO Friends ’ ( April ), two 
interviews with Maria A. Blasco and musician Luz Casal in El 
Mundo ( February ) and La Razón ( October ), the announcement 
that Manuel Valiente was elected EMBO Young Investigator 
( November ), and the interview with Giovanna Roncador in El 
País ( December ), to name a few.
3:05
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soCiaL EVEnts
Pedro Duque visited the CNIO a month 
after having been appointed as the 
Spanish Minister for Science, Innovation 
and Universities. Photo by Europa 
Press. July 16, 2018.
CNIO remained faithful to its standing 
appointment with society during the 
European Researchers ’ Night, which is 
funded by the EU Framework Pro-
gramme for Research & Innovation, 
Horizon 2020 — Marie Sklodowska-Cu-
rie actions. In the Madrid region, this 
event is promoted by the Department 
of Education and Research and coordi-
nated by Fundación madri+d. Up to 64 
CNIO volunteers and 200 visitors at-
tended this event that has the objective 
of demonstrating the reality of a col-
lective — the science community - that 
is key in the development of society. 
September 28, 2018.
During the 10th edition of the Visiting 
Researcher Programme, supported by 
the Jesús Serra Foundation ( part of the 
Catalana Occidente Group ), the Foun-
dation and CNIO announced that the 
Centre will host a sabbatical stay for 
Scott Lowe, Chair of the Cancer Biology 
and Genetics Program at the Memorial 
Sloan Kettering Cancer Center. Lowe will 
develop new collaborations with CNIO 
faculty and initiate mutually beneficial 
collaborations. December 4, 2018.
 Representatives from member insti-
tutions of the Severo Ochoa and Maria 
de Maetzu Alliance, SOMMa — which 
encompasses “ Severo Ochoa ” and 
“ María de Maeztu ” Centres and Units of 
Excellence — gathered at the CNIO for 
the 100xCiencia.3 : Bridging science and 
society Congress. In its third edition — 
the first since the establishment of this 
Alliance — 100xCiencia focused on the 
importance of the participation of soci-
ety in science. During the event, repre-
sentatives from the science commission 
of the Spanish Congress of Deputies 
debated on the strong and weak points 
of the science policy in our country. No-
vember 15, 2018.
Together with the Atresmedia Corpo-
ration and the AXA Foundation, we 
celebrated World Cancer Research Day 
at the City Council of Madrid with an 
event entitled “ Present and Future of 
Cancer Research ”. Elizabeth Blackburn, 
Nobel Prize winner in Medicine in 2009, 
held a press conference, gave the key-
note speech “ Resolving Paradoxes in 
Telomere Biology and Cancers ”, and 
participated in a roundtable discussion 
with CNIO Director Maria A. Blasco, 
Laura García Estévez ( MD Anderson 
Cancer Center ), María José Alonso 
Fernández ( University of Santiago de 
Compostela ), and Luz Casal ( musician, 
singer, author, songwriter and former 
cancer patient ). September 24, 2018.
SPANISH NATIONAL CANCER RESEARCH CENTRE, CNIO 183ANNUAL REPORT 2018 182
International 
Affairs
SPANISH NATIONAL CANCER RESEARCH CENTRE, CNIO 185ANNUAL REPORT 2018 184
InternatIonal affaIrs
INTERNATIONAL AFFAIRS
CAROLINA POLA Director of International Affairs
In 2018, we succeeded at consolidating our key alliances, thus 
adding to the goal of the Centre to reinforce CNIO’s scientific 
leadership. We started off the year by implementing a strategy 
to focus on the promotion, participation in, and coordination 
of international scientific consortia ; the execution of this 
strategy has created a considerable momentum that we will 
continue to push forward in light of the upcoming European 
framework programme. The active engagement of the 
Department of International Affairs ( IAs ) with the Spanish 
Ministry of Science, Innovation and Universities ( MICIU ), 
the Centre for the Development of Industrial Technology 
( CDTI ), the Foundation for Science and Technology ( FECYT ), 
the European Commission and other funding actors is crucial 
to better understand where the opportunities lie and how to 
leverage our strengths and opportunities.
As ‘ Severo Ochoa ’ Centre of Excellence and member of the 
Severo Ochoa and Maria de Maetzu Alliance ( SOMMa ), IAs 
keeps leading the Work package of Outreach and provides a 
bridge between the activities of SOMMa and the CNIO. In 
particular, in November, the CNIO co-organised with SOMMa 
the first ‘ 100xCiencia ’ conference taking place within the 
alliance’s framework. CNIO hosted the meeting, bringing 
together more than 140 people, both from SOMMa as well as 
from centres interested in sharing projects and views on 
Science Education and Public Engagement initiatives. The 
programme, which grasped the attention of various media 
outlets, hosted a roundtable with science representatives 
from various political parties and provided a forum for 
discussion with different societal actors. The impact and 
dissemination of the event was aligned with the objectives of 
SOMMa and CNIO to reach out to society and spread the 
knowledge obtained by the Spanish scientific community.
We have not ceased efforts to expand our reach, and this 
year—with the invaluable and instrumental collaboration of 
the Ramón Areces Foundation—the partnership with the 
prestigious Weizmann Institute of Science ( WIS ) is taking 
shape and growing into a fruitful alliance. The first call for 
CNIO-WIS joint projects was launched in June and the 
awarded projects will kick off in 2019. The Alliance has agreed 
that a second CNIO-WIS joint symposium on Cancer Discovery 
will take place in Israel for further strengthening the 
partnership and sowing the seeds for future collaborations. 
There is full commitment from all the partners in this tripartite 
alliance to achieve a model of international collaboration that 
will soon show a strong impact on science.
The CNIO has paid special attention to establishing a cancer 
research consortium in drug discovery for the Spanish 
Association Against Cancer ( AECC ) Accelerator Awards call, 
which we believe can exert a great impact on the field of cancer 
and contribute to speed up progress in oncology. The rippling 
effect of such consortia, that comprise top scientists from 
Spain, UK and Italy, will serve the international cancer 
community at large. In 2018, the CNIO also actively participated 
in the first symposium organised by the Milner Therapeutics 
Institute in Cambridge, an international drug discovery-
focused alliance in which the CNIO is an affiliate academic 
member. This alliance is key to place the CNIO at the heart 
of drug discovery in Europe and to boost collaborations with 
the big industry players in the field of biomedicine.
“Establishing and 
consolidating international 
partnerships remains an 
overarching goal to 
promote CNIO institutional 
leadership. We strive to 
foster collaborations and 
participation in H2020 and 
focus on preparing the 
Centre to excel in the 
upcoming Horizon Europe.”
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INSTITUTIONAL IMAGE & OUTREACH 
TO SOCIETY
AMPARO GARRIDO ( since October ) Coordinator
The Office of Institutional Image & Outreach to Society was 
created in October 2018. Although all our paths to knowledge 
may differ, it is fair to say that all of us at the CNIO are united 
by the experience, effort, creativity and care that we dedicate 
towards strengthening links between our Centre and the 
citizenry which it serves. We hope that our efforts will enable 
our message to be successfully transmitted to society and that 
we impress upon people our Centre’s reality of being a place 
where state-of-the-art scientific research is carried out 
intensively with the aim of defeating a disease that, one way 
or another, affects each and every one of us.
At the same time, we are at pains to foster an ever-deepening 
relationship between our teams of scientists and the public 
at large by organising and publicising various educational, 
recreational and other activities to heighten public awareness 
of the current state of play in advanced cancer research. Among 
those many activities is the initiative known as CNIO Arte.
CNIO Arte is an initiative created by CNIO, with support from 
the Banco de Santander Foundation, in conjunction with the 
Spanish Foundation for Science and Technology-Ministry of 
Science, Innovation and Universities, through CNIO & the 
City. Its goal is to bring together scientists and artists so that 
they can explore the uncharted territory where scientific 
research and artistic creation overlap.
We took our cue from CNIO’s recently published book entitled 
‘ Excelentes ’ that includes photographs by Amparo Garrido 
and texts by Monica G. Salomone, highlighting close-up 
portraits and biographical background sketches of several 
notable women and men who have been hosted at the CNIO 
over the past few years. Each year, CNIO Arte will invite one 
of these distinguished scientists to Madrid to take part in an 
inspirational dialogue with a respected artist who will then 
create one ( or more !) works of art based on their interaction.
Our inaugural encounter was called ‘ Binomio, a Dialogue 
between Art and Science ’. It was curated by Mireia Puigventós 
and proved to be a thought-provoking platform for its 
participants : pioneering molecular biologist Margarita Salas 
and renowned artist Eva Lootz, who was awarded Spain’s 
National Prize for the Plastic Arts. The result was a series 
of 59 drawings and an audio-visual presentation that remained 
on display at CNIO headquarters for two and a half months. 
The artwork also really attracted lots of attention at ARCO, 
Spain’s biggest and best known contemporary art fair. Sharing 
the credit for its success are Maria A. Blasco ( Director of the 
CNIO ), Susana Gómez ( Banco Santander Foundation ), Eva 
Lootz ( Plastic Artist ), Estrella de Diego ( Distinguished 
Professor of Art ), Amparo Garrido ( Artistic Director ) and 
Mireia A. Puigventós ( Curator ).
Artwork created by the artists who take part in CNIO Arte 
will be available to the public for viewing and 100% of the 
proceeds from their sales are earmarked by ‘ CNIO Friends ’ 
for the financing of cancer research at the Centre.
The year 2018 marks the launching of the new CNIO website, 
an important milestone for which we worked, and continue 
to do so, with dedication and motivation. One other major 
goal we have set for ourselves at the CNIO’s Office of 
Institutional Image and Outreach to Society, is to encourage 
and assist our researchers as they familiarise themselves with 
our ‘ corporate identity manual ’ in order to build an institutional 
brand that is eye-catching in its visuals and memorable in its 
content. Those criteria ensure that everyone’s creative 
endeavours, whether it be the design of a T-shirt with the 
CNIO logo or a presentation made before a congress of 
professional researchers, are all synergistically linked. Both 
criteria are of inestimable value in bolstering CNIO as a global 
brand. With so much ocular stimulation impacting on our 
daily lives, an effective and consistent visual identity can be 
particularly helpful in seeing that our message gets through 
to the public.
“We do not communicate 
through words alone. In 
order for a message to get 
across properly it has to 
surmount the complexities 
of stimuli that surround us. 
Our office takes care of 
creating and delivering a 
message that can prevail 
over everything else.”
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Cristina de Martos ( until July ) ( TS )*
*Titulado Superior ( Advanced Degree )
The success of the CNIO & The City’s first edition ( May 2017 
— March 2018 ) set a strong precedent and has motivated us 
to continue with our outreach efforts ; these are undertaken 
through educational activities for pre-university students 
and by supporting STEM careers to empower society as a 
whole, hereby emphasizing the full and growing commitment 
to science outreach. In April 2018, the Spanish Foundation 
for Science and Technology ( FECYT ) — Ministry of Science, 
Innovation and Universities, awarded funding to the CNIO 
to continue with the project for another year, this time focusing 
on strengthening the bridges between CNIO scientists, the 
educational community and society by means of co-creation.
The openness of research centres to society through outreach 
events, citizen science and public engagement is an aspect of 
increasing interest and importance for European institutions, 
funding bodies and evaluators. It is essential that research 
projects as well as institutions acknowledge the importance 
of this kind of outreach for achieving new standards of scientific 
excellence in the future. The CNIO has always celebrated 
special occasions with science outreach activities, such as the 
European Researchers ’ Night, the Science Week or the guided 
visits, and has always encouraged the staff to be actively 
involved. Thanks to CNIO & The City, this commitment can 
be upheld throughout the whole year.
This new project kicked off in May 2018, maintaining the two 
main gears of the project ( EDCUACNIO for students, and 
FORMACNIO devoted to teachers ), and since then even more 
students and teachers have ended up swelling the ranks of 
CNIO & The City participants : ‘ Lab Immersion ’ and ‘ My First 
Science Project ’ ( 88 Secondary students and 3 classrooms, 
70% women ) and the ‘ Stop Cancer Training Course for 
Secondary Teachers ’ ( 50 teachers, 80% women ). In 2018, 
CNIO & The City included new science workshops aimed at 
primary school students in order to start impacting on younger 
generations as a stepping stone for accomplishing our objective 
to foster STEM careers. In addition, the project has focused 
on supporting the CNIO Arte initiative, and facilitating 
educational talks at schools and inspirational and vocational 
material ( blog posts, videos…), which are available to the public 
and disseminated through our social channels.
As the above numbers reveal, this project is also committed 
to closing the gender divide in science. In CNIO & The City, 
we regard gender equity values and the importance of women 
in science as a transversal theme and we thereby strongly 
encourage the participation of female students in all the 
activities ; strategies to this regards are developed and 
implemented in collaboration with the CNIO WISE Office. 
In February, we marked the International Day of Women and 
Girls in Science by sending some of our female scientists to 
the schools and celebrating the event ‘ Mom, I want to be an 
artist…and a scientist !’; we benefitted from the special 
collaboration of the pioneering molecular biology scientist 
Margarita Salas and the renowned visual artist Eva Lootz .
All CNIO & The City activities represent a team effort and 
they would not be possible without the commitment and 
collaboration of the more than 70 CNIO volunteers, ranging 
from Principal Investigators to technicians and other 
administrative staff. The integration of science in societal 
culture is a long-standing demand in Spain, as the 9th Social 
Perception of Science Survey ( FECYT ) reveals, and we eagerly 
join other research centres in leading science outreach projects 
and meeting society’s needs.
PANTONE 344C
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History of Cancer (watch video at https://www.youtube.com/watch?v=wFAO7fDhZX8).
“ CNIO & The City is our instrument 
to reach out to the educational 
community and catalyse interaction 
between educators and CNIO 
scientists. We hope to promote 
knowledge co-creation and value in 
collaboration with different societal 
groups.”
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DEAN’S OFFICE
MARÍA S. SOENGAS
Dean for Academic Affairs
Genomics at the Technical University of Munich ( Germany ), 
who spoke about his experience in the field of data analysis 
based on a large volume of patient samples. Marisol Quintero, 
CEO of Bioncotech Therapeutics, presented a powerful example 
of how to transfer intellectual property from a research centre 
to a clinical trial. In addition, Gustavo Fúster Olaguibel, from 
Hoffmann Eitle, discussed his personal view on how it became 
possible for a pharmacist like himself to end up working in a 
law firm specialising in intellectual property and patents. We 
also had 15 outstanding talks given by CNIO trainees that 
covered exciting discoveries in the fields of epidemiology, 
epigenetics, proteomics, metastasis and drug development. 
Progress made in other basic and translational aspects of 
cancer were presented in over 60 posters, which together 
emphasised the breadth of research of our different Scientific 
Programmes.
Another main highlight of the Lab Day was the announcement 
of the recipients of our ‘ Director’s List Awards ’. These are 
recognitions to outstanding contributions made by our 
personnel in 3 categories : ( 1 ) predoctoral fellows with 
publications of the highest scientific impact ; ( 2 ) excellence 
in research by postdoctoral and staff investigators ; and ( 3 ) 
altruistic volunteering to further the mission of the Centre 
related to training, scientific divulgation and outreach.
1. Awards for Excellence in Research by Predoctoral 
Fellows
We are grateful again to the Agüera-Nieto family for their 
generous donation, in the name of their mother Antonia Nieto, 
to support an award acknowledging the PhD student authoring 
the article with the highest impact in a scientific journal. This 
year, the ‘ Antonia Nieto Award ’ went to Isidoro Cobo, from 
the Epithelial Carcinogenesis Group, for the finding that a 
gene that increases the risk of pancreatic cancer also controls 
inflammation in normal tissue ( published in Nature ).
Recipients of other awards in the PhD category were Panagiotis 
Karras ( for an article in Cancer Cell ), Manuel Sanclemente 
( Cancer Cell ), Alexandar Kojic ( Nature Structural and 
Molecular Biology ) and Juan José Montero (  Nature 
Communications ).
2. Award for Excellence in Research by Postdoctoral/
Staff Investigators
This award was shared ex aequo by Neibla Priego ( Brain 
Metastasis Group ), for mechanistic and pharmacological 
findings in brain metastases published in Nature Medicine, 
and by Carmen Guerra ( Experimental Oncology Group ), for 
her contribution in the training of researchers and her multiple 
accomplishments in the field of pancreatic cancer.
3. Outstanding Contribution to Outreach and Awareness
Isabel López de Silanes, from the Telomeres and Telomerase 
Group, received this award to honour her generous and 
altruistic contribution to CNIO’s Women in Science Office, 
organising seminars and lectures, inviting schools and colleges 
to attend these events, and securing funding for these activities.
In summary, we are as proud as ever of the achievements of 
our vibrant community of young investigators at the CNIO. 
We thank all those public and private contributors that have 
helped support and fuel their efforts, and we will make sure 
that the coming years will be even more successful in moving 
the cancer field forward.
The CNIO is recognised for the relevance and international 
projection of its Scientific Programmes. This success would 
not be possible without the hard work of our personnel in 
training. Indeed, over 60% of the CNIO’s workforce is 
comprised of PhD students, predoctoral and postdoctoral 
fellows, medical residents and a broad spectrum of visiting 
scientists. The CNIO places particular emphasis on career 
development and to that end, our Centre’s core mission is to 
maximise the chances of success of our personnel in training.
In addition to ensuring proper academic supervision, we 
acknowledge that scientists need soft skills beyond the bench. 
Therefore, we pay special attention to areas of public 
communication, management of intellectual property, and 
the creation of start-ups or spin offs. These activities are 
performed in concert with CNIO’s Training Programmes, as 
well as with the Innovation and Communication Offices. We 
are most grateful to the Fundación Jesús Serra for their 
continuous support to strengthen career development 
programmes at the CNIO.
We believe that an informed society is better prepared to 
understand ( and if needed, face ) the diseases that constitute 
human cancer. Therefore, we are actively involved in knowledge 
dissemination. For example, over 70 CNIO PhD students and 
postdoctoral fellow volunteers this year took part in the sixth 
edition of our ‘ Meet a Scientist, Become a Scientist ’ event. This 
is an open doors activity that we hold as part of the Marie 
Sklodowska Curie European Researchers’ Night and was 
attended by over 250 participants of all ages who learned 
about daily life at our Centre and had the opportunity to run 
an experiment side by side with our researchers.
A particularly inspirational event this year was our Annual 
CNIO Lab Day. We were fortunate to host Roland Rad, Director 
of the Institute of Molecular Oncology and Functional 
PARTICIPANTS
Personnel In Training :
Daniela Cerezo, Marta Contreras, Ana 
Cuadrado, Nicolás Cuesta, David 
Olmeda, Adrián del Rincón
Staff/Faculty :
Ana Losada, Jorge Martínez, 
Lola Martínez, Francisco X. Real, 
Manuel Valiente
“ PhD students, postdoctoral fellows, 
and in general all personnel in 
training are key assets for the CNIO. 
A main objective of our Centre is to 
train and empower them to fulfil 
their potential as future influential 
leaders.”
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to be recognised for their achievements ? We believe it is 
mainly due to the second cause and so we continue with our 
endeavours that take the form of a successful seminar series 
where we give all CNIO members and others ( including 
students from different high schools in Spain ) the opportunity 
to listen to and meet women who embody roles and positions 
that are traditionally not held by women. With this initiative, 
it is our mission to promote scientific vocations among girls 
− it is worrying to see the lack of female students in the so-called 
STEM careers − as well as to positively change the cultural 
and gender stereotypes that exist among teenagers. A real 
change is needed, and we are convinced that it needs to come 
through the education of our younger generations.
The Office counts two main working groups : 1 ) Life/Work 
Balance – aimed to promote and support initiatives to help 
improve the delicate balance between professional and 
personal life at CNIO; 2 ) Seminars and Events – aimed to raise 
and stimulate institutional awareness of gender issues, and 
to provide networking opportunities to all CNIO researchers.
In 2018, the WISE office seminar series continued to host 
several top female leaders from different areas. Some of the 
talks given during 2018 include :
 ɗ Laura Ferrero Carballo, writer, freelance editor and literary 
advisor Instituto Vasco Etxepare. Title : ‘ Decisiones 
racionales e irracionales : una breve historia de cómo llegué 
a ser escritora ’. 30/01/2018.
 ɗ Elisa Martín Garijo, Chief Technology Officer for IBM, 
Madrid, Spain. Title : ‘ Yes, we can ’. 20/02/2018.
 ɗ Fátima Bosch, Director of the Centre of Animal 
Biotechnology and Gene Therapy at the Autonoma 
University of Barcelona, Spain. Title : ‘ Translational Gene 
Therapy Approaches to Treat Metabolic and 
Neurodegenerative Diseases ’. 06/03/2018.
 ɗ Victoria Camps, Philosopher, Professor of Ethics 
Universidad Autónoma de Barcelona, Spain. Title : ‘ La 
filosofía como instrumento de emancipación ’. 24/04/2018.
 ɗ Laura González Molero, Ibex35-company Board member 
and ex-President of Merk-Serono and Bayer HealthCare. 
Title : ‘ Atrévete a ser el rector de tu propia vida ’. 05/06/2018.
 ɗ Pepe Verdes, from Librotea, interviewed the writer Elvira 
Sastre. Title : ‘ Escritoras, más allá del género y la biografía ’. 
25/09/2018.
 ɗ Eulalia Pérez Sedeño, research professor at the CSIC 
Institute of Philosophy. Title : ‘ Conocimiento y estereotipos 
de género. 23/10/2018.
 ɗ Marta Macho, professor of mathematics at the Universidad 
del País Vasco. Title : ‘ Entre el suelo pegajoso y el techo de 
cristal : la realidad de las mujeres en el ámbito laboral ’. 
11/12/2018.
The WISE Office signed an agreement with the ASTI 
Foundation to be a strategic partner for their project STEM 
Talent Girl Madrid. The goal of this project is to promote 
STEM careers among 13-14 year-old students. Eight Master 
classes given by top professional women from the STEM field 
have been organised to be held in the CNIO Auditorium. The 
first 2 already took place and were given by Rosa García, 
president of Siemems Spain ( November, 2018 ) and Marta 
Martinez, president of IBM Spain ( December, 2018 ). We also 
participated in other educational initiatives, through 
the 11defebrero.org platform, to promote scientific careers 
among students from the Comunidad de Madrid. This initiative 
was carried out in collaboration with ‘ CNIO and The City ’, a 
science outreach project, co-financed by the FECYT ( Fundación 
Española para la Ciencia y Tecnología ) and Obra Social ”la 
Caixa ”, with the aim of creating closer links between society 
and the education system.
The CNIO Women in Science Office ( WISE ) was established 
in 2012. Our main objectives are to give visibility to women, 
to raise awareness regarding the importance of gender equality, 
to help correct imbalances in the career ladder at the CNIO 
community, to try to promote and support women in their 
professional careers, as well as to come up with ideas and 
policies to improve the life/work balance at the CNIO. The 
WISE Office is composed of CNIO volunteers from across all 
the areas represented at the Centre and also includes the 
Director. All of us share the belief that women are still 
underrepresented in leadership positions in science and we 
are committed to ensuring gender equality within the research 
domain.
Several studies and statistics from different organisations 
within Spain and the European Union still display the ‘ scissors ’ 
graphic when it comes to gender distribution and career ladder 
positions. There is a clear lack of female talent in leadership 
positions, which, together with an average 20% salary gap 
between men and women, are clear indicators that there 
remains a lot of work to be done in terms of promoting female 
talent and facilitating access to areas that are still not 
traditionally open to women. Still to this day, women are 
underrepresented in academia. Although data from 
Universities here in Spain and other European countries show 
that the percentage of women undertaking university studies 
is over 50%, and the representation of women at the pre-
doctoral and post-doctoral stages is similar, those percentages 
diminish significantly as we move up the scientific career 
ladder : a poor 25% of women are represented at the Principal 
Investigator level, and it is even lower at the levels of 
department directors and beyond. Moreover, the 
acknowledgement of women when it comes to prizes continues 
to be very low and, in particular, when we consider the most 
prestigious ones ; is there simply not enough female talent 
present in the scientific fields, or is it still just harder for them 
CNIO WOMEN IN 
SCIENCE OFFICE
Isabel López de Silanes 
( since June )
Lola Martínez ( until June )
Coordinator
Members
Marinela Mendez ( Work-Life Balance 
Coordinator ), Isabel López de Silanes 
( Seminars and Events Coordinator ), 
Maria A. Blasco, Maria Jesús Alcamí, 
Cristina de Martos ( until July ), 
Raquel García-Medina, Diego Megías, 
Francisca Mulero, Fernando Peláez, 
Carolina Pola, Sandra Rodríguez
Here at the WISE Office, we share 
the view of the American journalist 
and social political activist Gloria 
Steinem : “ a feminist is anyone who 
recognises the equality and full 
humanity of women and men.” To 
this end, we endeavour to build a 
fair society for all where 
stereotypes, unconscious bias and 
gender barriers are eliminated, as 
we firmly believe that working 
together as equals, is the only way 
to reach true excellence.
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Facts  & Figures
SCIENTIFIC MANAGEMENT
ISABEL BARTHELEMY Scientific Management Director
The Scientific Management Department at the CNIO is 
committed to assisting with the facilitation of all those key 
areas that help our scientists to better focus their efforts on 
their research. The Department encompasses various Offices : 
Projects and Consortia, Education and Training Programmes, 
Scientific Events, Scientific Publishing, and Library and 
Archives.
The mission of the Projects’ Office is to guide the CNIO 
scientists through all stages related to the application and 
management processes of externally-funded projects, 
whether they be financed through either public and/or private 
institutions, or stem from either national or international 
funding bodies. The Office coordinates the internal call alerts, 
manages the ethical certification for projects involving animal 
experimentation or human samples, supports scientists with 
the preparation of the project proposals, manages the ongoing 
projects, and contacts the funding agencies to resolve any 
issues or deal with questions.
The Training Office is the central point for training at the 
CNIO ; it aids the recruitment process, serves as an advocate 
for all fellows, provides administrative support, and creates 
educational and learning opportunities. It is responsible for 
helping PhD students, Postdoctoral scientists and post-resident 
MDs by announcing call alerts and providing the relevant key 
information ; helping foreign students with their paperwork 
at the foreign office ; organising the summer training call ; and, 
in general, in collaboration with the Personnel Department, 
managing student’s grants.
The Events Office organises CNIO meetings, such as the 
CNIO−”la Caixa ” Foundation Frontiers Meetings, the 
Distinguished Seminars series, the external Scientific Advisory 
Board ( SAB ) meeting, CNIO Progress Reports, as well as 
Faculty retreats, among others. The Office also helps scientists 
by providing advice for the organisation of specific events, 
including science outreach events.
The Library administers the electronic subscriptions of 
over 300 scientific journals at the CNIO and manages journal 
article requests for journals that the CNIO is not subscribed 
to. The Library also provides information regarding reference 
management software, manages the open-acess repository 
REPISALUD and organises the CNIO guided visits.
The Scientific Publications Office is responsible for the 
preparation of institutional scientific publications, including 
the CNIO Annual Report, booklets of the Scientific Advisory 
Board meeting and those of other symposia, as well as scientific 
dissemination leaflets. The Office also provides support for 
the scientific editing of press notes and other publications of 
scientific divulgation to a non-specialised audience.
Raquel Ares, Sonia Cerdá, Almudena 
Del Codo, M. Dolores Liébanes, 
Victoria López, Mercedes Moro, 
Leyre Vergés, Helena Zamora ( since 
May )
“ All our efforts are dedicated 
towards building a strong and 
flexible framework to support our 
scientists and to help them achieve 
excellence.”
scientiFic ManageMent
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INTERNATIONAL GRANTS COLLABORATIvE PROJECTS
EUROPEAN COMMISSION 7TH FRAMEWORK PROGRAMME ( 2007-2013 )
ERA-NET ON TRANSLATIONAL CANCER RESEARCH ( TRANSCAN )
PRINCIPAL INVESTIGATOR PROJECT TITLE
Malats, Núria Bio-PaC : Biomarkers of tumor recurrence in pancreatic 
cancer ( financed by ISCIII, Ref.: AC14/00025 )
ERA NET NEURON II : NETWORK OF EUROPEAN FUNDING FOR NEUROSCIENCE RESEARCH
PRINCIPAL INVESTIGATOR PROJECT TITLE
Malumbres, Marcos MicroKin : Deciphering the multifaceted pathways 
underlying MCPH pathogenesis in the mouse and human 
( financed by MEIC, Ref.: PCIN-2015-007 )
HORIZON 2020 ( 2014-2020 )
MARIE SKŁODOWSKA-CURIE ACTIONS ( MSCA )
PRINCIPAL INVESTIGATOR PROJECT TITLE
Soengas, María S. ITN IMMUTRAIN : Training network for the 
immunotherapy of cancer ( Ref.: 641549 )
SOCIETAL CHALLENGE 1 : HEALTH, DEMOGRAPHIC CHANGE AND WELLBEING
PRINCIPAL INVESTIGATOR PROJECT TITLE
Benítez, Javier BRIDGES : Breast cancer risk after diagnostic gene sequencing ( Ref.: 634935 )
INTERREG SUDOE 
PROGRAMME  1
PRINCIPAL INVESTIGATOR PROJECT TITLE
Al-Shahrour, Fátima ONCONET : European Network for Translational Research and 
Innovation in Oncology /Réseau Européen de Recherche translationnelle 
et d’Innovation en oncologie ( Ref.: SOE1/P1/F0082 )
US NATIONAL INSTITUTES 
OF HEALTH ( NIH )
PRINCIPAL INVESTIGATOR PROJECT TITLE
Muñoz Fernández, Inés Targeting Mdm2-MdmX E3 ligase for treatment of drug-
resistant lymphoma ( Ref.: R01CA208352 )
Peinado, Héctor Exosome-mediated transfer of c-MET to bone marrow 
progenitors promotes metastasis ( Ref.: R01CA169416 )
Tress, Michael GENCODE 2 : Integrated human genome annotation : generation 
of a reference gene set ( Ref.: U41HG007234 )
COMPETITIVE  
FUNDING
The CNIO attracts a substantial proportion of its funding 
from external sources. Most of this funding comes from 
national and international funding bodies and is used not only 
to finance the Centre’s outstanding R&D activities, but also 
strategic actions in Innovation together with Industry partners. 
The funding is also used to support other relevant activities 
related to dissemination and scientific outreach ; these 
activities are aimed at promoting public awareness. In 2018, 
researchers at the CNIO were involved in 134 projects that 
received extramural funding.
In 2018, the CNIO actively participated in a total of 45 
collaborative projects : 14 were international collaborative 
projects ( 3 of which are coordinated by the CNIO ) and 31 
were collaborative projects at the national level ( 12 of them 
are coordinated by the CNIO ). The international collaborative 
projects were funded by institutions such as the European 
Commission through the 7th Framework Programme and 
Horizon 2020, the Interreg SUDOE Programme, the US 
National Institutes of Health ( NIH ), the US Department of 
Defense ( DoD ), the International Human Frontier Science 
Program Organization, the Melanoma Research Alliance 
( MRA ), the Paradifference Foundation and Worldwide Cancer 
Research. At the national level, collaborative projects received 
important public funding through grants from the Strategic 
Health Action that is managed by the Institute of Health Carlos 
III ( ISCIII ), the State Research Agency of the Spanish Ministry 
of Science, Innovation and Universities ( AEI/MICIU ), and 
the R&D Activities Programmes of the Community of Madrid ; 
most of the projects were cofunded by European Structural 
and Investment Funds ( European Regional Development 
Fund and European Social Fund ). Private funders and charities 
also recognised the excellence of our scientific projects, among 
them, the Scientific Foundation of the Spanish Association 
Against Cancer ( Fundación AECC ).
In addition to these collaborative projects, researchers at the 
CNIO attracted funding for projects carried out by individual 
groups. In 2018, 24 of these projects received international 
funds while 65 of them received national funding ( mainly 
from the AEI/MICIU, the ISCIII and private foundations ). 
The international individual projects are funded by the 
European Commission ( 3 ERC grants and 8 Marie Curie 
Actions ), Worldwide Cancer Research, the Howard Hughes 
Medical Institute ( HHMI ), the Prostate Cancer Foundation, 
the US DoD and the MRA.
1. This Programme is cofunded by the European Regional Development Fund ( ERDF ) 
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INTERNATIONAL GRANTS  INdIvIdUAL PROJECTS
EUROPEAN COMMISSION 7TH FRAMEWORK PROGRAMME ( 2007-2013 )
EUROPEAN RESEARCH COUNCIL ( ERC )
PRINCIPAL INVESTIGATOR PROJECT TITLE
Fernández-Capetillo, Óscar ERC Consolidator Grant RSHEALTH : Investigating the causes and 
consequences of replication stress in mammalian health ( Ref.: 617840 )
MARIE CURIE ACTIONS ( MCA )
PRINCIPAL INVESTIGATOR PROJECT TITLE
Peinado, Héctor WHRI COFUND ADIPOMET : Analyzing the crosstalk of tumor and 
adipose tissue during metastasis ( Ref.: 608765 WHRI-309 )
Plaza, Iván WHRI COFUND : Structure-Function studies of oncogenic RET 
kinase Fusions in non-small cell Lung Cancer ( NSCLC ): from 
structure to targeted therapy ( Ref.: 608765 WHRI-612 )
Ramón, Santiago 
Moreno, María
WHRI COFUND CAD_FL : Revealing the functional mechanism of CAD 
and its potential as a therapeutic target ( Ref.: 608765 WHRI-222 )
Real, Francisco X 
Paliwal, Sumit
WHRI COFUND : NFIC as a novel regulator of pancreatic acinar 
differentiation and homeostasis ( Ref.: 608765 WHRI-609 )
Squatrito, Massimo GLIDD : DNA Damage Response ( DDR ) signaling in tumor 
formation and therapeutic resistance of gliomas ( Ref.: 618751 )
Wagner, Erwin F. 
Gago, Nuria
WHRI COFUND STEM-PSO : Unraveling the contribution of Epidermal 
and Non-Epidermal Progenitor ( Ref.: 608765 WHRI-319 )
HORIZON 2020 ( 2014-2020 )
EUROPEAN RESEARCH COUNCIL ( ERC )
PRINCIPAL INVESTIGATOR PROJECT TITLE
Barbacid, Mariano ERC Advanced Grant THERACAN : Novel therapeutic strategies 
to treat pancreatic and lung cancer ( Ref.: 695566 )
Efeyan, Alejo ERC Starting Grant NutrientSensingVivo : The Physiology 
of Nutrient Sensing by mTOR ( Ref.: 638891 )
MARIE SKŁODOWSKA-CURIE ACTIONS ( MSCA )
PRINCIPAL INVESTIGATOR PROJECT TITLE
Soengas, María S. 
Frago, Susana
METMEL : Long range-acting drivers of premetastatic 




METLINK : Identification of links between cancer cell 
growth and metabolism genes ( Ref.: 794177 )
HOWARD HUGHES MEDICAL 
INSTITUTE ( HHMI )
PRINCIPAL INVESTIGATOR PROJECT TITLE






PRINCIPAL INVESTIGATOR PROJECT TITLE
Olmos, David Clinical qualification of DNA repair defects as prognostic and 
predictive biomarker in metastatic prostate cancer using genomics 
and tissue-based functional assays ( Ref.: W81XWH-18-1-0770 )
Peinado, Héctor Organ-tropic metastatic secretomes and exosomes 
in breast cancer ( Ref.: W81XWH-13-1-0427 )
MELANOMA RESEARCH 
ALLIANCE ( MRA )
PRINCIPAL INVESTIGATOR PROJECT TITLE
Soengas, María S. ( coordinator ) Imaging and targeting dormant and pro-metastatic 
melanoma lesions in vivo ( Ref.: 401181 )
THE PARADIFFERENCE 
FOUNDATION
PRINCIPAL INVESTIGATOR PROJECT TITLE




PRINCIPAL INVESTIGATOR PROJECT TITLE
Malats, Núria ( coordinator ) Oral microbiotic profiles and its association with risk of 





PRINCIPAL INVESTIGATOR PROJECT TITLE
Llorca, Óscar ( Coordinator ) Photochemical trap and high-resolution imaging of transient 
chromatin complexes from living cells ( Ref.: RGP0031/2017 )
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NATIONAL GRANTS  COLLABORATIvE PROJECTS
INSTITUTE OF HEALTH 
CARLOS III / INSTITUTO DE 
SALUD CARLOS III ( ISCIII ) 
STRATEGIC HEALTH ACTION 
/ ACCIÓN ESTRATÉGICA EN 
SALUD ( AES )
SUB-PROGRAMME OF GRANTS FOR RESEARCH SUPPORT PLATFORMS IN HEALTH SCIENCES AND TECHNOLOGY/ 
SUBPROGRAMA DE AYUDAS PARA PLATAFORMAS DE APOYO A LA INVESTIGACIÓN EN CIENCIAS Y TECNOLOGÍAS DE 
LA SALUD 2
PRINCIPAL INVESTIGATOR PROJECT TITLE
Artiga, Mª Jesús ( Coordinator ), 
Morente, Manuel ( until August 2018 )
Plataforma de Biobancos ( Coordination node 
and Group, Ref : PT13/0010/0001 )
Benítez, Javier Plataforma de recursos biomoleculares y bioinformáticos, 
PRB  2 ( Group, Ref : PT13/0001/0005 )
Muñoz, Javier Plataforma de recursos biomoleculares y bioinformáticos, 
PRB  2 ( Group, Ref : PT13/001/0010 )
Al-Shahrour, Fátima Plataforma de Bioinformática. Instituto Nacional de 
Bioinformática ( Group Ref : PT17/0009/0011 )
Artiga, Mª Jesús 
Morente, Manuel ( until August 2018 )
Plataforma de Biobancos ( Group, Ref : PT17/0015/0004 )
Benítez, Javier Plataforma de proteómica, genotipado y líneas celulares. Plataforma 
de recursos biomoleculares, PRB  3 ( Group, Ref : PT17/0019/0020 )
Muñoz, Javier Plataforma de proteómica, genotipado y líneas celulares. Plataforma 
de recursos biomoleculares, PRB  3 ( Group, Ref : PT17/0019/0005 )
RESEARCH PROJECTS IN HEALTH/PROYECTOS DE INVESTIGACIÓN EN SALUD 3
PRINCIPAL INVESTIGATOR PROJECT TITLE
Artiga, Mª Jesús ( Coordinator ) 
Morente, Manuel ( until August 2018 )
OPTIMARK project : Optimization of tissue samples for the development 
and validation of disease biomarkers ( Ref.: PI16/00946 )
Malats, Núria ( Coordinator ) Building and validation of risk prediction models for pancreas cancer. 
The application of a multi-omics approach ( Ref.: PI15/01573 )
Olmos, David ( Coordinator ) THERATLAS Project : integration of early and adaptive genetic 
events to establish therapeutic subgroups in Castration-
Resistant Prostate Cancer ( Ref.: PI16/01565 )
Robledo, Mercedes ( Coordinator ) Prognostic profiles in endocrine tumours identified by next generation 
sequencing, and definition of markers with clinical utility ( Ref.: PI14/00240 )
TECHNOLOGICAL DEVELOPMENT PROJECTS/PROYECTOS DE DESARROLLO TECNOLÓGICO 4
PRINCIPAL INVESTIGATOR PROJECT TITLE
Blasco, Maria ( Coordinator ) Translational Studies for the Development of Telomerase 
Gene Therapies as Treatments for Myocardial Infarction 
and Pulmonary Fibrosis ( Ref.: DTS17/00152 )
MELANOMA RESEARCH 
ALLIANCE ( MRA )
PRINCIPAL INVESTIGATOR PROJECT TITLE
Soengas, María S. Prognostic and therapeutic impact of lymphovascular 
niches in melanoma ( Ref.: 348673 )
Valiente Cortes, Manuel Blocking melanoma brain metastasis by targeting 
the environment ( REF.: 498103 )
PROSTATE CANCER 
FOUNDATION
PRINCIPAL INVESTIGATOR PROJECT TITLE
Olmos, David Integration of clinical, molecular and biological characteristics 
to define an aggressive subtype of prostate cancer 
based on deficient homologous recombination
Castro, Elena Prospective study of lethal prostate cancer clinical and 




PRINCIPAL INVESTIGATOR PROJECT TITLE
Blasco, Maria Targeting telomeres in cancer ( Ref.: 16-1177 )
Lietha, Daniel Targeting regulatory mechanisms for allosteric 
cancer drug discovery ( Ref.: 15-1177 )
Malumbres, Marcos New therapeutic strategies by inhibiting Mastl in breast tumors ( Ref.: 15-0278 )
Peinado, Héctor Evaluation of obesity as a novel risk factor in metastasis ( Ref.: 16-1244 )
Soengas, María S. Harnessing endo/exocytosis for a coordinated targeting of melanoma 






PRINCIPAL INVESTIGATOR PROJECT TITLE




PRINCIPAL INVESTIGATOR PROJECT TITLE
Valiente, Manuel Brain-specific strategies to improve responses to immunotherapy ( Ref.: 54545 )
BEUG FOUNDATION FOR 
METASTASIS RESEARCH
PRINCIPAL INVESTIGATOR PROJECT TITLE
Valiente, Manuel Altered brain vessels as a novel target in brain metastasis
2, 3, 4. This Programme is cofunded by the European Regional Development Fund ( ERDF ) 
SPANISH NATIONAL CANCER RESEARCH CENTRE, CNIO 209ANNUAL REPORT 2018 208
Facts  & Figures scientiFic ManageMent | COmPETITIvE FUNdINg 
MADRI+D FOUNDATION 
/ FUNDACIÓN PARA EL 
CONOCIMIENTO MADRI+D
PRINCIPAL INVESTIGATOR PROJECT TITLE
Dean’s Office for Academic Affairs 
Soengas, María S.
European Researchers ’ Night 2018-2019, organized by 
Madri+d Foundation and founded by EU-H2020 Programme. 
Marie Skłodowska-Curie actions GA 818528
SCIENTIFIC FOUNDATION OF 
THE SPANISH ASSOCIATION 
AGAINST CANCER / 
FUNDACIÓN CIENTÍFICA DE 
LA ASOCIACIÓN ESPAÑOLA 
CONTRA EL CÁNCER ( AECC )
PRINCIPAL INVESTIGATOR PROJECT TITLE
Barbacid, Mariano ( Coordinator ) A multifaceted approach to target pancreatic cancer ( Ref.: GC16173694BARB )
Malats, Núria 
Real, Francisco X. ( Coordinator )
Invasive bladder cancer : towards precision medicine ( Ref.: GCB14142293REAL )
Gómez, Gonzalo 
Peinado, Héctor 
Soengas, María S. ( Coordinator )
Distinct routes of metastatic dissemination in different melanoma 
subtypes. Implications in the validation of new tumor biomarkers 
and therapeutic targets ( Ref.: GCB15152978SOEN )
Valiente, Manuel Study of the molecular mechanisms involved in primary ( glioblastoma ) 
and secondary ( metastasis ) brain tumors to identify novel therapeutic 
targets and anti-cancer agents, biomarkers to select treatments and novel 
non-invasive methods for molecular diagnosis ( Ref.: GCTRA16015SEOA )
STATE RESEARCH 
AGENCY. MINISTRY OF 
SCIENCE, INNOVATION 
AND UNIVERSITIES / 
AGENCIA ESTATAL DE 
INVESTIGACIÓN. MINISTERIO 
DE CIENCIA, INNOVACIÓN Y 
UNIVERSIDADES
NATIONAL PLAN FOR SCIENTIFIC AND TECHNICAL RESEARCH AND INNOVATION (  2013-  2016 AND  2017-  2020 )
EXCELLENCE NETWORKS/REDES DE EXCELENCIA
PRINCIPAL INVESTIGATOR PROJECT TITLE
Efeyan, Alejo ( Coordinator ) METABOCANCER : Crosstalk between systemic and cellular 
metabolism in cancer ( Ref.: SAF2016-81975-REDT )
Fernández-Capetillo, Óscar 
( Coordinator )
UBIRed : Ubiquitin like proteins in signalling, proliferation 
and cancer ( Ref.: SAF2017-90900-REDT )
CHALLENGES-COLLABORATION PROJECTS/PROYECTOS RETOS-COLABORACIÓN 5
PRINCIPAL INVESTIGATOR PROJECT TITLE
Barbacid, Mariano New approaches for treatment of lung cancer. ( Ref.: RTC-2017-6576-1 )
Djouder, Nabil NRCANCER : Desarrollo de nueva terapia antitumoral basada 
en nicotinamida-ribosido ( Ref.: RTC-2016-5431-1 )
Muñoz, Inés
Martínez-Torrecuadrada, Jorge
ATTACK : Cancer immunotherapy with bispecific antibodies 
that engage T-lymphocytes ( Ref.: RTC-2017-5944-1 )
Real, Francisco X. IMMOPDL2 : Preclinical development of antibodies against 
the immunomodulator PD-L2 for the treatment of diseases 
caused by cellular damage. Validation of the strategy in 
residual tumors and fibrosis ( Ref.: RTC-2017-6123-1 )
COMMUNITY OF MADRID / 
COMUNIDAD AUTÓNOMA DE 
MADRID
R&D ACTIVITIES PROGRAMME IN BIOMEDICINE6 :
PRINCIPAL INVESTIGATOR PROJECT TITLE
Al-Shahrour Núñez, Fátima  
Roncador, Giovanna
Programa LINFOMAS-CM : Linfomas agresivos, análisis clínico y genómico 
integrado para una medicina de precisión ( Ref.: B2017/BMD-3778 )
Blasco, Maria Programa RyPSE-CM : RNA y proteínas de unión a RNA. 
Implicaciones en salud y enfermedad ( Ref.: B2017/BMD-3770 )
Djouder, Nabil Programa TomoXliver-CM : Estudio de la disfunción del hepatocito 
desde un abordaje multidisciplinar ( Ref.: B2017/BMD3817 )
Malumbres Marcos ( Coordinator ) 
Barbacid M., Mariano
Programa iLUNG-CM : Terapias personalizadas y nanotecnología 
en cáncer de pulmón ( Ref.: B2017/BMD-3884 )
Mulero, Francisca Programa RENIM-CM : Red Madrileña de Nanomedicina 
en Imagen Molecular ( Ref.: B2017/BMD-3867 )
Quintela, Miguel Ángel Programa IMMUNOTHERCAN-CM : Inmunidad tumoral e 
inmunoterapia del cáncer ( Ref.: B2017/BMD-3733 )
Robledo, Mercedes Programa TIRONET2-CM : Fisiopatología Tiroidea. Mecanismos 
implicados en cáncer, autoinmunidad y acción de las 
hormonas tiroideas ( Ref.: B2017/BMD-3724 )
Soengas, Maria S. Programa NANODENDMEDII-CM : Nanosistemas dendríticos 
como agentes y vectores terapéuticos en distintas aplicaciones 
biomédicas ( II ) ( Ref.: B2017/BMD-3703 )
5. This Programme is cofunded by the European Regional Development Fund ( ERDF ) 
6. These Programmes are cofunded by the European Regional Development Fund ( ERDF ) and European Social Fund ( ESF )
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Djouder, Nabil URIPAT : URI loss in intestinal pathologies ( Ref.: SAF2016-76598-R )
Efeyan, Alejo NUTRIENTOR : Physiology of nutrient sensing and signaling by the mTOR 
complex 1 ( Ref.: SAF2015-67538-R )
Fernández-Capetillo, Óscar BREAKINGRAD : Exploring the limits of radioresistance in mammals ( Ref.: 
SAF2014-59498-R )
Lietha, Daniel FAKACT : Structural studies elucidating the activation mechanism of Focal 
Adhesion Kinase ( Ref.: BFU2016-77665-R )
Llorca, Óscar RuvBL1-RuvBL2 ATPases in DNA/RNA surveillance and human diseases : 
molecular and structural mechanisms ( Ref.: SAF2014-52301-R )
Losada, Ana COHESIN2 : Molecular mechanisms of variant cohesin function ( Ref.: 
BFU2016-79841-R )
Malumbres, Marcos Cyclexit : Physiological and therapeutic relevance of mitotic kinases and 
phosphatases ( Ref.: SAF2015-69920-R )
Méndez, Juan REPLICON2 : Control of eukaryotic DNA replication ( Ref.: BFU2016-80402-R )
Muñoz, Javier EPI-MASS : Epigenetic modifiers in pluripotency : a proteomic analysis of 
non-histone protein methylation ( Ref.: SAF2016-74962-R )
Ortega, Sagrario ESSENCE : Extrinsic control of the skin stem cell niche in homeostasis and 
cancer ( Ref.: BFU2015-71376-R )
Ortega, Sagrario HaploEScancer : Haploid ES cells for cancer research ( Ref.: SAF2013-44866-R )
Osorio, Ana IPAGEN : Exploring the mechanism of action of PARP inhibitors in breast and 
ovarian cancer patients. Identification of new genetic predictors of response 
( Ref.: SAF2014-57680-R )
Peinado, Héctor EXO-NGFR : Analyzing the relevance exosome-derived NGFR during 
pre-metastatic niche formation ( Ref.: SAF2017-82924-R )
Plaza, Iván ESFORET : Structure-function studies of oncogenic RET kinase fusions in 
human cancers : from mechanism of action to targeted therapy ( Ref.: 
BFU2017-86710-R )
Real, Francisco X. TRANS-PDAC : Transcriptional control of pancreatic cancer development ( Ref.: 
SAF2015-70553-R )
Rodríguez, Cristina PREDICT : Identification of genetic markers and physiopathologic factors 
predictive of the peripheral neuropathy of paclitaxel and of other oncologic 
drugs : massive sequencing of candidate genes ( Ref.: SAF2015-64850-R )
Soengas, María S. MEL-STOP : Vesicular trafficking in melanoma progression and treatment 
response ( Ref.: SAF2014-56868-R )
Soengas, María S. MEL-STOP Whole-body imaging of melanoma metastasis as a platform for 
gene discovery and pharmacological testing ( Ref.: SAF2017-89533-R )
Valiente, Manuel ReACTIVE BrainMET : Dissecting the role of reactive astrocytes in brain 
metastasis ( Ref.: SAF2014-57243-R )
Valiente, Manuel Stat3 ReACTIVE : Biology of Stat3+ reactive astrocytes in brain metastasis 
( Ref.: SAF2017-89643-R )
Wagner, Erwin F. CANPSOR : Investigating Cancer Risk in Psoriasis ( Ref.: SAF2015-70857-R )
EXPLORA PROJECTS/PROYECTOS EXPLORA
PRINCIPAL INVESTIGATOR PROJECT TITLE
Blasco, Maria Non canonical treatment for neurodegenerative diseases : telomerase gene 
therapy ( Ref.: SAF2015-72455-EXP )
Djouder, Nabil Thermo-regulation of NAD+ to protect from age-related diseases and cancer 
( Ref.: SAF2017-92733-EXP )
Malumbres, Marcos Improving naive pluripotency and the generation of insulin-producing cells 
with a single microRNA ( Ref.: SAF2017-92729-EXP )
NATIONAL GRANTS INdIvIdUAL PROJECTS
INSTITUTE OF HEALTH 
CARLOS III / INSTITUTO DE 
SALUD CARLOS III ( ISCIII ) 
STRATEGIC HEALTH ACTION 
/ ACCIÓN ESTRATÉGICA EN 
SALUD ( AES )
RESEARCH PROJECTS IN HEALTH  7
PRINCIPAL INVESTIGATOR PROJECT TITLE
Benítez, Javier Massive sequencing contributes to decipher the genetic bases of families with 
rare tumors ( Ref.: PI16/00440 )
Cascón, Alberto Next-generation sequencing of genes directly and indirectly involved in the 
Krebs cycle, applied to pheochromocytomas/paragangliomas with 
hypermethylated phenotype ( Ref.: PI15/00783 )
Quintela, Miguel Ángel Tumor-tolerant immune reprogramming secondary to hypoxia-inducing 
antiangiogenics in breast cancer : physiopathogenic mechanisms and 
therapeutic utility ( Ref.: PI16/00354 )
Robledo, Mercedes Progression related mechanisms in endocrine and neuroendocrine tumours 
( Ref.: PI17/01796 )
Rodríguez, Sandra Ewing Sarcoma Model : induction of the t( 11 ;22 ) translocation in human 
mesenchymal stem and iPS cells by the CRISPR-Cas9 system and study of the 
cellular context and other secondary events role ( Ref.: PI14/01884 )
Rodríguez, Sandra Study of the role of epigenetic modifications in the development of Ewing 
sarcoma : High-throughput screening of epigenetic genes using CRISPR 
libraries in human ( 11 ; 22 ) + t cells ( Ref.: PI17/02303 )
Urioste, Miguel PTEN-hamartoma tumour syndrome research : Phenotypic spectrum, 
associated cancers, molecular basis and search of new gene ( Ref.: 
PI14/00459 )
STATE RESEARCH AGENCY. 
MINISTRY OF SCIENCE, 
INNOVATION AND 
UNIVERSITIES / AGENCIA 
ESTATAL DE INVESTIGACIÓN. 
MINISTERIO DE CIENCIA, 
INNOVACIÓN Y 
UNIVERSIDADES
NATIONAL PLAN FOR SCIENTIFIC AND TECHNICAL RESEARCH AND INNOVATION (  2013-  2016 )
CENTRES OF EXCELLENCE “ SEVERO OCHOA ” AND UNITS “ RAMIRO DE MAEZTU “ SUB-PROGRAMME/SUBPROGRAMA 
DE APOYO A CENTROS DE EXCELENCIA ‘ SEVERO OCHOA ’ Y UNIDADES ‘ RAMIRO DE MAEZTU ’
PRINCIPAL INVESTIGATOR PROJECT TITLE
Blasco, Maria Centre of Excellence “ Severo Ochoa ” ( Ref.: SEV-2015-0510 )
R&D EXCELLENCE PROJECTS/PROYECTOS DE I+D EXCELENCIA  8
PRINCIPAL INVESTIGATOR PROJECT TITLE
Fernández-Leiro, Rafael Macromolecular complexes in the mitochondrial DNA replication and repair 
pathways : structural and molecular mechanisms by cryo-EM ( Ref.: BFU2017-
87316-P )
Llorca, Óscar Structural and molecular mechanisms regulating the PIKK family of kinases, 
including DNA- PKcs, SMG1 and mTOR ( Ref.: SAF2017-82632-P )
Murga, Matilde 
Ruiz, Sergio ( until April 2018 )
Role of RAS signaling in pluripotency and totipotency ( Ref.: SAF2016-
80874-P )
CHALLENGES-RESEARCH PROJECTS/PROYECTOS RETOS-INVESTIGACIÓN  9
PRINCIPAL INVESTIGATOR PROJECT TITLE
Barbacid, Mariano PANTHER : A three prong strategy to fight pancreatic ductal adenocarcinoma 
( Ref.: SAF2014-59864-R )
Blasco, Maria TELOHEALTH : Telomeres and Disease ( Ref.: SAF2017-82623-R )
7, 8, 9. This Programme is cofunded by the European Regional Development Fund ( ERDF ) 
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FUNDACIÓN INOCENTE 
INOCENTE
PRINCIPAL INVESTIGATOR PROJECT TITLE
Blasco, Maria Validation of the TRF1 telomere protective protein as a novel anticancer target 
in pediatric glioma and ependymoma




CARMEN DELGADO/MIGUEL PÉREZ-MATEO GRANTS
PRINCIPAL INVESTIGATOR PROJECT TITLE
Guerra, Carmen Desarrollo de estrategias terapéuticas dirigidas contra el estroma del cáncer de 
páncreas
Malats, Núria Marcadores microbianos para el diagnóstico del adenocarcinoma ductal de 
páncreas
LEUKEMIA AND LYMPHOMA 
FOUNDATION / FUNDACIÓN 
LEUCEMIA Y LINFOMA
PRINCIPAL INVESTIGATOR PROJECT TITLE
Ortega, Ana “ Marcos Fernández ” Grant : Functional characterization of RagC mutations in 
Follicular Lymphoma pathogenesis
SPANISH ASSOCIATION OF 
GASTROENTEROLOGY / 
ASOCIACIÓN ESPAÑOLA DE 
GASTROENTEROLOGÍA
PRINCIPAL INVESTIGATOR PROJECT TITLE
Molina, Mª Esther Evaluación del valor pronóstico de diabetes mellitus tipo II ( DM2 ) en pacientes 
con cáncer de páncreas
FERO FOUNDATION / 
FUNDACIÓN FERO
PRINCIPAL INVESTIGATOR PROJECT TITLE
Peinado, Héctor Liquid biopsy by nanoplasmonic detection of exosomes : predicting response 
to ( immuno- and radio )-therapy




PRINCIPAL INVESTIGATOR PROJECT TITLE




PRINCIPAL INVESTIGATOR PROJECT TITLE
Peinado, Héctor Análisis de Hsp90 como una nueva diana en neurofibromatosis
BBVA FOUNDATION / 
FUNDACIÓN BBVA
LEONARDO GRANTS
PRINCIPAL INVESTIGATOR PROJECT TITLE
Olmeda, David Leonardo Grant : Nuevas estrategias para el tratamiento preventivo de la 
enfermedad metastásica en Melanoma ( Ref.: IN18_BBM_TRA_0293 )
Squatrito, Massimo Leonardo Grant : Precision glioma mouse models by somatic genome editing 
with the RCAS-CRISPR-Cas9 system ( Ref.: IN17_BBM_TRA_0366 )
FUNDACIÓN PFIZER PRINCIPAL INVESTIGATOR PROJECT TITLE
Peinado, Héctor Tumour exosome integrins determine organotropic metastasis
Djouder, Nabil 
Teijeiro, Ana I.
Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic 
Steatohepatitis and Hepatocellular Carcinoma
Rodríguez, Sandra Delivery of functional CRISPR component by pseudotyped virus-likes particles 
( Ref.: BIO2017-91272-EXP )
NETWORKS AND SCIENTIFIC MANAGERS-EUROPE/EUROPA REDES Y GESTORES
PRINCIPAL INVESTIGATOR PROJECT TITLE
Blasco, Maria CNIO in Horizon 2020 : support for proposal preparation and project 
management ( Ref.: EUC2014-51617 )
YOUNG RESEARCHERS PROGRAMME/PROGRAMA JÓVENES INVESTIGADORES  10
PRINCIPAL INVESTIGATOR PROJECT TITLE
Álvarez, Mónica GPGenCan : Functional relevance of Greatwall/PP2A pathway in the 




UBQREP : Modulation of DNA Replication by ubiquitination of chromatin 
proteins ( Ref.: BFU2014-55168-JIN )
SCIENTIFIC INFRASTRUCTURES/INFRAESTRUCTURAS CIENTÍFICO-TECNOLÓGICAS 11
PRINCIPAL INVESTIGATOR PROJECT TITLE
Muñoz, Javier Sistema cromatográfico UHLPC acoplado a Espectrómetro de Masas de alta 
resolución para estudios de proteómica avanzada ( Ref.: CNIO15-EE-2855 )
Al-Shahrour, Fátima Clúster SMP de Análisis HPC ( Ref.: CNIO15-EE-3845 )
SPANISH FOUNDATION FOR 
SCIENCE AND TECHNOLOGY 
/ FUNDACIÓN ESPAÑOLA 
PARA LA CIENCIA Y 
TECNOLOGÍA ( FECYT )
PRINCIPAL INVESTIGATOR PROJECT TITLE
Pola, Carolina ‘ CNIO and the City ’ – Construyendo un Puente a la Sociedad ( Ref.: FCT-16-11115 )
Pola, Carolina ‘ CNIO & the City ’ – Co-creando conocimiento con la sociedad ( Ref.: FCT-17-
12743 )
” LA CAIXA ” BANKING 
FOUNDATION AND CAIXA 
CAPITAL RISC
CAIXAIMPULSE PROGRAMME
PRINCIPAL INVESTIGATOR PROJECT TITLE
Blasco, Maria TRF1 inhibitors as a first-in-class therapy for glioblastoma and lung cancer 
( Ref.: CI18-00016 )
Rodríguez, Sandra Gene therapy for human cancers driven by fusion genes ( Ref.: CI18-00017 )
SCIENTIFIC FOUNDATION OF 
THE SPANISH ASSOCIATION 
AGAINST CANCER / 
FUNDACIÓN CIENTÍFICA DE 
LA ASOCIACIÓN ESPAÑOLA 
CONTRA EL CÁNCER ( AECC )
PRINCIPAL INVESTIGATOR PROJECT TITLE
Blasco, Maria Grant for projects in childhood cancer : Targeting telomeres in neuroblastoma 
( Ref.: CICPF18004BLAS )
de Cárcer, Guillermo 
( until September 2018)
Grant for Emerging Groups : Identification of new biomarkers for breast cancer : 
mechanisms of sensitivity and resistance to cell cycle drugs ( Ref.: 
LABAE16017DECÁ )
Efeyan, Alejo Grant for Emerging Groups : Nutrient signaling in the pathogenesis and 
treatment of B cell Lymphoma ( Ref.: LABAE16001EFEY )
Squatrito, Massimo Grant for emerging Groups : Novel therapeutic approaches for therapy-
resistant malignant brain tumors ( Ref.: LABAE16015SQUA )
Squatrito, Massimo “ Idea Semilla ” Grant : Identification of biomarkers of tumor treating fields 
( TTFields ) in glioblastoma ( Ref.: IDEAS185SQUA )
10, 11. This Programme is cofunded by the European Regional Development Fund ( ERDF ) 
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training OF Bsc/Msc stuDents
The CNIO is committed to training junior scientists at the 
onset of their careers. To this end, the Centre has established 
a Programme that offers BSc and MSc students the opportunity 
to obtain hands-on practical laboratory experience by working 
on ongoing research projects in one of the CNIO groups. The 
CNIO offers 2 types of short-term laboratory training :
 ɗ An annual Summer Training Programme for undergraduate 
students, from any country, who are in their last years of 
study in the biomedical field. The Programme 
encompasses 8 weeks of full-time laboratory training 
( 292.5 hours ). During this time, the students actively 
participate in research projects in one of the CNIO groups. 
During  2018, 5 students from  2 different countries 
participated in this programme.
 ɗ Additionally, students can apply for laboratory training 
throughout the academic year by directly contacting the 
Heads of CNIO individual Research Groups or Units. This 
year, 128 students participated in these programmes, of 
whom 8 ended up joining the CNIO as pre-doctoral 
students.
training OF PHD stuDents
The training of PhD students in cutting-edge cancer research 
is of key importance to the CNIO. The Centre offers many 
opportunities for bright and dynamic university graduates, 
of all nationalities, to pursue an ambitious PhD project. To 
attest this, 8 students obtained their PhD degrees in 2018 
and 21 others joined the CNIO in the same year. Over 15% of 
the 109 students working at the CNIO in 2018 were graduates 
from foreign universities, thus contributing to the 
internationalisation of the Centre.
Since 2008, the Fundación ” la Caixa ” offers international 
fellowships to PhD students to enable them to carry out their 
thesis projects in biomedical research in Spanish centres of 
excellence. The CNIO was chosen, as one of such centres, to 
launch a programme for outstanding young pre-doctoral 
students, from all over the world, who have an interest in 
pursuing an ambitious PhD project. Since 2013, the former 
Spanish Ministry of Economy, Industry and Competitiveness 
( now Ministry of Science, Innovation and Universities ) has 
undertaken efforts to link the ” la Caixa ”/CNIO International 
PhD Programme to distinguished research centres accredited 
as “ Severo Ochoa ” Centres of Excellence. In 2018, a new call 
for the doctoral fellowship programme of the ” la Caixa ” 
Foundation, named INPhINIT, was launched to recruit 
outstanding international students : 1 pre-doctoral student 
received one of these 3-year contracts. The Fundación ” la Caixa ” 
also launched another call to carry out a doctorate at Spanish 
universities and research centres ; the CNIO was chosen as a 
host institution. During 2018, 1 pre-doctoral student received 
this fellowship.
EDUCATION AND TRAINING  
PROGRAMMES
One of the principal goals of the CNIO is to increase its training 
capacity in order to give students and professionals the 
opportunity to advance their careers in the healthcare sector. 
During 2018, the CNIO signed several new agreements with 
Spanish Universities and other institutions, namely with the 
Universidad de Francisco de Vitoria, Universidad Alfonso X el 
Sabio, University Sapienza di Roma, Universidad Operta de 
Cataluña, Universidad San Pablo CEU ; IES Jose Luis San 
Pedro, IES Las Musas, Rozona Centro de Formación, Centro 
Educativo Maria Inmaculada and Fundación Juegaterapia.
TRAINING PROGRAMMES PARTICIPANTS IN EDUCATION AND TRAINING PROGRAMMES
2014 2015 2016 2017 2018
Training of PhD students 108 105 110 112 109
Post-doctoral training 55 48 51 44 50
Training for MDs 14 25 17 21 12
Laboratory training for MSc/BSc students 73 80 95 99 128
Laboratory training for technicians 21 27 26 20 13
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POst-DOctOraL training
One of the CNIO’s prime objectives is to attract young 
researchers, who have recently obtained their PhD or MD 
degrees, and to offer them highly attractive research projects 
at the forefront of cancer research.
In 2018, 50 postdoctoral fellows worked at the CNIO. Notably, 
about one third of these fellows were from outside of Spain, 
many coming from very prestigious international institutions.
In 2018, the Fundación Banco Santander signed a new annual 
agreement with the CNIO to continue the highly competitive 
fellowship programme aimed at supporting outstanding young 
scientists who have been trained in the UK or in the USA, and 
who wish to start or continue their postdoctoral training at 
the CNIO. One young scientist from the Memorial Sloan 
Kettering Cancer Center ( USA ) was awarded the Banco 
Santander Foundation-CNIO Fellowship in early 2018.
Thanks to the donations received through the ‘ CNIO Friends ’ 
platform launched in 2016, the third call of the ‘ CNIO Friends ’ 
Postdoctoral Contract Programme, in 2018, resulted in the 
recruitment of 4 scientists for a 2-year period each. Also, 
thanks to a ‘ Juegaterapia-CNIO Friends ’ Postdoctoral 
Contract, in 2018, one scientist was able to continue with her 
project related to paediatric oncology.
FunDing sOurces OF POst-DOctOraL researcHers nO.
SPANISH ORGANISATIONS 34
State Research Agency / Agencia Estatal de Investigación 
( AEI ). Ministry of Science, Innovation and Universities / 
Ministerio de Ciencia, Innovación y Universidades ( MICIU ) 
( Postdoctoral Fellowships )
3
State Research Agency / Agencia Estatal de Investigación 
( AEI ). Ministry of Science, Innovation and Universities / 
Ministerio de Ciencia, Innovación y Universidades ( MICIU ) ( I+D 
Projects )
9
Institute of Health Carlos III / Instituto de Salud Carlos III 
( ISCIII ) ( Postdoctoral Fellowships )
1
Spanish Association Against Cancer ( AECC ) / Fundación 
Científica de la AECC ( Fellowships )
3
Spanish Association Against Cancer ( AECC ) / Fundación 
Científica de la AECC ( I+D Projects )
2
Spanish Society of Haematology and Haemotherapy 1
Worldwide Cancer Research UK 1
La Marató TV3 Foundation/ Fundació La Marató TV3 1
Melanoma Research Alliance 1
CNIO 9
Centre for Molecular Biolocy “ Severo Ochoa ” / Centro de 
Biología Molecular Severo Ochoa ( CBMSO )
1
Banco Santander Foundation / Fundación Banco Santander 2
INTERNATIONAL ORGANISATIONS 16
European Commission Framework Programme / H2020 1
Marie Skłodowska-Curie actions of the European Commission 3
Pfizer 1
Worldwide Cancer Research UK 5
AstraZeneca– MedImmune 1
Daiichi Sankyo 1
European Research Council 2
The Paradifference Foundation 1
US Department of Defense 1
TOTAL 50
The distribution of students across the CNIO’s Research 
Programmes in 2018 was as follows : 48 % of students worked 
in the Molecular Oncology Programme, 13% in the Structural 
Biology Programme, 18% in the Cancer Cell Biology 
Programme, 13% in the Human Cancer Genetics Programme, 
1% in the Experimental Therapeutics Programme, 2% in the 
Biotechnology Programme, and 5% in the Clinical Research 
Programme.
Thanks to an individual donation received through the ‘ CNIO 
Friends ’ platform, CNIO created the Predoctoral Maria Oliva 
Contract Programme that offered one position to carry out a 
thesis at the CNIO. This call is expected to have only this one 
single edition.
FunDing OF PHD training nO.
SPANISH ORGANISATIONS  89
State Research Agency / Agencia Estatal de 
Investigación ( AEI ). Ministry of Science, Innovation 
and Universities / Ministerio de Ciencia, Innovación y 
Universidades ( MICIU ) ( Predoctoral Fellowships )
34
State Research Agency / Agencia Estatal de 
Investigación ( AEI ). Ministry of Science, Innovation 
and Universities / Ministerio de Ciencia, Innovación 
y Universidades ( MICIU ) ( I+D Projects )
16
Ministry of Education and Vocational Training / Ministerio de 
Educación y Formación Profesional ( Predoctoral Fellowships )
6
Institute of Health Carlos III / Instituto 
de Salud Carlos III ( ISCIII )
 8
”la Caixa ” Banking Foundation / Fundación 
Bancaria ” la Caixa ” ( Predoctoral Fellowships )
11
Spanish Association Against Cancer ( AECC ) / 
Fundación Científica de la AECC ( I+D Projects )
 2
Community of Madrid / Comunidad de Madrid  3
Cris Foundation / Fundación Cris  4
A3Media Foundation  1
CNIO  2
Banco Santander Foundation / Fundación Banco Santander  1
Inocente Inocente Foundation 1
INTERNATIONAL ORGANISATIONS  20
Celgene 1
China Scholarship Council ( CSC ) 2
Consejo Nacional de Ciencia y Tecnología ( Mexico ) 2
European Research Council 6
GENCODE 2
Human Frontier Science Program Foundation 1
Marie Skłodowska-Curie actions of the European Commission 2
National Institutes of Health 1
Pfizer 1
Portuguese Foundation for Science and Technology ( FCT ) 1
Roche 1
TOTAL 109
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LaBOratOrY training FOr tecHnicians
This training programme has been developed for students in 
Anatomical Pathology, Clinical Diagnostic Laboratory, and 
Archiving/Recording ; it is organised through agreements 
with 19 institutions that provide secondary education for 
laboratory technicians in Spain. It provides students with 
hands-on knowledge in cellular and molecular biology 
techniques. The programme consists of 14 weeks ( 370-400 
hours ) of laboratory training for students. Of the 13 students 
who participated in this programme in 2018, 2 were hired by 
the CNIO.
training FOr MDs
In line with CNIO’s commitment to bridge the “ bench to 
bedside ” gap, the Centre offers 3 training opportunity 
programmes to MDs and other health care professionals. 
Training usually consists of a 3-month period during residency. 
In 2018, 12 medical residents from 10 different hospitals 
enjoyed the benefits of rotations within the different Groups 
and Units at the CNIO.
aDVanceD training OF scientists tHrOugH eXtraMuraL PrOgraMMes
During 2018, the Ramón y Cajal Programme supported 7 
scientists. This special initiative, established in 2001 by the 
former Spanish Ministry of Science and Technology ( currently 
the State Research Agency of the Spanish Ministry of Science, 
Innovation and Universities ) aims to encourage Spanish or 
foreign scientists working abroad to return to or relocate to 
Spain. Successful candidates are selected on the basis of their 
potential capacity to lead independent projects and groups, 
or to contribute successfully to the ongoing research in the 
existing groups. Eight other scientists were funded by similar 
programmes, including the Juan de la Cierva programme 
( Spanish Ministry of Science, Innovation and Universities, 2 
contracts ); Miguel Servet programme ( 1 contract ) of the 
Institute of Health Carlos III ; and the Spanish Association 
Against Cancer ( AECC, 5 contracts ).
Visiting researcHer PrOgraMMe
The Jesús Serra Foundation, part of the Catalana Occidente 
Group, aims to help eminent international specialists work 
together with CNIO researchers for a few months in order for 
them to expand their knowledge in areas of common interest. 
During 2018, Scott Lowe, from the Memorial Sloan Kettering 
Cancer Centre in New York ( USA ) was beneficiary of the Jesús 
Serra Foundation’s Visiting Researcher Programme.
‘ science BY WOMen ’ PrOgraMMe
Thanks to the ‘ Science by Women ’ Programme, launched by 
the Spanish ‘ Fundación Mujeres por África ’, the CNIO has 
selected Hayet Rafa, from the University of Science and 
Technology Houari Boumediene in Algiers ( Algeria ), to carry 
out a 6-month stay at the CNIO during 2019.
POstgraDuate PrOgraMMes
In addition, the CNIO — in collaboration with academic 
institutions across Spain — provides access to a variety of 
postgraduate programmes that cover the areas of Cellular & 
Molecular Biology, Molecular Biomedicine, Biotechnology, 
Biocomputing, Clinical & Applied Cancer Research, and 
Therapeutic Targets.
Official Postgraduate Programmes in Molecular Biosciences
The majority of the international postgraduate trainings 
offered at the CNIO are developed in collaboration with the 
Faculty of Medicine and Faculty of Sciences at the Autonomous 
University of Madrid ( UAM ). These trainings fall under 4 
official Postgraduate Programmes, namely, the Doctorate in 
Molecular Biosciences, Master’s in Biomolecules & Cell 
Dynamics, Master’s in Molecular Biomedicine, and Master’s 
in Biotechnology. CNIO also collaborates with the UAM as a 
partner institution of UAM’s Doctoral School ( EDUAM ), and 
is a member of the Management Committee.
Master’s Degree in Biocomputing Applied to Personalised Medicine and Health
The Master’s in Bioinformática Aplicada a Medicina 
Personalizada y Salud is organised together with the National 
School of Health of the National Institute of Health Carlos 
III ( Escuela Nacional de Sanidad del Instituto de Salud Carlos 
III, ENS-ISCiii ).
Official Master’s Degree in Clinical and Applied Cancer Research
The CNIO and the CEU-San Pablo University in Madrid 
( USP-CEU ) co-organise a Postgraduate Training Programme 
in Clinical and Applied Cancer Research : the Máster 
Universitario en Investigación Clínica y Aplicada en Oncología.
Official Master’s Degree in Therapeutic Targets of Cell Signalling : Research and Development
The CNIO collaborates with the Biochemistry and Molecular 
Biology Department at the University of Alcala de Henares 
( UAH ) for the Máster Oficial en Dianas Terapéuticas en 
Señalización Celular : Investigación y Desarrollo.
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 · Cynthia Kenyon, University of California at San 
Francisco ; Calico Laboratories, US
 · Thomas Rando, Stanford University, US
 · Manuel Serrano, Institute for Research in Biomedicine, 
Barcelona, Spain
 · David Sinclair, Harvard Medical School, US
 · Jan van Deursen, Mayo Clinic, Rochester, US
In addition, 8 short talks were selected among participants ’ 
contributions and 26 posters were presented.
FrOntiers in iMMunOMODuLatiOn anD cancer tHeraPY 
9-11 JULY 2018
ORGANISERS
 · Victoria Aranda, Senior Editor, Nature, New York, US
 · Nabil Djouder, Growth Factors, Nutrients and Cancer 
Group, CNIO, Madrid, Spain
 · Joao Monteiro, Chief Editor at Nature Medicine, New 
York, US
 · Marisol Soengas, Melanoma Group, CNIO, Madrid, Spain
 · Laurence Zitvogel, Gustave Roussy Institute, Paris, 
France
SESSIONS
 · TUMOR-STROMA-IMMUNE SYSTEM CROSSTALK
 · IMMUNOMODULATION AND IMMUNOTOLERENCE 1
 · IMMUNOMODULATION AND IMMUNOTOLERENCE 2
 · MICROBIOTA, IMMUNE SYSTEM AND TUMOR 
PROGRESSION
 · TARGETING IMMUNE SYSTEM : IMMUNOTHERAPY
SPEAKERS
 · Yasmine Belkaid, The National Institute of Health 
( NIH ), Bethesda, US
 · Nina Bhardwaj, Icahn School of Medicine at Mount 
Sinai, New York, US
 · Marcus W. Bosenberg, Yale Cancer Center, New Haven, 
US
 · Peter Carmeliet, VIB-KU Leuven Center for Cancer 
Biology, Belgium
 · Thomas Gajewski, The University of Chicago, US
 · Carola García de Vinuesa, John Curtin School of Medical 
Research, The Australian National Univ., Australia
 · Nicholas W. Haining, Dana-Farber Cancer Institute & 
Broad Institute, US
 · Guido Kroemer, The Cordeliers Research Centre ( CRC ), 
Paris, France
 · Dan R. Littman, The Helen L. and Martin S. Kimmel 
Center for Stem Cell Biology, NYU Langone, US
 · Randy Longman, Weill Cornell Medicine, US
 · Alberto Mantovani, Humanitas Clinical and Research 
Center, Milan, Italy
 · Glenn Merlino, Center for Cancer Research, NCI, 
Bethesda, US
 · Graham Pawelec, The University of Tübingen, 
Germany
 · Mercedes Rincon, University of Vermont Medical 
Center, Burlington, US
 · Andrea Schietinger, Memorial Sloan Kettering Cancer 
Center, NY, US
 · Ton Schumacher, The Netherlands Cancer Institute 
( NIK ), Amsterdam, Netherlands
 · Melody Swartz, Institute for Molecular Engineering, 
University of Chicago, US
 · Erwin Wagner, Spanish National Cancer Research 
Centre ( CNIO ), Madrid, Spain
 · Jennifer Wargo, The University of Texas MD Anderson 
Cancer Center, Houston, US
 · Laurence Zitvogel, Gustave Roussy Institute, Villejuif, 
France
In addition, 10 short talks were selected among participants ’ 
contributions and 35 posters were presented.
SCIENTIFIC EVENTS
cniO-”La caiXa ” BanKing FOunDatiOn FrOntiers Meetings
The “ CNIO -”la Caixa ” Banking Foundation Frontiers 
Meetings ” are the main international conferences co-organised 
by the CNIO and the ” la Caixa ” Banking Foundation. They 
focus on specific, cutting-edge aspects of cancer research, 
thus providing a unique platform for an intensive and dynamic 
exchange and debate on scientific ideas. The invited speakers 
— 20 internationally renowned leaders in oncology — present 
their latest findings during two and a half days. The provided 
learning environment encourages delegates to : exchange 
experiences, ideas and practices upheld at their companies ; 
network to and create connections with researchers with 
similar interests ; listen to and meet the keynote speakers ; 
enjoy the extra-curricular conference programme ; and hear 
about the latest developments in the research field. Up to 100 
additional participants are selected — via a widely publicised 
call for applications — based on their potential to make relevant 
contributions to the conference by presenting hot topics as 
posters or short talks.
MOLecuLar, ceLLuLar anD OrganisMaL HaLLMarKs OF aging 
7-9 mAY 2018
ORGANISERS
 · Maria A. Blasco, Spanish National Cancer Research 
Centre ( CNIO ), Madrid, Spain
 · Kathleen Collins, University of California at Berkeley, US
 · Alejo Efeyan, Spanish National Cancer Research Centre 
( CNIO ), Madrid, Spain
 · Thomas Rando, Stanford University, US
SESSIONS
 · STEM CELLS AND REGENERATION
 · GENOME INSTABILITY
 · NUTRIENTS
 · SENESCENCE
 · ENERGY AND MITOCHONDRIA
SPEAKERS
 · Johan Auwerx, Ecole Polytechnique Fédérale de 
Lausanne, Switzerland
 · Salvador Aznar Benitah, Institute for Research in 
Biomedicine, Barcelona, Spain
 · Shelley Berger, The Perelman School of Medicine at the 
University of Pennsylvania, US
 · Maria A. Blasco, Spanish National Cancer Research 
Centre, Madrid, Spain
 · Anne Brunet, Stanford University, US
 · Judith Campisi, Buck Institute for Research on Aging, 
Novato, US
 · Kathleen Collins, University of California at Berkeley, US
 · Alejo Efeyan, Spanish National Cancer Research Centre, 
Madrid, Spain
 · José Antonio Enríquez, Spanish National Center for 
Cardiovascular Research, Madrid, Spain
 · Manel Esteller, The Bellvitge Biomedical Research 
Institute, Barcelona, Spain
 · Óscar Fernández Capetillo, Spanish National Cancer 
Research Centre, Madrid, Spain
 · Marcia Haigis, Harvard Medical School, Boston, US
 · Jan Hoeijmakers, Erasmus MC Rotterdam, Netherlands
 · Steve Horvath, UCLA David Geffen School of Medicine, 
Los Angeles, US
 · Juan Carlos Izpisua Belmonte, Salk Institute for 
Biomedical Studies, La Jolla, US
 · Matt Kaeberlein, University of Washington, Seattle, US
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cniO-sOMMa : 100Xciencia.3 BriDging science anD sOcietY 
15 NOvEmBER 2018
ORGANISER
The twelve selected 10-minute flash talks presented by both 
SOMMa and external partners showcased ongoing projects 
revolving around science education and public engagement.
The 100xciencia.3 welcomed Prof. Robert Huber, 1988 
Chemistry Nobel Prize winner, as the keynote speaker ; he 
delivered an exciting talk on “ The century of vision : Protein 
structures for drug research ”.
The challenges and opportunities resulting from citizen science 
and science education were discussed over three different 
round tables :
 · The media as a channelling agent for science
 · Scientists and science policy united for society
 · Scientific empowerment of society
training cOurses anD WOrKsHOPs
The CNIO is committed to disseminating the results of state-
of-the-art cancer research to the wider community, including 
medical professionals and junior scientists, thereby enabling 
them to stay abreast of recent developments in specialised 
techniques. This is achieved through training courses and 
hands-on workshops organised by CNIO scientists and 
technologists.
WOrKsHOP : transcriPtOMe anaLYsis OF tuMOurs 
30 JANUARY 2018
ORGANISERS
 · Núria Malats, Genetic and Molecular Epidemiology 
Group, CNIO
 · Francisco X. Real, Epithelial Carcinogenesis Group, 
CNIO
 · Invited Speaker : Aurélien De Reyniès, CIT Program, 
Ligue Nationale Contre le Cancer, Paris, France.
The event mainly addressed researchers with an interest in 
the genomic analysis of tumours.
statisticaL MetHODs FOr MicrOBiOMe stuDies 
9 mARCH 2018
ORGANISERS
 · Núria Malats, Genetic & Molecular Epidemiology Group, 
CNIO
 · CIBERONC ISCIII
 · Invited Speaker : M. Luz Calle, Biostatistics and 
Bioinformatics at the Systems Biology Department, 
University of Vic, Spain.
OtHer Meetings & cOnFerences
The CNIO annually hosts various international meetings and 
conferences.
RETOS DE LA MEDICINA PERSONALIZADA DE PRECISIÓN EN ESPAÑA 
4 JUNE 2018
ORGANISERS
 · Fátima Al-Shahrour, Jefa de la Unidad de Bioinformática, 
Centro Nacional de Investigaciones Oncológicas ( CNIO )
 · Enrique Carrillo de Santa Pau, Jefe del Grupo de Biología 
Computacional, IMDEA Alimentación
 · Alfonso Valencia, Director del Departamento de Ciencias 
de la Vida, Centro de Supercomputación de Barcelona




reD BiOBancOs-ciBer-cniO : JOrnaDa De cOMitÉs De Ética 
De LOs BiOBancOs ; traBaJO en reD 
24 OCTOBER 2018
ORGANISERS
 · Plataforma de la Red Nacional de Biobancos
 · Centro Nacional de Investigaciones Oncológicas ( CNIO )
 · Consorcio Centro de Investigación Biomédica en Red, M.P, 
( CIBER )






15 NOV 2018 MADRID
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cniO’s HigH cOntent screening user grOuP Meeting – sOutH eurOPe 
15 - 16 OCTOBER 2018
ORGANISERS
 · Diego Megías, Spanish National Cancer Research Centre, 
CNIO
 · PerkinElmer
HOW tO successFuLLY PerFOrM & anaLYse a MuLticOLOr FLOW eXPeriMent WOrKsHOP 
24 - 26 OCTOBER 2018
ORGANISERS
 · Lola Martinez, Head of the Flow Cytometry Unit. CNIO. 
Madrid. Spain
 · Andrea Valle, Application Specialist FCS Express, 
DeNovo Software. Milano. Italy
SESSIONS
 · Multicolour Flow : tricks and pitfalls
 · Multicolour Flow panel design exercise
 · Multicolour Flow hands-on practical exercise
 · High-Dimensional analysis using FCS Express 6
WORKSHOP DE VESÍCULAS EXTRACELULARES -EXOMAS : BIOLOGÍA Y APLICACIONES EN EL CAMPO DE LA BIOMEDICINA 




 · Taller A1 : “ Recogida de Muestras Sólidas ”
 · Taller B1 : “ Análisis de Riesgos y Oportunidades ”
 · Taller B2 : “ Recogida de Muestras Prospectivas ”
 · Taller A2 : “¿ Qué es un Biobanco ?”
 · Taller B3 : “ Cesión de Muestras y/o Colaboración 
Científica ”
 · Taller B4 : “ Poblaciones de Referencia ”
 · MESA DE DEBATE “ Interacciones con stakeholders 
externos : Plataformas ISCIII/Biotecs/Pacientes/
Instituciones/Salud Pública ”
 · Conferencia de Clausura “ QUALITY MATTERS : 
INTERNATIONAL STANDARS FOR BIOBANKING ”
cOurse OF aniMaL LaBOratOrY FrOM FunctiOn c tO D 









The session was geared towards scientists, entrepreneurs, 
researchers and business development professionals of 
healthcare start-ups. In addition, there was a half-day workshop 
where attendees learned pitching basics, business development 
skills and received information about funding opportunities 
in Spain.
TALLER CEGEN-PRB2 : ESTUDIOS DE ASOCIACIÓN : DISEÑO Y ANÁLISIS DE DATOS 
24 SEPTEmBER 2018
ORGANISERS
 · Javier Benítez, Spanish National Cancer Research 
Centre, CNIO
 · Angel Carracedo, The University of Santiago de 
Compostela USC
 · Anna González-Neira, Spanish National Cancer 
Research Centre, CNIO
 · Inés Quintela, The University of Santiago de Compostela 
USC
 · Maria Torres, The University of Santiago de Compostela 
USC
FLOW cYtOMetrY cOurse 
9 - 10 OCTOBER 2018
ORGANISERS
 · Lola Martinez, Head of the Flow Cytometry Unit. CNIO. 
Madrid. Spain
SESSIONS
 · Intro to Flow ! Fundamentals & to collect accurate data in 
the cytometer
 · Main Cytometry Applications – from cell cycle to single 
cell sorting
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DATE SPEAKER ORGANISATION TITLE
JANUARY
19/01/2018 Antoni Castells Hospital Clinic of Barcelona, Spain Clinical management of polyposis and non-
polyposis colorectal cancer syndromes
26/01/2018 Andrés Aguilera Andalusian Center for Molecular 
Biology and Regenerative Medicine, 
CABIMER, CSIC, Sevilla, Spain
Interplay between RNA and chromatin in 
the maintenance of genome integrity
FEBRUARY
02/02/2018 Raúl Méndez Institute for Research in Biomedicine 
( IRB Barcelona ), Spain
The CPEB-family of RNA-binding 
proteins, mechanisms of action and new 
functions in cell cycle and cancer
16/02/2018 Jörg Hoheisel DKFZ German Cancer Research 
Center, Heidelberg, Germany
Pancreatic cancer : mechanistic 
insights, personalised diagnostics, 
and novel therapy options
23/02/2018 John Rubinstein The Hospital for Sick Children 
Research Institute, Toronto, Canada
Electron cryomicroscopy of rotary ATPases
26/02/2018 Shirley Kutner Hebrew University of 
Jerusalem, Israel
The women of the Start-up Nation
MARCH
23/03/2018 Kiyoshi Nagai MRC Laboratory of Molecular 
Biology, Cambrigde, UK
CryoEM snapshots of the spliceosome 
provide insights into the molecular 
mechanism of pre-mRNA splicing
APRIL
06/04/2018 Stefan Kubicek CeMM Research Center for Molecular 
Medicine of the Austrian Academy 
of Sciences, Vienna, Austria
Targeting chromatin for cancer 
cell synthetic lethality
13/04/2018 Arlene Sharpe Harvard Medical School, Boston, US Biology of PD-1 Checkpoint Blockade
20/04/2018 Adrian R. Krainer Cold Spring Harbor Laboratory, 
Watson School of Biological 
Sciences, NY, US
Antisense Therapy for Spinal Muscular Atrophy : 
Harnessing the Power of a Backup Gene
MAY
25/05/2018 Edith Heard Professor at Collège de France 
/ Institut Curie, Paris, France
Exploring epigenetic dynamics in 
development and disease using the 
paradigm of X inactivation
JUNE
01/06/2018 Kun-Liang Guan Sanford Consortium for Regenerative 
Medicine ( SCRM ) The University 
California, San Diego, US
The Hippo pathway in cell growth, 
organ size, and cancer
15/06/2018 Roger Lo Jonsson Comprehensive Cancer 
Center, David Geffen School 
of Medicine at UCLA, US
Strategies to overcome therapeutic 
resistance in melanoma
cniO DistinguisHeD seMinars
The purpose of the Distinguished Seminars Series is to invite 
outstanding and internationally renowned scientists to give 
a seminar and to meet with researchers at the CNIO. 
Distinguished Seminars are recurrent events that are open 
to the general public and are held throughout the year, usually 
on Fridays at noon in the CNIO Auditorium. Each Distinguished 
Seminar series includes world-leading scientists who address 
topics that are of general interest to the CNIO faculty.
The idea behind this international seminar series is not simply 
to host outstanding cancer researchers to the CNIO, but also 
serves to, annually, invite 3 to 4 opinion leaders from other 
areas of science, technology, and literature ; the overarching 
goal is to enable the CNIO to present its know-how as well as 
its vision on contemporary and future technological, societal 
and cultural challenges. These “ out-of-the-box ” seminars are 
sponsored by the Fundación Banco Sabadell and the French 
Embassy. The breadth of expertise and topics covered creates 
a multidisciplinary and intellectually challenging environment 
that goes far beyond the frontiers of cancer research.
In total, the CNIO hosted 18 distinguished speakers in 2018.
Friday 6 Oct
Paola Scaffidi





Howard Hughes Medical Institute, UT  
Southwestern Medical Center, Dallas, US
Friday 19 Jan
Antoni Castells
Hospital  Clinic of Barcelona, Spain
Friday 20 Oct
Peter Carmeliet
Vesalius Research Center, Leuven, Belgium
Friday 6 Apr
Stefan Kubicek
CeMM Research Center for Molecular  




O. Wayne Rollins Research Center,  
Emory University, Atlanta, US
Friday 2 Feb
Raúl Méndez










Harvard Medical School, Boston, US 
Friday 15 Jun
Roger Lo
Jonsson Comprehensive Cancer Center,  
David Geffen School of Medicine at UCLA, US
Friday 1 Jun
Kun-Liang Guan
Sanford Consortium for Regenerative Medicine 






Brigham and Women’s Hospital, Dana-Farber/
Harvard Cancer Center, Boston, US
Friday 8 Sep
Timothy Rebbeck
Dana Farber Cancer Institute and Harvard T.H.  
Chan School of Public Health, Boston, US
Out-of-the Box Seminars supported by
www.cnio.es/eventos/seminars
Melchor Fernández Almagro 3










St. Giles Foundation, Watson School  








Andalusian Center for Molecular Biology and 




Hebrew University of Jerusalem, Israel 
2018—19
Out-of-the Box Seminars supported by
www.cnio.es/eventos/seminars





Center for Brain Immunology and Glia (BIG)









IncRNAs and Gene Regulation in Cancer CIMA. 
University of Navarra, Pamplona, Spain
Friday 18 Jan
Jeremy N. Rich
Department of Medicine, Division of Regenerative 
Medicine. Director of Neuro-Oncology & Brain Tumor 
Institute, University of California, San Diego, US
Friday 23 Nov
Nicolas Winssinger














Max Planck Institute, Bad Nauheim, Germany
Friday 5 Apr
Kathrin Plath
UCLA School of Medicine, Los Angeles, US
Friday 8 Mar
W. Kimryn Rathmell
Vanderbilt University Medical Center, Tenessee, US
Friday 26 Apr
Charles M. Perou
UNC School of Medicine, Chapel Hill, US
Friday 17 May
Johanna Joyce
University of Lausanne, Switzerland
Friday 24 May
Susan Taylor
University of California, San Diego, US
Friday 29 Mar
Magdalena Götz
German Research Center for Environmental Health, 
Helmholtz Zentrum München, Germany
Friday 27 Sep
Himisha Beltrán
Dana Farber Cancer Institute, Boston, US
Friday 21 Sep
Karim Labib
Sir James Black Centre, School of Life Sciences, 
University of Dundee, Dundee, Scotland
Friday 25 Jan
Jan H. J. Hoeijmakers
Erasmus MC, Rotterdam, Netherlands
Friday 30 Nov
Caetano Reis e Sousa
The Francis Crick Institute, London, UK 
Friday 12 Apr
Katherine L. Nathanson
Perelman School of Medicine, University of 
Pennsylvania, Philadelphia, US 
Friday 28 Jun
David Sancho
Spanish National Center for Cardiovascular Research, 
Madrid Spain
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MARCH
07/03/2018 Pasi Janne Dana Farber Cancer Institute and 
Harvard University, Boston, US
Strategies to prevent and overcome 
resistance to EGFR inhibitors in lung cancer
APRIL
05/04/2018 Doryen Bubeck Imperial College, London, UK Cryo-EM of the membrane attack 
complex reveals a flexible nanopore
05/04/2018 Giuseppe Bosso SAPIENZA University of Rome, Italy Insights into the epigenetic maintenance 
of Drosophila telomeres as revealed by 
the Hp1a - Effete/UbcD1 relationship
12/04/2018 Mario Rossi National Scientific and Tecnological 
Research Council ( CONICET ); 
Max Planck Partner Institute of 
Biomedicine of Buenos Aires 
( IBioBA-MSPS ), Argentina
Role of protein Ubiquitylation in 




Pathology, Karolinska Institutet, 
Stockholm, Sweden
A second DNA binding site in BRCA2 
promotes homologous recombination
25/04/2018 Sander van 
den Heuvel
Institute of Biodynamics 
and Biocomplexity ( IBB ); 
Faculty of Science, Utrecht 
University, The Netherlands
Cell division, differentiation and tumor 
formation ; insights from C. elegans
25/04/2018 Manuel Saldivia 
Concepcion
Centre for Immunology & Infection, 
The University of York, UK
Lighting up parasite development : 
How I met your kinase
MAY
03/05/2018 Guillaume Belthier Centre National de la 
Recherche Scientifique ( CNRS ), 
Montpellier, France
Innovative strategies to isolate CTCs 
with stemness properties
10/05/2018 Rubén Fernández 
Busnadiego
Max-Planck-Institute of Biochemistry. 
Dept of Molecular Structural 
Biology, Martinsried, Germany
Cryo-electron tomography : The cell 
biology that came in from the cold
10/05/2018 Eri Sakata Max-Planck-Institute of Biochemistry. 
Dept of Molecular Structural 
Biology, Martinsried, Germany
Conformational landscape of 
the 26S proteasome gives insights 
into the gate-opening
16/05/2018 Heinz Neumann Max Planck Institute of Molecular 
Physiology Dortmund, Germany
Studying chromatin with neo-
functionalized proteins
22/05/2018 Miguel Jimenez 
Alcázar
University Medical Center 
Hamburg-Eppendorf, Germany
The Role of Neutrophil Extracellular 
Traps in Thrombosis
24/05/2018 Florian Karreth H. Lee Moffitt Cancer 
Center, Florida. USA
Maximizing melanoma modeling in the mouse
28/05/2018 Ilse Rooman Vrije Ujniversiteit Brussel, Belgium Pancreatic cancer - where did it go wrong ?
JUNE
04/06/2018 Daniel Herranz Rutgers Cancer Institute 
of New Jersey, USA
Dissecting NOTCH1-controlled transcriptional 
and metabolic oncogenic programs in T-ALL
05/06/2018 Melania Sauri Karolinska Institute, 
Stockholm, Sweden
Finding cancer Achilles’s heels 
in metabolic pathways
11/06/2018 Luis Álvarez-Vallina Aarhus University, Denmark Engineering the Immune System for 
Enhanced Cancer Immunotherapy
SEPTEMBER
21/09/2018 Karim Labib Sir James Black Centre, School 
of Life Sciences, University 
of Dundee, Scotland
Destroying the eukaryotic replisome
OCTOBER
05/10/2018 Rafael Yuste The NeuroTechnology Center 
at Columbia University 
Biological Sciences, US
Reading the neural code : emergent 
properties of neural circuits
NOVEMBER
23/11/2018 Nicolas Winssinger University of Geneva, Switzerland DNA-templated assemblies and 
reaction in chemical biology
30/11/2018 Caetano Reis 
e Sousa
The Francis Crick Institute, 
London, UK
Dendritic cells in immunity to 
infection and cancer
DECEMBER
21/12/2018 Jonathan Kipnis Center for Brain Immunology 
and Glia ( BIG ), University of 
Virginia, Charlottesville, US
Meningeal lymphatics in brain 
function ( and dysfunction )
AD-HOC seMinars
In addition to the CNIO Distinguished Seminar Series, the CNIO also hosts numerous ad-hoc seminars throughout the year. 
Ad hoc seminars are organised for the purpose of academic interactions, academic elevation and enrichment, as well as 
academic vis-a-vis social networking ; in addition to socialising with colleagues from other institutions. A total of 45 ad-hoc 
seminars were organised by CNIO researchers in 2018.
DATE SPEAKER ORGANISATION TITLE
JANUARY
29/01/2018 Salvador Aznar 
Benitah
Institute for Research in Biomedicine 
( IRB Barcelona ), Spain
Adult stem cells in health and disease : 
interplay between time, diet and epigenetics
31/01/2018 Antoni Montserrat 
Moliner
Active Senior Adviser on Public Health 
European Commission, Luxembourg
30 years of public health action from the 
European Commission in the field of cancer : 
From the European Cancer Code 1986 
to the iPAAC Joint Action in 2018
FEBRUARY
07/02/2018 Cédric Blanpain Université Libre de Bruxelles 
( ULB ), Belgium
Cancer cell of origin and tumor heterogeneity
20/02/2018 Marco Cordani Faculty of Medicine, Autonomous 
University of Madrid ( UAM ), Spain
Mutant p53 proteins alter signaling 
pathways involved in autophagy and 
redox regulation of cancer cells
23/02/2018 Kyohei Oyama Asahikawa Medical University, Japan Challenge to stable cell cycle 
exit in cardiac myocytes
27/02/2018 Pablo Baquero Wolfson Wohl Cancer Research 
Centre, University of Glasgow, UK
Targeting Autophagy and Mitochondrial 
Metabolism to Eliminate Leukaemic Stem Cells
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NOVEMBER
06/11/2018 Oriol Gallego Experimental and Health Sciences 
( DCEXS ) Pompeu Fabra University 
( UPF ), Barcelona, Spain
Cell engineering to implement live-
cell structural biology : towards novel 
mechanisms that control exocytosis
20/11/2018 Steve C. Ley Imperial College London, UK Regulation of inflammation 
by the TPL-2 complex
27/11/2018 Timm Maier University of Basel, Switzerland The structural basis for regulation 
of acetyl-CoA carboxylase 1
29/11/2018 Victor Borrell The Institute of Neurosciences, 
Alicante, Spain
Genetic evolution of cerebral 
cortex size determinants
29/11/2018 Aoife McGinley School of Biochemistry 
and Immunology at Trinity 
College Dublin, Ireland
IL-17A is pathogenic in CNS autoimmunity 
by promoting IL-1β production that 
drives encephalitogenic T cells
DECEMBER
03/12/2018 Aline Bozec Universitätsklinikum 
Erlangen, Germany
HIF1α expression in Immune Cells regulates 
Autoimmune and Infection Diseases ’
12/12/2018 Yacine Kharraz Cytek Biosciences Inc. 
Fremont, CA. US
Full-spectrum flow cytometry : How 
new technologies may drive changes 
in multicolor flow cytometry
20/12/2018 Antonio Maraver Oncogenic Pathways in Lung Cancer ; 
Institut de Recherche en Cancérologie 
de Montpellier ( IRCM ), France
Role of the Notch pathway in 
lung adenocarcinoma : beyond 
the KrasG12V mouse model
WOMen in science seMinars
30/01/2018 Laura Ferrero 
Carballo
Writer, freelance editor and literary 
advisor Instituto Vasco Etxepare. 
Barcelona
Decisiones racionales e irracionales : una breve 
historia de cómo llegué a ser escritora
20/02/2018 Elisa Martín Garijo Chief Technology Officer for IBM, 
Madrid, Spain
Yes, we can
06/03/2018 Fátima Bosch Autonomous University of Barcelona, 
Spain
Translational Gene Therapy Approaches to 
Treat Metabolic and Neurodegenerative 
Diseases
24/04/2018 Victoria Camps Philosopher, Professor of Ethics 
Universidad Autónoma de Barcelona, 
Spain
La filosofía como instrumento de emancipación
05/06/2018 Laura González 
Molero
Consejero Independiente de Acerinox 
y Ezentis
Atrévete a ser el rector de tu propia vida
25/09/2018 Elvira Sastre Escritora y traductora literaria ; Writter 
and literary translator
Escritoras, más allá del género y la biografía
23/10/2018 Eulalia Pérez 
Sedeño
Department Science, Technology and 
Society, IFS-CCHS CSIC, Madrid, Spain
Conocimiento y estereotipos de género
11/12/2018 Marta Macho UPV ( University of the Basque 
Country ), Spain
Entre el suelo pegajoso y el techo de cristal : la 
realidad de las mujeres en el ámbito laboral
14/06/2018 Paweł Kordowitzki Institute of Animal Reproduction 
and Food Research PAS ( IARFR ) 
of the Polish Academy of 
Sciences, Olsztyn, Poland
In vino veritas ? A large animal model 
for human reproductive aging
19/06/2018 Maria Ibarra Dauden EMBL Heidelberg - The European 
Molecular Biology Laboratory, 
Heidelberg, Germany
Structure basis of the tRNA binding 
on the Elongator sub-complex
JULY
04/07/2018 René Medema The Netherlands Cancer Institute, 
Amsterdam, Netherlands
Cell fate decisions after DNA damage : 
location, location, location ?
13/07/2018 Daniel Rico Institute of Cellular Medicine, 
Newcastle University, UK
Short and long distance relationships 
( in chromosomes )
16/07/2018 Bruno Conti Dorris Neuroscience Center, 
The Scripps Research Institute 
La Jolla, California
Mechanisms of Aging and Age-
Associated Diseases : Neuroimmunology 
of Parkinson’s Disease
17/07/2018 Martin Leeb University of Vienna, MFPL, 
Vienna, Austria
Dissecting the genetic complexity of 
embryonic stem cell differentiation
AUGUST
23/08/2018 Joana Nunes Meyer Cancer Center, Weill Cornell 
Medicine, New York, USA
The Metabolic Needs of Epithelial 
to Mesenchymal Transition
SEPTEMBER
07/09/2018 Israel Sanchez 
Fernandez
Biochemistry and Molecular 
Biophysics, Columbia 
University, New York, USA
What do crickets and ribosomes 
have to do with cancer ?
18/09/2018 Sofia Merajver Breast and Ovarian Cancer Risk 
Evaluation Program, University 
of Michigan Comprehensive 
Cancer Center, US
Personalized Oncology for primary 
tumors and brain metastasis : from the 
clinic to the lab and back in 7 days
25/09/2018 Fernando 
Martín-Sánchez
Institute of Health Carlos 
III, Madrid, Spain
CHARACTERIZING THE HUMAN EXPOSOME : 
a key step for Precision Medicine
27/09/2018 Marcus Bosenberg Yale Cancer Center, Yale 
University, New Haven, US
Defining Genetic Drivers of Melanoma and 
Mechanisms of Anti-Cancer Immune Responses
OCTOBER
02/10/2018 Fernando Martín 
Belmonte
Department of Developmental 
Biology and Differentiation at the 
Centro de Biología Molecular Severo 
Ochoa ( CBMSO ), Madrid, Spain
Epithelial tube organization and 
patterning in development and disease
09/10/2018 Carlos Fernandez 
Tornero
The Biological Research Center 
( Centro de Investigaciones 
Biológicas - CIB ), CSIC, Madrid
The role of RNA polymerase I in the protection 
against UV light-induced DNA damage
17/10/2018 Sonia Laín Professor in Molecular Cancer 
Pharmacology at Karolinska 
Institutet, Stockholm, Sweden
From phenotypic screens to the 
structure of a small molecule bound to 
its target, and the challenges beyond
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researcHers ’ nigHt 
28 SEPTEmBER 2018
This year, the CNIO participated in Researchers ’ Night ; an 
activity aimed at bringing researchers closer to the general 
public and concerned families in order to give them the 
opportunity to learn more about what researchers do for society. 
Each year, more than 300 European cities participate in parallel 
in what is ultimately a great night for science. During the 
activities − promoted by the European Commission and 
coordinated by the Madrid Regional Government and the 
madri+d Foundation − a total of 220 people came to the Spanish 
National Cancer Research Centre ( CNIO ) to attend Researchers ’ 
Night ( September 28, 2018 ) to learn about cancer research. 
The activities were entirely organised and held thanks to the 
voluntary efforts of 64 researchers. The guests were provided 
with the opportunity to meet researchers in an interactive and 
entertaining way, including welcome talks and short talks, 
hands-on experiments, view of a virtual tour through the 
facilities via a video project recorded by scientists from CNIO 
“ CNIO for Kids ”, and a speed dating session with the researchers.
OPen DOOrs DaY : inVestigating tO DisarM cancer 
5-18 NOvEmBER 2018
The CNIO also dedicates considerable efforts to bringing 
science and society closer together ; one of these endeavours 
is its collaboration with the madri+d research network for the 
organisation of the Madrid Science Week ( XVII Semana de 
la Ciencia, 5-18 November 2018 ). In 2018, 57 people participated 
in the guided visit to the Centre’s facilities.
steM taLent girL - MaDriD
The objective of the Stem Talent Girl project is to inspire, educate 
and empower the next generation of leading women in science 
and technology. The Stem Talent Girl project in Madrid , organised 
by ASTI Foundation and CNIO, offers eight “ masterclasses ” 
during the academic year ; the classes were given by women of 
international prestige in the STEM areas and took place between 
November 2018 and June 2019.
guiDeD Visits
Throughout the year, the CNIO provides tailor-made 
opportunities to visit its installations and to learn about the 
essentials of cancer research. During 2018, more than 830 
people participated in such guided visits ; most of them were 
ESO and Bachillerato student groups, but also professionals 






 · Banco Santander Foundation
The first edition of CNIO Arte, “ Binomio : a dialogue between 
art and science ”, curated by Mireia A. Puigventós, was born from 
the dialogue between two brilliant women from totally different 
fields of action : the scientist Margarita Salas and the visual artist 
Eva Lootz. For the occasion, Eva Lootz made an audio-visual 
piece and a series of 59 drawings representing insights and 
reflections on Margarita Salas’ main lines of research. The 
artworks were exhibited at the CNIO from February to April.
OPen DOOrs DaY : ‘cniO FrienDs ’ 
20 JUNE 2018
The purpose of this event is to welcome all our donors in order 
to give them the opportunity to visit our facilities, as well as 
for us to showcase some of our Research Programmes. Maria 
A. Blasco, Marcos Malumbres and Nabil Djouder gave a talk 
in the Auditorium.
WOrLD cancer researcH DaY : ‘Present anD Future OF cancer researcH ’ 
eXcLusiVe Meeting WitH nOBeL Laureate PrOF. eLiZaBetH BLacKBurn 
24 SEPTEmBER 2018
ORGANISERS
 · Constantes y Vitales
 · Spanish National Cancer Research Centre ( CNIO )
 · Fundación AXA
Our guest of honour was Nobel Prize winner Prof. Elizabeth 
Blackburn, who gave an inspiring talk entitled : “ Resolving 
Paradoxes in Telomere Biology and Cancers ”. After her talk, 
there was a panel discussion in which the following speakers 
took part :
SPEAKERS
 · Prof. Elizabeth Blackburn, Nobel Prize of Physiology or 
Medicine 2009
 · Maria A. Blasco, Director of the Spanish National Cancer 
Research Centre ( CNIO )
 · María José Alonso Fernández, Professor of Pharmacy 
and Pharmaceutical Technology, University of Santiago 
de Compostela ( USC )
 · Laura García Estévez, MD Anderson Cancer Center, 
Head of the Breast Tumors Section
 · Luz Casal, musician, singer, author songwriter and 
former cancer patient.
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ADMINISTRATION
BOarD OF trustees
 ȹ Honorary President
 · Pedro Francisco Duque Duque
Minister of Science, Innovation and Universities
Ministro de Ciencia, Innovación y Universidades
 ȹ President
 · Rafael Rodrigo Montero
General Secretary for Scientific Policy Coordination of 
the Spanish Ministry of Science, Innovation and 
Universities
Secretario General de Coordinación de Política Científica 
del Ministerio de Ciencia, Innovación y Universidades
 ȹ Vice-President
 · Raquel Yotti Álvarez
Director of the National Institute of Health Carlos III
Directora del Instituto de Salud Carlos III
 ȹ Appointed Members
 · Faustino Blanco González
General Secretary for Health and Consumer Affairs of the 
Spanish Ministry of Health, Consumer Affairs and Social 
Welfare
Secretario General de Sanidad y Consumo del Ministerio 
de Sanidad, Consumo y Bienestar Social
 · Rosa Menéndez López
President of the Spanish National Research Council 
( CSIC ), as representative of the Spanish Ministry of 
Science, Innovation and Universities
Presidenta de la Agencia Estatal del Consejo Superior 
de Investigaciones Científicas, como representante del 
Ministerio de Ciencia, Innovación y Universidades
 · Borja Luis Cabezón Royo
Director of the Department of National Affairs of the 
Cabinet of the Presidency of the Government
Director del Departamento de Asuntos Nacionales del 
Gabinete de la Presidencia del Gobierno
 · Margarita Blázquez Herranz
Deputy Director General for Networks and Cooperative 
Research Centres of the National Institute of Health 
Carlos III
Subdirectora General de Redes y Centros de Investigación 
Cooperativa del Instituto de Salud Carlos III
 · Carlos Pesquera González
Head of Cabinet of the Healthcare Counsellor of the 
Government of Cantabria
Jefe de Gabinete de la Consejera de Sanidad del Gobierno 
de Cantabria
 · Beatriz Allegue Requeijo
Director of the Galician Health Knowledge Agency - ACIS
Directora de la Agencia Gallega del Conocimiento en Salud 
- ACIS
 · Luis Gabilondo Pujol
General Director of Health of the Health Department 
of the Government of Navarre
Director General de Salud de la Consejería de Salud del 
Gobierno Foral de Navarra
 · Sandra García Armesto
Managing Director of the Aragon Institute of Health 
Sciences
Directora Gerente del Instituto Aragonés de Ciencias de la 
Salud
 ȹ Elected Members
 · ”la Caixa ” Banking Foundation Caixa d ’Estalvis i 
Pensions de Barcelona
Representatives : Angel Font Vidal, Director / Jaume Giró 
Ribas, General Director
 · BBVA Foundation
Representatives : Rafael Pardo Avellaneda, General 
Director/Francisco González Rodriguez, Chairman
 · Grupo PRISA
Representative : Ignacio Polanco Moreno, Chairman
 ȹ Secretary
 · Margarita Blázquez Herranz
Deputy Director General for Networks and Cooperative 
Research Centres of the National Institute of Health 
Carlos III
Subdirectora General de Redes y Centros de Investigación 
Cooperativa, Instituto de Salud Carlos III
 ȹ Legal Advisor
 · Fernando Arenas Escribano
Chief State’s Attorney of the Spanish Ministry of Health, 
Consumer Affairs and Social Welfare
Abogado del Estado-Jefe en el Ministerio de Sanidad, 
Consumo y Bienestar Social
* In accordance with the Spanish Transparency Legislation ( Spanish Royal Decree 451/2012, of March 5 ), the following information is hereby 
provided :
— At the close of the financial year, the accumulated remuneration received by the Top Management of the Foundation — the CNIO’s Director plus 
the Managing Director - has amounted to a total of 272,471 euros (251,488 euros in 2017).
— Members of the CNIO Board of Trustees are not remunerated.
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 · Mariann Bienz, PhD, FRS, FMedSci ( Chair )
Joint Divisional Head
Division of Protein and Nucleic Acid Chemistry
Medical Research Council Laboratory of Molecular 
Biology
Cambridge, United Kingdom
 · Lauri A. Aaltonen, MD, PhD
Academy Professor
Director, Genome Scale Biology Research Programme
Biomedicum, University of Helsinki
Helsinki, Finland
 · Genevieve Almouzni, PhD
Director, Institut Curie Research Centre
Head of Nuclear Dynamics & Genome Plasticity Unit
Institut Curie, Paris, France
 · J. Michael Bishop, MD
Chancellor Emeritus and Professor in the Dept. of 
Microbiology and Immunology
Director of the G.W. Hooper Research Foundation
University of California at San Francisco
San Francisco, USA
 · José Costa, MD, FACP
Professor of Pathology and of Orthopaedics and 
Rehabilitation
Director of the Translational Diagnostics and the 
Musculoskeletal Tumor Programs
Yale University School of Medicine
New Haven, USA
 · Sara Courtneidge, PhD, DSc ( hc )
Associate Director for Translational Sciences, Knight 
Cancer Institute
Professor, Departments of Cell, Developmental and 
Cancer Biology and Biomedical Engineering
Oregon Health & Science University
Portland, USA
 · John F.X. Diffley, PhD
Associate Research Director
The Francis Crick Institute
London, United Kingdom
 · Stephen Frye, PhD
Director, Center for Integrative Chemical Biology and 
Drug Discovery
Fred Eshelman Distinguished Professor
The University of North Carolina at Chapel Hill
Chapel Hill, USA
 · Denise Galloway, PhD
Associate Division Director, Human Biology Division at 
Fred Hutchinson Cancer Research Center
Research Professor of Microbiology at the University of 
Washington
Seattle, USA
 · Scott W. Lowe, PhD
Chair, Cancer Biology and Genetics Program, SKI
Chair, Geoffrey Beene Cancer Research Center
Memorial Sloan-Kettering Cancer Center
New York, USA
 · Ángela Nieto, PhD
Full Professor and Head of the Developmental 
Neurobiology Unit
Neuroscience Institute of Alicante ( CSIC-UMH )
Alicante, Spain
 · Josep Tabernero, MD PhD
Director, Vall d’Hebron Institute of Oncology ( VHIO )
Head, Medical Oncology Department of Vall d’Hebron 
University Hospital
Barcelona, Spain
 · Alfred Wittinghofer, PhD
Emeritus Group Leader
Department of Structural Biology
Max Planck Institute for Molecular Physiology ( MPI )
Dortmund, Germany
 · Ada E. Yonath, PhD
Director, the Helen and Milton A. Kimmelman Center for 
Biomolecular Structure and Assembly
Martin S. and Helen Kimmel Professor of Structural 
Biology
Weizmann Institute of Science
Rehovot, Israel
SPANISH NATIONAL CANCER RESEARCH CENTRE, CNIO 239ANNUAL REPORT 2018 238
Facts  & Figures aDMinistratiOn | mANAgEmENT
DIRECTOR
Sanz, Anabel Director Marín, M. Cruz ( Technology 
Tejedor, Ignacio Pérez, Fernando D.Pola, Carolina Director
Zamora, Helena Head ( since May )
Garrido, 
Blasco, Maria A. SECRETARIATE Alcamí, María Jesús
September, Communications 






Ámez, María del Mar
Muñoz, Laura
COMMUNICATION Noriega, Nuria Head


























Moreno, Ana María Head Hernando, M. Elena
DIRECTOR’S OFFICE
Peláez, Fernando Director
INSTITUTIONAL IMAGE & 
OUTREACH TO SOCIETY
Fernández-Capetillo, Óscar
















Liébanes, M. Dolores Head Ares, Raquel
Vergés, Leyre
EDUCATION & TRAINING PROGRAMMES
Communications Officer ) Pombo, Vanessa ( since 
Pola, Carolina Director
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CANCER CELL BIOLOGY 8% 35
BIOTECHNOLOGY 20% 88
CLINICAL RESEARCH 17% 74
MOLECULAR 
ONCOLOGY 27% 117
STRUCTURAL BIOLOGY 11% 47
HUMAN CANCER 
GENETICS 10% 45




STAFF SCIENTISTS 16% 69
GRADUATE STUDENTS 24% 103
POST-DOCTORAL 
FELLOWS 9% 37







mALE  23% 41
FEmALE  300
mALE   135
FEmALE 39% 18
mALE  61% 28
STAFF SCIENTISTS
FEmALE 75% 52








mALE  43% 16
GENDER DISTRIBUTION IN SENIOR ACADEMIC AND MANAGEMENT POSITIONS
SCIENTIFIC DIRECTION: 





mALE  47% 7
FEmALE 29% 4
mALE  71% 10
FEmALE 59% 10
mALE  41% 7
GROUP LEADERS, HEADS OF CLINICAL 
RESEARCH UNIT/SECTION
FEmALE 30% 8
























aDMinistratiOn | CNIO PERSONNEL 2018
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DISTRIBUTION BY PROFESSIONAL CATEGORY IN: BASIC RESEARCH
PRINCIPAL 
INVESTIGATORS 11% 22
STAFF SCIENTISTS 15% 31




DISTRIBUTION BY PROFESSIONAL CATEGORY IN: INNOVATION































SCIENTIFIC PERSONNEL: NATIONAL ORIGIN
DISTRIBUTION OF SCIENTIFIC PERSONNEL BY NATIONAL ORIGIN





STAFF SCIENTISTS 12% 8




















Total foreign scientific personnel 49
Percent values represent percentages of foreign employees 
of the total CNIO personnel in each category
aDMinistratiOn | CNIO PERSONNEL 2018
1
AFRICA 0.23%
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Facts  & Figures PriVate sPOnsOrs
The Fundación Jesús Serra-
C a t a l a n a  O c c i d e n t e 
continues to fund the Visiting 
Researcher Programme that 
was established to support 
prestigious international professors for short stays at the 
CNIO. The recipient of the Jesús Serra Foundation’s Visiting 
Researcher Award in 2018 was Scott W. Lowe, Chair of the 
Cancer Biology and Genetics Program and the Geoffrey Beene 
Cancer Reseach Center at Memorial Sloan Kettering Cancer 
Center ( MSKCC ) in New York ( USA ).
The AXA Research Fund 
( ARF ) − a global initiative 
of scientific philanthropy 
run by the insurance group AXA − awarded an AXA-CNIO 
Endowed Permanent Chair position in Molecular Oncology 
to Mariano Barbacid as part of its 2011 call.
OtHer sPOnsOrs
Our activities are also 
supported by individual 
donations − citizens who wish 
to contribute personally to 
the battle against cancer − 
donations from companies 
and foundations, as well as 
via external fundraising from 
local associations that are 
equally dedicated to the 
b a tt l e  a g a i n st  c a n c e r. 
During 2018, our research 
activities and seminars were 
supported by : Fundación 
Juegaterapia, Fundación Inocente Inocente, Fundación 
Española de Hematología y Hematoterapia, Fundación 
Investigación Biomédica Hospital Universitario 12 de 
Octubre, Fundación PFIZER, Asociación Bandera Rosa, 
Asociación de Mujeres Afectadas de Cáncer de Mama ROSAE, 
Fressia Group, Colectivo de afectados “ El árbol de la Vida ”, 
Santa Lucía Seguros, Petroplast, and the Fundación Banco 
Sabadell, among others.
Lastly,  we extend our 
heartfelt thanks to all ‘CNIO 
Friends ’ donors, sponsors 
and benefactors who, thanks 
to their generous donations 
to support cancer research at 
the CNIO, have ensured the 
continuation of our research 
endeavours throughout 2018.
PRIVATE SPONSORS
“ We take this opportunity to express our thanks and 
appreciation to all our sponsors and donors for the 
generous support that we received from them in 2018. 
They play an inherent role in our present and future 
successes.”
The Fundación ” la Caixa ” 
helps finance our most 
prominent international 
conferences, the CNIO-”la 
Caixa ” Foundation Frontiers Meetings. Another main goal of 
the ” la Caixa ” Foundation is to support an innovative 
programme aimed at fostering international fellowships in 
order to attract the most outstanding students from the 
international arena to obtain their doctoral degrees at 
accredited “ Severo Ochoa ” Centres of Excellence. Since 2017, 
the CNIO participates in the new doctoral fellowship 
programme of the ” la Caixa ” Foundation, INPhINIT.
Fundación CRIS is dedicated 
to the promotion and 
development of research with 
the aim of eliminating the 
serious health threat of cancer. Fundación CRIS generously 
supports 3 research groups at the CNIO : the Prostate Cancer 
Clinical Research Unit ( CRU ), headed by David Olmos ; the 
Breast Cancer CRU, headed by Miguel Quintela ; and the 
H12O-CNIO Haematological Malignancies CRU, led by Joaquín 
Martínez-López. These Groups focus on the translation of 
advances in cancer research into improvements in patient 
care.
The Fundación Marcelino Botín and the 
Banco Santander are committed to 
supporting scientific research and 
knowledge transfer from academia to the 
market through science programmes ; 
this transfer is regarded as one of the 
main driving forces for Spain’s economic 
and social development. These 2 well-recognised organisations 
collaborate with the CNIO in this regard by supporting the 
research groups led by Maria A. Blasco and Óscar 
Fernández-Capetillo.
T h e  F u n d a c i ó n  B a n c o 
Santander funds the Banco 
Santander Foundation – CNIO 
Fe l l o w s h i p s  f o r  Yo u n g 
Researchers. These fellowships 
have the aim to support highly talented and motivated young 
scientists who have been trained in the UK or in the USA, and 
who wish to pursue their postdoctoral training at the CNIO. 
One young scientist, Luis Javier Leandro-García from the 
Memorial Sloan Kettering Cancer Center in New York, was 
the recipient of a Santander Foundation-CNIO Fellowship 
in 2018. Additionally, thanks to the support of the Fundación 
Banco Santander, a group of 2 young researchers received 
training on managerial and entrepreneurial skills, in 
collaboration with the IE Business School.
T h e  Fu n d a c i ó n  S e v e 
Ballesteros is a private not-
for-profit  institution 
foc u sed  on sec ur ing, 
financing and promoting research projects centred on brain 
tumours. Fundación Seve Ballesteros supports the Seve 
Ballesteros Foundation – CNIO Brain Tumour Group, headed 
by Massimo Squatrito, since 2012. This Group focuses on the 
identification of markers for brain tumours as its principal 
activity.
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‘ CNIO Friends ’ has just celebrated its four-year anniversary 
with a clean bill of health, closing 2018 with close to 1,200 
donors and about 880,000€ collected since the beginning of 
the initiative. During these first few years, this philanthropic 
association has been working hard to put CNIO on society’s 
visible spectrum and has become a meeting place for the 
charitable initiatives of a society that is increasingly aware of 
the importance of biomedical research.
Since the launch of the ‘ CNIO Friends ’ Postdoctoral Contracts 
Programme, six scientists — in addition to one pre-doctoral 
researcher — have been recruited to investigate new avenues 
for advancement in the treatment and diagnosis of the disease. 
In addition, in 2018, calls for applications were launched for 
further contracts that will come into effect in 2019 ; these will 
open up new avenues of innovative research against cancer. 
Also in 2018, we continued to receive donations in the form 
of legacies and bequests.
One of the most rewarding experiences organised in the 
framework of ‘ CNIO Friends ’ was the launch of CNIO Arte ; 
an initiative launched by the Centre with the support of the 
Banco Santander Foundation, which connects leading 
international scientists and artists and explores the common 
territories shared by scientific research and artistic creation. 
In 2018, our inaugural encounter was called ‘ Binomio, a 
Dialogue between Art and Science ’. This dialogue between 
researcher and artist has resulted in the creation of unique 
artwork from which the proceeds will help to fund cancer 
research.
The project, inspired by the book Excelentes — which compiles 
portraits by Amparo Garrido and texts by Mónica G. Salomone 
about eminent figures who have visited CNIO in recent years 
— featured two exceptional individuals in this first edition : 
Margarita Salas, a global pioneer in molecular biology, and 
Eva Lootz, winner of the National Visual Arts Prize. Based on 
their conversations and meetings, Lootz created an audiovisual 
piece and a series of 59 drawings, conceived of as thoughts or 
‘ illuminations ’ that reflect on Salas ’ main lines of research. 
The exhibition was on display at the CNIO between February 
and May 2018, and was presented at the prestigious ARCO art 
fair in Madrid.
In April, we were visited by the Juegaterapia Foundation and 
its Honorary Ambassador, the singer David Bisbal, to celebrate 
a new donation of 100,000 euros received from the Foundation. 
Thanks to this collaboration with CNIO, a new Juegaterapia-
CNIO Friends postdoctoral contract was funded, leading to 
the incorporation of a young researcher, Miguel Jiménez 
Alcázar, to the Seve-Ballesteros Foundation Brain Tumours 
Group in order to develop a project focused on searching for 
new therapeutic strategies for gliomas, the most common 
type of brain tumour in children and adolescents.
In addition, throughout the year, we received support from 
all around Spain : in February, the ROSAE association, 
composed of breast cancer patients or ex-patients, collaborated 
with ‘ CNIO Friends ’ and invited us to their sisterhood lunch 
held in Valdepeñas ( Ciudad Real ). In June, the Bandera Rosa 
association donated the money they had raised in El Campo 
de Gibraltar ( Cádiz ), where they support breast cancer patients 
and their families. Later in the year, in October, the collective 
El Árbol de la Vida, from Las Pedroñeras ( Cuenca ), held its 
III Charity Race Against Cancer, which was attended by 
almost 3,000 people, donating some of the money raised to 
‘ CNIO Friends ’. The year came to a close with a San Silvestre 
charity race in Soto del Real ( Madrid ) in support of our 
initiative, in which hundreds of runners donned their trainers 
for this good cause and ran to the beats dropped by leading 
international DJs.
In June, we celebrated one of the most eagerly anticipated 
events of the year : the ‘ CNIO Friends ’ Open Doors Day event. 
On this day, our Friends came to CNIO to meet our researchers 
and explore our labs. With them were the director of CNIO, 
Maria A. Blasco, and other researchers such as Carolina Maestre 
and Sebastián Thompson, the latest two recipients of the 
‘ CNIO Friends ’ postdoctoral contracts to investigate cellular 
proliferation in tumours and the use of nanoparticles against 
cancer.
We would like to take this opportunity to thank our community 
of donors as well as all supporters in general for their 
encouragement and support. Now that we have more than 1,000 
Friends, we feel responsible for the trust they have placed in 
us and we are responding in the best way we know : through 
cancer research.
CNIO FRIENDS
“‘ CNIO Friends ’ places us 
on society ’s visible 
spectrum.”
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CNIO ARTE ‘ JUEGATERAPIA-CNIO FRIENDS ’ 
POSTDOCTORAL CONTRACT
Margarita Salas, worldwide pioneer in molecular biology, and 
Eva Lootz, National Prize Winner for Plastic Arts, both starred 
together in the first edition of CNIO Arte with the project 
entitled ‘ Binomio, a Dialogue between Art and Science ’. This 
CNIO initiative, with the support of the Banco Santander 
Foundation, aims to bring together leading international 
scientists and artists in order for them to jointly explore the 
common territories of scientific research and artistic creation.
On February 23, Binomio was unveiled at the prestigious ARCO 
Art Fair with a roundtable on the synergies between art and 
science. Participants included Eva Lootz, CNIO Director 
Maria A. Blasco, visual artist Amparo Garrido, Susana Gómez 
from the Fundación Banco Santander, Art Professor Estrella 
de Diego, and project curator Mireia A. Puigventós.
The Juegaterapia Foundation donated 100,000 euros to ‘ CNIO 
Friends ’ thanks to the successful sales of the Baby Pelones 
dolls. Juegaterapia visited the Centre with the singer David 
Bisbal who designed one of these dolls. Those appearing in 
the picture are from left to right : Mónica Esteban ( Chair of 
Juegaterapia ), Maria A. Blasco ( CNIO Director ), David Bisbal 
( Honorary Ambassador ), Valle Sallés ( Vice-chair ) and Pablo 
Ibáñez ( Honorary Chair ).
This donation will support a new ‘ Juegaterapia-CNIO Friends ’ 
postdoctoral contract, through which Miguel Jiménez Alcázar, 
from the University Medical Center in Hamburg, Germany, 
will spend two years at CNIO’s Seve-Ballesteros Foundation 
Brain Tumour Group. In his project, he will focus his research 
on gliomas, the most common type of brain tumours in children 
and adolescents.
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A MEETING STARRED 
BY OUR ‘ FRIENDS ’
On June 20th, we celebrated the CNIO Friends Day, an event 
designed to welcome some of the hundreds of CNIO’s most 
loyal supporters and to bring our science closer to them. They 
could learn about the research projects that were made possible 
thanks to our ‘ CNIO Friends ’ and they also had the opportunity 
to visit the Centre’s labs and facilities. This year, in addition, 
we also celebrated the fact that ‘ CNIO Friends ’ surpassed the 
mark of 1,000 supporters.
 ȹ Benefactor Friends
· Alberto Heras Hermida 
Majadahonda, Madrid
· Alfonso Agüera Nieto 
Santa Ana-Cartagena, Murcia
· Alvaro Gil Conejo 
Mijas, Málaga
· Andrés Sánchez Arranz 
Madrid, Madrid
· Ángel Simón Garrido 
Olot, Girona
· Anunciación Calvo Prieto 
Madrid, Madrid
· Anunciación de los Milagros García Calvo 
Madrid, Madrid
· Asociación de Afectados de Cáncer-AFECC 
Llerena, Badajoz
· Asociación Recreativo-Cultural de apoyo a personas 
afectadas de cáncer : Asociación Esperanza 
Burela, Lugo
· Asociación Usuarios SAP España-AUSAPE 
Madrid, Madrid
· Breatel, S.L.U. 
Madrid, Madrid
· CEIP Mare Nostrum 
Cartagena, Murcia
· Centro Educativo Zola, S.A 
Villanueva de la Cañada, Madrid
· Encarnación Fernández Pérez 
Madrid, Madrid
· Esther Valdivia Carrión 
Madrid, Madrid
· Fernando Pascual Carreras 
Madrid, Madrid
· Francisco Javier Gállego Franco 
Barbastro, Huesca
· Gema Rubio González 
Madrid, Madrid
· Ismael Serrano del Amo 
Vigo, Pontevedra
· International Road Technology Consulting S.L 
Parla, Madrid
· iZanda Portable Machine 
Tools, S.L. 
Castellón de la Plana, Castellón
· Jaime Escobar Fermoselle 
Cadalso de los Vidrios, Madrid
· Jesús Labrador Fernández 
Tres Cantos, Madrid
· Jesús Miguel Iglesias Retuerto 
Valladolid, Valladolid
· José Enrique León Santos 
Getafe, Madrid
· José Limiñana Valero 
Alicante, Alicante
· José Luis Pérez Fuente 
Madrid, Madrid
· Lydia Limiñana Valero 
Alicante, Alicante
· Luis David Sanz Navarro 
Madrid, Madrid
· María Dolores Díaz Almagro 
Sevilla, Sevilla
· María Jesús Amores Molero 
Jábaga, Cuenca
· María Jesús Fernández Ruiz 
Madrid, Madrid
· María Rodríguez López 
Valladolid, Valladolid
· Mercedes Cáceres Alonso 
Madrid, Madrid
· Nemesio Carro Carro 
León, León
· Pablo Nicolás Gaviglio Serrani 
Córdoba, Argentina
· Promega Biotech Ibérica, S.L 
Alcobendas, Madrid
· Santiago Rodríguez Uriel 
Madrid, Madrid
· Vicente Belenguer Tarín 
Valencia, Valencia
· Victoria Munárriz Elizondo 
Pamplona, Navarra
BeNeFACTOr FrIeNds/sPONsOr FrIeNds
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 ȹ Sponsor Friends
· Asociación Bandera Rosa 
Algeciras, Cádiz
· Asociación de Mujeres Afectadas de cáncer de mama 
ROSAE 
Valdepeñas, Ciudad Real
· Colectivo de afectados “ El árbol de la Vida ” 
Las Pedroñeras, Cuenca
· Compañía Logística 
de Hidrocarburos CLH, S.A.
· Freesia Group 
Salou, Tarragona
· Fundación Inocente Inocente 
Madrid, Madrid
· Fundación Juegaterapia 
Madrid, Madrid
· Javier Campos 
Granada, Granada




· Santa Lucía Seguros 
Madrid, Madrid
Last but not least, we would also like to extend our heartfelt thanks to all the anonymous benefactors who have donated their 
legacies to support cancer research at the CNIO ; in doing so they have contributed to society for generations to come.




(100,000€ from the Juegaterapia Foundation)
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UNDERBAU DESIGN AMPARO GARRIDO PHOTOGRAPHY 
In order to pour the Annual Report into a more creative concept, 
the CNIO works closely with selected professionals in the 
artistic and creative sectors who ensure delivery of an end 
product that is attractive in more ways than one. We extend 
our thanks to the creative team, the visual artist Amparo 
Garrido, and the graphic design studio underbau whose 
invaluable work created the images and design that illustrate 
this Annual Report.
A Madrid-based visual artist working with photography and 
video, Amparo Garrido has been represented in individual 
and group shows both in Spain and abroad since 1998. Her 
work has been honoured in several prestigious competitions. 
She obtained the first place in the 2001 edition of the ABC 
Photography Prize, and second place in the 2007 Purificación 
García Prize. Other honourable mentions include the Pilar 
Citoler and Ciudad de Palma prizes. Her work can be found 
in major collections, including the Museo Nacional Centro de 
Arte Reina Sofia in Madrid, the photographic holdings of the 
Madrid regional authority, the Coca-Cola Foundation, the Es 
Baluard Museum of Modern and Contemporary Art in Palma 
de Mallorca, and the ‘ Types and Trends on the Threshold of 
the 21st Century ’ Alcobendas Collection, among many others. 
Amparo’s most recent solo exhibitions in Spain were shown 
at the Sala Robayera de Miengo, Cantabria 2017, Galería Trinta, 
Santiago de Compostela 2015, and the Museo del Romanticismo, 
Madrid 2012. Her first feature film ‘ El silencio que queda ’ was 
selected to be part of the Documentary Feature Film section 
of the 22nd Málaga Film Festival 2019.
CREATIVE TEAM
Underbau is a design studio that emerged in 2008 from 
professional designers with 15 years of experience in the field 
of corporate design, publishing and advertising. From the 
very beginning, the studio has sought to maintain its primary 
focus on art and culture, working together with Spanish and 
international bodies such as the Orquesta y Coro Nacionales 
de España, Instituto Cervantes and Museo Thyssen-Bornemisza. 
Underbau’s total-design approach puts the emphasis on 
coherency. To achieve that, the studio assumes full 
responsibility for the entire creative process, from the initial 
concept to the final product.
Centro Nacional de Investigaciones Oncológicas ( CNIO )
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